SAMPLE_ID,SAMPLE_NAME,PUBCHEM_SID,PRIMARY_MOA,ASSAY_NAME,LIBRARY,CAS,ALIAS,AC50(uM),label,LOG_AC50,AUC,CURVE_CLASS2,DATA_POINTS,DRUG_NAME,EFFICACY,MAX_RESPONSE,P_HILL,R2,GENE_ID,GENE_SYMBOL,SMILES,SUPPLIER,SUPPLIER_ID,DATA0,DATA1,DATA2,DATA3,DATA4,DATA5,DATA6,DATA7,DATA8,DATA9,DATA10,DATA11,DATA12,DATA13,DATA14,CONC0(M),CONC1(M),CONC2(M),CONC3(M),CONC4(M),CONC5(M),CONC6(M),CONC7(M),CONC8(M),CONC9(M),CONC10(M),CONC11(M),CONC12(M),CONC13(M),CONC14(M)
NCGC00167506-04,Pimecrolimus,405558652,Macrolide Antibiotic,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),137071-32-0,,10.62129087,0,-4.973822698,-78.9329987,-2.2,7,,-82.54024594,-78.98267188,0.001237392,0.985288505,,,CC[C@@H]1/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)/C(C)=C/[C@@H]4CC[C@H](Cl)[C@@H](C4)OC,Selleck,S5004,0.46638166,-10.50679852,0,-5.13513514,-12.10653753,-46.3,-78.98267188,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00017244-16,ENOXOLONE,,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),471-53-4,,13.37141299,0,-4.873822698,-44.03484925,-2.2,7,,-65.11319173,-60.31302404,0.00537356,0.968499249,,,[H][C@@]12C[C@](C)(CC[C@]1(C)CC[C@]3(C)C2=CC(=O)[C@]4([H])[C@@]5(C)CC[C@H](O)C(C)(C)[C@]5([H])CC[C@@]34C)C(O)=O,Microsource,1500990,0.77730276,0,-8.44881538,0,3.09927361,-28.5,-60.31302404,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00483924-02,Brigatinib,384569265,IGF-1R Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1197953-54-0,,1.888762287,1,-5.723822698,-38.56947423,-1.4,7,,-28.21520402,-29.34600335,0.003020446,0.976707628,,IGFR1,COC1=C(NC2=NC=C(Cl)C(=N2)NC3=CC=CC=C3[P](C)(C)=O)C=CC(=C1)N4CCC(CC4)N5CCN(C)CC5,MedChem Express,HY-12857,0.38865138,-1.85414091,0,3.06306306,-17.14285714,-25.1,-29.34600335,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00510317-02,Elbasvir,405558499,Nonstructural protein 5A Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1370468-36-2,,4.74435636,1,-5.323822698,-113.1468344,-1.1,7,,-108.5073225,-98.99385131,5.89336E-05,0.996849763,,,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C2=NC=C([NH]2)C3=CC=C4C(=C3)O[C@H]([N]5C6=C(C=C(C=C6)C7=CN=C([NH]7)[C@@H]8CCCN8C(=O)[C@@H](NC(=O)OC)C(C)C)C=C45)C9=CC=CC=C9,MedChem Express,HY-15789,1.9432569,2.01895344,0,-5.85585586,-27.40920097,-83.7,-98.99385131,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00389453-01,Chlortetracycline HCl,405558866,translation Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),64-72-2 ,,13.37141299,0,-4.873822698,-37.91680678,-2.2,7,,-43.33705981,-41.97875908,0.001756053,0.982400281,,,CN(C)C1C2CC3\C(=C(O)/C4=C(O)C=CC(=C4C3(C)O)Cl)C(=O)C2(O)\C(=C(C(N)=O)/C1=O)O,APExBIO,B1699,-1.55460552,-4.65595385,0,0,-7.07021792,-19.5,-41.97875908,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00025341-06,Isradipine,170465070,Calcium Channel Blocker,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),75695-93-1,";Isradipine; Isradipine; DynaCirc; Lomir; Isradipine, (S)-Isomer; Dynacirc; Isaradipine; Isradipine, (R)-Isomer; Isradipine, (+-)-Isomer",15.00297213,0,-4.823822698,-36.9148602,-2.2,7,,-67.07142857,-61.03896104,5.48554E-05,0.99696192,,,O=C(OC)C3=C(C)NC(C)=C(C(=O)OC(C)C)C3c1cccc2nonc12,Tocris,2004,0,0.91743119,0,-0.58381985,1.53568202,-24.14772727,-61.03896104,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00018258-10,Econazole nitrate,170465422,Antifungal Agent,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),24169-02-6,; Pevisone; Spectazole;Econazole nitrate;ECONAZOLE NITRATE; Econazole nitrate salt,10.62129087,0,-4.973822698,-65.45876306,-2.1,7,,-88.71003542,-87.48524203,0.000445586,0.991257693,,,[O-][N+](=O)O.Clc3ccc(C(OCc1ccc(Cl)cc1)Cn2ccnc2)c(Cl)c3,Microsource,1501185,0,-6.55307995,3.15018315,0,0,-46.49621212,-87.48524203,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00166298-02,Melengestrol acetate,170465702,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),2919-66-6,,10.62129087,0,-4.973822698,-18.02814956,-2.4,7,,-28.22727272,-27.27272727,0.000113408,0.995626526,,,CC(=O)[C@@]3(OC(C)=O)C(=C)C[C@H]2[C@@H]4C=C(C)C1=CC(=O)CC[C@]1(C)[C@H]4CC[C@@]23C,Prestwick,Prestw-1435,0.48048048,0,0,2.08507089,0,-14.86742424,-27.27272727,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00183009-01,Pranazepide,144206813,Cholecystokinin A receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),150408-73-4,Panazepide; ,16.8336116,0,-4.773822698,-39.88535076,-2.1,7,"PANAZEPIDE;PRANAZEPIDE;FK480;FR120480;CIPLUS_709224;1H-Indole-2-carboxamide, N-(1-(2-fluorophenyl)-3,4,6,7-tetrahydro-4-oxopyrrolo(3,2,1-jk)(1,4)benzodiazepin-3-yl)-, (S)-;Panazepide;LS-173385;FR 120480;FK 480;Pranazepide;N-(1-(2-fluorophenyl)-3,4,6,7-tetrahydro-4-oxo-pyrrolo(3,2,1-jk)(1,4)benzodiazepin-3-yl)-1H-indole-2-carboxamide;FR-120480;pranazepide;pranazepidum;",-95.69752066,-84.88783943,9.70369E-05,0.995951909,,,Fc6ccccc6C3=N[C@H](NC(=O)c1cc2ccccc2n1)C(=O)N5CCc4cccc3c45,Pharmaron,PH-NIH-126867,0.6006006,0,4.68864469,2.66889074,4.06504065,-26.79924242,-84.88783943,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00390241-07,LX1606 (Hippurate),405559103,5-HT Release Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1137608-69-5,,13.37141299,0,-4.873822698,-61.84388344,-2.2,7,,-76.53996646,-72.72219117,0.003408248,0.975179584,,TPH1,CCOC(=O)[C@@H](N)CC1=CC=C(C=C1)C2=CC(=NC(=N2)N)O[C@H](C3=C(C=C(Cl)C=C3)[N]4C=CC(=N4)C)C(F)(F)F,MedChem Express,HY-13055,-0.3109211,2.84301607,0,-11.35135135,-6.48910412,-36.7,-72.72219117,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00160481-02,Tioxidazole,124892286,microtubule polymerization Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,42.28412057,0,-4.373822698,-16.04241073,-2.4,7,,-29.55645612,-25.8803801,0.049158238,0.893105331,,,CCCOC1=CC=C2N=C(NC(=O)OC)SC2=C1,Chembridge,5175278,-1.47687524,0,-0.49173,0.54054054,-8.52300242,0.4,-25.8803801,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00532506-01,SODIUM LAURYL SULFOACETATE,405559116,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,18.88762287,0,-4.723822698,-19.06509279,-3,7,,-46.55953046,-42.09055338,0.00035639,0.992197539,,,CCCCCCCCCCCCOC(=O)C[S]([O-])(=O)=O,SIGMA,MFCD00214054,0,0,0,0,3.48668281,-9.7,-42.09055338,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00538320-01,NCGC00538320-01,405558505,Prostamide/prostaglandin F synthase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,23.7781084,0,-4.623822698,-19.68265239,-3,7,,-51.30184461,-43.09670207,0.00037852,0.99195556,127281,FAM213B,OC(=O)C1CCC2=C1C=C(Cl)C(=C2)C3CCCCC3,Pharmaron,PH-NIH-2017-009-L1-7-0,0,3.50226617,-1.29637908,0,0,-8.8,-43.09670207,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00181296-02,Seratrodast,170465940,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),112665-43-7," Bronica; (+-)-7-(3,5,6-trimethyl-1,4-benzoquinon-2-yl)-7-phenylheptanoic acid;Seratrodast;AA 2414; ",21.19226141,0,-4.673822698,-54.09304574,-2.2,7,,-77.61486864,-67.13247624,0.002719697,0.977928132,6915,TBXA2R,O=C2C(C)=C(C)C(=O)C(C)=C2C(CCCCCC(=O)O)c1ccccc1,Tocris,3025,-4.74154683,-9.51792336,1.60929817,0,-5.81113801,-23.9,-67.13247624,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00188440-01,Zinc dibutyldithiocarbamate,144206589,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),136-23-2,,0.119172844,1,-6.923822698,-55.96768505,-1.2,7,ZINC DIBUTYLDITHIOCARBAMATE,-32.6054054,-13.35941867,0.028236433,0.956071434,,,[Zn+2].[S-]C(=S)N(CCCC)CCCC.CCCCN(CCCC)C([S-])=S,APAC,878050,0,3.50226617,-8.71703174,-33.96396396,-25.18159806,-31.5,-13.35941867,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00182710-02,Flurbiprofen axetil,144206486,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),91503-79-6,,26.67947643,0,-4.573822698,-6.638807522,-3,7,Flurbiprofen Axetil;CIPLUS_701423;Flurbiprofen axetil;FLURBIPROFEN AXETIL;Ropion;FP83;FP 83;FP-83;1-acetoxyethyl-2-(2-fluoro-4-biphenyl)propionate;,-35.70318613,-32.25265511,0.001179864,0.985655007,,,Fc2cc(ccc2c1ccccc1)C(C)C(=O)OC(C)OC(C)=O,ACC,Flurbiprofen Axetil,0,3.83189122,2.81627179,0,0,0,-32.25265511,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00263529-01,Lacidipine,170465580,Ca channel blocker - DHP class,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),103890-78-4,,8.436791229,1,-5.073822698,-62.02130419,-2.2,7,,-81.00413223,-78.51239669,2.47957E-05,0.997960505,,,CC=1NC(C)=C(C(C=1C(=O)OCC)c2ccccc2/C=C/C(=O)OC(C)(C)C)C(=O)OCC,Sequoia,SRP00900l,0.96096096,4.32503277,0,0,-1.17434508,-53.88257576,-78.51239669,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00017331-08,(-)-Epicatechin,170465932,superoxide anion generation Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),490-46-0,,8.436791229,1,-5.073822698,-21.44099604,-1.2,7,,-32.12750886,-30.10625738,0.001614783,0.983146019,,,Oc1ccc(cc1O)[C@H]2Oc3cc(O)cc(O)c3C[C@H]2O,Microsource,210205,2.28228228,0,0,0,4.78771454,-23.39015152,-30.10625738,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00018250-06,Sulconazole nitrate,170465344,Lanosterol 14-alpha demethylase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),61318-91-0,,6.701581484,1,-5.173822698,-85.91899481,-1.1,7,,-82.13884298,-83.47107438,0.002930234,0.977053871,,,[O-][N+](=O)O.Clc3ccc(C(SCc1ccc(Cl)cc1)Cn2ccnc2)c(Cl)c3,Microsource,1501148,3.24324324,-13.23722149,1.39194139,0,-9.48509485,-64.10984848,-83.47107438,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00182552-02,Atazanavir,170465290,HIV Protease Inhibitors,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),198904-31-3, ;ATAZANAVIR SULFATE; Atazanavir;Atazanavir sulfate; Reyataz,23.7781084,0,-4.623822698,-2.827218642,-2.4,7,,-29.8772137,-26.56434475,0.007173269,0.963340579,,,CC(C)(C)[C@H](NC(=O)OC)C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)Cc2ccc(cc2)c3ccccn3,Sequoia,229975-97-7,0,0,4.46886447,0,4.78771454,0,-26.56434475,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00181912-01,Iomazenil,144206800,GABAergic synapse Modulator,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),127985-21-1,,2.667947643,1,-5.573822698,-7.087176904,-2.4,7,"IOMAZENIL (123I);iomazenilum (123I);iomazenil (123 I);Ro 16-0154;Iomazenil(123I);Ro-16-0154;IOMAZENIL (123 I);CIPLUS_208012;Iomazenil (123I);Benzodine;ethyl 7-iodo-5,6-dihydro-5-methyl-6-oxo-4H-imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylate;iomazenil;Iomazenil ((sup 123)I);(123I)iomazenil;",-24.15909091,0,0.009982888,0.978819849,,,O=C(OCC)c3ncn2c3CN(C)C(=O)c1c(I)cccc12,Pharmaron,PH-NIH-10,3.12312312,0,3.2967033,0,-6.23306233,-22.63257576,0,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00015273-19,Chlorpromazine,170465371,Histamine H1 receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),50-53-3,,18.88762287,0,-4.723822698,-32.09816044,-2.2,7,,-66.38311689,-61.27508855,7.36E-07,0.9996497,,,CN(C)CCCN1c3ccccc3Sc2ccc(Cl)cc12,Vitas,STK182870,0,0,0,0,0.36133695,-15.625,-61.27508855,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167500-02,Etretinate,170465372,Retinoic acid receptor alpha Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),54350-48-0,,3.768576213,1,-5.423822698,-98.86780347,-1.2,7,,-73.11924439,-79.92916175,0.005557156,0.967931146,,,Cc1c(C)c(/C=CC(\C)=C\C=C\C(\C)=C\C(=O)OCC)c(C)cc1OC,LKT Lab,E7668,4.56456456,-15.72739187,-5.05494505,0,-12.73712737,-73.95833333,-79.92916175,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00024494-02,D-Alanine,170465038,Alanine aminotransferase 1 Substrate,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),338-69-2,,21.19226141,0,-4.673822698,-3.726263204,-3,7,,-36.39728453,-34.12042503,0.002110186,0.980655511,,,C[C@@H](N)C(=O)O,Tocris,205,4.92492492,4.19397117,0.21978022,0,0.90334237,0,-34.12042503,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00253587-01,Sitaxentan,170465720,Endothelin ETA Receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),184036-34-8,Sitaxentan,7.519298098,1,-5.123822698,-44.91122427,-1.2,7,,-43.54899646,-45.21841795,0.000927275,0.987310025,,EDNRA,O=C(Cc1cc2OCOc2cc1C)c3sccc3S(=O)(=O)Nc4onc(C)c4Cl,GVK,FFS-11-286-NCI-102,0,0,0,-5.75479566,0,-35.89015152,-45.21841795,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00178086-03,Aminolevulinic acid hydrochloride,170464700,DNA Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),5451/9/2,,26.67947643,0,-4.573822698,-26.65008311,-3,7,,-51.97107438,-50.41322314,0.003431526,0.975097926,,,Cl.NCC(=O)CCC(=O)O,Microsource,1504184,-7.80780781,0,0.80586081,0,0,-3.50378788,-50.41322314,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016960-07,Glimepiride,170464966,K(ATP) Channel Blocker,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),93479-97-1, Glimepride; Glimepiride; Amaryl;Glimepiride; ,11.91728437,0,-4.923822698,-25.20500914,-2.2,7,,-45.24557261,-40.96812279,0.000759843,0.988537675,,KCNJ8,CC=3CN(C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C(=O)C=3CC,Sequoia,SRP01525g,0,4.98034076,0,0,0,-20.54924242,-40.96812279,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00159491-04,Rimantadine,170465164,M2 Channel Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1501-84-4,"; Flumadine; Riamantadine;Rimantadine hydrochloride; Rimantadina; ; Hydrochloride, Rimantadin; Flumadine Oral; Roflual;RIMANTADINE HYDROCHLORIDE; Rimantadine hydrochloride; Rimantadine Hcl",37.68576212,0,-4.423822698,-13.01153164,-3,7,,-41.89669421,-37.19008264,8.00E-10,0.999988489,,,Cl.CC(N)C12CC3CC(C1)CC(C2)C3,Vitas,STK177253,0,0,0,0,0,0,-37.19008264,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00164613-08,Epalrestat,405558568,Aldose Reductase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),82159-09-9,,16.8336116,0,-4.773822698,-49.29967681,-2.2,7,,-81.14086082,-72.83398547,2.25972E-05,0.998053463,,AKR1B1,CC(=C/C1=CC=CC=C1)\C=C2/SC(=S)N(CC(O)=O)C2=O,MedChem Express,HY-66009,-0.69957248,0,0,-3.24324324,-1.8401937,-28.1,-72.83398547,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00182081-04,Zotepine,170465934,Histamine H1 receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),26615-21-4,,18.88762287,0,-4.723822698,-29.67252191,-2.2,7,,-64.93264394,-59.41866965,1.86178E-05,0.998233878,3269,HRH1,CN(C)CCOC1=Cc3ccccc3Sc2ccc(Cl)cc12,Prestwick,Prestw-1368,0,0,0,-0.36036036,1.8401937,-14.2,-59.41866965,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00387301-01,Timiperone,405558737,serotonin receptor signaling pathway Modulator,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,15.00297213,0,-4.823822698,-27.93323201,-2.2,7,,-55.88932365,-49.91615428,0.001451417,0.984038127,,,FC1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)N3C(=S)NC4=C3C=CC=C4,Toronto Research,T443110,-2.48736883,-1.4421096,3.84443451,2.43243243,2.42130751,-19,-49.91615428,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00015741-13,"4,4 -(2,3-Dimethyltetramethylene)dipyrocatechol",405558741,5-Lipoxygenase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),500-38-9,,8.436791229,1,-5.073822698,-84.3485579,-2.1,7,,-102.6618781,-90.16210173,2.03067E-05,0.998154882,,ALOX5,CC(CC1=CC(=C(O)C=C1)O)C(C)CC2=CC(=C(O)C=C2)O,Prestwick,Prestw-NAT-0055,0,0,2.45864998,0,-19.56416465,-58.5,-90.16210173,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00388506-02,Pinaverium bromide,405559006,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),53251-94-8,,37.68576212,0,-4.423822698,-13.98737001,-2.4,7,,-31.84935718,-29.45779765,0.032354345,0.916199153,,,COC1=C(OC)C=C(C[N+]2(CCOCCC3CC[C@H]4C[C@@H]3C4(C)C)CCOCC2)C(=C1)Br,Prestwick,Prestw-1601,0,0,0,-8.01801802,1.2590799,1.5,-29.45779765,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00091367-05,Danthron,170465532,DNA topoisomerase II alpha Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),117-10-2,,2.99348649,1,-5.523822698,-102.7249736,-1.2,7,,-68.15289257,-71.90082645,0.002312783,0.979702618,,,Oc3cccc2C(=O)c1cccc(O)c1C(=O)c23,Labotest,LT00455159,0,-12.7129751,0,-2.41868224,-29.53929539,-66.38257576,-71.90082645,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00164605-02,Ampiroxicam,170466020,Cyclooxygenase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),99464-64-9,,2.37781084,1,-5.623822698,-26.83069325,-1.4,7,,-24.11363636,-20.18890201,0.004675906,0.970747111,,,O=C(OCC)OC(C)OC=2c1ccccc1S(=O)(=O)N(C)C=2C(=O)Nc3ccccn3,Sequoia,SRP05637a,0.6006006,0,1.24542125,4.42035029,-9.66576332,-25.09469697,-20.18890201,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00249921-01,Omoconazole,170465847,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),74512-12-2,,10.62129087,0,-4.973822698,-62.01743367,-2.1,7,,-88.44710744,-87.24911452,0.000322237,0.992581776,,,C\C(=C(\OCCOc1ccc(Cl)cc1)c2ccc(Cl)cc2Cl)n3ccnc3,GVK,FFS-11-286-NCI-199,1.2012012,-2.88335518,-3.2967033,3.75312761,2.25835592,-46.49621212,-87.24911452,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00182055-03,Bazedoxifene,170466793,Selective Estrogen Receptor Modulators (SERM),Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),198481-33-3,TSE-424/WAY-140424;Bazedoxifene; Bazedoxifene,4.74435636,1,-5.323822698,-150.7485415,-1.1,7,,-105.7866109,-101.8890201,0.005100486,0.969345935,2099,ESR1,CC(=O)O.Oc1ccc(cc1)c5c(C)c2cc(O)ccc2n5Cc3ccc(cc3)OCCN4CCCCCC4,APAC,872287,-0.72072072,-18.34862385,-13.11355311,-9.92493745,-33.33333333,-89.10984848,-101.8890201,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00090905-12,Busulfan,170465232,DNA Alkylating Agent,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),55-98-1,Busulfan; 4   Busulfan; Busulfex;; ; Busulfan;BUSULFAN; Myleran; Busulfano,37.68576212,0,-4.423822698,-7.760632047,-3,7,,-39.6664699,-34.35655254,0.003753725,0.973915898,,H2AFX,O=S(C)(=O)OCCCCOS(C)(=O)=O,Microsource,1500152,0,3.53866317,-0.80586081,-1.08423686,0,4.45075758,-34.35655254,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00018158-09,Doxazosin mesylate,170465395,alpha1-Adrenoceptor Antagonists,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),77883-43-3,; Doxazosin Mesilate; Doxazosin mesylate salt;Doxazosin mesylate; Doxazosin mesilate; Doxazosin hydrochloride;DOXAZOSIN MESYLATE,26.67947643,0,-4.573822698,-65.72233844,-2.1,7,,-105.7086186,-84.65171192,0.007620349,0.962096151,148,ADRA1A,CS(=O)(=O)O.COc1cc2nc(nc(N)c2cc1OC)N3CCN(CC3)C(=O)C4COc5ccccc5O4,Microsource,1505976,0,-16.77588467,0,-0.41701418,-7.31707317,-27.1780303,-84.65171192,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00183005-01,Zanapezil fumerate,144206802,Acetylcholinesterase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),263248-42-6,CIPLUS_775863; Zanapezil Fumarate; ,26.67947643,0,-4.573822698,-26.92606549,-3,7,CIPLUS_775863;ZANAPEZIL;Zanapezil Fumarate;CIPLUS_3882440;CIPLUS_3882439;zanapezilum;,-67.84651712,-58.20543093,2.5091E-06,0.999352859,,,O=C(O)/C=C/C(=O)O.O=C(CCC2CCN(Cc1ccccc1)CC2)c3ccc4CCCCNc4c3,Pharmaron,PH-NIH-100582,0,0,0,0,-1.53568202,-7.85984848,-58.20543093,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016902-04,Etifenin,170466635,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),63245-28-3,,2.119226141,1,-5.673822698,-107.6954004,-1.2,7,,-57.50568182,-51.35773318,0.042482977,0.901771266,,,O=C(Nc1c(cccc1CC)CC)CN(CC(=O)O)CC(=O)O,"Prestwick Chemical, Inc.",Prestw-504,2.76276276,-18.21756225,-2.71062271,-3.75312761,-35.32068654,-72.06439394,-51.35773318,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00319020-01,NCGC00319020-01,225144374,Prostanoid IP receptor Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,10.62129087,0,-4.973822698,-24.62656811,-2.2,7,,-34.12996088,-31.35830073,4.2759E-06,0.999155543,,,CCCCC[C@@H](O)CC[C@@H]1[C@@H](O)C[C@H]2CC3=C(C[C@@H]12)C=CC=C3OCC(O)=O,GVK,FFS-11-286-NCI-96,0.54411193,0.32962505,0,0,-3.29297821,-17.3,-31.35830073,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00346655-02,Linagliptin,405558934,DPP-IV Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),668270-12-0,,8.436791229,1,-5.073822698,-25.08960504,-2.2,7,,-38.4038569,-36.94801565,0.00025816,0.993372117,,DPP4,CC#CC[N]1C(=NC2=C1C(=O)N(CC3=NC4=CC=CC=C4C(=N3)C)C(=O)N2C)N5CCC[C@@H](N)C5,Selleck,S3031,0,2.59579728,0,3.42342342,1.2590799,-24.7,-36.94801565,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00091325-09,Dichlorophen,170465475,"Indoleamine 2,3-dioxygenase Inhibitor",Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),97-23-4,,18.88762287,0,-4.723822698,-42.50831311,-2.2,7,,-79.27922078,-73.3175915,0.006885834,0.964084753,,,Oc2ccc(Cl)cc2Cc1cc(Cl)ccc1O,Microsource,1500626,0,-11.27129751,0,4.08673895,3.97470641,-20.9280303,-73.3175915,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00159458-05,Atorvastatin calcium,170465113,HMG-CoA Reductase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),134523-03-8,,11.91728437,0,-4.923822698,-68.5305552,-2.2,7,,-54.39874674,-59.62219599,0.004172167,0.9724198,,,[Ca+2].O[C@H](CCn1c(c(c(c1C(C)C)C(=O)Nc2ccccc2)c3ccccc3)c4ccc(F)cc4)C[C@@H](O)CC([O-])=O.[O-]C(=O)C[C@H](O)C[C@H](O)CCn4c(c1ccc(F)cc1)c(c2ccccc2)c(C(=O)Nc3ccccc3)c4C(C)C,Prestwick,Prestw-1232,-8.76876877,-8.38794233,-2.71062271,-10.92577148,-2.07768744,-32.67045455,-59.62219599,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00094516-08,Coumaphos,170466302,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),56-72-4,,16.8336116,0,-4.773822698,-32.34528107,-2.2,7,,-49.74675325,-46.39905549,0.003978676,0.973101117,,,CCOP(=S)(OCC)Oc1ccc2c(c1)OC(=O)C(Cl)=C2C,Microsource,330012,0,1.17955439,-7.10622711,0,0,-17.14015152,-46.39905549,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00142384-03,Cholic Acid,405559065,Bile acid receptor FXR Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),81-25-4,,11.91728437,0,-4.923822698,-65.0823461,-2.4,7,,-50.97520662,-45.21841795,0.077412197,0.85888076,,,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C,SIGMA,C1129,-8.04804805,-14.67889908,0,0,-18.33785005,-26.98863636,-45.21841795,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00090797-12,Digoxin,405558822,Steroid,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),20830-75-5,; ; 12beta-Hydroxydigitoxin; Card-Cosaldon; Lanoxin;Digoxin; Digoxin,6.701581484,1,-5.173822698,-40.90098587,-1.2,7,,-38.01180638,-38.6068477,0.000243286,0.99356789,,RORC,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]2[C@@H](O)C[C@@H](O[C@@H]2C)O[C@H]3[C@@H](O)C[C@@H](O[C@@H]3C)O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]7(C)[C@H](CC[C@]67O)C/8=C/C(=O)OC8)C4,Prestwick,Prestw-437,-3.6036036,0.1310616,0,0,-4.24570912,-30.39772727,-38.6068477,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00253597-01,Isosulfan blue,170464639,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),68238-36-8,,6.701581484,1,-5.173822698,-88.76770622,-2.1,7,,-93.50578513,-90.08264463,1.34144E-05,0.998501203,,,[Na+].CC/[N+](CC)=C1\C=C/C(C=C1)=C(/c2ccc(cc2)N(CC)CC)c3cc(ccc3S([O-])(=O)=O)S([O-])(=O)=O,GVK,FFS-11-286-NCI-038,0,-2.09698558,-1.0989011,1.41784821,-14.00180668,-66.19318182,-90.08264463,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00263198-04,Lenvatinib,405559112,VEGFR-1/2/3 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),417716-92-8,,10.62129087,0,-4.973822698,-44.09051138,-2.2,7,,-49.4491336,-38.84851873,0.008279977,0.960406489,,FLT1,COC1=C(C=C2C(=CC=NC2=C1)OC3=CC(=C(NC(=O)NC4CC4)C=C3)Cl)C(N)=O,APExBIO,A2174,0,0,0,-8.64864865,-15.20581114,-19.8,-38.84851873,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00094852-04,L-Thyroxine,405558662,synthetic hormone,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),51-48-9,,7.32725503,1,-5.135058692,-76.4036305,-2.1,7,,-100.0230855,-90.72107323,0.000190844,0.994307357,,THRA,NC(CC1=CC(=C(OC2=CC(=C(O)C(=C2)I)I)C(=C1)I)I)C(O)=O,APExBIO,B2107,0,0,0,3.06306306,3.87409201,-39.3,-90.72107323,,,,,,,,,1.83E-09,9.14E-09,4.57E-08,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,
NCGC00018185-23,Tranilast,405558891,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),53902-12-8,,23.7781084,0,-4.623822698,3.040781558,-2.4,7,,-26.16601453,-22.63834544,0.004590819,0.971044127,,TNF,COC1=CC=C(\C=C\C(=O)NC2=CC=CC=C2C(O)=O)C=C1OC,Enzo,CT110,4.27516518,2.96662546,0,4.77477477,1.3559322,1,-22.63834544,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00408859-01,Cetilistat,405559027,Pancreatic lipase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),282526-98-1,,26.67947643,0,-4.573822698,-14.13189794,-3,7,,-38.58133035,-33.81777529,9.99E-08,0.999871047,,,CCCCCCCCCCCCCCCCOC/1=N/C2=C(C=C(C)C=C2)C(=O)O1,Glixx,GLXC-06700,0.3109211,0,0,0,0,-3.7,-33.81777529,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00248225-03,9(Z)-Hexadecenoic acid,405558987,Gap junction Modulator,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),373-49-9,,29.9348649,0,-4.523822698,-55.05538683,-2.2,7,,-83.00027948,-67.80324203,0.005200981,0.969036022,,,CCCCCC\C=C/CCCCCCCC(O)=O,Enzo,BL103,0,-9.51792336,-4.60438087,-4.41441441,-11.91283293,-14.4,-67.80324203,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00181765-03,Pranlukast hydrate,384568399,Leukotriene CysLT1/2 (LTD4) Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),103177-37-3,,3.358747085,1,-5.473822698,-61.3154262,-1.2,7,,-63.81553941,-62.9960872,7.08062E-05,0.996545571,,CYSLTR1,O=C(NC1=CC=C2C(=O)\C=C(/OC2=C1)C3=NN=N[NH]3)C4=CC=C(OCCCCC5=CC=CC=C5)C=C4,Selleck,S1829,4.04197435,0,1.74340635,4.05405405,-8.52300242,-58.8,-62.9960872,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00390804-01,Goserelin (acetate),405558960,LNCaP Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),145781-92-6,,11.61291662,0,-4.935058692,-40.19580097,-3,7,,-31.83733929,-32.36444941,0.139835031,0.792094719,,,CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC2=C[NH]C3=C2C=CC=C3)NC(=O)[C@H](CC4=CN=C[NH]4)NC(=O)[C@@H]5CCC(=O)N5)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N6CCC[C@H]6C(=O)NNC(N)=O,MedChem Express,HY-13673A,-0.77730276,-9.27070457,2.72686634,-12.88288288,-0.8716707,-9.1,-32.36444941,,,,,,,,,1.83E-09,9.14E-09,4.57E-08,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,
NCGC00167419-03,ENZACAMENE,405559131,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),36861-47-9,,21.19226141,0,-4.673822698,-31.02812297,-2.2,7,,-73.9935065,-65.52538371,1.28141E-05,0.998535435,,,CC1=CC=C(C=C1)\C=C/2C3CCC(C)(C2=O)C3(C)C,SIGMA,78551,2.64264264,0,0,0,0,-15.05681818,-65.52538371,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00015870-27,Quercetin,170466817,Flavone,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),6151-25-3, Quercetine; quercetin-ATS; quercetin 3-O-glucuronide; quercetin RGRGal; ;quercetin 3-3AcAra-Gal;Quercetin dihydrate;Quercetine; quercetin HMGGlc; QME-Ara-Glc; amurenoside B; amurenoside A; Q-RR cpd; quercetin 3-O-fGalp; Q3MG cpd; Q-3-AP cpd; Q-tC-L-A-D-G;Sophoretin; Quercetin hydrate; Q-M-beta-D-G; flavonol 3-OMT; quercetin digal-Gal; quercetin 3-XR; Quercetine dihydrate;Meletin;Quercetin (Sophoretin); quercetin 3-RhaGlcGal,11.91728437,0,-4.923822698,-72.41653076,-2.1,7,,-92.50354191,-81.58205431,1.50288E-05,0.998413426,,CYP75A12,O.O.Oc1ccc(cc1O)C=3Oc2cc(O)cc(O)c2C(=O)C=3O,Vitas,STK365650,0,0,0,-2.91909925,-14.72448058,-45.17045455,-81.58205431,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00166312-02,Closantel,170466628,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),57808-65-8,,9.466235454,1,-5.023822698,-78.92542742,-2.1,7,,-98.04793389,-96.69421488,7.0365E-06,0.998915215,,,Clc3cc(NC(=O)c1cc(I)cc(I)c1O)c(C)cc3C(C#N)c2ccc(Cl)cc2,Vitas,STK378904,0,0,-1.83150183,0,0.9936766,-63.73106061,-96.69421488,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00348365-01,INDOCYANINE GREEN,405558700,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),3599-32-4,,1.888762287,1,-5.723822698,-154.4459512,-1.1,7,,-104.5451004,-100.2361275,5.60476E-05,0.996928226,,,CC1(C)C(=C\C=C\C=C\C=C\C2=[N+](/CCCC[S]([O-])(=O)=O)C3=CC=C4C=CC=CC4=C3C2(C)C)/N(CCCC[S]([O-])(=O)=O)C5=CC=C6C=CC=CC6=C15,SIGMA,I2633,0,0.91743119,0,-15.26271893,-56.45889792,-100.094697,-100.2361275,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00015802-18,Pimozide,170464864,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),2062-78-4,,29.9348649,0,-4.523822698,-26.20896173,-3,7,,-70.89669421,-60.33057851,0.001070649,0.98634103,,,Fc1ccc(cc1)C(CCCN2CCC(CC2)N3c4ccccc4NC3=O)c5ccc(F)cc5,NCGCChem,NCGC00015802-17pur,0,3.80078637,0,0,-5.32971996,-5.77651515,-60.33057851,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00095056-04,Retinyl palmitate,225144218,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),79-81-2,,29.9348649,0,-4.523822698,-18.26125515,-3,7,,-39.81109799,-33.17591499,0.000494452,0.990792806,,,CCCCCCCCCCCCCCCC(=O)OC\C=C(C)\C=C\C=C(C)\C=C\C1=C(C)\CCCC1(C)C,SIGMA,R1512,0,0.2621232,-1.97802198,0,-2.98102981,-4.82954545,-33.17591499,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00249912-01,Floctafenine,170465681,Prostaglandin G/H synthase 2 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),23779-99-9,,10.62129087,0,-4.973822698,-12.56910401,-2.4,7,,-22.36009445,-21.13341204,0.00671398,0.964627408,5743,PTGS2,OCC(O)COC(=O)c3ccccc3Nc1ccnc2c(cccc12)C(F)(F)F,GVK,FFS-11-286-NCI-159,0,0,0,0,4.4263776,-11.83712121,-21.13341204,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00015466-11,Gabapentin,170464715,Calcium Channels (Voltage-Gated) alpha2/delta-1 Subunit Ligands,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),60142-96-3, Go 3450;; Gabapentin hydrochloride;Gabapentin hydrochloride; ; Neurontin;Gabapentin; Gabapentino; Gabapentin; gabapentin ISTD,29.9348649,0,-4.523822698,-39.01661653,-3,7,,-54.19598583,-51.82998819,0.025391657,0.926912934,,CACNA2D1,NCC1(CC(=O)O)CCCCC1,Vitas,STK598009,-12.37237237,3.53866317,-3.44322344,-7.08924103,0,-6.72348485,-51.82998819,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00183277-01,Micronomicin sulfate,144206497,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),66803-19-8,,23.7781084,0,-4.623822698,-47.10443828,-2.2,7,"D-Streptamine, O-2-amino-6-(methylamino)-2,3,4,6-tetradeoxy-alpha-D-erythro-hexopyranosyl-(1-4)-O-(3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6))-2-deoxy-;micronomicine;Santemycin;micronomicin;XK-62-2;KW-1062;Micronomicin Sulfate;gentamicin C2b;D-Streptamine, O-2-amino-2,3,4,6-tetradeoxy-6-(methylamino)-alpha-D-erythro-hexopyranosyl-(1-4)-O-(3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6))-2-deoxy;LS-146966;CIPLUS_684924;Micronomicine;MICRONOMICIN;Micronomicina;MICRONOMICIN SULFATE;Micronomicin sulfate;6'-N-methylgentamicin C;Micronomicin;DE 020;Micronomicinum;sagamicin;DE-020;micronomicinum;KW 1062;CIPLUS_749329;Sagamicin;",-54.15846842,-44.43823365,0.014405839,0.946617099,,,O=S(=O)(O)O.N[C@@H]3CC[C@@H](CNC)O[C@@H]3O[C@H]2[C@H](O)[C@@H](O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O)[C@H](N)C[C@@H]2N,ACC,Micronomycin sulfate,-10.18266615,0.53564071,0,-6.12612613,-6.97336562,-19.3,-44.43823365,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00386213-04,Rupatadine (Fumarate),405558713,Platelet activating factor receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),182349-12-8,,11.91728437,0,-4.923822698,-69.19938022,-2.2,7,,-74.66852991,-63.89044159,0.010946279,0.95398696,,,CC1=CN=CC(=C1)CN2CCC(CC2)=C3C4=CC=C(Cl)C=C4CCC5=CC=CN=C35,MedChem Express,HY-13511A,-7.69529732,-0.20601566,0.53643272,0,-23.24455206,-34.1,-63.89044159,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167449-02,Desogestrel,225144285,Progesterone receptor Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),54024-22-5,,29.9348649,0,-4.523822698,-18.30332422,-3,7,,-59.42370039,-56.51201789,9.8941E-06,0.998713568,,,CC[C@]12CC(=C)[C@H]3[C@@H](CCC/4=C/CCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C,SIGMA,32809,0,2.1013597,0,0,0,0,-56.51201789,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00188865-03,Pazopanib,170465625,VEGFR-1/2/3 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),444731-52-6,Pazopanib; Pazopanib;GSK-786034/Votrient/Armala,4.74435636,1,-5.323822698,-30.76533793,-2.2,7,,-38.00810509,-32.92342091,0.000439773,0.991320889,10715,FLT1,NS(=O)(=O)c1cc(ccc1C)Nc2nccc(n2)N(C)c3ccc4c(C)n(C)nc4c3,Sequoia,SRP010772p,0,3.6670787,3.88913724,0,-8.71670702,-26.4,-32.92342091,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00261966-01,NCGC00261966-01,405558496,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,Selamectin,7.519298098,1,-5.123822698,-90.53612388,-2.1,7,,-100.5394075,-95.75181666,1.98307E-05,0.998176679,,,CO[C@H]1C[C@H](O[C@@H](C)[C@H]1O)O[C@H]\2[C@@H](C)\C=C\C=C\3CO[C@@H]4C\C(=C/[C@@H](C(=O)O[C@H]5C[C@@H](C/C=C2C)O[C@@]6(CC[C@H](C)[C@H](O6)C7CCCCC7)C5)[C@]34O)C,GVK,FFS-11-286-NCI-104,0,-2.34857849,0,0.63063063,-17.04600484,-62.9,-95.75181666,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00187912-17,Ibrutinib (PCI-32765),,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),936563-96-1,,29.9348649,0,-4.523822698,-27.43483038,-3,7,,-55.02124092,-48.3510341,0.00133713,0.984697572,695,BTK,NC1=C2C(=NC=N1)[N](N=C2C3=CC=C(OC4=CC=CC=C4)C=C3)[C@@H]5CCCN(C5)C(=O)C=C,APExBIO,A3001,0,0,0,-5.94594595,-2.90556901,-6.2,-48.3510341,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167443-02,Afloqualone,405558862,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),56287-74-2,,16.8336116,0,-4.773822698,-36.86297411,-2.2,7,,-70.39267747,-63.55505869,0.003143195,0.976205177,,,CC1=CC=CC=C1N2C(=O)C3=C(C=CC(N)=C3)N=C2CF,DC Chemicals,DC9026,-6.29615235,0,3.71032633,0.72072072,4.55205811,-21.7,-63.55505869,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00262959-01,Difethialone,170465892,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),104653-34-1,"2H-1-benzothiopyran-2-one,",10.62129087,0,-4.973822698,-74.46952889,-2.1,7,,-104.4268005,-101.8890201,2.6118E-06,0.999339564,,,Brc1ccc(cc1)c2ccc(cc2)C4Cc3ccccc3C(C4)C5=C(O)c6ccccc6SC5=O,GVK,FFS-11-286-NCI-261,0,0,0,0,0,-55.58712121,-101.8890201,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167496-03,Methylene blue,170465461,antimalarial agents,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),61-73-4,"; Ehrlich's reagent III; Urolene Blue; Yamamoto Methylene Blue B; Methylene Blue Hydrate; Azure II eosinate; Blue, Swis; Taylor's Blue; Cloruro de metiltioninio; Blue, Methylen; ; Methylene blue trihydrate; N, Methylene Blu; Methylene blue; Methylene blue hydrate; Methylene Blue hydrate; Basic Blue 9; Chromosmon;Methylene blue; Methylene Blue solution; Blue N, Methylen; Azure II; Methylene Blue N;Methylene Blue",7.519298098,1,-5.123822698,-100.0420029,-2.1,7,,-103.2395193,-86.92006708,0.002593712,0.978461101,,MAOA,[Cl-].CN(C)c1ccc2nc3ccc(cc3[s+]c2c1)N(C)C,Labotest,LT00032971,-6.29615235,0,2.72686634,-3.6036036,-34.28571429,-56.3,-86.92006708,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00013556-15,Liothyronine Sodium,405559084,Thyroid hormone receptor beta-1 Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1955/6/1,,13.37141299,0,-4.873822698,-65.65147086,-2.1,7,,-103.7580212,-95.08105087,7.7235E-06,0.998863418,,,N[C@@H](CC1=CC(=C(OC2=CC(=C(O)C=C2)I)C(=C1)I)I)C(O)=O,APExBIO,B1779,-1.47687524,1.68932839,0,0,-2.13075061,-44,-95.08105087,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00021125-03,Diclofenac sodium,170464642,Cyclooxygenase-1/2/3 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),15307-79-6,,7.519298098,1,-5.123822698,-33.20009856,-1.2,7,,-39.24262102,-38.37072019,0.001029239,0.986616716,,PTGS1,[Na+].Clc2cccc(Cl)c2Nc1ccccc1CC([O-])=O,Vitas,STK984493,4.32432432,0.1310616,-2.56410256,0,0,-31.53409091,-38.37072019,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00021925-03,Prednisolone acetate,170464632,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),52-21-1,; Pred forte;PREDNISOLONE ACETATE;Prednisolone acetate (Omnipred); Supercortyl;Prednisolone acetate,15.00297213,0,-4.823822698,-11.53880903,-2.4,7,,-24.57674144,-20.89728453,0.001151639,0.985850966,,NRC31,CC(=O)OCC(=O)[C@@]4(O)CC[C@@H]3[C@]4(C)C[C@H](O)[C@H]2[C@H]3CCC1=CC(=O)C=C[C@@]12C,Bosche,P0845,0,2.75229358,0,0,0,-8.80681818,-20.89728453,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00253573-01,Tepoxalin,170466265,platelet aggregation Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),103475-41-8,,11.91728437,0,-4.923822698,-47.9438369,-2.2,7,,-82.8051948,-79.22077922,0.000013629,0.998489302,,,CN(O)C(=O)CCc2cc(c1ccc(Cl)cc1)n(n2)c3ccc(OC)cc3,GVK,FFS-11-286-NCI-124,2.52252252,1.44167759,3.73626374,0,0.72267389,-38.16287879,-79.22077922,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00091268-12,Oxytetracycline,225144208,Tetracycline Antibiotic,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),79-57-2,; ; Oxytetracycline hydrochloride; Terramycin hydrochloride; Oxitetraciclina;Oxytetracycline hydrochloride;OXYTETRACYCLINE; Oxytetracycline Base;Oxytetracycline; Riomitsin;Oxytetracycline dihydrate; Oxytetracycline HCl; Oxytetracycline base; Oxytetracycline dihydrate; oxycort A; Terramycin,10.62129087,0,-4.973822698,-83.71980381,-2.1,7,,-109.7041322,-93.38842975,8.56921E-05,0.996197329,,,CN(C)[C@H]\1[C@@H]2[C@@H](O)[C@H]3\C(=C(O)/[C@]2(O)C(=O)\C(=C1O)C(N)=O)C(=O)C4=C(C=CC=C4O)[C@@]3(C)O,Prestwick,Prestw-307,0,0,0,1.91826522,-19.42186089,-55.58712121,-93.38842975,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016296-07,Dicumarol,170465275,Vitamin k epoxide reductase complex subunit 1 isoform 1 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),66-76-2,,7.519298098,1,-5.123822698,-21.02920593,-1.4,7,,-27.31050768,-26.09208973,0.000977109,0.986974881,,,OC=3c4ccccc4OC(=O)C=3CC1=C(O)c2ccccc2OC1=O,Vitas,STK801287,3.84384384,0,0,0,0,-22.06439394,-26.09208973,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00378622-03,Osimertinib mesylate,405558589,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1421373-65-0,,4.74435636,1,-5.323822698,-103.4728596,-2.1,7,,-105.1193963,-93.51593069,8.41182E-05,0.996232577,,EGFR,COC1=C(NC2=NC=CC(=N2)C3=C[N](C)C4=C3C=CC=C4)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C,Axon Medchem,2342,3.96424407,0,-1.11756817,-1.62162162,-32.44552058,-71.3,-93.51593069,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00346501-07,Bleomycin sulfate,405558521,glycopeptide antibiotic,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),9041-93-4,,1.062129087,1,-5.973822698,-46.66482795,-1.4,7,,-25.05326876,-22.07937395,0.021615254,0.933245618,,,C[C@@H](O)[C@@H](NC(=O)[C@H](C)[C@@H](O)[C@H](C)NC(=O)[C@@H](NC(=O)C1=C(C)C(=NC(=N1)[C@H](CC(N)=O)NC[C@@H](N)C(N)=O)N)C(O[C@H]2O[C@H](CO)[C@H](O)[C@@H](O)[C@H]2O[C@H]3O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]3O)C4=C[NH]C=N4)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C,Selleck,S1214,2.02098717,-6.46889164,0,2.25225225,-28.37772397,-25.8,-22.07937395,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00522017-01,rac Alminoprofen,405558807,Cyclooxygenase-2 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),39718-89-3,,23.7781084,0,-4.623822698,-11.97323394,-3,7,,-34.1665735,-31.80547792,0.004394698,0.971680027,,,CC(C(O)=O)C1=CC=C(NCC(C)=C)C=C1,Toronto Research,A575150,-2.87602021,3.83189122,0,-0.63063063,1.6464891,-2.3,-31.80547792,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00510931-01,Mavacoxib,405558811,Cyclooxygenase-2 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),170569-88-7,,23.7781084,0,-4.623822698,-11.62444386,-2.2,7,,-48.6724427,-34.60033538,0.002280725,0.979862036,,,N[S+]([O-])(=O)C1=CC=C(C=C1)[N]2N=C(C=C2C3=CC=C(F)C=C3)C(F)(F)F,SantaCruz Bio,sc-488033,0,3.04903173,4.60438087,4.86486486,-1.8401937,-10,-34.60033538,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00384190-03,(S)-Crizotinib,405558812,HGFR (MET; c-Met) Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1374356-45-2,,11.91728437,0,-4.923822698,-93.24134741,-2.1,7,,-114.6704863,-95.97540525,4.34782E-05,0.99729629,,MET,C[C@H](OC1=CC(=CN=C1N)C2=C[N](N=C2)C3CCNCC3)C4=C(Cl)C=CC(=C4Cl)F,Axon Medchem,2296,0.93276331,-2.1013597,-1.02816272,-7.11711712,-21.98547215,-54.4,-95.97540525,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00370833-02,NS-304,405558607,platelet aggregation Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),475086-01-2,,16.8336116,0,-4.773822698,-46.13967451,-2.2,7,,-75.00894355,-69.70374511,0.014223115,0.946963971,,,CC(C)N(CCCCOCC(=O)N[S+](C)([O-])=O)C1=NC(=C(N=C1)C2=CC=CC=C2)C3=CC=CC=C3,MedChem Express,HY-14870,-0.3109211,-13.63823651,0,4.5045045,3.29297821,-24.9,-69.70374511,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00482960-01,Xanthophyll,405558848,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),127-40-2,,37.68576212,0,-4.423822698,-7.191505691,-2.4,7,,-25.53186138,-22.52655115,0.03447154,0.913161619,,,CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(\C)CC(O)CC1(C)C)\C=C\C=C(C)\C=C\C2\C(=C/C(O)CC2(C)C)C,DC Chemicals,DCY-149,4.11970462,-0.53564071,0.58113545,0,-4.84261501,0.4,-22.52655115,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00160530-13,Toremifene citrate,405558853,Selective Estrogen Receptor Modulators (SERM),Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),89778-27-8,,11.91728437,0,-4.923822698,-96.10933027,-2.1,7,,-106.9628284,-90.38569033,0.005117077,0.96929512,,ESR1,CN(C)CCOC1=CC=C(C=C1)/C(=C(/CCCl)C2=CC=CC=C2)C3=CC=CC=C3,MedChem Express,HY-B0005,-4.89700738,0,1.38578453,-13.24324324,-29.15254237,-44.9,-90.38569033,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016912-06,Terconazole,405558493,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),67915-31-5,,21.19226141,0,-4.673822698,-39.7967568,-2.2,7,,-73.67747345,-55.05869201,0.008156857,0.960704848,,,CC(C)N1CCN(CC1)C2=CC=C(OC[C@@H]3CO[C@](CN4C=NC=N4)(O3)C5=C(Cl)C=C(Cl)C=C5)C=C2,Prestwick,Prestw-495,0,3.62587557,1.20697363,0,-14.33414044,-19.9,-55.05869201,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00161605-02,L-Ascorbyl 6-palmitate,405558500,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),137-66-6,,9.466235454,1,-5.023822698,-57.23156482,-2.2,7,,-66.69200671,-65.45556177,0.001202997,0.985500225,,,CCCCCCCCCCCCCCCC(=O)OCC(O)C\1OC(=O)\C(=C1O)O,APExBIO,B2105,-0.62184221,-6.88092295,1.20697363,3.24324324,-5.71428571,-40.2,-65.45556177,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00179392-03,Beclomethasone,170464981,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),4419-39-0,,23.7781084,0,-4.623822698,-36.25627687,-2.2,7,,-67.3016529,-61.74734357,0.002204834,0.980201022,,,OCC(=O)[C@@]4(O)[C@@H](C)C[C@@H]3[C@]4(C)C[C@H](O)[C@@]2(Cl)[C@H]3CCC1=CC(=O)C=C[C@@]12C,"Prestwick Chemical, Inc.",Prestw-855,0,0,-8.57142857,0,0,-12.40530303,-61.74734357,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00183856-01,Phenyl 11-iodo-10-undecynoate,144206805,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),2020-25-9,,37.68576212,0,-4.423822698,-18.87704748,-3,7,"Phenyliodoundecynoate;PHENYLIODOUNDECYNOATE;CIPLUS_3885239;CIPLUS_3845000;10-UNDECYNOIC ACID, 11-IODO-, PHENYL ESTER;11-IODOUNDECYNOIC ACID PHENYL ESTER;002020259;",-61.00885478,-53.95513577,2.30E-09,0.999980382,,,O=C(Oc1ccccc1)CCCCCCCCC#CI,Pharmaron,PH-NIH-102558,0,0,0,0,0,0,-53.95513577,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00164620-02,Nadifloxacin,170465882,DNA gyrase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),124858-35-1,,37.68576212,0,-4.423822698,-21.05964075,-3,7,,-39.3583235,-36.71782763,0.009541906,0.957289557,,,O=C(O)C3=CN2C(C)CCc1c(c(F)cc(c12)C3=O)N4CCC(O)CC4,Sequoia,SRP00810n,0.36036036,-7.86369594,0,-1.25104254,-2.25835592,-0.85227273,-36.71782763,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00091208-09,4-Hexylresorcinol,170465471,Tyrosinase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),136-77-6,,10.62129087,0,-4.973822698,-24.64463469,-2.2,7,,-41.96044864,-39.31523022,0.000680686,0.989162467,,,Oc1cc(O)ccc1CCCCCC,Microsource,1500330,0,3.66972477,0,0,2.80036134,-22.06439394,-39.31523022,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00508820-02,Dalfopristin,405559042,Bacterial 70S ribosome Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),112362-50-2,,16.8336116,0,-4.773822698,-74.96686475,-2.1,7,,-98.6804919,-93.51593069,0.00822108,0.960530643,,,CCN(CC)CC[S+]([O-])(=O)[C@@H]1CCN2[C@H]1C(=O)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(=C\[C@@H](O)CC(=O)CC3=NC(=CO3)C2=O)C,MedChem Express,HY-A0241_cm1,-0.93276331,1.77173465,-18.90925346,-2.61261261,-2.71186441,-36.8,-93.51593069,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00181099-01,Siccanin,144206268,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),22733-60-4,Siccanin; Ladar; Sicanina; Piadar; ,23.7781084,0,-4.623822698,-11.4532441,-3,7,"Siccaninum;LS-173961;siccanine;Siccanine;Siccanin;Ladar;SICCANIN;CIPLUS_214175;Sicanina;Benzoic acid, 2-hydroxy-, 2-hydroxyethyl ester, mixt. with (4aS-(4aalpha,6aalpha,11balpha,13aR*,13balpha))-1,2,3,4,4a,5,6,6a,11b,13b-decahydro-4,4,6a,9-tetramethyl-13H-benzo(a)furo(2,3,4-mn)xanthen-11-ol;CIPLUS_769555;siccaninum;Piadar;siccanin;",-58.6098379,-46.67411962,0.000192781,0.994280286,,,Cc1cc2O[C@@]4(C)CC[C@H]5C(C)(C)CCCC53CO[C@@H](c2c(O)c1)[C@H]34,NCI,NSC-135048,4.508356,3.58467244,2.9950827,0,2.90556901,-8.4,-46.67411962,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167490-03,Lumefantrine,170465388,antimalarial agents,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),82186-77-4,";benflumetol, (+-)-isomer;Lumefantrine; Lumefantrine",5.972790784,1,-5.223822698,-101.0462743,-2.1,7,,-101.1036892,-85.1313583,0.000010335,0.998684865,,,CCCCN(CCCC)CC(O)c4cc(Cl)cc3c4c1ccc(Cl)cc1\C3=C\c2ccc(Cl)cc2,SIGMA,L5420,-0.85503304,1.4421096,0,-9.54954955,-30.99273608,-61.8,-85.1313583,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00386387-01,Buclizine HCl,405558507,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),129-74-8,,21.19226141,0,-4.673822698,-12.0968866,-3,7,,-39.52487423,-34.48854108,0.001033337,0.986594606,,,CC(C)(C)C1=CC=C(CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(Cl)C=C4)C=C1,Selleck,S4140,0,2.18376597,0,0,3.97094431,-6.2,-34.48854108,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00160673-01,Propicillin,144205529,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),551-27-9,Propicillin; Levopropylcillin; Propicilina; ,31.6227766,0,-4.5,-13.31253006,-2.4,7,Propicillinum;CIPLUS_782900;Propicillin;levopropicillinum;levopropicilline;LS-175596;CIPLUS_750386;Propicilina;CIPLUS_206990;PROPICILLIN POTASSIUM;Propicillin potassium;LS-175076;CIPLUS_669806;Levopropylcillin Potassium;propicilline;Propicilline;brocillin;propicillin;propicillinum;Propicillin Potassium;alpha-phenoxy propylpenicillin;LS-174659;Levopropylcillin potassium;Levopropylcillin;PROPICILLIN;,-27.22722191,-26.43935159,0.020182914,0.935788785,,,OC(=O)[C@@H]2N3C(=O)[C@@H](NC(=O)C(CC)Oc1ccccc1)[C@H]3SC2(C)C,Vitas,STK177353,-4.27516518,4.65595385,0,0.9009009,0,-4,-26.43935159,,,,,,,,,7.31E-09,3.66E-08,1.83E-07,9.14E-07,0.00000457,2.29E-05,0.000114,,,,,,,,
NCGC00183007-01,Risarestat,144206824,Aldose reductase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),79714-31-1,CT-112; Risrestat; ,29.9348649,0,-4.523822698,-22.40814526,-2.4,7,"LS-151322;CT-112;Risarestat;risarestatum;5-(3-ethoxy-4-pentyloxyphenyl)-2,4-thiazolidinedione;RISARESTAT;5-(3-ETHOXY-4-PENTYLOXYPHENYL)-2,4-THIAZOLIDINEDIONE;Risrestat;CIPLUS_709552;2,4-Thiazolidinedione, 5-(3-ethoxy-4-(pentyloxy)phenyl)-;CT 112;",-37.17859139,-28.89882616,0.038109812,0.907918684,,,CCCCCOc1ccc(cc1OCC)C2SC(=O)NC2=O,Pharmaron,PH-NIH-149775,0,-0.61804697,0,0,-9.58837772,-7.4,-28.89882616,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00018102-12,Flunarizine,170466037,Calcium Channel Blocker,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),52468-60-7,"Sibelium; ; Flu Narizine;Flunarizine dihydrochloride; Hydrochloride, Flunarizin;Flunarizine; Flunarizin; Flunarizina; Flunarizine",9.466235454,1,-5.023822698,-47.74183378,-2.2,7,,-60.40200708,-60.094451,1.8303E-06,0.999447322,,,Fc1ccc(cc1)C(c2ccc(F)cc2)N3CCN(CC3)C/C=C/c4ccccc4,Enzo,CA225,0,0,-0.65934066,0,0,-37.59469697,-60.094451,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00090730-03,D-Camphor,170465497,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),464-49-3,,37.68576212,0,-4.423822698,-12.23374773,-2.4,7,,-25.76033058,-23.96694215,0.01502415,0.945452386,,,CC2(C)[C@H]1CC(=O)[C@]2(C)CC1,Vitas,STK803534,-2.4024024,-4.45609436,0,2.08507089,0,0,-23.96694215,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00164568-04,Montelukast sodium,170465230,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),151767-02-1,,8.436791229,1,-5.073822698,-83.67805142,-2.1,7,,-103.5971665,-101.1806375,2.09342E-05,0.998126437,,,[Na+].CC(C)(O)c5ccccc5CC[C@@H](SCC1(CC([O-])=O)CC1)c2cccc(c2)/C=C/c3ccc4ccc(Cl)cc4n3,Sequoia,SRP06641m,4.2042042,-1.57273919,0,0,-1.17434508,-71.875,-101.1806375,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00179578-03,Mometasone furoate,170464666,Corticosteroid,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),83919-23-7,; 2-Furoate;Mometasone furoate; Nasonex; Mometasone Fuorate; Elocon; Sch 32088,15.00297213,0,-4.823822698,-53.72658559,-2.1,7,,-97.46458088,-84.17945691,1.56349E-05,0.998381638,,CYP3A4,ClCC(=O)[C@@]5(OC(=O)c1ccco1)[C@H](C)C[C@@H]3[C@]5(C)C[C@H](O)[C@]2(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]23,"Prestwick Chemical, Inc.",Prestw-572,0,2.88335518,3.66300366,0,-3.52303523,-37.78409091,-84.17945691,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00018163-10,Bithionol,170465515,Adenylate cyclase type 10 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),97-18-7,,10.62129087,0,-4.973822698,-67.96172864,-2.1,7,,-101.2884298,-96.69421488,1.60774E-05,0.998358755,,,Oc2c(Sc1cc(Cl)cc(Cl)c1O)cc(Cl)cc2Cl,Specs,AN-153/J117612,0,3.93184797,1.17216117,1.41784821,0,-55.39772727,-96.69421488,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00015163-09,Benserazide,170465804,DOPA decarboxylase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),14919-77-8,; ; Benserazida; Benserazide Hcl; Ro 8-0576-12; Ro 8-0576-7;Benserazide hydrochloride; Benserazide hydrochloride; Ro 8-0576;BENSERAZIDE HYDROCHLORIDE; Benseraszide; Ro 4460; Ro 4 460,23.7781084,0,-4.623822698,-38.70359337,-2.2,7,,-69.28571429,-53.24675325,0.001942843,0.981454234,1644,DDC,Cl.Oc1ccc(CNNC(=O)C(N)CO)c(O)c1O,Microsource,1500137,0,-4.45609436,0.51282051,2.66889074,-7.67841012,-19.79166667,-53.24675325,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00015096-17,Amiodarone hydrochloride,170464920,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1951-25-3,; Ancaron; Kordaron; Amiodarone;Amiodarone; Amiodarona;Amiodarone hydrochloride;Amiodarone?HCl,11.91728437,0,-4.923822698,-57.5326078,-2.2,7,,-70.85714286,-71.42857143,0.000701355,0.98899177,,CHRM3,CCN(CC)CCOc1c(I)cc(cc1I)C(=O)c2c3ccccc3oc2CCCC,Microsource,2300165,1.92192192,-3.53866317,-1.68498168,-6.08840701,0,-37.78409091,-71.42857143,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00185770-01,"Sucrose octasulfate, sodium salt",144207173,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),74135-10-7,,37.68576212,0,-4.423822698,-25.30316335,-3,7,,-36.74321133,-35.30106257,0.038869454,0.906811479,,,[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]S(=O)O[C@H]1[C@H](O[C@H](COS([O-])=O)[C@@H](OS([O-])=O)[C@@H]1OS([O-])=O)O[C@]2(COS([O-])=O)O[C@H](COS([O-])=O)[C@@H](OS([O-])=O)[C@@H]2OS([O-])=O,Toronto Research,S699020,-6.96696697,0,0,-9.42452043,0,0,-35.30106257,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00246968-04,Olmesartan,405558442,Angiotensin AT1 Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),144689-24-7,,29.9348649,0,-4.523822698,-18.38084347,-2.4,7,,-39.1176635,-29.68138625,0.019811312,0.93643126,,AGT,CCCC1=NC(=C([N]1CC2=CC=C(C=C2)C3=CC=CC=C3C4=N[NH]N=N4)C(O)=O)C(C)(C)O,Microsource,1505206,-3.49786242,0,0,4.77477477,-4.35835351,-7.3,-29.68138625,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00241103-06,Masitinib,405558715,FGFR 3 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1048007-93-7,,10.62129087,0,-4.973822698,-51.44041782,-2.2,7,,-75.81414198,-68.80939072,0.000100865,0.995872585,,FGFR3,CN1CCN(CC1)CC2=CC=C(C=C2)C(=O)NC3=CC=C(C)C(=C3)NC4=NC(=CS4)C5=CC=CN=C5,Axon Medchem,1419,1.47687524,0,-0.22351363,3.15315315,-7.74818402,-36.3,-68.80939072,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00178854-03,Minocycline hydrochloride,170465049,Tetracycline Antibiotic,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),13614-98-7,,9.466235454,1,-5.023822698,-39.45423055,-2.2,7,,-55.73896032,-54.38792622,0.000109269,0.995703302,,PARP1,Cl.CN(C)c2ccc(O)c1C(=O)C3=C(O)[C@]4(O)C(=O)C(=C(O)[C@@H](N(C)C)[C@@H]4C[C@@H]3Cc12)C(N)=O,Microsource,1500414,0,-0.45323445,0,1.89189189,2.71186441,-33.4,-54.38792622,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00249414-01,Fonazine,144206752,Serotonin (5-HT) receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),7456-24-8,,31.6227766,0,-4.5,-78.81022355,-2.1,7,,-113.9636668,-85.57853549,0.00062559,0.989613385,3269,,CN(C)S(=O)(=O)c1cc2N(CC(C)N(C)C)c3ccccc3Sc2cc1,NCGCChem,DJM10-019,0,0,3.08448815,-10,-18.98305085,-44.2,-85.57853549,,,,,,,,,7.31E-09,3.66E-08,1.83E-07,9.14E-07,0.00000457,2.29E-05,0.000114,,,,,,,,
NCGC00166249-03,Erythrosin B,170465719,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),15905-32-5,,7.519298098,1,-5.123822698,-104.2176564,-2.1,7,,-93.4805156,-97.31693684,0.000016742,0.99832509,,,Ic4c5Oc1c(I)c(O)c(I)cc1C3(OC(=O)c2ccccc23)c5cc(I)c4O,SIGMA,200964,-3.26467159,-2.59579728,-7.46535539,-4.41441441,-11.81598063,-69.9,-97.31693684,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00018125-05,Tripelennamine citrate,170465118,Histamine H1 receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),6138-56-3,,37.68576212,0,-4.423822698,-24.09500088,-3,7,,-56.31700118,-51.59386068,0.004391678,0.97167138,,,O=C(O)C(O)(CC(=O)O)CC(=O)O.CN(C)CCN(Cc1ccccc1)c2ccccn2,Microsource,1500597,0,-8.65006553,0,0,0,0,-51.59386068,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00188690-02,Prasugrel,174006898,P2Y12 (P2T) Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),389574-19-0,Prasugrel(Effient);Prasugrel hydrochloride,29.9348649,0,-4.523822698,-16.0823534,-3,7,,-51.89433293,-49.4687131,8.8251E-06,0.998785327,64805,P2RY12,Cl.Fc1ccccc1C(N2CCc3sc(cc3C2)OC(C)=O)C(=O)C4CC4,Selleck,S1258,0,0,0,1.75145955,0,0,-49.4687131,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016642-04,Piperacetazine,170465363,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),3819-00-9,,11.91728437,0,-4.923822698,-39.246302,-2.2,7,,-66.14698937,-59.85832349,0.000263926,0.993295368,,,CC(=O)c2cc3N(CCCN1CCC(CCO)CC1)c4ccccc4Sc3cc2,Prestwick,Prestw-1048,4.92492492,1.96592398,1.02564103,-2.08507089,-3.34236676,-30.20833333,-59.85832349,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00090548-04,Deferiprone,405558541,Iron Chelating Agent,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),30652-11-0,,50.11872336,0,-4.3,-41.89429753,-2.2,7,,-56.45360537,-44.66182225,0.014671474,0.946080701,,,CN/1\C=C/C(=O)/C(=C1C)O,Selleck,S4067,-4.27516518,-0.53564071,0,-1.53153153,-12.97820823,-15.2,-44.66182225,,,,,,,,,7.31E-09,3.66E-08,1.83E-07,9.14E-07,0.00000457,2.29E-05,0.000114,,,,,,,,
NCGC00263173-09,Rucaparib,405558795,PARP Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),283173-50-2,,16.8336116,0,-4.773822698,-52.38711205,-2.1,7,,-109.9792063,-98.88205702,5.36587E-05,0.996994851,,PARP1,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=CC(=CC(=C34)[NH]2)F,APExBIO,A8893,0,4.12031314,0,0,3.00242131,-32.6,-98.88205702,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016348-15,Ethoxyquin,405559074,Heat shock protein HSP 90-beta Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),91-53-2,,10,0,-5,-107.6546217,-2.1,7,,-103.8827278,-98.54667412,1.83248E-05,0.998247456,3326,HSP90AB1,CCOC1=CC\2=C(NC(C)(C)\C=C2C)C=C1,Prestwick,Prestw-765,0,-1.11248455,0,-0.72072072,-28.37772397,-74.7,-98.54667412,,,,,,,,,7.31E-09,3.66E-08,1.83E-07,9.14E-07,0.00000457,2.29E-05,0.000114,,,,,,,,
NCGC00182074-03,Nicomolol,170465790,Cholesterol biosynthesis Modulator,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),27959-26-8,,2.667947643,1,-5.573822698,-62.04793862,-2.2,7,,-55.10061487,-47.45667971,0.018363375,0.938994711,311849,,O=C(OCC4(COC(=O)c1cccnc1)CCCC(COC(=O)c2cccnc2)(COC(=O)c3cccnc3)C4O)c5cccnc5,Kemprotec,27959-26-8,0,0.94767202,3.30800179,-15.13513514,-25.66585956,-28.5,-47.45667971,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00253613-01,Anileridine,170465266,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),144-14-9,,21.19226141,0,-4.673822698,-20.02168103,-3,7,,-36.80072667,-35.15930688,0.065868976,0.872347167,,,O=C(OCC)C2(CCN(CCc1ccc(N)cc1)CC2)c3ccccc3,GVK,FFS-11-286-NCI-043,-10.3381267,4.57354759,-0.93875726,0.36036036,4.26150121,-5.8,-35.15930688,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00387269-01,Rifaximin,405558998,Pregnane X Receptor (PXR) Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),[80621-81-4],,10.62129087,0,-4.973822698,-20.87795604,-2.4,7,,-34.61738401,-25.09782001,0.037263871,0.909116313,,rpoB,CO[C@H]1\C=C/O[C@@]2(C)OC3=C(C)C(=C4C(=C(NC(=O)\C(=C/C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C)C5=C(N=C6C=C(C)C=C[N]56)C4=C3C2=O)O)O,Tocris,5359,0,2.67820354,4.69378632,-3.33333333,-10.55690073,-10.8,-25.09782001,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00159510-05,Aripiprazole,170465392,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),129722-12-9, Abilify;;Aripiprazole; ;ARIPIPRAZOLE; Aripiprazole,21.19226141,0,-4.673822698,-32.56298489,-3,7,,-80.73140496,-76.85950413,2.32E-07,0.999803322,3356,HTR2A,Clc4cccc(N3CCN(CCCCOc1ccc2CCC(=O)Nc2c1)CC3)c4Cl,Microsource,1505851,0,0,0.43956044,0,0.81300813,-9.375,-76.85950413,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167523-03,Ormetoprim,170465718,Folate biosynthesis Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),6981-18-6,,9.466235454,1,-5.023822698,-21.06239545,-2.4,7,,-29.36068477,-28.21723731,5.26907E-05,0.997025442,,,Nc2nc(N)ncc2Cc1cc(OC)c(OC)cc1C,Sequoia,SRP01245o,0,0,1.68498168,0,0,-17.70833333,-28.21723731,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00015938-05,Salmeterol xinafoate,170465397,Beta-2 adrenergic receptor Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),94749-08-3,,18.88762287,0,-4.723822698,-37.08273367,-2.2,7,,-63.53246753,-54.19126328,2.19484E-05,0.998082054,,,OCc1cc(ccc1O)C(O)CNCCCCCCOCCCCc2ccccc2.O=C(O)c2ccc1ccccc1c2O,"Prestwick Chemical, Inc.",Prestw-945,0,0,-2.41758242,0,-2.98102981,-20.54924242,-54.19126328,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167507-04,Lapatinib,170465125,EGFR Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),231277-92-2,;Lapatinib; Lapatinib;GW-572016F?; Lapatinib base;LAPATINIB DITOSYLATE; Tykerb;Tykerb,2.37781084,1,-5.623822698,-98.61410803,-1.2,7,,-81.46576152,-78.04014168,3.24249E-05,0.997666589,1956,EGFR,Fc1cccc(c1)COc2ccc(cc2Cl)Nc3ncnc4ccc(cc34)c5ccc(CNCCS(C)(=O)=O)o5,Sequoia,231277-92-2,4.08408408,0,3.22344322,-6.42201835,-37.85004517,-66.38257576,-78.04014168,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00379044-01,Paricalcitol-D6 (ABT-358),405559020,Vitamin D Receptor (VDR) Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,16.8336116,0,-4.773822698,-27.0989902,-2.2,7,,-50.37199553,-46.11514813,1.9266E-06,0.999433115,,VDR,C[C@H](\C=C\[C@H](C)C(C([2H])([2H])[2H])(C([2H])([2H])[2H])O)[C@H]1CC[C@H]2C(/CCC[C@]12C)=C/[CH]=[C]3C[C@@H](O)[CH2][C@H](O)C3,MedChem Express,HY-76585,0,0,0,0,0,-15.7,-46.11514813,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00017258-08,Methergine,170465383,Serotonin 2b (5-HT2b) receptor Partial Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),113-42-8,,26.67947643,0,-4.573822698,-28.77651215,-3,7,,-67.82998819,-59.85832349,3.79155E-05,0.997476462,,,CC[C@@H](CO)NC(=O)[C@@H]2C=C1c3cccc4ncc(C[C@H]1N(C)C2)c34,Enzo,AC576,-3.003003,0,0,0,0,-7.29166667,-59.85832349,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00182711-02,Picosulfate sodium,225144334,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,8.436791229,1,-5.073822698,-17.9057086,-2.4,7,,-24.26033058,-23.96694215,0.00047676,0.99096478,,,[O-][S](=O)(=O)OC1=CC=C(C=C1)C(C2=CC=C(O[S]([O-])(=O)=O)C=C2)C3=CC=CC=N3,APAC,877841,0,0,0.87912088,0,2.43902439,-16.95075758,-23.96694215,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00262588-02,Merbromin,225144359,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),129-16-8,,33.58747085,0,-4.473822698,-34.36451744,-3,7,,-73.26634991,-66.46171045,0.018175872,0.9393277,,,O.O.O.[Na+].[Na+].O[Hg]C1=C([O-])C(=CC2=C1OC3=CC(=C(Br)C=C3C24OC(=O)C5=CC=CC=C45)[O-])Br,Prestwick,Prestw-787,0,4.73836012,3.62092088,-12.79279279,-7.36077482,-4.1,-66.46171045,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00371130-03,Vilazodone Hydrochloride,405558674,Sodium-dependent serotonin transporter Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),163521-08-2,,5.972790784,1,-5.223822698,-86.49585559,-2.1,7,,-88.91028508,-84.68418111,0.000134517,0.995228023,6532,SLC6A4,NC(=O)C1=CC2=CC(=CC=C2O1)N3CCN(CCCCC4=C[NH]C5=C4C=C(C=C5)C#N)CC3,APExBIO,A3919,-0.54411193,-2.67820354,4.96200268,-2.52252252,-19.37046005,-61.1,-84.68418111,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00163732-03,Moxidectin,405558680,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),113507-06-5,,23.7781084,0,-4.623822698,-81.63100762,-2.1,7,,-127.3194522,-99.10564561,0.000221723,0.993859497,,,CO\N=C/1C[C@]2(C[C@@H]3C[C@@H](C\C=C(C)\C[C@@H](C)\C=C\C=C\4CO[C@@H]5[C@H](O)\C(=C/[C@@H](C(=O)O3)[C@]45O)C)O2)O[C@@H]([C@H]1C)\C(C)=C\C(C)C,MedChem Express,HY-B0777,-7.92848815,1.68932839,-3.62092088,-5.13513514,-9.39467312,-40.4,-99.10564561,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00166115-02,Dibutyltin dilaurate,170466843,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),77-58-7,,15.00297213,0,-4.823822698,-27.57473223,-2.2,7,,-44.2314142,-41.0844047,0.009542236,0.95727767,,,O=C(O[Sn](CCCC)(OC(=O)CCCCCCCCCCC)CCCC)CCCCCCCCCCC,SIGMA,291234,4.27516518,-6.79851669,0,0.18018018,-0.968523,-16.9,-41.0844047,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00179585-04,Rescinnamin,363676949,Serotonergic synapse Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,6.300027489,1,-5.200657556,-101.6709307,-2.1,7,,-107.2296814,-83.90162102,0.001828079,0.982022469,,,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([NH]C5=C4C=CC(=C5)OC)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)\C=C\C6=CC(=C(OC)C(=C6)OC)OC,Analyticon,NP-011016,3.26467159,-7.04573548,-2.10102816,4.23423423,-12.30024213,-37.5,-83.90162102,,,,,,,,,1.21E-09,6.03E-09,3.02E-08,1.51E-07,7.54E-07,0.00000377,0.0000189,,,,,,,,
NCGC00179358-04,Methacycline hydrochloride,170465224,Tetracycline Antibiotic,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),3963-95-9,,11.91728437,0,-4.923822698,-112.7532078,-2.1,7,,-114.6821688,-90.38569033,0.001980563,0.98126426,,,Cl.NC(=O)C=3C(=O)[C@@]4(O)C(O)=C2C(=O)c1c(O)cccc1C(=C)[C@H]2[C@H](O)[C@H]4[C@@H](C=3O)N(C)C,"Prestwick Chemical, Inc.",Prestw-964,0,-11.08364236,0,-16.3963964,-32.25181598,-56.4,-90.38569033,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00242497-12,Vismodegib,405558608,Hedgehog Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),879085-55-9,,21.19226141,0,-4.673822698,-59.5027508,-2.4,7,,-41.37730576,-34.37674679,0.256889646,0.672211324,,SHH,C[S+]([O-])(=O)C1=CC=C(C(=C1)Cl)C(=O)NC2=CC(=C(Cl)C=C2)C3=NC=CC=C3,ActiveBioChem,A-1113,-15.62378546,-11.49567367,0.75994636,-7.38738739,-11.91283293,-17.5,-34.37674679,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00389674-01,Apremilast (CC-10004),405558478,Phosphodiesterase 4 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),608141-41-9,,26.67947643,0,-4.573822698,-17.01235513,-3,7,,-49.18110677,-36.50083846,0.001108054,0.986106267,,,CCOC1=C(OC)C=CC(=C1)C(C[S+](C)([O-])=O)N2C(=O)C3=C(C2=O)C(=CC=C3)NC(C)=O,APExBIO,A4317,0.38865138,0,4.24675905,-0.09009009,-1.8401937,-8.9,-36.50083846,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00183285-15,Nilotinib,405558616,Bcr-Abl Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),641571-10-0,,21.19226141,0,-4.673822698,-35.83570423,-2.2,7,,-65.9136389,-48.79821129,0.042458149,0.901830066,,ABL1,CC1=C[N](C=N1)C2=CC(=CC(=C2)NC(=O)C3=CC(=C(C)C=C3)NC4=NC(=CC=N4)C5=CC=CN=C5)C(F)(F)F,Glixx,GLXC-90226,0,3.50226617,3.03978543,0,-18.20823245,-15.2,-48.79821129,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00262929-01,BIBR-1048,170466107,Thrombin Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),211915-06-9,Bibr 1048;BIBR-1048 (Dabigatran);3-((2-((4-Amino((e)-hexyloxycarbonylimino)methyl)-phenylamino)methyl-1-1h-benzoimidazole-5-carbonyl)pyridin-2-yl-amino)propionic acid ethyl ester;Dabigatranum etexilatum;Dabigatran etexilate; Dabigatran etexilate,11.91728437,0,-4.923822698,-56.15424549,-2.2,7,,-79.28040142,-64.81700118,0.002505702,0.978845484,,F2,O=C(OCCCCCC)\N=C(\N)c1ccc(cc1)NCc3nc2cc(ccc2n3C)C(=O)N(CCC(=O)OCC)c4ccccn4,GVK,FFS-12-73-NCI-1548,0,2.49017038,0,0,-18.69918699,-31.72348485,-64.81700118,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00015998-06,THIOTHIXENE,405558925,dopamine secretion Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),"5591-45-7, 3313-26-6 [//Z//]",,23.7781084,0,-4.623822698,-24.21304246,-2.2,7,,-51.04220234,-38.28954723,0.006157635,0.966167841,,,CN(C)[S+]([O-])(=O)C1=CC2=C(SC3=C(C=CC=C3)\C2=C/CCN4CCN(C)CC4)C=C1,Microsource,1500576,-3.80878352,4.90317264,0,1.26126126,-3.77723971,-12.9,-38.28954723,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167969-02,Rubitecan,124893436,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,31.6227766,0,-4.5,-22.75210517,-3,7,,-53.98267189,-53.49357183,0.000004918,0.999093647,,,CC[C@@]1(O)C(=O)OC/C2=C1/C=C/3N(CC4=CC5=C(C=CC=C5[N+]([O-])=O)N=C34)C2=O,SIGMA,R3655,1.32141469,0,0.26821636,0,1.4527845,-9.9,-53.49357183,,,,,,,,,7.31E-09,3.66E-08,1.83E-07,9.14E-07,0.00000457,2.29E-05,0.000114,,,,,,,,
NCGC00095029-08,NCGC00095029-08,,Staphylococcus aureus Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,15.00297213,0,-4.823822698,-58.04621681,-2.1,7,,-95.80547792,-88.70877585,0.000885906,0.98759866,,,CC[C@H]([C@H]1O[C@@](CC)(C[C@@H]1C)[C@H]2CC[C@](O)(CC)[C@H](C)O2)C(=O)[C@@H](C)[C@@H](O)[C@H](C)CCC3=C(C([O-])=O)C(=C(C)C=C3)O,Analyticon,NP-009923,0,-5.48001648,-1.74340635,0,4.55205811,-36,-88.70877585,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00164615-02,Prulifloxacin,170465849,Antibacterial,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),123447-62-1, ;Prulifloxacin; Prulifloxacin; Sword,23.7781084,0,-4.623822698,-60.81668668,-2.2,7,,-79.95146091,-79.69303424,0.000135165,0.995216857,,,CC=5OC(=O)OC=5CN1CCN(CC1)c2cc3c(cc2F)C(=O)C(=C4SC(C)N34)C(=O)O,Bosche,P2859,-3.48348348,-6.81520315,-7.10622711,-3.91993328,-9.1237579,-15.625,-79.69303424,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016490-12,Flufenamic acid,170465857,Cyclooxygenase-2 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),530-78-9,,29.9348649,0,-4.523822698,-10.19015887,-2.4,7,,-39.7107438,-28.92561983,0.001068997,0.986365418,,,FC(F)(F)c1cc(ccc1)Nc2ccccc2C(=O)O,Vitas,STK985630,0,0.91743119,3.80952381,0,0,-4.82954545,-28.92561983,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00241108-04,Axitinib,170466656,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),319460-85-0,AG-013736;Inlyta;Axitinib; Axitinib;AG-13736,10.62129087,0,-4.973822698,-60.95853232,-2.2,7,,-70.47316937,-59.97764114,5.56248E-05,0.996940608,2321,FLT1,CNC(=O)c4ccccc4Sc1ccc3c(c1)nnc3/C=C/c2ccccn2,Sequoia,319460-85-0,-1.16595414,-0.45323445,0,-6.03603604,-11.91283293,-37.3,-59.97764114,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00345789-05,Venetoclax (ABT-199),405558742,Bcl-2 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),8444499-71-4,,8.436791229,1,-5.073822698,-90.28798011,-2.1,7,,-96.51598658,-89.26774734,7.48366E-05,0.996447865,,BCL2,CC1(C)CCC(=C(\C1)C2=CC=C(Cl)C=C2)/CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)N[S+]([O-])(=O)C5=CC=C(NCC6CCOCC6)C(=C5)[N+]([O-])=O)OC7=CN=C8[NH]C=CC8=C7,ChemieTek,CT-A769,1.39914497,0,-5.76665177,-3.78378378,-17.62711864,-59.2,-89.26774734,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00017074-02,Hydergine,144206902,Adrenergic receptor alpha Blocker,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),8067-24-1,,16.8336116,0,-4.773822698,-51.59036876,-2.2,7,,-86.01928451,-78.42370039,8.7729E-06,0.998788599,,,CS(=O)(=O)O.CN1C[C@@H](C[C@@H]2c3cccc4ncc(C[C@@H]12)c34)C(=O)N[C@@]7(O[C@]6(O)N([C@H](C(=O)N5CCC[C@H]56)C(C)C)C7=O)C(C)C,"Prestwick Chemical, Inc.",CAS-8067-24-1,-2.79828993,0,0,0,-2.32445521,-28.6,-78.42370039,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00094047-10,Ivermectin,405558905,Glutamate-gated Chloride Channel Activator,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),70288-86-7,,11.91728437,0,-4.923822698,-61.76649809,-2.2,7,,-85.42202347,-79.09446618,3.19192E-05,0.99768503,,,[H][C@@](C)(CC)[C@@]1([H])O[C@]2(CC[C@@H]1C)C[C@@H]3C[C@@]([H])(C\C=C(C)\[C@@H](O[C@@]4([H])C[C@H](OC)[C@@H](O[C@@]5([H])C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)[C@@H](C)\C=C\C=C6/CO[C@]7([H])[C@H](O)C(C)=C[C@@]([H])(C(=O)O3)[C@]67O)O2,APExBIO,A2813,0,0,0,-0.81081081,-9.10411622,-38.9,-79.09446618,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00015713-13,Nitrendipine,170465897,Intermediate conductance calcium-activated potassium channel protein 4 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),39562-70-4,,18.88762287,0,-4.723822698,-39.1950457,-2.2,7,,-80.38961039,-59.38606848,4.70718E-05,0.997186772,,,CC=1NC(C)=C(C(C=1C(=O)OCC)c2cccc(c2)[N+]([O-])=O)C(=O)OC,SigmaAldrich,N144,3.36336336,0,3.003663,0,-6.59439928,-27.1780303,-59.38606848,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00378832-01,Eldecalcitol,405558953,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),104121-92-8,,21.19226141,0,-4.673822698,-2.055895797,-3,7,,-40.87562885,-37.17160425,0.00055707,0.990213899,,,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C/3C[C@@H](O)[C@@H](OCCCO)[C@H](O)C3=C,MedChem Express,HY-A0020,3.18694131,2.76060981,4.87259723,0,3.87409201,0,-37.17160425,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00180889-03,Flunixin meglumine,170466598,Prostaglandin G/H synthase 2 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),42461-84-7,,23.7781084,0,-4.623822698,-6.561739105,-2.4,7,,-23.71015348,-21.84179457,0.014372721,0.946767242,791253,PTGS2,CNC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO.FC(F)(F)c2cccc(Nc1ncccc1C(=O)O)c2C,Microsource,1505113,0,-2.62123198,4.17582418,0.41701418,0.9936766,-1.42045455,-21.84179457,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00164283-07,Hexadecyltrimethylammonium bromide,170465714,Cell membrane Interacts,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),57-09-0,,37.68576212,0,-4.423822698,-11.20616825,-2.4,7,,-26.8270366,-24.43919717,0.003347942,0.975453261,,,[Br-].C[N+](C)(C)CCCCCCCCCCCCCCCC,Microsource,1503200,0,-3.80078637,0,0,0,0,-24.43919717,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00091596-05,Octadecanoic acid,170465630,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1957/11/4,,33.58747085,0,-4.473822698,-35.28638382,-3,7,,-67.85301062,-64.34474616,0.01739989,0.940771366,,,O=C(O)CCCCCCCCCCCCCCCCC,Specs,AE-562/J263018,-6.24624625,1.17955439,4.90842491,0,-13.27913279,-2.93560606,-64.34474616,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00179580-04,Biotin,170464763,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),58-85-5,,0.015002972,1,-7.823822698,-334.3508389,-1.1,7,,-99.71171171,-100,0.003066635,0.976504766,,,O=C1N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]2N1,Vitas,STK801941,-0.24024024,-58.19134993,-80.65934066,-92.9941618,-96.92863595,-99.33712121,-100,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00160387-04,Clothiapine,170465938,GABA-A receptor; benzodiazepine site Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),2058-52-8,,21.19226141,0,-4.673822698,-22.65759198,-3,7,,-38.40909091,-35.53719008,0.005797205,0.967235561,,,CN1CCN(CC1)C3=Nc4ccccc4Sc2ccc(Cl)cc23,Enzo,D108,1.68168168,-2.75229358,-5.34798535,0,0.45167118,-9.18560606,-35.53719008,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00378937-01,Setiptiline,405559104,serotonin receptor signaling pathway Modulator,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),57262-94-9,,33.58747085,0,-4.473822698,-32.91017495,-3,7,,-34.10564561,-32.58803801,0.19465838,0.736200071,,,CN1CC\C2=C(/C1)C3=C(CC4=CC=CC=C24)C=CC=C3,MedChem Express,HY-32329,-0.3109211,-7.37536053,-6.57130085,-15.58558559,3.97094431,-4.8,-32.58803801,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00263156-14,Nintedanib,405559117,VEGFR-1/2/3 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),928326-83-4,,2.99348649,1,-5.523822698,-53.84873036,-1.2,7,,-45.032,-42.53773058,0.000604192,0.989797737,2324,FLT1,COC(=O)C1=CC=C\2C(=C1)NC(=O)C2=C(\NC3=CC=C(C=C3)N(C)C(=O)CN4CCN(C)CC4)C5=CC=CC=C5,APExBIO,A8252,2.254178,2.26617223,0,-2.97297297,-11.42857143,-46.6,-42.53773058,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00510316-02,Ombitasvir,405559012,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1258226-87-7,,5.972790784,1,-5.223822698,-104.8339244,-1.1,7,,-94.01783119,-95.75181666,0.000716855,0.988867249,,,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC2=CC=C(C=C2)[C@@H]3CC[C@H](N3C4=CC=C(C=C4)C(C)(C)C)C5=CC=C(NC(=O)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)C(C)C)C=C5,MedChem Express,HY-13997,0,3.00782859,-5.3196245,-10.81081081,-12.39709443,-76.6,-95.75181666,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00182034-01,Teprenone,144206513,Heat shock 70 kDa protein 1 Modulator,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),6809-52-5,Teprenone; Selbex; Teprenona; ,37.68576212,0,-4.423822698,-21.40201646,-3,7,"CIPLUS_165824;tetraprenylacetone;geranyl-geranyl-acetone;Teprenone;teprenonum;Selbex;LS-174701;teprenon;TEPRENONE;LS-174702;Teprenona;geranylgeranylacetone, (Z,E,E)-isomer;6,10,14,18-tetramethyl-5,9,13,17-nonadecatetraen-2-one;CIPLUS_3885398;LS-96803;tetraprenyl acetone;geranylgeranylacetone;Teprenonum;geranylgeranylacetone, (E,E,E)-isomer;teprenone;",-56.94354388,-51.70486305,0.013388664,0.948691944,,,C/C(C)=C\CCC(\C)=C\CCC(\C)=C\CCC(C)=CCCC(C)=O,ACC,TEPRENONE,4.27516518,0,-10.32632991,0,0,0,-51.70486305,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00159476-09,Tribromsalan,170465542,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1987/10/5,,18.88762287,0,-4.723822698,-32.92035459,-2.2,7,,-76.67532468,-67.17827627,0.000145892,0.995029276,,,Oc1c(cc(Br)cc1Br)C(=O)Nc2ccc(Br)cc2,SIGMA,R416568,0,3.93184797,-1.24542125,1.91826522,2.07768744,-20.17045455,-67.17827627,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00262960-01,Resocortol butyrate,170466824,Glucocorticoid receptor Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),76738-96-0,Resocortol,23.7781084,0,-4.623822698,-12.83257786,-2.4,7,,-38.79397875,-27.74498229,0.002568911,0.978594239,,,CCC(=O)[C@@]4(OC(=O)CCC)CC[C@@H]2[C@]4(C)C[C@H](O)[C@@H]1[C@@]3(C)CCC(=O)C=C3CC[C@H]12,GVK,FFS-11-286-NCI-149,0.24024024,4.84927916,0.36630037,0,-0.63233966,-9.375,-27.74498229,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00538147-01,NCGC00538147-01,405558439,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,5.972790784,1,-5.223822698,-23.06874791,-1.4,7,,-26.19060928,-25.9921744,0.023703659,0.929730182,,,CCCCCCCCNC(=N)NC(=N)NCC1=CC(=C(Cl)C=C1)Cl,Pharmaron,PH-NIH-2017-009-L1-5-0,4.66381656,2.51339102,-5.85605722,0,-1.1622276,-21.6,-25.9921744,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167586-03,Piroctone Olamine,225144295,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),68890-66-4,,2.667947643,1,-5.573822698,-163.054958,-1.1,7,,-88.7211438,-92.8451649,0.002600197,0.978432366,,,CC(CC/1=C/C(=C\C(=O)N1O)C)CC(C)(C)C,Bosche,P6136,-4.74154683,-12.07251751,-5.58784086,-21.44144144,-42.71186441,-98.9,-92.8451649,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00186054-01,Tannic acid,124896727,Beta-secretase 1 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,0.211922614,1,-6.673822698,-226.6650307,-1.1,7,,-102.6317496,-98.43487982,0.000177746,0.994507857,,,OC1=CC(=CC(=C1O)O)C(=O)OC2=CC(=CC(=C2O)O)C(=O)OC[C@H]3O[C@@H](OC(=O)C4=CC(=C(O)C(=C4)OC(=O)C5=CC(=C(O)C(=C5)O)O)O)[C@H](OC(=O)C6=CC(=C(O)C(=C6)OC(=O)C7=CC(=C(O)C(=C7)O)O)O)[C@@H](OC(=O)C8=CC(=C(O)C(=C8)OC(=O)C9=CC(=C(O)C(=C9)O)O)O)[C@@H]3OC(=O)C%10=CC(=C(O)C(=C%10)OC(=O)C%11=CC(=C(O)C(=C%11)O)O)O,SIGMA,16201,1.32141469,-9.02348578,-33.48234242,-64.05405405,-77.57869249,-92.7,-98.43487982,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00263152-12,Ponatinib,405558658,FGFR Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1114544-31-8,,10.62129087,0,-4.973822698,-53.32786127,-2.2,7,,-82.14645053,-79.76523197,7.64394E-05,0.996409906,,FGFR1,CN1CCN(CC1)CC2=CC=C(NC(=O)C3=CC(=C(C)C=C3)C#CC4=CN=C5C=CC=N[N]45)C=C2C(F)(F)F,Glixx,GLXC-01988,0,0,0,4.59459459,0,-41,-79.76523197,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00163700-12,Vincristine sulfate,404904683,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),[2068-78-2],,13.37141299,0,-4.873822698,-64.03785197,-2.2,7,,-60.16706021,-60.80283353,0.012076424,0.951480852,,,CC[C@]1(O)C[C@H]2CN(CCC3=C([NH]C4=C3C=CC=C4)[C@@](C2)(C(=O)OC)C5=CC6=C(C=C5OC)N(C=O)[C@H]7[C@](O)([C@H](OC(C)=O)[C@]8(CC)\C=C/CN9CC[C@]67[C@H]89)C(=O)OC)C1,Tocris,1257,-14.77477477,-5.37352556,0,-2.08507089,-4.24570912,-30.20833333,-60.80283353,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00013687-03,Pyrophosphoric acid,405559136,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),2466/9/3,,13.37141299,0,-4.873822698,-29.35487079,-2.4,7,,-26.07733176,-27.9811098,0.045210588,0.898251872,,,O[P](O)(=O)O[P](O)(O)=O,SIGMA,433314,0,-8.25688073,-5.64102564,0,0,-14.10984848,-27.9811098,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00182058-01,Doxercalciferol,405558580,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),54573-75-0,,16.8336116,0,-4.773822698,-48.49274796,-2.1,7,,-97.01542761,-87.92621576,8.5694E-06,0.998802706,,,[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C3/CC(=C)[C@@H](O)C[C@@H]3O)[C@H](C)\C=C\C(C)C(C)C,Axon Medchem,1746,1.71006607,0,0,2.97297297,0,-30.6,-87.92621576,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00181026-02,Robenidine,170465629,Eimeria tenella Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),25875-51-8,,6.701581484,1,-5.173822698,-85.68480519,-2.1,7,,-95.14868642,-89.15595305,3.2569E-06,0.99926242,,,Clc2ccc(/C=N/NC(=N)N\N=C/c1ccc(Cl)cc1)cc2,SIGMA,33979,0,2.51339102,0,0,-17.33656174,-63.2,-89.15595305,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00538142-01,NCGC00538142-01,405558454,vasoconstriction Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,23.7781084,0,-4.623822698,-31.30330567,-2.2,7,,-53.70709894,-42.20234768,0.000243016,0.993571967,,,CCCCCCC(COC(=O)C1=CN=CC=C1)(COC(=O)C2=CN=CC=C2)COC(=O)C3=CN=CC=C3,Pharmaron,PH-NIH-2017-009-L1-20-0,-2.72055966,0.61804697,0,-0.99099099,-4.64891041,-15.1,-42.20234768,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167356-07,Raltegravir,405559137,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),871038-72-1,,10.62129087,0,-4.973822698,-21.27705997,-2.4,7,,-29.4273908,-28.68949233,0.003477186,0.974944145,,,CN1C(=O)C([O-])=C(N=C1C(C)(C)NC(=O)C2=NN=C(C)O2)C(=O)NCC3=CC=C(F)C=C3,Selleck,S2005,3.003003,0,0,-3.25271059,0,-16.76136364,-28.68949233,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00018296-07,Meclizine hydrochloride,170464899,Constitutive Androstane Receptor Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1104-22-9,; Meclozine dihydrochloride;Meclozine dihydrochloride; Meclizine Hcl;Meclizine dihydrochloride;MECLIZINE HYDROCHLORIDE;Meclizine hydrochloride; Meclozina,37.68576212,0,-4.423822698,0.940480407,-2.4,7,,-25.79338842,-20.66115702,0.006455321,0.965362302,9970,NR1I3,Cl.Cl.Cc1cccc(c1)CN2CCN(CC2)C(c3ccc(Cl)cc3)c4ccccc4,Microsource,1500376,1.92192192,1.70380079,4.54212454,0,0,2.93560606,-20.66115702,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00095188-05,Pantoprazole,170466337,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),102625-70-7,; ; Protonix; PANTOPRAZOLE;Pantoprazole; Pantoprazol; Pantoprazole;PANTOPRAZOLE,8.436791229,1,-5.073822698,-36.11982331,-2.2,7,,-29.67768595,-32.23140496,0.025553172,0.926687422,,ATP4A,COc3c(OC)ccnc3CS(=O)c1nc2cc(ccc2n1)OC(F)F,Microsource,1505818,0,-7.99475754,-5.93406593,1.75145955,0,-23.39015152,-32.23140496,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00182704-02,Luliconazole,144206804,Lanosterol 14-alpha demethylase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),187164-19-8,Luliconazole; Lulicon; ,13.37141299,0,-4.873822698,-34.67999488,-2.2,7,Lulicon;Luliconazole;LULICONAZOLE;CIPLUS_787907;,-67.01298701,-59.85832349,0.001049543,0.986478826,3641571,ERG11,N#C/C(=C1/SC[C@H](S1)c2ccc(Cl)cc2Cl)n3ccnc3,Pharmaron,PH-NIH-102266,0,0,0,3.66972477,4.96838302,-28.31439394,-59.85832349,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167436-02,Azelnidipine,174006618,Ca channel blocker - DHP class,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),123524-52-7, ; Calblock;Azelnidipine; Azelnidipine,5.32325539,1,-5.273822698,-104.9855158,-1.1,7,,-98.20826447,-96.69421488,0.000543745,0.990327396,,,[O-][N+](=O)c1cccc(c1)C2C(C(=O)OC(C)C)=C(C)NC(N)=C2C(=O)OC3CN(C3)C(c4ccccc4)c5ccccc5,Bosche,A2998,4.08408408,0,0,-10.25854879,-16.16982836,-80.77651515,-96.69421488,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00183024-01,Proglumetacin,144206876,Cyclooxygenase-2 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),57132-53-3,Proglumetacin; Miridacin; Proglumetacina; ,9.466235454,1,-5.023822698,-62.61077644,-2.2,7,"LS-82118;proglumetacine;Proglumetacinum;proxil;Proglumetacina;Proglumetacin Maleate;Proglumetacin;Proglumetacine;CIPLUS_182770;proglumetacin;Proglumetacin maleate;METACINE-P;LS-175816;Miridacin;PROGLUMETACIN MALEATE;PROTACINE;3'-(4-(2-(1-p-chlorobenzoyl-5-methoxy-2-methylindol-3-ylacetoxy)ethyl)piperazin-1-yl)propyl-4-benzamido-N,N-dipropylglutaramate (+-) dimaleate;PROGLUMETACIN;proglumetacinum;CIPLUS_685564;3-(4-(2-HYDROXYETHYL)-1-PIPERAZINYL)PROPYL DL-4-BENZAMIDO-N,N-DIPROPYLGLUTARAMATE 1-(4-CHLOROBENZOYL)-5-METHOXY-2-METHYLINDOLE-3-ACETATE;",-78.2231405,-75.20661157,3.3261E-06,0.999254657,,,CCCN(CCC)C(=O)C(NC(=O)c1ccccc1)CCC(=O)OCCCN5CCN(CCOC(=O)Cc4c2cc(OC)ccc2n(C(=O)c3ccc(Cl)cc3)c4C)CC5,Pharmaron,PH-NIH-183347,0,-1.31061599,1.17216117,0,-5.14905149,-46.68560606,-75.20661157,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00015826-13,Perphenazine,170464834,Muscarinic acetylcholine receptor M1 Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),58-39-9,,8.436791229,1,-5.073822698,-72.94932066,-2.2,7,,-89.59504133,-71.90082645,0.001252075,0.985199468,1128,CHRM1,OCCN1CCN(CC1)CCCN2c4ccccc4Sc3ccc(Cl)cc23,Microsource,1503934,0,3.01441678,-0.36630037,0,-26.28726287,-44.79166667,-71.90082645,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00253606-01,Mexazolam,170465840,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),31868-18-5,,5.32325539,1,-5.273822698,-22.03521236,-2.4,7,,-28.12691853,-23.02243211,0.003372168,0.975353671,,,Clc1ccccc1C34OCC(C)N4CC(=O)Nc2ccc(Cl)cc23,GVK,FFS-11-286-NCI-217,0,3.80078637,0,0,-8.76242096,-15.05681818,-23.02243211,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00253576-01,Amelometasone,170465753,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),123013-22-9,,10.62129087,0,-4.973822698,-26.55733283,-2.4,7,,-25.31050768,-26.09208973,0.003105685,0.976388019,,,COCC(=O)[C@]3(OC(=O)CC)[C@@]4(C)C[C@H](O)C2(F)[C@@H](CCC1=CC(=O)C=C[C@@]12C)[C@@H]4C[C@@H]3C,GVK,FFS-11-286-NCI-162,-2.4024024,-4.32503277,0,0,-2.61969286,-14.86742424,-26.09208973,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00095122-05,Irbesartan,170464670,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),138402-11-6,,26.67947643,0,-4.573822698,-18.60236186,-3,7,,-52.79752067,-43.09327037,6.66343E-05,0.996650953,,,CCCCC5=NC1(CCCC1)C(=O)N5Cc2ccc(cc2)c3ccccc3c4nnnn4,Microsource,1504259,0,2.62123198,0,0,0,-7.67045455,-43.09327037,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00015455-10,Felodipine,170464849,Voltage-gated calcium channel alpha2/delta subunit 1 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),72509-76-3,,7.519298098,1,-5.123822698,-43.03745598,-1.2,7,,-39.97284534,-41.2042503,0.000177754,0.99451006,,,CC=1NC(C)=C(C(C=1C(=O)OCC)c2cccc(Cl)c2Cl)C(=O)OC,Specs,AE-641/11429675,0,-1.57273919,-3.88278388,0,-1.7163505,-33.80681818,-41.2042503,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00164552-06,Bromfenac Na,,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,37.68576212,0,-4.423822698,-12.50283488,-3,7,,-48.04958678,-42.14876033,8.11842E-05,0.996301238,,,NC1=C(CC([O-])=O)C=CC=C1C(=O)C2=CC=C(Br)C=C2,Sequoia,SRP034005b,0,0.65530799,0,0,0,2.55681818,-42.14876033,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00166248-03,Green S,405559150,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),3087-16-9,,4.74435636,1,-5.323822698,-111.1376576,-1.1,7,,-107.2920897,-97.87485242,4.50424E-05,0.997247778,,,CN(C)C1=CC=C(C=C1)C(=C/2\C=C/C(/C=C2)=[N+](C)C)C3=C4C=CC(=CC4=CC(=C3O)[S]([O-])(=O)=O)[S]([O-])(=O)=O,SIGMA,199583,0,0,0,-1.25104254,-28.63595303,-80.20833333,-97.87485242,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00346716-02,Dabrafenib,405558586,Raf kinase B Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1195765-45-7,,6.701581484,1,-5.173822698,-61.64727558,-1.2,7,,-67.64868642,-66.79709335,6.5296E-06,0.998955188,,BRAF,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(F)C(=CC=C3)N[S+]([O-])(=O)C4=C(F)C=CC=C4F,Selleck,S2807,-1.01049359,0.20601566,2.05632544,0,-4.64891041,-51.1,-66.79709335,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00181091-01,Bunamidine hydrochloride,144206260,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1055-55-6,Bunamidine hydrochloride; Bunamidina; Scolaban; ,4.74435636,1,-5.323822698,-25.55609807,-1.4,7,"bunamidinum;bunamidine monohydrochloride;N,N-DIBUTYL-4-(HEXYLOXY)-1-NAPHTHAMIDINE MONOHYDROCHLORIDE;bunamidine;LS-174664;Scolaban;CIPLUS_738221;CIPLUS_157296;Bunamidinum;N,N-dibutyl-4-(hexyloxy)-1-naphthamidine monohydrochloride;LS-95153;NSC-106571;1-Naphthamidine, N,N-dibutyl-4-hexyloxy-, monohydrochloride;CIPLUS_3885993;1-naphthalenecarboximidamide, n,n-dibutyl-4-(hexyloxy)-, hydrochloride;BUNAMIDINE HYDROCHLORIDE;Bunamidine hydrochloride;Bunamidina;BUNAMIDINE;Bunamidine;",-22.62,-19.73169368,0.003876258,0.973487687,,,Cl.CCCCN(CCCC)C(=N)c1ccc(OCCCCCC)c2ccccc12,NCI,NSC-106571,0,-1.60692213,0,0,0,-25.1,-19.73169368,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00094772-04,PYRVINIUM PAMOATE,405558483,Cryptosporidium parvum Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,2.667947643,1,-5.573822698,-134.4643352,-1.1,7,,-96.05729458,-99.55282281,0.000104556,0.995796617,,,CN(C)C1=CC=C2C(=C1)C=CC(=[N+]2C)/C=C/C3=C(C)[N](C(=C3)C)C4=CC=CC=C4.OC(=O)C5=CC6=CC=CC=C6C(=C5O)CC7=C(O)C(=CC8=CC=CC=C78)C([O-])=O,Microsource,MS-01500521,0,0.94767202,-2.54805543,-6.12612613,-39.4188862,-95.5,-99.55282281,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00165722-03,Plerixafor hydrochloride,405558840,Chemokine CXCR4 (SDF-1 Receptor) Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),155148-31-5,,2.119226141,1,-5.673822698,-80.44387129,-2.4,7,,-45.21408609,-37.28339855,0.079256001,0.856833501,,CXCR4,C1CNCCNCCCN(CCNC1)CC2=CC=C(CN3CCCNCCNCCCNCC3)C=C2,Selleck,S3013,-8.3948698,-2.92542233,0,-14.5045045,-4.74576271,-19.8,-37.28339855,,,,,,,,,3.66E-10,1.83E-09,9.14E-09,4.57E-08,2.29E-07,1.14E-06,5.71E-06,,,,,,,,
NCGC00249919-01,Nandrolone furylpropionate,170465918,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),7642-64-0,,11.91728437,0,-4.923822698,-46.89363336,-2.2,7,,-65.14994097,-63.87249115,0.000289766,0.99297088,,,O=C4C=C5CC[C@@H]2[C@H](CC[C@]3(C)[C@@H](OC(=O)CCc1ccco1)CC[C@@H]23)[C@H]5CC4,GVK,FFS-11-286-NCI-187,-4.32432432,2.22804718,0,0,0,-31.72348485,-63.87249115,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00013226-32,NCGC00013226-32,,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,18.88762287,0,-4.723822698,-62.48196407,-2.2,7,,-101.3311688,-76.38724911,0.002856299,0.977357863,,,CN1CCN(CCCN2C3=C(SC4=C2C=C(C=C4)C(F)(F)F)C=CC=C3)CC1,Labotest,LT00452002,0,0,0.87912088,0,-19.78319783,-32.29166667,-76.38724911,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00160514-02,Idebenone,170465611,Free Radical Scavenger,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),58186-27-9, ;Idebenone;IDEBENONE; Idebenone,13.37141299,0,-4.873822698,-58.54039358,-2.1,7,,-90.93506493,-82.52656434,2.0036E-06,0.999421662,,,COC1=C(OC)C(=O)C(C)=C(CCCCCCCCCCO)C1=O,Vitas,STK801942,0,0,0,0,-2.80036134,-39.6780303,-82.52656434,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00164625-04,Cerivastatin sodium,170465109,HMG-CoA reductase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),143201-11-0,,6.701581484,1,-5.173822698,-32.63540551,-2.2,7,,-37.05076741,-36.0094451,0.004515769,0.971261559,,,[Na+].CC(C)c1nc(c(/C=C/[C@@H](O)C[C@@H](O)CC([O-])=O)c(c1COC)c2ccc(F)cc2)C(C)C,Sequoia,143201-11-0,0.96096096,0,4.3956044,-4.75396163,-3.16169828,-26.42045455,-36.0094451,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00346580-04,Vinflunine (Tartrate),,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1201898-17-0,,3.358747085,1,-5.473822698,-35.61621523,-1.2,7,,-32.70318613,-32.25265511,1.63709E-05,0.998344766,,,[H][C@@]12N3CC[C@@]14C5=CC(=C(OC)C=C5N(C)[C@@]4([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)\C=C/C3)C(=O)OC)[C@]6(C[C@H]7C[C@H](CN(C7)CC8=C6NC9=C8C=CC=C9)C(C)(F)F)C(=O)OC,MedChem Express,HY-B0628A,1.78779635,0,0,0.54054054,-5.61743341,-32.1,-32.25265511,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00522021-01,Dexamethasone 21-Palmitate,405558516,Glucocorticoid receptor Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),14899-36-6,,2.119226141,1,-5.673822698,-37.41613073,-2.2,7,,-40.348,-2.73896031,0.036325734,0.94734772,,,CCCCCCCCCCCCCCCC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC\4=C\C(=O)\C=C/[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C,Toronto Research,D298830,1.47687524,-8.36423568,1.56459544,-4.77477477,-24.50363196,-38.9,-2.73896031,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00024822-03,EVANS BLUE,405559142,Serum albumin Binding Agent,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),314-13-6,,2.99348649,1,-5.523822698,-135.4615597,-1.1,7,,-92.54120425,-98.11097993,0.012051403,0.951522911,6339,,CC1=C(C=CC(=C1)C2=CC=C(\N=N\C3=C(O)C4=C(C=C3)C(=CC(=C4N)[S]([O-])(=O)=O)[S]([O-])(=O)=O)C(=C2)C)/N=N/C5=C(O)C6=C(N)C(=CC(=C6C=C5)[S]([O-])(=O)=O)[S]([O-])(=O)=O,SIGMA,206334,2.88288288,-3.53866317,-25.86080586,0.08340284,-25.02258356,-94.22348485,-98.11097993,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00091470-05,Isoeugenol,170465654,Tyrosyl-DNA phosphodiesterase 2 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),97-54-1,,23.7781084,0,-4.623822698,-32.47429366,-2.2,7,,-73.5909091,-55.37190083,0.001305735,0.984880307,,,Oc1ccc(cc1OC)C=CC,Bosche,I1325,4.44444444,-3.66972477,0,2.58548791,-3.88437218,-19.60227273,-55.37190083,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00166307-05,ERGOCALCIFEROL,405559070,Vitamin D receptor Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),50-14-6,,16.8336116,0,-4.773822698,-45.63839671,-2.2,7,,-77.47402597,-71.19244392,4.08947E-05,0.997378491,,,CC(C)[C@@H](C)/C=C/[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C/3C[C@@H](O)CCC3=C,SIGMA,E5750,0,-2.62123198,0,-1.58465388,0,-25.47348485,-71.19244392,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00013895-08,Benzbromarone,170465792,Xanthine dehydrogenase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),3562-84-3,,15.00297213,0,-4.823822698,-55.83768284,-2.1,7,,-96.76918536,-89.13813459,5.46358E-05,0.99696756,,,Brc1cc(cc(Br)c1O)C(=O)c2c3ccccc3oc2CC,Labotest,LT00134669,0,-2.75229358,0,2.58548791,0,-35.13257576,-89.13813459,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00164547-06,Zafirlukast,174007053,Leukotriene CysLT1 (LTD4) Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),107753-78-6, ; Zafirlukast;Zafirlukast,9.466235454,1,-5.023822698,-73.51090982,-2.1,7,,-99.405549,-95.98583235,0.000045893,0.997221822,10800,CYSLTR1,Cc1ccccc1S(=O)(=O)NC(=O)c5ccc(Cc3cn(C)c2ccc(cc23)NC(=O)OC4CCCC4)c(OC)c5,Sequoia,SRP00200z,-1.2012012,4.71821756,0,0,0,-60.3219697,-95.98583235,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00018200-12,Phenolphthalein,170465559,store-operated calcium entry Blocker,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1977/9/8,,7.519298098,1,-5.123822698,-25.01370535,-1.2,7,,-34.24439198,-32.70365998,0.001118707,0.986036241,,,Oc1ccc(cc1)C3(OC(=O)c2ccccc23)c4ccc(O)cc4,Vitas,STK029876,0,4.98034076,0,0,1.62601626,-26.04166667,-32.70365998,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00253586-01,Isalon,170465491,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),5579-81-7,,8.436791229,1,-5.073822698,-3.931415794,-2.4,7,,-33.84090909,0,0.011100702,0.977200475,,,O=C(N)NC1N=C(O[Al](O)O)NC1=O,GVK,FFS-11-286-NCI-89,0,0.2621232,0,3.91993328,2.80036134,-25.28409091,0,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00022003-06,Diflorasone diacetate,170465294,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),33564-31-7,,4.74435636,1,-5.323822698,-20.74026836,-1.4,7,,-22.06818182,-16.88311688,0.020287675,0.935589925,,,CC(=O)OCC(=O)[C@@]4(OC(C)=O)[C@@H](C)C[C@@H]3[C@]4(C)C[C@H](O)[C@@]2(F)[C@H]3C[C@H](F)C1=CC(=O)C=C[C@@]12C,"Prestwick Chemical, Inc.",Prestw-619,0,1.70380079,0,0,2.52935863,-25.47348485,-16.88311688,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00094619-06,Chloramphenicol sodium succinate,170465429,Bacterial 70S ribosome Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),982-57-0,,21.19226141,0,-4.673822698,-6.877173871,-2.4,7,,-21.29338842,-20.66115702,0.001719776,0.982622104,,,[Na+].O=[N+]([O-])c1ccc(cc1)[C@@H](O)[C@@H](COC(=O)CCC([O-])=O)NC(=O)C(Cl)Cl,SIGMA,C3787,-0.96096096,0,0,2.41868224,0,-0.66287879,-20.66115702,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00090987-05,1-Naphthaleneacetic acid,170466030,Fusarium oxysporum Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),86-87-3,,37.68576212,0,-4.423822698,-10.56017493,-3,7,,-36.17768595,-32.23140496,0.007137158,0.963426067,,,O=C(O)Cc2cccc1ccccc12,Specs,AE-562/J257199,0,0,4.61538462,-3.58632193,0,0,-32.23140496,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00091195-08,Hexachlorophene,170464690,Glucose-6-phosphate dehydrogenase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),70-30-4,,9.466235454,1,-5.023822698,-75.84383889,-2.1,7,,-98.91983471,-97.63872491,7.88E-07,0.999637428,,,Clc2c(Cc1c(O)c(Cl)cc(Cl)c1Cl)c(O)c(Cl)cc2Cl,Vitas,STK377478,1.2012012,0.3931848,0,0,0,-61.64772727,-97.63872491,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00164544-02,Lanoconazole,170465886,Lanosterol 14-alpha demethylase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),101530-10-3,,23.7781084,0,-4.623822698,-30.99086497,-2.2,7,,-63.79870129,-49.4687131,0.000144521,0.995054064,3641571,ERG11,N#C\C(=C1/SCC(S1)c2ccccc2Cl)n3ccnc3,Sequoia,SRP01160l,0,-1.17955439,0,1.83486239,-4.24570912,-16.00378788,-49.4687131,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00179382-03,Hexylcaine hydrochloride,170465088,Sodium channel alpha subunit Blocker,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),532-76-3,,2.99348649,1,-5.523822698,-40.07097501,-1.4,7,,-16.3763553,-19.00826446,0.028004453,0.922911891,,,Cl.CC(CNC1CCCCC1)OC(=O)c2ccccc2,"Prestwick Chemical, Inc.",Prestw-788,-5.40540541,-2.35910878,-7.3992674,-0.91743119,-8.03974706,-22.06439394,-19.00826446,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00263155-09,Belinostat,404904701,HDAC Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),414864-00-9,,18.88762287,0,-4.723822698,-39.02632512,-2.2,7,,-62.70011179,-47.12129681,0.012816922,0.949899553,,HDAC1,ONC(=O)/C=C/C1=CC(=CC=C1)[S+]([O-])(=O)NC2=CC=CC=C2,MedChem Express,HY-10225,0.85503304,0.61804697,0,-0.9009009,-15.20581114,-17.9,-47.12129681,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00168786-02,Deserpidine,144206653,Synaptic vesicular amine transporter Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),131-01-1,Deserpidine,15.00297213,0,-4.823822698,-54.66268816,-2.1,7,"deserpidinum;CIPLUS_151707;LS-178544;CIPLUS_743119;deserpidine;reserpidine;ORETICYL FORTE;Deserpidine;METHYCLOTHIAZIDE;LS-7299;3-beta,20-alpha-Yohimban-16-beta-carboxylic acid, 18-beta-hydroxy-17-alpha-methoxy-,methyl ester, 3,4,5-trimethoxybenzoate (ester);Deserpidina;Deserpidinum;LS-178610;DESERPIDINE;",-102.2084405,-92.7333706,2.15531E-05,0.99809893,,,COc1cc(cc(OC)c1OC)C(=O)O[C@@H]3C[C@@H]4CN5CCc2c6ccccc6nc2[C@H]5C[C@@H]4[C@@H]([C@H]3OC)C(=O)OC,GVK,GVK-NIH-19,0,4.16151628,1.92221726,0,0,-37.9,-92.7333706,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00487176-01,EAA-090,405558601,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),144912-63-0,,79.43282347,0,-4.1,-7.033036395,-2.4,7,,-24.21464506,-20.17887088,6.50E-09,0.999967069,,,O[P](O)(=O)CCN1CCCN/C2=C1/C(=O)C2=O,SIGMA,SML0206,0,0,0,0,0,0,-20.17887088,,,,,,,,,7.31E-09,3.66E-08,1.83E-07,9.14E-07,0.00000457,2.29E-05,0.000114,,,,,,,,
NCGC00346629-02,Dolutegravir (GSK1349572),405558481,HIV Integrase Inhibitors,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1051375-16-6,,8.436791229,1,-5.073822698,-40.57302796,-3,7,,-96.568,0,0.009466379,0.979543234,,,C[C@@H]1CCO[C@H]2CN\3/C=C(/C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)\C(=C3C(=O)N12)O,Selleck,S2667,-4.35289545,0,-11.75681717,0.18018018,0,-81.8,0,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00183867-06,ALOIN,,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),5133-19-7,,7.519298098,1,-5.123822698,-86.31324081,-2.2,7,,-73.61878144,-76.85858021,0.005187238,0.969074924,,,[H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@@]2([H])C3=C(C(O)=CC=C3)C(=O)C4=C2C=C(CO)C=C4O,Microsource,1503427,0,-4.16151628,0,-16.21621622,-6.77966102,-57.9,-76.85858021,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00094819-07,Hexetidine,170465729,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),141-94-6,,37.68576212,0,-4.423822698,-9.624402766,-2.4,7,,-31.01062574,-27.50885478,7.00E-10,0.999989394,,,CCC(CCCC)CN1CC(C)(N)CN(CC(CCCC)CC)C1,Microsource,1500633,0,0,0,0,0,0,-27.50885478,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00166104-04,alpha-Lipoic acid amide,170465868,apoptotic process Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),940-69-2,,10.62129087,0,-4.973822698,-11.93260078,-2.4,7,,-25.69362456,-23.49468713,0.001783511,0.982276006,,,NC(=O)CCCCC1CCSS1,Microsource,1505740,1.2012012,3.80078637,0,0,1.7163505,-12.40530303,-23.49468713,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016373-08,Benzethonium chloride,170465473,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),121-54-0,,4.228412057,1,-5.373822698,-25.94636696,-1.4,7,,-28.25,-24.20306966,0.004028179,0.972935223,,,[Cl-].CC(C)(C)CC(C)(C)c2ccc(OCCOCC[N+](C)(C)Cc1ccccc1)cc2,Microsource,1500138,3.96396396,0,0,0,0,-30.20833333,-24.20306966,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00386216-07,Indacaterol (maleate),405559054,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),753498-25-8,,26.67947643,0,-4.573822698,-41.2625401,-2.2,7,,-84.99161543,-65.90273896,0.001760864,0.982368045,,,CCC1=CC2=C(CC(C2)NC[C@H](O)C3=CC=C(O)C4=C3\C=C/C(=O)N4)C=C1CC,MedChem Express,HY-14299A,-0.15546055,1.11248455,0,0,-9.97578692,-17,-65.90273896,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00480787-02,Cangrelor (AR-C69931),405559017,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),163706-36-3,,10.62129087,0,-4.973822698,-56.67265396,-2.1,7,,-91.7705422,-88.03801006,2.50171E-05,0.997951352,,,CSCCNC1=NC(=NC2=C1N=C[N]2[C@@H]3O[C@H](CO[P](O)(=O)O[P](O)(=O)C(Cl)(Cl)[P](O)(O)=O)[C@@H](O)[C@H]3O)SCCC(F)(F)F,DC Chemicals,DC7005,3.73105325,0,0.26821636,3.15315315,1.4527845,-46.8,-88.03801006,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00274062-01,Zosuquidar trihydrochloride,174006281,P-Glycoprotein (MDR-1) Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),167465-36-3,LY335979,11.91728437,0,-4.923822698,-60.42453246,-2.2,7,,-83.36948016,-77.19396311,0.000047471,0.997174462,,ABCBA,Cl.Cl.Cl.FC3(F)[C@@H]2c7ccccc7[C@H](c1ccccc1[C@@H]23)N4CCN(CC4)C[C@@H](O)COc6cccc5ncccc56,Selleck,S1481,-0.23319083,2.76060981,0.6705409,-2.43243243,-8.03874092,-40.5,-77.19396311,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00159443-05,"BETAMETHASONE 17,21-DIPROPIONATE",405558654,Glucocorticoid steroid,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),5593-20-4,,16.8336116,0,-4.773822698,-17.32091045,-2.4,7,,-31.67859139,-28.89882616,0.009265392,0.957975386,,NR3C1,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CC\C4=C\C(=O)\C=C/[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C,Microsource,1503210,1.9432569,0,0,-4.59459459,1.937046,-10.2,-28.89882616,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00178065-03,TENIPOSIDE,405559077,DNA Topoisomerase II Inhibitors,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),29767-20-2,,18.88762287,0,-4.723822698,-46.93253936,-2.2,7,,-90.82839575,-68.80939072,0.000065334,0.996682664,,TOP2A,COC1=C(O)C(=CC(=C1)[C@H]2[C@@H]3C(COC3=O)C(O[C@@H]4O[C@@H]5CO[C@H](OC5[C@H](O)[C@H]4O)C6=CC=CS6)C7=C2C=C8OCOC8=C7)OC,Microsource,1504094,1.78779635,0,2.45864998,1.98198198,-8.91041162,-30.6,-68.80939072,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00160469-01,Gamolenic acid,144205388,prostanoid metabolic process Interacts,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),506-26-3,Gamolenic acid; ,7.943282347,1,-5.1,-22.02027829,-2.4,7,"CIS,CIS,CIS-6,9,12-OCTADECATRIENOIC ACID;GAMMA-LINOLENIC ACID (18:3 N-6);CIPLUS_710725;gamma-Linolenic Acid;cis,cis,cis-6,9,12-Octadecatrienoic acid;GAMMA-LINOLENIC ACID;GAMMA-LINOLENIC ACID (18:3 n-6);CIS-LINOLEIC ACID/GAMMA-LINOLENIC ACID;GAMOLENIC ACID;NCGC00160469-03;EVENING PRIMROSE OIL;6,9,12-Octadecatrienoic acid, (Z,Z,Z)-;acide gamolenique;Gamolenic acid;acidum gamolenicum;CIPLUS_153754;gamma-Linolenic acid;",-21.18,-15.14812745,0.042047223,0.902478839,,,O=C(O)CCCC\C=C/C/C=C\C/C=C\CCCCC,FLUKA,FLUKA_62172,0,0,0,2.43243243,0,-26.4,-15.14812745,,,,,,,,,7.31E-09,3.66E-08,1.83E-07,9.14E-07,0.00000457,2.29E-05,0.000114,,,,,,,,
NCGC00522551-01,Monepantel,405558479,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),887148-69-8,,37.68576212,0,-4.423822698,-17.58027483,-3,7,,-35.23979877,-32.69983231,0.030178844,0.919450105,,,C[C@](COC1=CC(=CC=C1C(F)(F)F)C#N)(NC(=O)C2=CC=C(SC(F)(F)F)C=C2)C#N,MedChem Express,HY-14774,0,-3.6670787,-7.28654448,0.99099099,-2.32445521,3.5,-32.69983231,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00168748-02,Rotigotine,170465204,Dopamine D4 receptor Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),99755-59-6,,15.00297213,0,-4.823822698,-26.07895038,-2.4,7,,-29.61738401,-25.09782001,0.035974842,0.910996696,,,Oc2cccc1C[C@H](CCc12)N(CCC)CCc3cccs3,Tocris,3896,-0.46638166,0,-0.6705409,-4.68468468,-9.39467312,-9.4,-25.09782001,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00159435-03,Amiloxate,29215377,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,Amiloxate; Neo Heliopan; ,28.18382931,0,-4.55,-49.61307419,-2.2,7,"3-MPMBEPA;3-(4-methoxyphenyl)-2-propenoic acid 3-methylbutyl ester;CIPLUS_669269;3-(4-Methoxy-phenyl)-acrylic acid pentyl ester;3-(4-methoxyphenyl)-3-methylbutylester, propenoic acid;AMILOXATE;ISOAMY 4-METHOXYCINNAMATE;Amiloxate;Neo Heliopan;amiloxatum;",-64.88904416,-62.21352711,0.001838227,0.981973605,,,COC1=CC=C(\C=C\C(=O)OCCC(C)C)C=C1,Chembridge,CB_5258581,-7.53983677,-1.93654718,1.65400089,0,0,-26.6,-62.21352711,,,,,,,,,7.31E-09,3.66E-08,1.83E-07,9.14E-07,0.00000457,2.29E-05,0.000114,,,,,,,,
NCGC00346550-02,Lumacaftor,405559081,CFTR Channel Modulator,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),936727-05-8,,13.37141299,0,-4.873822698,-35.17255928,-2.2,7,,-40.33566238,-38.73672443,0.001257771,0.985174481,,CFTR,CC1=C(N=C(NC(=O)C2(CC2)C3=CC4=C(OC(F)(F)O4)C=C3)C=C1)C5=CC=CC(=C5)C(O)=O,Selleck,S1565,0,-2.59579728,-0.22351363,-3.06306306,-7.16707022,-17.9,-38.73672443,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00482976-01,Vorapaxar Sulfate,405558904,Proteinase-activated receptor 1 Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),705260-08-8,,10.62129087,0,-4.973822698,-50.6654977,-2.2,7,,-67.97512576,-67.13247624,3.15953E-05,0.997696978,2149,F2R,CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]3C([C@@H](C)OC3=O)[C@H]2\C=C\C4=NC=C(C=C4)C5=CC(=CC=C5)F,DC Chemicals,DC8229,-2.48736883,0,0.53643272,0,0,-36.2,-67.13247624,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167832-06,Carvedilol tartrate,170465440,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),NOCAS_45916,"; carvedilol, 14C-labeled; 8   Carvedilol;Carvedilol; Coreg; carvedilol, (S)-isomer; Carvedilol; carvedilol, (R)-isomer",7.519298098,1,-5.123822698,-19.2652219,-1.4,7,,-21.42680047,-21.60566706,1.9897E-06,0.999424656,153,ADRB1,O=C(O)C(O)C(O)C(=O)O.COc4ccccc4OCCNCC(O)COc2cccc3nc1ccccc1c23,Microsource,1504257,0,0,0,0,0,-16.76136364,-21.60566706,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00161621-03,Cepharanthine,170465994,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),481-49-2,,9.466235454,1,-5.023822698,-86.22772193,-2.1,7,,-97.24510035,-97.87485242,0.002116659,0.980609836,,,COc8ccc1cc8Oc7ccc(C[C@H]4c5c(Oc3cc2c(CCN(C)[C@@H]2C1)cc3OC)c6OCOc6cc5CCN4C)cc7,Vitas,STK801907,1.8018018,1.17955439,-13.40659341,1.91826522,-7.85907859,-58.61742424,-97.87485242,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00095312-04,Deracoxib,170465679,Prostaglandin G/H synthase 2 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),169590-41-4,,37.68576212,0,-4.423822698,-33.95351588,-3,7,,-69.35301062,-64.34474616,0.02400314,0.92917389,791253,PTGS2,NS(=O)(=O)c1ccc(cc1)n3nc(cc3c2ccc(OC)c(F)c2)C(F)F,Microsource,1505222,3.72372372,-12.5819135,-10.91575092,0,2.25835592,0,-64.34474616,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00179663-03,"(-)-(5S,8R)-Lisuride",170465966,Dopamine D5 receptor Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),159701-44-7,,21.19226141,0,-4.673822698,-28.50404454,-3,7,,-72.51416766,-70.01180638,0.000238935,0.993623838,,,CCN(CC)C(=O)N[C@@H]2C=C1c3cccc4ncc(C[C@@H]1N(C)C2)c34,Tocris,4052,0,-2.88335518,0,0,4.24570912,-7.10227273,-70.01180638,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00091038-04,Sodium deoxycholate monohydrate,225144203,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),145224-92-6,,18.88762287,0,-4.723822698,-43.97275098,-2.2,7,,-75.66883117,-69.06729634,0.000061409,0.996784472,,,C[C@H](CCC([O-])=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C,SIGMA,D5670,-2.64264264,0,-1.24542125,-2.91909925,0,-20.73863636,-69.06729634,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00093926-05,Doxifluridine,170465861,thymidylate synthase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),3094/9/5, ;5'dFUrd; Ro 21-9738; Furtulon; 5'dFUrd;Doxifluridine; Doxifluridine; Doxifluridina; 5-Fluro-5??-Deoxyuridine;5-fluoro-5'-deoxyuridine; 5-fluoro-5'-deoxyuridine,37.68576212,0,-4.423822698,-4.194262374,-2.4,7,,-24.07674144,-20.89728453,0.008162249,0.960770805,7298,TYMS,FC1=CN(C(=O)NC1=O)[C@@H]2O[C@H](C)[C@@H](O)[C@H]2O,Bosche,D1649,1.68168168,0,-0.07326007,0,-1.35501355,3.69318182,-20.89728453,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00093976-08,Idarubicin hydrochloride,170464627,DNA Topoisomerase II Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),57852-57-0," ; Idarubicina; Idamycin; Idarubicin hydrochloride;Idarubicin HCl; Idarubicin Hcl; 4 Desmethoxydaunorubici; IDARUBICIN HCl; 4 Demethoxydaunorubici; 4-Desmethoxydaunorubicin;Idarubicin; Idarubicin; Hydrochloride, Idarubici;Idarubicin?HCl",13.37141299,0,-4.873822698,-86.63414533,-2.1,7,,-108.5005903,-96.93034238,0.002677376,0.978103403,7153,TOP2A,Cl.CC(=O)[C@@]4(O)C[C@H](O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1)c5c(O)c3C(=O)c2ccccc2C(=O)c3c(O)c5C4,Sequoia,57852-57-0,0.12012012,0,4.32234432,-13.76146789,-17.79584463,-48.39015152,-96.93034238,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00015693-09,Mitoxantrone,170465183,DNA Topoisomerase II Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),70476-82-3, ;Mitoxantrone; Mitoxantrone Hcl; Mitoxantrone; Mitozantrone;MITOXANTRONE HYDROCHLORIDE; Mitoxantrone dihydrochloride;Mitoxantrone dihydrochloride; Mitoxantrona;Mitoxantrone di?HCl;MITOXANTHRONE HYDROCHLORIDE,0.597279078,1,-6.223822698,-184.7717547,-1.1,7,,-102.03125,-98.11097993,6.96716E-05,0.996573135,7153,TOP2A,Cl.Cl.OCCNCCNc3ccc(NCCNCCO)c2C(=O)c1c(O)ccc(O)c1C(=O)c23,Microsource,1503278,3.24324324,0,3.003663,-38.7823186,-84.28184282,-99.52651515,-98.11097993,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00182059-03,Febuxostat,170465220,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),144060-53-7, ; Febuxostat;Febuxostat,18.88762287,0,-4.723822698,-18.48205012,-2.2,7,,-52.68181819,-47.10743802,0.000310015,0.992728164,7498,XDH,CC(C)COc1ccc(cc1C#N)c2nc(C)c(s2)C(=O)O,Tocris,4427,0,1.44167759,0,3.25271059,3.7037037,-11.26893939,-47.10743802,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00015774-06,Oxatomide,170466059,Histamine H1 receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),60607-34-3,,15.00297213,0,-4.823822698,-30.99809654,-2.2,7,,-52.3051948,-47.57969303,1.93808E-05,0.998198232,3269,HRH1,O=C5Nc1ccccc1N5CCCN2CCN(CC2)C(c3ccccc3)c4ccccc4,Enzo,EI114,0,0,0,0,0,-20.54924242,-47.57969303,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00161599-09,Troglitazone,170465091,CCL2 Expression Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),97322-87-7,; Rezulin;GR-92132X;Troglitazone; Troglitazone; Prelay;CS-045;CI-991,6.701581484,1,-5.173822698,-113.841448,-2.1,7,,-105.2061393,-101.8890201,0.000061245,0.996788286,6347,CCL2,Cc1c(O)c(C)c(C)c2OC(C)(CCc12)COc4ccc(CC3SC(=O)NC3=O)cc4,"Prestwick Chemical, Inc.",Prestw-1467,-2.4024024,-7.20838794,0,-4.25354462,-23.57723577,-73.76893939,-101.8890201,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00183658-01,Quadrisol,144207184,Prostaglandin G/H synthase 2 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),71109-09-6,,15.00297213,0,-4.823822698,-38.53610342,-2.4,7,CIPLUS_214418;Vedaprofen;vedaprofen;VEDAPROFEN;vedaprofenum;2-(4-cyclohexyl-1-naphthalenyl)propanoic acid;,-34.09334824,-30.91112353,0.241391357,0.688262254,791253,PTGS2,O=C(O)C(C)c2ccc(c1ccccc12)C3CCCCC3,Toronto Research,,-5.90750097,-9.92995468,3.44210997,4.86486486,-16.94915254,-13.4,-30.91112353,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00091023-06,Cetylpyridinium bromide,170465500,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),140-72-7,,37.68576212,0,-4.423822698,-26.21127606,-3,7,,-93.311098,-82.29043684,2.93267E-05,0.997781363,,,[Br-].CCCCCCCCCCCCCCCC[n+]1ccccc1,Vitas,STK177346,0,0,0,0,0,3.69318182,-82.29043684,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00095150-08,Telmisartan,170464873,Angiotensin AT1 Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),144701-48-4,; Telmisartan and diuretics;Telmisartan; Telmisartan; Micardis; Telmisartan Sodium;TELMISARTAN,15.00297213,0,-4.823822698,-42.90290807,-2.2,7,,-79.96753247,-73.08146399,0.000127889,0.995348328,189,AGT,O=C(O)c1ccccc1c2ccc(cc2)Cn3c4cc(cc(C)c4nc3CCC)c6nc5ccccc5n6C,Microsource,1505261,0,-1.31061599,0,4.42035029,0,-27.93560606,-73.08146399,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00160622-04,D-delta-Tocopherol,144206758,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),119-13-1,,10.62129087,0,-4.973822698,-21.96017673,-2.2,7,,-33.81109799,-33.17591499,7.35118E-05,0.996482367,,,CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2cc(O)cc(C)c2O1,NCGCChem,XJB03-045,1.32132132,0,0,0,1.53568202,-18.08712121,-33.17591499,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00238452-03,Enzastaurin,170465609,"PKCa, PKCb, PKCg inhbitor",Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),170364-57-5, Enzastaurin;LY-317615;Enzastaurin,5.32325539,1,-5.273822698,-113.9072066,-2.1,7,,-106.5613932,-98.58323495,2.80191E-05,0.997831425,5578,PRKCA,Cn2cc(c1ccccc12)C=3C(=O)NC(=O)C=3c7cn(C5CCN(Cc4ncccc4)CC5)c6ccccc67,Selleck,S1055,0,0,-4.90842491,-4.58715596,-30.62330623,-73.57954545,-98.58323495,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00091146-08,Phenothiazine,170466563,Trichostrongylus colubriformis Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),92-84-2,,4.74435636,1,-5.323822698,-101.366578,-1.1,7,,-95.58972846,-92.68004723,6.7586E-06,0.998936885,,,c1ccc2Sc3ccccc3Nc2c1,SIGMA,P14831,0,2.09698558,-0.95238095,0.58381985,-18.33785005,-82.10227273,-92.68004723,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00091112-09,Methylrosaniline chloride,170464787,TNFR1 (p55/CD120a) Modulator,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),548-62-9,; Triple Dye; Basic Violet 3; ; Methyl violet 2B; Hexamethyl-p-rosaniline chloride (Gentian violet); Crystal Violet;GENTIAN VIOLET; Genapax; Methyl Violet 10B; Gentian violet; Crystal violet solution;Gentian violet,0.474435636,1,-6.323822698,-202.6202779,-1.1,7,,-101.3783943,-102.1251476,1.17739E-05,0.99859599,,TNFR1,[Cl-].C/[N+](C)=C1\C=C\C(C=C1)=C(/c2ccc(cc2)N(C)C)c3ccc(cc3)N(C)C,Microsource,1500315,0,0,0,-46.62218515,-93.67660343,-98.57954545,-102.1251476,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00024196-05,Megestrol acetate,170465406,Progesterone Receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),595-33-5,; Novacyclin 22; Serial C; Megeron; Megace;Megestrol acetate; Megestrol 17-acetate;Megestrol Acetate; Oraconal; Me-quingestanol,4.74435636,1,-5.323822698,-28.32475592,-1.4,7,,-26.84090909,-26.32821724,1.30191E-05,0.998524763,5241,PGR,CC(=O)[C@@]3(OC(C)=O)CC[C@H]2[C@@H]4C=C(C)C1=CC(=O)CC[C@]1(C)[C@H]4CC[C@@]23C,"Prestwick Chemical, Inc.",Prestw-956,0,0,0,0,0,-27.36742424,-26.32821724,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016246-09,Chlorhexidine,170464748,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),55-56-1," Corsodyl ICI; Chlorhexidine base; Anticataracticum; Arlacide H; Lisium; 8   Chlorhexidine Base; Hibiclens; Tubilicid blue label; Hexidine; Curasept ADS 220; Clorhexidina;Chlorhexidine; Eludril; Instillagel; Hibisol; Trisdine; A, Sebidi; Sebidin A; Chlorhexidine; Gibitan; Hibident; Progaron; ; Anticataracticum tablet; Perio Chip; Chlorhexamed; Tubilicid red label;CHLORHEXIDINE; Tubilicid; Acetate, Chlorhexidin;Chlorhexidine diacetate; Novalsan; Hibiscrub; Dyna-Hex; Peridex; Dantroche hibitane",4.228412057,1,-5.373822698,-23.38718342,-3,7,,-45.87500001,0,0.00056262,0.996970692,4312,MMP1,Clc2ccc(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)cc2,Vitas,STK089248,-2.28228228,-0.2621232,0,0,-9.30442638,-41.95075758,0,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00480885-01,INT-747 (Obeticholic acid),405558423,Bile acid receptor FXR Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),459789-99-2,,23.7781084,0,-4.623822698,-21.32681873,-3,7,,-54.32615987,-49.02179989,1.5942E-06,0.999484345,,,CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]4(C)CC[C@@H](O)C[C@@H]14,Glixx,GLXC-05527,1.01049359,0,0,0,0,-7.3,-49.02179989,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00017343-11,RETINOL,405558473,Retinol dehydrogenase 12 Substrate,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),68-26-8,,37.68576212,0,-4.423822698,-11.58617098,-3,7,,-38.81693683,-34.48854108,4.26E-07,0.999733673,145226,RDH12,CC(=C\CO)/C=C/C=C(C)/C=C/C1=C(\C)CCCC1(C)C,Microsource,1501203,0.15546055,0,0,0,0.4842615,0,-34.48854108,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167492-03,Lercanidipine hydrochloride,170465587,Voltage-gated L-type calcium channel Blocker,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),132866-11-6,,5.972790784,1,-5.223822698,-85.64489552,-2.1,7,,-86.81721632,-84.12520961,1.3684E-06,0.999522126,,,Cl.CC=3NC(C)=C(C(C=3C(=O)OC(C)(C)CN(C)CCC(c1ccccc1)c2ccccc2)c4cccc(c4)[N+]([O-])=O)C(=O)OC,Sequoia,132866-11-6,0,-0.53564071,0,0,-16.94915254,-63,-84.12520961,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00263905-04,TOLTRAZURIL,405558935,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),69004-03-1,,3.768576213,1,-5.423822698,-86.72127629,-2.2,7,,-77.11934042,-65.45556177,0.014217037,0.946975686,,,CN1C(=O)NC(=O)N(C1=O)C2=CC=C(OC3=CC=C(SC(F)(F)F)C=C3)C(=C2)C,Microsource,1505681,2.17644773,0,2.27983907,-23.24324324,-20.72639225,-52.5,-65.45556177,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00181319-01,Plicamycin,144206340,DNA Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),18378-89-7,"Plicamycin; Mithracin; Mithramycine; Mitramycin; Plicamicina; Mithramycinum; Mitramicina; Acid, Aureoli; ",13.37141299,0,-4.873822698,-61.96139686,-2.1,7,"Mithramycine;Plicamycinum;CIPLUS_741126;plicamycinum;Mithramycinum;Acid, Aureoli;Mithracin;mithramycin A;PA-144;Mithramycin A;NCGC00162423-01;NSC-24559;Mithramycin A Streptomyces plicatus;MITHRAMYCIN A;mithramycin;Plicamycin;MITHRAMYCIN;WHO NO. 2029;Mitramycin;Plicamicina;CIPLUS_171437;Aureolic acid;Plicamycine;PLICAMYCIN;Mitramicina;Mithramycin;plicamycin;AUREOLIC ACID;plicamycine;A-2371;LS-91528;",-94.96031302,-87.92621576,0.000166375,0.994688251,,,C[C@@H](O)[C@H](O)C(=O)[C@@H](OC)C6Cc7cc8cc(O[C@H]2C[C@@H](O[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1)[C@@H](O)[C@@H](C)O2)c(C)c(O)c8c(O)c7C(=O)[C@H]6O[C@H]5C[C@@H](O[C@H]4C[C@@H](O[C@H]3C[C@](C)(O)[C@H](O)[C@@H](C)O3)[C@H](O)[C@@H](C)O4)[C@H](O)[C@@H](C)O5,SIGMA,M6891,0,0,0,-4.86486486,0,-39.8,-87.92621576,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00161602-06,Doxycycline,170465097,Matrix Metalloproteinase (MMP) Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),10592-13-9,; ; Monodox;DOXYCYCLINE HYDROCHLORIDE; Doryx; 1   Doxycycline Mono; Doxycycline hydrochloride; Doxycycline SSa; Atridox;Doxycycline; Doxiciclina; Vibramycin; Vibra-Tabs;Doxycycline hydrochloride; 0   Doxycycline Hyclate; Periostat,16.8336116,0,-4.773822698,-42.11265662,-2.4,7,,-47.5064935,-43.56552538,0.096608799,0.837512647,4312,MMP1,Cl.NC(=O)C=3C(=O)[C@@]4(O)C(O)=C2C(=O)c1c(O)cccc1[C@H](C)[C@H]2[C@H](O)[C@H]4[C@@H](C=3O)N(C)C,Prestwick,Prestw-1399,0,0,0,-17.764804,0.81300813,-21.49621212,-43.56552538,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00178241-04,Dichloro(ethylenediamine)platinum(II),170466890,DNA Alkylating Agent,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),14096-51-6,,1.191728437,1,-5.923822698,-168.2771672,-1.1,7,,-102.0863636,-99.52774498,0.000101995,0.995848746,,,[Cl-][Pt]1([Cl-])NCCN1,Microsource,1502107,-1.32132132,0,2.27106227,-23.10258549,-68.20234869,-100.2840909,-99.52774498,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00015889-11,Raloxifene hydrochloride,170465341,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),82640-04-8, ; Keoxifene;Evista; Raloxifene Lilly Bran; Evista;RALOXIFENE HYDROCHLORIDE; Lilly Brand of Raloxifene; Raloxifene hydrochloride;Raloxifene hydrochloride,7.519298098,1,-5.123822698,-101.9455396,-2.1,7,,-114.9,-100,0.000155639,0.994863746,2099,ESR1,Cl.Oc1ccc(cc1)c3sc2cc(O)ccc2c3C(=O)c5ccc(OCCN4CCCCC4)cc5,Microsource,1505622,2.64264264,0,-3.88278388,0,-27.73261066,-67.70833333,-100,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016059-13,Thioridazine,170465080,Serotonin 2c (5-HT2c) receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),50-52-2,,9.466235454,1,-5.023822698,-64.59874924,-2.1,7,,-83.11865408,-82.05430933,7.07E-07,0.999656665,,,CN4CCCCC4CCN1c3ccccc3Sc2ccc(SC)cc12,Enzo,NS835,0,0,0.21978022,0,0,-51.60984848,-82.05430933,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00346704-03,Cabazitaxel,405558547,Tubulin depolymerization Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),183133-96-2,,3.358747085,1,-5.473822698,-71.05490635,-1.2,7,,-45.28926775,-43.99105646,0.019000512,0.937836619,,TUBB,CO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)C4=CC=CC=C4)[C@]5(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C6=CC=CC=C6)/C(=C(/[C@@H](OC)C(=O)[C@]13C)C5(C)C)C,APExBIO,B2157,-7.85075787,1.68932839,0,-14.77477477,-17.53026634,-38.8,-43.99105646,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00262603-04,Idelalisib,405558681,PI3Kdelta Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),870281-82-6,,26.67947643,0,-4.573822698,-16.82597197,-3,7,,-54.94270543,-43.20849637,0.000305414,0.992783827,,PIK3CD,CC[C@H](NC1=C2N=C[NH]C2=NC=N1)C/3=N/C4=C(C(=CC=C4)F)C(=O)N3C5=CC=CC=C5,Axon Medchem,2170,3.10921104,0,1.47518999,1.35135135,-1.8401937,-7.5,-43.20849637,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00346438-03,Retaspimycin (Hydrochloride),405558694,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),857402-63-2,,11.91728437,0,-4.923822698,-71.4728663,-2.1,7,,-101.235886,-87.92621576,0.000142257,0.995091571,,HSP90AB1,CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=CC(=C2O)NC(=O)C(=C\C=C/[C@H](OC)[C@@H](OC(N)=O)C(=C\[C@H](C)[C@H]1O)/C)/C)O,MedChem Express,HY-10210,0,3.09023486,0,0,-15.98062954,-45.4,-87.92621576,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00386267-03,(R)-Lansoprazole,405558696,H+/K+-ATPase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),138530-94-6,,21.19226141,0,-4.673822698,-14.62644653,-3,7,,-50.68278368,-43.32029067,0.000558126,0.99020299,,ATP4A,CC1=C(C[S@@+]([O-])C2=NC3=C([NH]2)C=CC=C3)N=CC=C1OCC(F)(F)F,MedChem Express,HY-13662B,1.63233579,0,0.13410818,4.86486486,2.51815981,-8.9,-43.32029067,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00095123-10,Candesartan cilexetil (Atacand),405558788,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),145040-37-5,,5.972790784,1,-5.223822698,-89.38266791,-1.3,7,,-90.3138625,-90.72107323,0.365152292,0.997155918,,,CCOC1=NC2=CC=CC(=C2[N]1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NN=N[NH]5)C(=O)OC(C)OC(=O)OC6CCCCC6,Adooq,A10176,-71.97823552,0,4.8278945,0,-4.16464891,-83.2,-90.72107323,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00166146-02,Quinestrol,170465054,Estrogen receptor Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),152-43-2,,13.37141299,0,-4.873822698,-56.2886127,-2.4,7,,-67.25684741,-60.31302404,0.727536791,0.975908326,,,C#C[C@]5(O)CC[C@@H]2[C@]5(C)CC[C@@H]3c4ccc(OC1CCCC1)cc4CC[C@@H]23,SIGMA,E7887,-95.06412748,-2.59579728,0,0,-15.69007264,-28.7,-60.31302404,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00179431-03,Carbenoxolone sodium,170465951,gap junction assembly Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),7421-40-1,,11.91728437,0,-4.923822698,-52.20029559,-2.2,7,,-62.18654073,-62.92798111,0.006868445,0.964135468,,,[Na+].[Na+].[O-]C(=O)CCC(=O)O[C@H]4CC[C@]3(C)[C@H]5C(=O)C=C1[C@@](C)(CC[C@@]2(C)CC[C@@](C)(C[C@@H]12)C([O-])=O)[C@]5(C)CC[C@H]3C4(C)C,"Prestwick Chemical, Inc.",Prestw-837,0,-12.0576671,0,0,0,-31.15530303,-62.92798111,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00024667-14,Methyldopa,170464643,DOPA decarboxylase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),41372-08-1,"; L-alpha-Methyl DOPA;METHYLDOPA; L-alpha-Methyl-DOPA;Methyldopa; ; DL-alpha-Methyl-DOPA; Methoplain; Metildopa;L-alpha-Methyl DOPA; alpha-Methyl-L-DOPA; L(-)-alpha-Methyldopa;Methyldopa sesquihydrate; Methyldopa (L,-);Methyldopa (L,-); L-Methyldopa; Methyldopa sesquihydrate; Aldomet; L-Alphamethyl Dopa",13.37141299,0,-4.873822698,-62.10455741,-2.1,7,,-99.31936245,-91.49940968,1.88425E-05,0.998222859,1644,DDC,O.O.O.Oc1ccc(C[C@](C)(N)C(=O)O)cc1O.O=C(O)[C@@](C)(N)Cc1cc(O)c(O)cc1,Microsource,1500403,0,0,0,0,0,-43.08712121,-91.49940968,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00018268-08,Itraconazole,,cytochrome inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),84625-61-6,,9.466235454,1,-5.023822698,-88.00053897,-2.1,7,,-109.379575,-92.68004723,0.000318996,0.992619542,,,CCC(C)N1N=CN(C1=O)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(OCC5COC(CN6C=NC=N6)(O5)C7=CC=C(Cl)C=C7Cl)C=C4,Selleck,S2476,-3.96396396,2.35910878,2.63736264,0,-22.85456188,-56.53409091,-92.68004723,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00262957-01,Tobicillin,170466044,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),151287-22-8,Tobicillinum;Tobicilline;Tobicillin,37.68576212,0,-4.423822698,-17.58790404,-3,7,,-44.95388485,-40.7490218,0.009771296,0.956731814,,,CC(C)C(=O)OCc4cc(OC(=O)[C@@H]2N3C(=O)[C@@H](NC(=O)Cc1ccccc1)[C@H]3SC2(C)C)ccc4,GVK,FFS-11-286-NCI-195,0,0,0,-7.56756757,2.80871671,0,-40.7490218,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00390584-01,Exatecan,384569198,DNA Topoisomerase I Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),169869-90-3,,16.8336116,0,-4.773822698,-20.56814554,-2.2,7,,-46.43627725,-40.8608161,0.001425848,0.984186516,,TOP1,CC[C@@]1(O)C(=O)OC/C2=C1/C=C3\N(CC4=C5[C@@H](N)CCC6=C5C(=CC(=C6C)F)N=C34)C2=O,MedChem Express,HY-13631A,3.96424407,0,2.77156907,-2.43243243,0,-14.5,-40.8608161,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00346455-05,Cobimetinib,405558491,Mek Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1453848-26-4,,15.00297213,0,-4.823822698,-40.43575045,-2.2,7,,-64.58021241,-59.53046395,0.00019318,0.994273427,,MAP2K1,OC1(CN(C1)C(=O)C2=C(NC3=C(F)C=C(I)C=C3)C(=C(F)C=C2)F)[C@@H]4CCCCN4,ActiveBioChem,A-1318,-3.65332297,0,0,0,0,-23.3,-59.53046395,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00522464-01,Lusutrombopag,405558628,Thrombopoietin receptor Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1110766-97-6,,5.972790784,1,-5.223822698,-96.30868105,-1.1,7,,-92.59094466,-93.40413639,2.6303E-06,0.999337234,,,CCCCCCO[C@@H](C)C1=C(OC)C(=CC=C1)C2=CSC(=N2)NC(=O)C3=CC(=C(/C=C(C)/C(O)=O)C(=C3)Cl)Cl,MedChem Express,HY-19883,-1.32141469,0.12360939,-2.45864998,-0.27027027,-13.17191283,-73.6,-93.40413639,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00022398-05,Fluocinonide,170464717,Glucocorticoid steroid,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),356-12-7,;Fluocinonide; Lidex; Fluocinonido;Fluocinonide (Vanos),21.19226141,0,-4.673822698,-23.53585953,-3,7,,-41.77272728,-38.84297521,0.001945829,0.981446931,,NRC31,CC(=O)OCC(=O)[C@]45OC(C)(C)O[C@@H]5C[C@@H]3[C@]4(C)C[C@H](O)[C@@]2(F)[C@H]3C[C@H](F)C1=CC(=O)C=C[C@@]12C,"Prestwick Chemical, Inc.",Prestw-774,0,-5.24246396,0,0,0,-8.99621212,-38.84297521,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016806-13,Mebendazole,170464914,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),31431-39-7,; ; Vermox;Mebendazole; Mebendazol; Mebendazole;MEBENDAZOLE,23.7781084,0,-4.623822698,-36.57079435,-3,7,,-78.94805194,-76.62337662,0.000141694,0.995101694,203068,TUBB,O=C(OC)Nc1nc2cc(ccc2n1)C(=O)c3ccccc3,Microsource,1501110,-5.40540541,0,0,0,0,-6.91287879,-76.62337662,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00013683-06,Chlorprothixene,170465069,Serotonin (5-HT) receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),113-59-7,,11.91728437,0,-4.923822698,-38.66953131,-2.2,7,,-62.05548996,-59.85832349,8.84941E-05,0.996135914,3269,,CN(C)CC\C=C1/c3ccccc3Sc2ccc(Cl)cc12,Microsource,1503203,0,0.3931848,0,1.25104254,2.80036134,-29.82954545,-59.85832349,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00091058-11,Linolenic acid,225144205,Fatty acid desaturase 2 Substrate,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),463-40-1,,37.68576212,0,-4.423822698,-10.77983151,-3,7,,-40.51239669,-35.53719008,0.000127577,0.995357254,9415,FADS2,CC\C=C/C/C=C\C\C=C/CCCCCCCC(O)=O,SIGMA,62160,0,0,0,0,0,2.36742424,-35.53719008,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00021569-09,Enalapril maleate,170464969,Angiotensin-I Converting Enzyme Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),75847-73-3," Enalaprila;;Enalapril; 7   Enalapril; Enalapril; ; Vasotec; Maleate, Enalapri; Renitec; 8   Enalapril maleate;Enalapril maleate; Enalapril maleate salt; Renitek;ENALAPRIL MALEATE; Renivace",7.519298098,1,-5.123822698,-82.10643564,-1.1,7,,-79.50354191,-81.58205431,0.0017517,0.982412618,1636,ACE,OC(=O)[C@@H]2CCCN2C(=O)[C@H](C)N[C@@H](CCc1ccccc1)C(=O)OCC,Microsource,1501214,0,-11.9266055,0,2.75229358,0,-67.51893939,-81.58205431,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00013058-02,Malachite green oxalate,170465712,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),2437-29-8,,2.667947643,1,-5.573822698,-129.3034187,-1.1,7,,-96.43530106,-99.52774498,5.4507E-06,0.999045433,,,C/[N+](C)=C1\C=C/C(C=C1)=C(/c2ccccc2)c3ccc(cc3)N(C)C.[O-]C(=O)C(=O)O.[O-]C(=O)C(=O)O.O=C(O)C(=O)O.CN(C)c1ccc(cc1)C(\c2ccccc2)=C3/C=C/C(C=C3)=[N+](/C)C,SIGMA,38800,-2.88288288,0,0,-2.75229358,-32.06865402,-96.68560606,-99.52774498,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00023509-13,Lovastatin,170464913,HMG-CoA Reductase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),75330-75-5,; ; Lovastatin (Mevinolin); Monacolin K; Mevacor;LOVASTATIN; Mevinolin (lovastatin); 6-Methylcompactin; 6 Methylcompacti; Lovastatin;Lovastatin; 6-alpha-Methylcompactin; 6alpha-Methylcompactin,37.68576212,0,-4.423822698,-18.42451222,-3,7,,-49.74144038,-44.51003542,0.002008381,0.981137281,3156,HMGCR,C[C@@H](CC)C(=O)O[C@H]2C[C@@H](C)C=C3C=C[C@H](C)[C@H](CC[C@@H]1C[C@@H](O)CC(=O)O1)[C@@H]23,Vitas,STK801953,-4.56456456,1.83486239,2.12454212,0,-2.07768744,0,-44.51003542,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00183001-01,Tolvaptan,124894207,Vasopressin (AVP) V2 Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),150683-30-0, ; Tolvaptan;Tolvaptan,16.8336116,0,-4.773822698,-67.06845945,-2.2,7,"OPC 41061;OPC-41061;7-chloro-5-hydroxy-1-(2-methyl-4-(2-methylbenzoylamino)benzoyl)2,3,4,5-tetrahydro-1H-1-benzazepine;tolvaptan;TOLVAPTAN;Tolvaptan;7-CHLORO-5-HYDROXY-1-(2-METHYL-4-(2-METHYLBENZOYLAMINO)BENZOYL)-2,3,4,5-TETRAHYDRO-1H-BENZAPINE, DL-;CIPLUS_789421;tolvaptanum;",-64.75349358,-57.29457798,0.023394744,0.930196436,554,AVPR2,Cc1ccccc1C(=O)Nc2ccc(c(C)c2)C(=O)N4CCCC(O)c3cc(Cl)ccc34,Pharmaron,PH-NIH-116369,-3.03148076,-8.776267,0.13410818,-15.4954955,-12.30024213,-26.9,-57.29457798,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00378669-02,Boldenone Undecylenate,405558970,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),13103-34-9,,37.68576212,0,-4.423822698,-14.31515035,-3,7,,-40.22861934,-36.16545556,0.012350133,0.95091387,,,C[C@]12CC[C@H]3[C@@H](CCC\4=C\C(=O)\C=C/[C@]34C)[C@@H]1CC[C@@H]2OC(=O)CCCCCCCCC=C,MedChem Express,HY-17434,-0.46638166,-5.48001648,2.63746089,-2.52252252,0,3.6,-36.16545556,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00093644-07,Amsacrine,404904675,DNA Topoisomerase II Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),54301-15-4,,15.00297213,0,-4.823822698,-52.62560827,-2.2,7,,-63.6704863,-59.97764114,0.000950755,0.987145732,,TOP2A,COC1=C(NC2=C3C=CC=CC3=NC4=C2C=CC=C4)C=CC(=C1)N[S+](C)([O-])=O,Glixx,GLXC-03289,-7.38437621,0,0,-3.51351351,-5.13317191,-27,-59.97764114,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00263180-14,Trametinib,405558802,Mek 1/2 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1204531-25-8,,21.19226141,0,-4.673822698,-11.31448433,-3,7,,-39.80072667,-35.15930688,0.004501198,0.971315243,,MAP2K1,CN1C(=O)C(=C/2N(C(=O)N(C3CC3)C(=O)C2=C1/NC4=CC=C(I)C=C4F)C5=CC=CC(=C5)NC(C)=O)\C,ActiveBioChem,A-1258,0,4.3263288,-1.56459544,0,4.64891041,-6,-35.15930688,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00182044-02,Toltrazuril (sulfone),405558806,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),69004-04-2,,37.68576212,0,-4.423822698,-21.36174205,-3,7,,-50.70849637,-46.67411962,0.009020003,0.958541892,,,CN1C(=O)NC(=O)N(C1=O)C2=CC=C(OC3=CC=C(C=C3)[S+]([O-])(=O)C(F)(F)F)C(=C2)C,MedChem Express,HY-17008,3.49786242,0.86526576,0,-4.86486486,-7.07021792,-0.7,-46.67411962,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00344326-02,"9(E),12(E)-Octadecadienoic acid",405558983,Streptococcus mutans Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),n/a,,9.466235454,1,-5.023822698,-64.80951188,-2.2,7,,-63.58831749,-64.89659027,0.012340133,0.950904732,,,CCCCC/C=C/C/C=C/CCCCCCCC(O)=O,Enzo,BL118,-14.61329188,-0.45323445,3.88913724,0,-2.42130751,-42.2,-64.89659027,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00182983-01,Fezatione,144206829,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),15387-18-5,Fezatione; ,2.37781084,1,-5.623822698,-102.2607917,-1.2,7,Fezatione;FEZATIONE;fezationum;fezatione;3-((P-METHYLBENZYLIDENE)AMINO)-4-PHENYL-4-THIAZOLINE-2-THIONE;CIPLUS_789398;,-68.43801653,-73.55371901,0.004599788,0.970966784,,,S=C2SC=C(N2/N=C/c1ccc(C)cc1)c3ccccc3,Pharmaron,PH-NIH-150803,-0.24024024,-12.7129751,3.07692308,2.08507089,-35.32068654,-66.38257576,-73.55371901,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00024596-08,Carbidopa,225144194,decarboxylase inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),28860-95-9,,26.67947643,0,-4.573822698,-2.416504714,-2.4,7,,-24.92680047,-21.60566706,0.00360139,0.974505904,,DDC,C[C@@](CC1=CC(=C(O)C=C1)O)(NN)C(O)=O,Prestwick,Prestw-1177,0,2.35910878,0,4.00333611,0.9936766,0,-21.60566706,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00159456-11,Imatinib,170465393,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),220127-57-1,GGP-57148B; ; Imatinib base; Imatinib base(IMA-3);STI-571; Imatinib;Imatinib;Gleevec; Glivec,37.68576212,0,-4.423822698,-14.27579078,-3,7,,-33.47756789,-30.81463991,0.083012785,0.852610946,25,ABL1,CS(=O)(=O)O.Cc3ccc(cc3Nc1nc(ccn1)c2cccnc2)NC(=O)c4ccc(cc4)CN5CCN(C)CC5,Prestwick,Prestw-1290,4.56456456,-9.96068152,-3.44322344,0,2.43902439,0,-30.81463991,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00532501-01,ARIPIPRAZOLE LAUROXIL,405558833,Serotonin 1a (5-HT1a) receptor Partial Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,7.130753683,1,-5.146864565,-92.37344229,-2.4,7,,-65.95627178,-53.71716042,0.292832382,0.633601203,,,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=CC=C(OCCCCN3CCN(CC3)C4=C(Cl)C(=CC=C4)Cl)C=C12,Astatech,42552,-5.05246794,-5.97445406,-2.45864998,-7.47747748,-35.64164649,-9.4,-53.71716042,,,,,,,,,9.14E-10,4.57E-09,2.29E-08,1.14E-07,5.71E-07,2.86E-06,0.0000143,,,,,,,,
NCGC00390545-01,Valrubicin,405558480,DNA Topoisomerase II Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),56124-62-0,,3.768576213,1,-5.423822698,-86.40934209,-2.2,7,,-84.3353829,-78.0883175,9.40332E-05,0.996015448,,TOP2A,CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)C3=C(C1)C(=C4C(=O)C5=C(C(=O)C4=C3O)C(=CC=C5)OC)O,MedChem Express,HY-13772,1.78779635,0.28842192,4.60438087,-1.98198198,-29.24939467,-60.6,-78.0883175,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00348215-03,Bedaquiline (TMC-207),405558612,ATP synthase subunit c Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),843663-66-1,,26.67947643,0,-4.573822698,-6.422932599,-2.4,7,,-22.15371716,-20.96143097,0.007944976,0.961334399,886937,atpE,COC1=NC2=C(C=C(Br)C=C2)C=C1[C@@H](C3=CC=CC=C3)[C@@](O)(CCN(C)C)C4=CC=CC5=C4C=CC=C5,Adooq,A12327,0,-2.59579728,2.72686634,1.17117117,0,0,-20.96143097,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00018130-09,Phenazopyridine hydrochloride,170465267,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),136-40-3,,8.436791229,1,-5.073822698,-80.59794806,-2.1,7,,-79.15761511,-80.40141676,0.000346167,0.992307963,,,Cl.Nc2nc(N)ccc2/N=N/c1ccccc1,Microsource,1500473,-2.64264264,0,0,-8.59049208,-7.85907859,-55.20833333,-80.40141676,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00015155-11,Bepridil,170465240,Calcium Channel Blocker,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),64706-54-3," ; Bepridil, (-)-Isomer; Bepridil;Bepridil; Vascor;Bepridil hydrochloride; Bepridil, (+)-Isomer",37.68576212,0,-4.423822698,-12.76924426,-2.4,7,,-24.62691853,-23.02243211,0.021462484,0.933597149,,KCNT1,CC(C)COCC(CN(Cc1ccccc1)c2ccccc2)N3CCCC3,BIOMOL,AC104,-5.76576577,0.78636959,0,0,0,0,-23.02243211,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00182990-01,Tandospirone,144206869,Serotonin 1a (5-HT1a) receptor Partial Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),87760-53-0,Tandospirone citrate; Sediel; ,21.19226141,0,-4.673822698,-19.73900874,-3,7,"LS-178008;TANDOSPIRONE;Sediel;CIPLUS_196843;CIPLUS_667992;TANDOSPIRONE CITRATE;tandospirone;Tandospirone;tandospironum;SM-3997;sm 3997;(3A-A,4B,7B,7A-A)-HEXAHYDRO-2-(4-(4-(2-PYRIMIDINYL)-1-PIPERAZINYL)-BUTYL)-4,7-METHANO-1H-ISOINDOLE-1,3(2H)-DIONE DIHYDROGEN CITRATE;SM 3997;Tandospirone citrate;LS-90979;4,7-Methano-1H-isoindole-1,3(2H)-dione, hexahydro-2-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-, (3aalpha,4beta,7beta,7aalpha)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1);3a,4,7,7a-hexahydro-2-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-4,7-methano-1H-isoindole-1,3(2H)-dione;",-44.91735538,-41.2042503,1.5729E-06,0.999487913,,,O=C4N(CCCCN1CCN(CC1)c2ncccn2)C(=O)[C@@H]5[C@H]3CC[C@H](C3)[C@H]45,Pharmaron,PH-NIH-172250,0,0,0.80586081,0,0,-8.4280303,-41.2042503,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00160623-04,Octinoxate,170464894,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),5466-77-3,,18.88762287,0,-4.723822698,-51.63371633,-2.1,7,,-87,-81.81818182,0.002747456,0.977809269,,,COc1ccc(C=CC(=O)OCC(CC)CCCC)cc1,SIGMA,437174,-10.93093093,3.40760157,0,0,0,-22.06439394,-81.81818182,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016507-05,Thonzonium bromide,170465335,osteoclast development Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),553-08-2,,7.519298098,1,-5.123822698,-91.17826774,-1.1,7,,-97.45371901,-98.34710744,0.000370771,0.99203517,,,[Br-].COc1ccc(cc1)CN(CC[N+](C)(C)CCCCCCCCCCCCCCCC)c2ncccn2,"Prestwick Chemical, Inc.",Prestw-925,0,0.78636959,-8.57142857,2.91909925,0,-76.42045455,-98.34710744,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00164634-02,Balsalazide disodium,170465305,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),80573-04-2,Balsalazide; Balsalazide; ;Balsalazide disodium; balsalzide Disodium; Colazide; Balsalazide sodium,37.68576212,0,-4.423822698,-15.68834931,-2.4,7,,-31.27744982,-29.39787485,0.023069888,0.930805958,,ADORA1,OC(=O)c1cc(ccc1O)/N=N/c2ccc(cc2)C(=O)NCCC(=O)O,Sequoia,SRP00900b,0,-7.73263434,0,0,0,0,-29.39787485,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00164604-10,Fluvastatin Na,405559141,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,29.9348649,0,-4.523822698,-31.51004694,-3,7,,-60.3961039,-53.24675325,0.000517918,0.990566979,,,CC(C)N1C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C(C2=C1C=CC=C2)C3=CC=C(F)C=C3,Sequoia,SRP01980f,0,-3.27653997,0,-5.25437865,-2.80036134,-7.10227273,-53.24675325,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00166134-02,Estradiol cypionate,170464789,Androgen Receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),313-06-4,,9.466235454,1,-5.023822698,-54.55936864,-2.2,7,,-61.81134712,-62.32532141,0.000949501,0.987153356,,,Oc4cc5CC[C@@H]1[C@H](CC[C@]2(C)[C@H](CC[C@@H]12)OC(=O)CCC3CCCC3)c5cc4,SIGMA,E8004,0,0,0,-7.38738739,0,-39.5,-62.32532141,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00182046-04,Efonidipine hydrochloride monoethanolate,,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),[111011-76-8],,10.62129087,0,-4.973822698,-79.29385223,-2.3,7,,-108.617943,-93.96310788,0.354263721,0.997568083,,,CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P3(=O)OCC(C)(C)CO3)C(=O)OCCN(Cc4ccccc4)c5ccccc5,Tocris,3733,0.85503304,-59.12649361,0,1.35135135,-16.56174334,-52.8,-93.96310788,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00506887-01,Sodium aurothiomalate(I),405558583,Prostaglandin E synthase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),12244-57-4,,0.532325539,1,-6.273822698,-38.16293109,-2.4,7,,-24.92,-4.86305198,0.018110378,0.967963153,,,OC(=O)CC(S[Au])C([O-])=O,Alfa Aesar,39740,0,4.57354759,0,2.34234234,0,-21.6,-4.86305198,,,,,,,,,3.66E-10,1.83E-09,9.14E-09,4.57E-08,2.29E-07,1.14E-06,5.71E-06,,,,,,,,
NCGC00389554-01,DORAMECTIN,405558736,chloride transmembrane transport Activator,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),117704-25-3,,7.519298098,1,-5.123822698,-90.01877241,-2.1,7,,-103.2890442,-90.72107323,0.000213668,0.9939732,,,CO[C@H]1C[C@@H](O[C@@H](C)[C@@H]1O)O[C@@H]2[C@H](C)O[C@@H](C[C@@H]2OC)O[C@H]\3[C@@H](C)\C=C\C=C\4CO[C@@H]5C(O)\C(=C/[C@@H](C(=O)O[C@H]6C[C@@H](C/C=C3C)O[C@@]\7(C6)O[C@@H]([C@@H](C)\C=C7)C8CCCCC8)[C@]45O)C,Microsource,1505902,1.9432569,-2.01895344,0,0,-25.76271186,-58.2,-90.72107323,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00183866-01,Oxypertine hydrochloride,144206763,Adenylate cyclase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),17506-66-0,,23.7781084,0,-4.623822698,-60.44692986,-2.1,7,"OXYPERTINE;LS-82918;oxypertine;CIPLUS_152240;Indole, 5,6-dimethoxy-2-methyl-3-(2-(4-phenyl-1-piperazinyl)ethyl)-;Oxipertina;Equipertine;Forit;CIPLUS_179718;Oxypertinum;Oxypertin;oxypertinum;1H-Indole, 5,6-dimethoxy-2-methyl-3-(2-(4-phenyl-1-piperazinyl)ethyl)-;Oxypertine;",-105.7657909,-80.88317496,0.010752092,0.954424116,,,Cl.COc3cc4nc(C)c(CCN1CCN(CC1)c2ccccc2)c4cc3OC,NCI,NSC_169107,-1.08822386,1.27729707,1.92221726,0,-21.30750605,-26.5,-80.88317496,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00531790-01,JTT-501,405558852,Peroxisome proliferator-activated receptor gamma Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),170861-63-9,,26.67947643,0,-4.573822698,-46.38062326,-2.2,7,,-85.09055338,-68.25041923,0.000270817,0.993207323,5468,PPARG,CC1=C(CCOC2=CC=C(CC3C(=O)NOC3=O)C=C2)N=C(O1)C4=CC=CC=C4,Glixx,GLXC-08947,-2.17644773,0,-0.6705409,-3.24324324,-7.55447942,-17.9,-68.25041923,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016557-06,Ethaverine hydrochloride,170466346,Voltage-gated L-type calcium channel Blocker,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),985-13-7,,29.9348649,0,-4.523822698,-49.36755225,-2.2,7,,-62.23376623,-50.17709563,0.038702021,0.907003738,,,Cl.CCOc1ccc(cc1OCC)Cc3nccc2cc(OCC)c(cc23)OCC,Microsource,1501000,-5.76576577,0,0,-15.26271893,-7.85907859,-14.86742424,-50.17709563,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00017112-10,Ciclopirox,170464708,Antifungal Agent,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),41621-49-2,; Dafnegin-CSC;Ciclopirox ethanolamine; Ciclopirox ethanolamine; Penlac;Ciclopirox; Batrafen; Loprox;ciclopirox; ciclopirox,2.667947643,1,-5.573822698,-117.0183805,-1.1,7,,-92.38016529,-95.04132231,1.25593E-05,0.998549835,,CAT,CC=2C=C(C1CCCCC1)N(O)C(=O)C=2.NCCO,Microsource,1500189,0.96096096,0,0,-1.25104254,-30.26196929,-89.6780303,-95.04132231,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00344583-01,Vinblastine sulfate,170464976,Tubulin Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),18556-44-0,,11.91728437,0,-4.923822698,-57.69540067,-2.2,7,,-76.43801653,-73.55371901,0.000344083,0.992331774,,TUBB,O=S(=O)(O)O.O=C(OC)[C@@]2(C[C@@H]4C[C@@](O)(CC)C[N@](CCc1c3ccccc3nc12)C4)c5cc9c(cc5OC)N(C)[C@@H]6[C@]98CCN7CC=C[C@@](CC)([C@@H](OC(C)=O)[C@]6(O)C(=O)OC)[C@H]78,SIGMA,V1377,0,-5.76671035,0,2.08507089,-3.16169828,-38.92045455,-73.55371901,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167584-01,Nicametate citrate,144206129,cell growth Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1641-74-3,"Buffer solution from sodium citrate; Citric acid ammonium salt; Advil PM; Citric acid disodium salt; Euclidan; Alka-Seltzer; Sodium citrate buffer; Ammonium citrate dibasic; Sodium citrate monobasic; Citrate, Calciu; Tectlol; Pectamol; Citric acid-2,2,4,4-d4; Tc-99m-citrate; Citrate standard for IC; Bryrel; Astomatop; Pax??ladine; Caffeine, citrated; Antepar; Etoheptazina; Bismuth(III) citrate; Citric acid-13C6; DACH-Pt(II)citrate; Isoaminilo; Chemosol; Peracon; Aciletten; Tussimol; (239)Pu citrate; Tripelenamina; Anhydrous Citric Acid; Alverine citrate salt; Tritec; Tripelennamine Maleate; Toness; Citrato de galio (67 Ga); Cafcit; Oseltamivir citrate; Ferriseltz; Ammonium bismuth citrate; Citric acid solution; Ga-67 citrate; Sodium dihydrogencitrate; Pentoxyverine citrate; Tricalcium dicitrate; Silver citrate hydrate; Uralyt U; Zinc citrate dihydrate; Ascarex Syrup; Sinutab; Sodium dihydrogen citrate; DN 1417, (S)-isomer; Pyribenzamine; Tipepidina; AD 1308, citrate; Naldecon; U, Uraly; Oxeladin citrate salt; Citrate, Potassiu; 0.5 citrate CPD; Ammonium hydrogencitrate; Raniberl; technetium Tc 99m citrate; Citric acid lead salt; Citric acid calcium salt; Azanplus; Pentoxyverine Citrate; Citracal; Citric acid-2,4-13C2; Neoscan; Azaron; Citrates, Calciu; copper(II) citrate; Toclase; Citra ph; Citrate Solution; Banminth D; Oxeladina; Anhydrous citric acid; ethoheptazine HCl; Citric acid-1,5-14C; Clinitest; Oxeladin Tannate; Lithium citrate hydrate; Citric acid-1,5-13C2; Pylorid; Asverin; Tripotassium citrate; Alka Seltzer; DN 1417 citrate (1:1); Hetrazan; Butethamate citrate salt; DADP-PrD; ACD-A solution; Tri-lithium citrate; Gallii (67 Ga) citras; Citric acid zinc salt; Citric acid barium salt; Carricide citrate; gallii (67Ga) citras; Potassium hydroxycitrate; 67Ga-labeled; Negram-Citrat; Provasan; Banmint D; ACD solution; Iron(III) citrate; Mictral; Platinex; Acid, Citri; Trisodium citrate hydrate; Perogan; Norgesic forte; Orfenadrina; Citric Acid (Renacidin); Ammonium citrate tribasic; Magurlit; Sinecod; Cerebyx; Tetrodotoxin citrate; Dietilcarbamazina; ",26.67947643,0,-4.573822698,-29.76427502,-2.4,7,"Nicametate Citrate;2-(diethylamino)ethyl nicotinate;nicametatum;NICAMETATE CITRATE;Nicametate citrate;Nicotinic acid, 2-(diethylamino)ethyl ester;3-(diethylaminoethoxycarbonyl)pyridine citrate;LS-96550;Nicametate;Provasan;Euclidan;NICAMETATE;nicametate;Nicametatum;2-(diethylaminoethyl)nicotinate citrate;LS-96549;CIPLUS_213922;CIPLUS_669827;",-36.80881664,-29.45779765,0.001921091,0.981583941,,,O=C(O)C(O)(CC(=O)O)CC(=O)O.CCN(CC)CCOC(=O)c1cccnc1,SigmaAldrich,R288020,-3.42013214,-1.85414091,-4.1573536,-0.45045045,-5.42372881,-11.5,-29.45779765,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00018166-02,Estradiol valerate,405558513,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),979-32-8,,10.62129087,0,-4.973822698,-36.38238185,-2.2,7,,-54.54863052,-52.82280604,2.28211E-05,0.998044106,,,CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=C(C=CC(=C4)O)[C@H]3CC[C@]12C,APExBIO,B1506,0,0,1.96691998,0,0,-27.6,-52.82280604,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00178027-08,VALSARTAN,405559028,Neprilysin Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),137862-53-4,,21.19226141,0,-4.673822698,-35.60566777,-2.2,7,,-57.87367245,-52.93460034,0.011651104,0.952417291,,,CCCCC(=O)N(CC1=CC=C(C=C1)C2=C(C=CC=C2)C3=N[NH]N=N3)[C@@H](C(C)C)C(O)=O,Microsource,1505209,-4.89700738,-8.69386073,4.78319177,0.72072072,-0.8716707,-14,-52.93460034,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00345881-04,Conivaptan hydrochloride,405559087,Vasopressin (AVP) V1a/V2 Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),168626-94-6,,11.91728437,0,-4.923822698,-67.59639047,-2.1,7,,-96.42621576,-88.82057015,0.000067019,0.996639602,,AVPR1A,CC1=NC2=C([NH]1)C3=CC=CC=C3N(CC2)C(=O)C4=CC=C(NC(=O)C5=CC=CC=C5C6=CC=CC=C6)C=C4,APExBIO,A8402,-1.9432569,0,4.06794814,-1.17117117,-7.74818402,-44.9,-88.82057015,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00013369-07,Pamoic acid disodium salt,,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),[6640-22-8],,16.8336116,0,-4.773822698,-65.51417544,-2.2,7,,-63.50677837,-60.42481833,0.008947621,0.958713356,,,OC(=O)C1=C(O)C(CC2=C3C=CC=CC3=CC(C(O)=O)=C2O)=C4C=CC=CC4=C1,Tocris,4298,-3.03148076,-9.76514215,-1.56459544,-3.69369369,-17.33656174,-27.2,-60.42481833,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00166262-03,Ensulizole,170465490,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),27503-81-7,,26.67947643,0,-4.573822698,-7.648012115,-2.4,7,,-28.31050768,-26.09208973,7.71091E-05,0.996399546,,,O=S(=O)(O)c1cc2nc(nc2cc1)c3ccccc3,Vitas,STK034479,1.68168168,0,0,0.58381985,0,-0.66287879,-26.09208973,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00178054-06,Clarithromycin,405558922,Macrolide Antibiotic,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),81103-11-9,";CLARITHROMYCIN;Clarithromycin (Biaxin, Klacid); 6-O-Methylerythromycin; 14-OH-clarithromycin; Claritromicina;Clarithromycin; Erythromycin, 6-O-methyl-; Biaxin",37.68576212,0,-4.423822698,-10.47438708,-3,7,,-36.67768595,-32.23140496,0.001627476,0.983081939,,,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC,SIGMA,C9742,-2.28228228,0,0,3.08590492,0,1.04166667,-32.23140496,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00017324-07,Simvastatin,170464984,HMG-CoA Reductase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),79902-63-9,; Zocor;Simvastatin;SIMVASTATIN,23.7781084,0,-4.623822698,-18.49221441,-3,7,,-48.04545454,-45.45454545,4.07E-07,0.999739466,3156,HMGCR,CC(C)(CC)C(=O)O[C@H]2C[C@@H](C)C=C3C=C[C@H](C)[C@H](CC[C@@H]1C[C@@H](O)CC(=O)O1)[C@@H]23,Vitas,STK801938,0.12012012,0,0.58608059,0,0,-4.45075758,-45.45454545,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00022680-05,Chlormadinone acetate,170465776,Androgen receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),302-22-7,,21.19226141,0,-4.673822698,-53.6582122,-2.2,7,,-87.03896103,-70.48406139,0.000119057,0.995513217,367,AR,CC(=O)[C@@]3(OC(C)=O)CC[C@H]2[C@@H]4C=C(Cl)C1=CC(=O)CC[C@]1(C)[C@H]4CC[C@@]23C,Prestwick,Prestw-1374,-3.84384384,0,0.65934066,-4.25354462,-5.14905149,-27.74621212,-70.48406139,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016372-07,4-Hydroxy-3-nitrophenylarsonic acid,170465666,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),121-19-7,,6.701581484,1,-5.173822698,-17.20123397,-2.4,7,,-26.72668241,-20.18890201,0.026419262,0.925380463,,,O=[N+]([O-])c1cc(ccc1O)[As](O)(O)=O,Microsource,1500530,0,4.32503277,0,1.91826522,-9.30442638,-11.45833333,-20.18890201,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00095156-06,Carbadox,170466261,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),6804/7/5,,23.7781084,0,-4.623822698,-14.75236708,-3,7,,-37.6446281,-35.53719008,0.000852116,0.987851929,,,O=C(OC)N\N=C\c2c[n+]([O-])c1ccccc1[n+]2[O-],Microsource,1505294,0,-0.3931848,0,-2.41868224,2.61969286,-3.125,-35.53719008,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00018254-08,Bifonazole,170465826,Cytochrome P450 51 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),60628-96-8,,11.91728437,0,-4.923822698,-64.77096431,-2.1,7,,-94.50354191,-81.58205431,6.20149E-05,0.996768257,,,c1cc(ccc1c2ccccc2)C(c3ccccc3)n4ccnc4,Microsource,1505309,0,0,3.58974359,0,-12.37579042,-43.08712121,-81.58205431,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00018098-07,Iodoquinol,170465640,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),83-73-8,,4.74435636,1,-5.323822698,-109.884175,-1.1,7,,-103.4634002,-100.94451,2.1486E-06,0.999401036,,,Oc1c(I)cc(I)c2cccnc12,Vitas,STK070581,0,-1.04849279,0,0,-18.87985547,-86.83712121,-100.94451,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167522-02,Hexoprenaline sulfate,170465755,Beta-2 adrenergic receptor Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),32266-10-7,,16.8336116,0,-4.773822698,-56.19165053,-2.1,7,,-103.3825266,-87.95749705,2.25482E-05,0.99805543,,,Oc1ccc(cc1O)C(O)CNCCCCCCNCC(O)c2ccc(O)c(O)c2.O=S(=O)(O)O,Sequoia,SRP01560h,0,0,0,3.75312761,-3.88437218,-36.26893939,-87.95749705,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167453-02,Clinofibrate,174007296,treatment of lipoprotein diseases,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),30299-08-2, ; Lipoclin;Clinofibrate; Clinofibrate; Clinofibrato,8.436791229,1,-5.073822698,-33.26742221,-2.2,7,,-51.54899646,-45.21841795,2.71699E-05,0.997865427,,HMGCR,O=C(O)C(C)(CC)Oc1ccc(cc1)C2(CCCCC2)c3ccc(OC(C)(CC)C(=O)O)cc3,Selleck,S2664,3.72372372,2.35910878,1.24542125,0,-5.32971996,-28.125,-45.21841795,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00024584-17,BROMOCRIPTINE,,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),22260-51-1,,10.62129087,0,-4.973822698,-72.53188441,-2.1,7,,-97.51239669,-95.04132231,8.65434E-05,0.996178346,,,[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N3C(=O)[C@](NC(=O)[C@H]4CN(C)[C@]5([H])CC6=C(Br)NC7=CC=CC(=C67)C5=C4)(O[C@@]23O)C(C)C,SIGMA,B2134,0,0,1.83150183,-4.75396163,0,-53.31439394,-95.04132231,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00263164-17,Cabozantinib,405558578,VEGFR-2 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),849217-68-1,,5.972790784,1,-5.223822698,-76.01258364,-2.2,7,,-68.33314701,-65.34376747,0.003147404,0.976187911,,KDR,COC1=C(OC)C=C2C(=CC=NC2=C1)OC3=CC=C(NC(=O)C4(CC4)C(=O)NC5=CC=C(F)C=C5)C=C3,MedChem Express,HY-13016,0,-8.61145447,0,0,-21.98547215,-45.5,-65.34376747,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00242511-03,Seocalcitol,,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),134404-52-7,,26.67947643,0,-4.573822698,-41.14161581,-2.1,7,,-95.05366127,-80.99496926,0.000748664,0.988619201,,VDR,CCC(O)(CC)/C=C/C=C/[C@@H](C)[C@H]1CC[C@H]2\C(CCCC12C)=C\C=C3/C[C@@H](O)C[C@H](O)C3=C,MedChem Express,HY-32341,-4.35289545,3.87309436,-4.78319177,2.52252252,-1.2590799,-13,-80.99496926,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00263129-08,Palbociclib,405558929,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),571189-11-2,,10.62129087,0,-4.973822698,-31.42820787,-2.2,7,,-50.49301286,-42.53773058,0.000995094,0.986845584,,CDK4,CC(=O)C\1=C(/C)C2=CN=C(NC3=CC=C(C=N3)N4CCNCC4)N=C2N(C5CCCC5)C1=O,Axon Medchem,1505,0,2.92542233,0,4.14414414,-7.16707022,-23.6,-42.53773058,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00183015-01,Temoporfin,144206848,cell proliferation Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),122341-38-2,Temoporfin; ,1.191728437,1,-5.923822698,-147.764041,-1.1,7,"M-THPC;CIPLUS_197002;5,10,15,20-TETRA(3-HYDROXYPHENYL)-CHLORIN;TEMOPORFIN;Temoporfin;LS-172529;temoporfinum;",-89.69952774,-92.91617473,4.33892E-05,0.997298978,,,Oc1cccc(c1)c9c2CCc(n2)c(c3cccc(O)c3)c4ccc(n4)c(c5cccc(O)c5)c6C=Cc(n6)c(c7cccc(O)c7)c8ccc9n8,Pharmaron,PH-NIH-154455,0,0,0,-12.26021685,-68.74435411,-83.99621212,-92.91617473,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00164633-02,Nisoldipine,170465320,Ca2+ channel blocker (dihydropyridine),Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),63675-72-9,Nisoldipine;Nisoldipine; Sular; Bay K 5552; Nisoldipino; ; Nisoldipine;NISOLDIPINE,2.99348649,1,-5.523822698,-137.3160111,-1.1,7,,-96.57982113,-98.88205702,0.000158264,0.994820204,,,CC=1NC(C)=C(C(C=1C(=O)OCC(C)C)c2ccccc2[N+]([O-])=O)C(=O)OC,Sequoia,SRP03410n,-8.62806063,0,-0.58113545,-8.73873874,-41.1622276,-85.3,-98.88205702,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00386518-01,Cannabidiol,377020361,Cannabinoid Receptor Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),13956-29-1,,18.88762287,0,-4.723822698,-48.22092654,-2.2,7,,-68.66349916,-64.89659027,0.006368589,0.965543206,,CNR1,CCCCCC1=CC(=C([C@@H]2\C=C(C)/CC[C@H]2C(C)=C)C(=C1)O)O,Axon Medchem,1234,0,-12.3197363,0,0,-2.80871671,-21.4,-64.89659027,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00161327-01,Calcitriol,26754891,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),32222-06-3,"; ;Calcitriol (Rocaltrol); Receptors, Calcitriol; 1(alpha),25-DIHYDROXYVITAMIN D3;Calcitriol; Calcitriol",29.9348649,0,-4.523822698,-61.55029131,-2.2,7,"Receptors, Calcitriol;Calcitriolum;9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, (1alpha,3beta,5Z,7E)-;1alpha,25-Dihydroxyvitamin D3;RO-21-5535;CIPLUS_177636;Calcitriol;1,25-dihydroxyvitamin D3 monoglucuronide;1(alpha),25-DIHYDROXYVITAMIN D3;calcitriol glycoside;1,25-DIHYDROXY VITAMIN D3;CIPLUS_701127;1,25-DVDMG;calcitriolum;NCGC00161327-02;NCGC00161327-03;1 alpha,25-dihydroxy-previtamin D(3);1,25-dihydroxycholecalciferol glycoside;beta-D-Glucopyranosiduronic acid, (1alpha,3beta,5Z,7E)-dihydroxy-9,10-secocholesta-5,7,10(19)-trienyl;1,25-DIHYDROXYCHOLECALCIFEROL;HS_1248;LS-53093;CIPLUS_710322;1,25-dihydroxy-previtamin D(3);1,25-dihydroxytachysterol;1alpha,25-Dihydroxycholecalciferol;HS_234;9,10-secocholesta-5(10),6,8-triene-1,3,25-triol, (1 alpha,3 beta,6Z)-;Rocaltrol;CALCITRIOL;rocaltrol;1,25-dihydroxy-previtamin D(3), (1alpha,3alpha,6Z)-isomer;CIPLUS_682461;calcitriol;",-87.27110118,-69.14477362,0.007512661,0.962386677,7421,VDR,[H][C@@]12CC[C@H]([C@H](C)CCCC(C)(C)O)[C@@]1(C)CCC\C2=C/C=C3/C[C@@H](O)C[C@H](O)C3=C,BIOMOL,BIOMOL_DM200,-6.37388263,0,-5.05140814,-12.43243243,-10.65375303,-17,-69.14477362,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00253604-01,Rescimetol,170465875,smooth muscle contraction Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),73573-42-9,,5.972790784,1,-5.223822698,-128.15995,-2.1,7,,-103.7350475,-98.65846842,0.000593729,0.98988539,,,Oc1ccc(cc1OC)/C=C/C(=O)O[C@@H]3C[C@@H]4CN5CCc2c6ccc(OC)cc6nc2[C@H]5C[C@@H]4[C@@H]([C@H]3OC)C(=O)OC,GVK,FFS-11-286-NCI-194,-5.36338904,-11.82529872,0,-8.64864865,-31.57384988,-75,-98.65846842,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016981-05,Troleandomycin,405558894,70S ribosome Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),311074,,4.228412057,1,-5.373822698,-32.52182392,-1.2,7,,-32.556,-25.6567915,0.015189926,0.945045588,,,CO[C@@H]1C[C@@H](O[C@H](C)[C@H]1OC(C)=O)O[C@H]2[C@H](C)[C@H](O[C@@H]3O[C@@H](C)C[C@H]([C@H]3OC(C)=O)N(C)C)[C@H](C)C[C@]4(CO4)C(=O)[C@H](C)[C@H](OC(C)=O)[C@H](C)[C@H](C)OC(=O)[C@@H]2C,Enzo,EI249,0,0,0,3.69369369,0.3874092,-37.8,-25.6567915,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00188442-01,Estradiol enanthate,144206583,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),4956-37-0,,11.91728437,0,-4.923822698,-38.67169778,-2.2,7,ESTRADIOL?ENANTHATE,-61.25740637,-57.18278368,8.4594E-06,0.998810634,,,CCCCCCC(=O)O[C@H]2CC[C@H]3[C@@H]4CCc1cc(O)ccc1[C@H]4CC[C@]23C,APAC,877917,0,0,1.34108181,1.89189189,-1.1622276,-28.8,-57.18278368,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00346470-02,ZilpaterolHCl,405558976,beta1-Adrenoceptor Antagonists,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),119520-06-8,,23.7781084,0,-4.623822698,-27.80647618,-3,7,,-64.27808832,-60.64840693,0.000450264,0.991212899,,ADRB1,CC(C)N[C@@H]1CCN2C(=O)NC3=CC=CC(=C23)[C@H]1O,Enzo,AR113,0,-3.58467244,0,-2.34234234,3.09927361,-6.6,-60.64840693,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00532514-01,FLUPENTIXOL DECANOATE,405558676,Serotonin 2 (5-HT2) receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,10.62129087,0,-4.973822698,-57.41598286,-2.2,7,,-73.05701509,-72.27501397,0.00469942,0.970639743,,,CCCCCCCCCC(=O)OCCN1CCN(CC\C=C2/C3=CC=CC=C3SC4=CC=C(C=C24)C(F)(F)F)CC1,SynInnova,SL-1062,4.58608628,0,2.63746089,-11.08108108,-1.8401937,-41.7,-72.27501397,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00015817-14,Promethazine,170465107,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),60-87-7,,9.466235454,1,-5.023822698,-44.66796823,-2.2,7,,-62.15702479,-60.33057851,0.000156849,0.994844477,,,CN(C)C(C)CN1c3ccccc3Sc2ccccc12,Enzo,AC765,0,4.58715596,0,-0.91743119,0,-37.40530303,-60.33057851,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00095978-06,Lufenuron,170465736,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),103055-07-8,,37.68576212,0,-4.423822698,-10.59010647,-2.4,7,,-26.26033058,-23.96694215,0.010730121,0.954556409,,,Clc2cc(NC(=O)NC(=O)c1c(F)cccc1F)c(Cl)cc2OC(F)(F)C(F)C(F)(F)F,Microsource,1505355,-4.2042042,0,0,2.3352794,0,0,-23.96694215,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167982-04,Pirarubicin,405559004,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),72496-41-4,,5.32325539,1,-5.273822698,-98.27413957,-1.1,7,,-98.18229044,-93.62455726,3.1085E-06,0.999279432,,,[H][C@]1(N)C[C@]([H])(O[C@@]2([H])C[C@@](O)(CC3=C(O)C4=C(C(=O)C5=C(OC)C=CC=C5C4=O)C(O)=C23)C(=O)CO)O[C@@]([H])(C)[C@@]1([H])O[C@@]6([H])CCCCO6,SIGMA,P8624,0,1.70380079,0,0,-22.31255646,-73.20075758,-93.62455726,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00178810-03,Novobiocin sodium,170465360,Heat Shock Protein 90 (hsp90) Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1476-53-5,,13.37141299,0,-4.873822698,-29.04030888,-2.2,7,,-47.69480519,-43.32939787,2.21382E-05,0.998074103,,HSP90AB1,[Na+].C/C(C)=C\Cc1cc(ccc1O)C(=O)NC3=C([O-])c4ccc(O[C@@H]2OC(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@H]2O)c(C)c4OC3=O,Microsource,1500444,0,0,0,-0.08340284,0,-19.79166667,-43.32939787,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00181911-01,Bucolome,144206890,Cytochrome P450 2C9 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),841-73-6,Bucolome; Bucolom; Paramidine; Paramidin; Bucolomo; ,29.9348649,0,-4.523822698,-6.627572851,-2.4,7,"Paramidine;2,4,6(1H,3H,5H)-Pyrimidnetrione, 5-butyl-1-cyclohexyl-;Barbituric acid, 5-butyl-1-cyclohexyl-;bucolome;CIPLUS_156649;LS-23912;Bucolomo;Paramidin;Bucolomum;Bucolome;bucolomum;1-cyclohexyl-5-butylbarbituric acid;Bucolom;BUCOLOME;CIPLUS_165895;",-24.56021252,-22.5501771,0.000215308,0.993962526,,,O=C2C(CCCC)C(=O)NC(=O)N2C1CCCCC1,Pharmaron,PH-NIH-95,0,0,0,0,1.80668473,0,-22.5501771,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00160540-03,Ethiazide,170465925,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1824-58-4,,8.436791229,1,-5.073822698,-3.815019875,-2.4,7,,-25.93181818,2.00708383,0.029635885,0.954605553,,,NS(=O)(=O)c2cc1c(NC(NS1(=O)=O)CC)cc2Cl,Menai,H2748,0,0,0,0,4.69738031,-20.35984848,2.00708383,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00096056-02,Ethacridine lactate hydrate,170465798,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),6402-23-9,,18.88762287,0,-4.723822698,-59.32236508,-2.1,7,,-111.6270366,-100.472255,0.00023324,0.993700305,,,O.O=C(O)C(C)O.CCOc1ccc2nc3cc(N)ccc3c(N)c2c1,Labotest,LT00244813,0,0,-4.90842491,0,3.16169828,-32.85984848,-100.472255,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00165957-07,Amlodipine,225144262,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),88150-42-9,,21.19226141,0,-4.673822698,-18.32425718,-3,7,,-42.36221353,-40.30184461,0.015340819,0.944750998,,,CCOC(=O)C/1=C(COCCN)/N\C(=C(C1C2=C(Cl)C=CC=C2)\C(=O)OC)C,Prestwick,Prestw-1219,-4.89700738,4.65595385,0,-3.24324324,4.84261501,-5.9,-40.30184461,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167451-04,Halobetasol Propionate,,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),66852-54-8,,26.67947643,0,-4.573822698,-42.70463463,-2.4,7,,-42.63247625,-38.73672443,0.08396681,0.851520726,,,CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3C[C@H](F)\C4=C\C(=O)\C=C/[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl,APExBIO,B1767,0,-11.08364236,-10.50514081,-8.82882883,0,-11.3,-38.73672443,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00386347-01,Ospemifene,405558829,Selective Estrogen Receptor Modulators (SERM),Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),128607-22-7,,11.91728437,0,-4.923822698,-42.91311434,-2.2,7,,-58.93376188,-51.25768586,0.002517679,0.978796539,2100,ESR2,OCCOC1=CC=C(C=C1)\C(=C(\CCCl)C2=CC=CC=C2)C3=CC=CC=C3,Selleck,S4285,0,0,2.23513634,0.36036036,-13.46246973,-24.9,-51.25768586,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167444-04,Cefpiramide (sodium),405558753,Bacterial penicillin-binding protein Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),74849-93-7,,37.68576212,0,-4.423822698,-4.553542098,-2.4,7,,-30.01984349,-25.43320291,0.003041372,0.97664047,,,C[N]1N=NN=C1SCC/2=C(/N3[C@H](SC2)[C@H](NC(=O)[C@H](NC(=O)C4=C(O)C=C(C)N=C4)C5=CC=C(O)C=C5)C3=O)C(O)=O,MedChem Express,HY-B0798,-1.08822386,1.93654718,0,0,2.90556901,2.8,-25.43320291,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00090764-04,2-Ethylhexyl 4-(dimethylamino)benzoate,170465499,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),21245-02-3,,37.68576212,0,-4.423822698,-24.99040203,-3,7,,-80.42857143,-71.42857143,1.00E-09,0.999987147,,,CN(C)c1ccc(cc1)C(=O)OCC(CC)CCCC,Bosche,E2279,0,0,0,0,0,0,-71.42857143,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00178754-06,Primaquine diphosphate,174006623,antimalarial,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),63-45-6,,18.88762287,0,-4.723822698,-35.68471471,-2.2,7,,-82.46103896,-74.97048406,4.50825E-05,0.997246856,,,O=P(O)(O)O.O=P(O)(O)O.CC(CCCN)Nc1cc(cc2cccnc12)OC,Microsource,1500500,4.2042042,0,0,0,0,-19.03409091,-74.97048406,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00025000-14,Ketoconazole,405559066,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),13463-41-7,; ; Ketoconazol; Nizoral;Ketoconazole; Ketoconazole; Ketocanazole,8.436791229,1,-5.073822698,-77.48038272,-2.1,7,,-94.38961039,-94.33293979,0.0000477,0.997167389,1588,CYP19A1,CC(=O)N1CCN(CC1)C2=CC=C(OC[C@H]3CO[C@@](C[N]4C=CN=C4)(O3)C5=CC=C(Cl)C=C5Cl)C=C2,SIGMA,K1003,0,-0.3931848,0,0,4.60704607,-67.89772727,-94.33293979,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00164617-04,Adapalene,170464674,topical retinoid,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),106685-40-9, ; Differin; Alcon brand of adapalene; Differine; Adapalene;Adapalene; Adapalene (Differin); Adaferin; Adapaleno,1.191728437,1,-5.923822698,-71.89718073,-2.4,7,,-49.03128689,-47.57969303,0.121485583,0.999388203,,RARB,O=C(O)c1ccc2cc(ccc2c1)c3cc(c(OC)cc3)C46CC5CC(CC(C4)C5)C6,Tocris,2852,2.16216216,0.65530799,0,-8.25688073,-33.69467028,-78.88257576,-47.57969303,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00159462-04,Ritonavir,170464891,HIV Protease Inhibitors,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),155213-67-5,,26.67947643,0,-4.573822698,-10.30990538,-3,7,,-45.35064935,-34.35655254,0.001301732,0.984912274,,,CC(C)c4nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc3cncs3)C(C)C)cs4,Bosche,R1692,3.72372372,0,0,3.91993328,0,-6.34469697,-34.35655254,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00164631-05,Sunitinib malate,170465289,VEGFR-1/2/3 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),341031-54-7, Sunitinib malate;Sunitinib malate; Sunitinib base; ;Sutent,8.436791229,1,-5.073822698,-61.11530856,-2.2,7,,-74.19303424,-73.78984652,3.5642E-06,0.999228403,2321,FLT1,O=C(O)C(O)CC(=O)O.CCN(CC)CCNC(=O)C1C(C)=C(N=C1C)/C=C2/c3cc(F)ccc3NC2=O,Sequoia,SRP01785s,-0.36036036,1.83486239,0,0,0.27100271,-52.1780303,-73.78984652,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00183020-01,Minopafant,144206826,Platelet activating factor receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),128420-61-1,Menopafant; Minopafant; ,7.519298098,1,-5.123822698,-84.44287294,-1.1,7,E-5880;E 5880;1-ethyl-2-(N-(2-methoxy)benzoyl-N-(2-methoxy-3-(4-octadecylcarbamoyloxy)piperidinocarbonyloxypropyloxy)carbonyl)aminomethylpyridinium chloride;MENOPAFANT;CIPLUS_707454;Minopafant;Menopafant;minopafantum;,-88.60661157,-88.42975207,3.20E-09,0.999976955,,,[Cl-].COc1ccccc1C(=O)N(Cc2cccc[n+]2CC)C(=O)OC[C@@H](COC(=O)N3CCC(CC3)OC(=O)NCCCCCCCCCCCCCCCCCC)OC,Pharmaron,PH-NIH-150353,0,0,0,0,0,-76.60984848,-88.42975207,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00188864-02,Iloperidone,170465198,Dopamine D2 Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),133454-47-4,Iloperidone,37.68576212,0,-4.423822698,3.339761927,-2.4,7,,-26.11710452,-20.51425377,0.008961509,0.958751702,1813,DRD2,CC(=O)c4ccc(OCCCN1CCC(CC1)c3noc2cc(F)ccc23)c(OC)c4,Bosche,I2337,2.79828993,3.09023486,0,3.6036036,0,4.7,-20.51425377,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00249929-01,Neticonazole,170466035,ergosterol biosynthetic process Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),130726-68-0,,23.7781084,0,-4.623822698,-60.67256492,-2.1,7,,-113.7917831,-86.58468418,0.001205317,0.985484698,,,CS\C=C(/c1ccccc1OCCCCC)n2ccnc2,GVK,FFS-11-286-NCI-232,3.18694131,3.50226617,0,-6.75675676,-12.30024213,-32.1,-86.58468418,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00408838-01,Piroheptine Hydrochloride,405558780,Muscarinic acetylcholine receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),16378-22-6,,37.68576212,0,-4.423822698,-5.853474303,-2.4,7,,-24.15371716,-20.96143097,0.024920122,0.927817259,,,CCN1CCC(C1C)=C2C3=CC=CC=C3CCC4=CC=CC=C24,Glixx,GLXC-06115,-0.3109211,3.91429749,0,0,-3.38983051,2,-20.96143097,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167543-05,CEFTIOFUR HYDROCHLORIDE,405558783,Cephalosporin antibiotic,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),80370-57-6,,23.7781084,0,-4.623822698,-39.91848875,-2.2,7,,-60.15315819,-56.17663499,0.001738679,0.982485049,,,CO\N=C(\C(=O)N[C@H]1[C@H]2SC\C(=C(/N2C1=O)C(O)=O)CSC(=O)C3=CC=CO3)C4=CSC(=N4)N,Microsource,1504832,-7.46210649,-3.33745365,-3.71032633,0,0.2905569,-12.5,-56.17663499,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00351599-02,Abemaciclib,405558877,CDK4/6 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1231930-82-7,,2.37781084,1,-5.623822698,-27.07143556,-1.4,7,,-22.68,-21.18501956,0.001323296,0.984793016,,CDK4,CCN1CCN(CC1)CC2=CN=C(NC3=NC=C(F)C(=N3)C4=CC(=C5N=C(C)[N](C(C)C)C5=C4)F)C=C2,Selleck,S7158,0,0,3.71032633,0,-10.46004843,-21.4,-21.18501956,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00262569-03,Thiostrepton,405558975,Toll-like receptor 9 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1393-48-2,,6.701581484,1,-5.173822698,-107.512829,-2.1,7,,-91.9195081,-90.83286752,0.001946885,0.981428966,2305,,CCC(C)[C@@H]1N[C@@H]2\C=C/C3=C(N=C(C=C3[C@H](C)O)C(=O)O[C@H](C)[C@@H]4NC(=O)C5=CSC(=N5)[C@@H](NC(=O)[C@H]\6CSC(=N6)\C(NC(=O)[C@@H](NC(=O)C7=CSC(=N7)[C@]8(CCC(=N/[C@H]8C9=CSC4=N9)\C%10=NC(=CS%10)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C/C)[C@@](C)(O)[C@@H](C)O)[C@H]2O,Prestwick,Prestw-522,-8.00621842,-8.85867326,0,0,-27.50605327,-61.6,-90.83286752,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00262575-02,Cyproterone acetate,170465682,Androgen Receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),427-51-0,,23.7781084,0,-4.623822698,-21.23250167,-2.2,7,,-55.87898267,-41.19619899,0.001905422,0.981643238,,AR,CC(=O)[C@@]4(OC(C)=O)CC[C@H]3[C@@H]5C=C(Cl)C2=CC(=O)[C@@H]1C[C@@H]1[C@]2(C)[C@H]5CC[C@@]34C,Prestwick,Prestw-1074,0,0,4.47027269,3.42342342,-4.16464891,-13.5,-41.19619899,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00531792-01,PYRETHRIN II,405559034,Plasmodium falciparum Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),121-29-9,,37.68576212,0,-4.423822698,-17.30749476,-3,7,,-55.89463387,-49.46897708,1.40E-09,0.999984585,,,COC(=O)C(/C)=C/[C@H]1[C@H](C(=O)O[C@@H]2CC(=O)/C(=C2/C)C\C=C\C=C)C1(C)C,Toronto Research,P991240,0,0,0,0,0,0,-49.46897708,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00183837-01,Monatepil,124894552,Calcium Channel Blocker,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),103377-41-9,Monatepil; Monatepil,1.500297213,1,-5.823822698,-56.67955926,-1.2,7,"CIPLUS_696267;AJ 2615;MONATEPIL;monatepil, (S)-isomer;monatepil, (+-) monatepil;LS-172819;LS-172817;Monatepil Maleate;monatepil maleate;LS-173001;maleate;LS-171860;11-((4-(4-(4-fluorophenyl)-1-piperazinyl)butyryl)amino)-6,11-dihydrodibenzo(b,e)thiepin maleate;1-Piperazinebutanamide, N-(6,11-dihydrodibenzo(b,e)thiepin-11-yl)-4-(4-fluorophenyl)-, (Z)-2-butenedioate (1:1);CIPLUS_3853864;MONATEPIL MALEATE;monatepil;Monatepil maleate;CIPLUS_197056;monatepil x maleate;monatepil, (R)-isomer;monatepilum;LS-173055;AJ-2615;N-(6,11-DIHYDRODIBENZO(B.E)THIEPIN-11-YL)-4-(4-FLUOROPHENYL)-1-PIPERAZINEBUTYRAMIDE MALEATE, DL-;LS-173056;",-32.83,-27.55729458,0.013976501,0.947487726,,,Fc1ccc(cc1)N2CCN(CC2)CCCC(=O)NC3c5ccccc5SCc4ccccc34,Pharmaron,PH-NIH-152406,0,-3.17264112,2.63746089,-3.6036036,-24.50363196,-38.7,-27.55729458,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00522030-01,Budralazine,405558679,adrenergic receptor signaling pathway Modulator,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),36798-79-5,,29.9348649,0,-4.523822698,-39.31405526,-2.4,7,,-41.22973729,-34.26495249,0.067581368,0.87036749,,,CC(C)=C\C(C)=N/NC1=NN=CC2=C1C=CC=C2,Toronto Research,B689515,-6.60707346,-1.77173465,-5.14081359,0,-13.17191283,-10.4,-34.26495249,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167488-08,Sorafenib,170465175,VEGFR-1/2/3 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),475207-59-1,;Sorafenib;BAY-54-9085; Sorafenib Tosilate;BAY-43-0006; Sorafenib base;sorafenib; Sorafenib; Nexavar;Nexavar,23.7781084,0,-4.623822698,-31.35462278,-2.2,7,,-82.31818181,-61.98347107,0.000320615,0.992601871,2321,FLT1,O=C(NC)c3cc(Oc2ccc(NC(=O)Nc1cc(c(Cl)cc1)C(F)(F)F)cc2)ccn3.O=S(=O)(O)c1ccc(C)cc1,Sequoia,284461-73-0,4.8048048,0,2.78388278,0,-4.06504065,-18.84469697,-61.98347107,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00166245-04,Proflavin hemisulfate,170466523,RNA Binding Agent,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1811-28-5,,18.88762287,0,-4.723822698,-56.56572352,-2.1,7,,-110.4,-100,0.000113501,0.995619387,,,O=S(=O)(O)O.Nc1cc2nc3cc(N)ccc3cc2cc1.Nc1cc2nc3cc(N)ccc3cc2cc1,Vitas,STK380650,-4.68468468,3.53866317,0,0,0,-28.31439394,-100,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00164566-09,Pitavastatin Calcium,,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),147526-32-7,,5.972790784,1,-5.223822698,-40.19536912,-1.2,7,,-34.65986585,-35.04751258,0.025009593,0.927551848,,,O[C@H](C[C@H](O)\C=C\C1=C(C2=CC=C(F)C=C2)C3=C(C=CC=C3)N=C1C4CC4)CC([O-])=O,APExBIO,A8504,1.01049359,3.58467244,-9.52168082,0,-6.87651332,-28.5,-35.04751258,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00522039-01,Pyrethrin 1,405558749,Trypanosoma brucei rhodesiense Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),121-21-1,,37.68576212,0,-4.423822698,-20.63209827,-3,7,,-66.72750139,-58.97149245,3.70E-09,0.999975262,,,CC(C)=C[C@H]1[C@H](C(=O)O[C@H]\2CC(=O)\C(=C2C)C\C=C/C=C)C1(C)C,Toronto Research,P991245,0,0,0,0,0,0,-58.97149245,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00373220-03,CEFMENOXIME HYDROCHLORIDE,405558647,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),75738-58-8,,37.68576212,0,-4.423822698,0.32657261,-2.4,7,,-25.48295136,-20.40245947,0.005021413,0.969663494,,,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC3=NN=NN3C)=C(N2C1=O)C(O)=O)C4=CSC(N)=N4,Microsource,1502422,0,4.03790688,0,1.71171171,2.03389831,2.9,-20.40245947,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00018204-13,Vinpocetine,170465859,"Na channel blocker, also PDE1, IKK inhibitor",Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),42971-09-5,;Vinpocetine; Cavinton,18.88762287,0,-4.723822698,-32.76997533,-2.2,7,,-50.61688311,-47.81582054,0.007143242,0.963390165,,,O=C(OCC)C1=C[C@@]5(CCCN4CCc3c(n1c2ccccc23)[C@@H]45)CC,"Prestwick Chemical, Inc.",Prestw-268,0,-9.04325033,0,0,0,-13.92045455,-47.81582054,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00017358-15,Rotenone,170466816,NADH-Ubiquinone Oxidoreductase (Complex I) Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),83-79-4,;ROTENONE;Rotenone,11.91728437,0,-4.923822698,-64.22924757,-2.2,7,,-91.85005903,-79.69303424,0.000601422,0.989819565,51103,NDUFAF1,C=C(C)[C@@H]2Oc3ccc1C(=O)[C@H]4c5cc(OC)c(OC)cc5OC[C@H]4Oc1c3C2,Microsource,200013,2.16216216,0.78636959,0,2.41868224,-17.07317073,-41.00378788,-79.69303424,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00015562-25,Indomethacin,170464705,Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),53-86-1, Indocin;; Cu salt; Indocid; Al salt; Indocin I.V.; ; Li salt; Cu(2+) salt; Metindol; Mg salt; Indomethacin; Ca salt; Osmosin; Cu-IMCC; Zn salt; Combiflex;Indomethacin; Indomet 140; Amuno; NH4 salt;INDOMETHACIN; Indometacina,26.67947643,0,-4.573822698,-15.28694167,-3,7,,-62.69598583,-51.82998819,0.000189548,0.994328499,,PTGS2,Clc1ccc(cc1)C(=O)n3c2ccc(cc2c(CC(=O)O)c3C)OC,Microsource,1500350,0,3.93184797,3.36996337,0,2.16802168,-5.39772727,-51.82998819,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00178778-07,DIETHYLCARBAMAZINE CITRATE,405559090,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1642-54-2,,23.7781084,0,-4.623822698,-26.50376122,-2.2,7,,-48.12381218,-36.83622135,0.028579224,0.921886611,,,CCN(CC)C(=O)N1CCN(C)CC1,Microsource,1500242,2.02098717,-7.70498558,0,4.59459459,-5.23002421,-13.8,-36.83622135,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00095136-09,Olmesartan medoxomil,405558542,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),144689-63-4,,9.466235454,1,-5.023822698,-30.06823279,-2.4,7,,-30.30044718,-27.33370598,0.006765046,0.964464963,,,CCCC1=NC(=C([N]1CC2=CC=C(C=C2)C3=CC=CC=C3C4=N[NH]N=N4)C(=O)OCC/5=C(C)/OC(=O)O5)C(C)(C)O,APExBIO,A4082,-0.93276331,0.45323445,0,-6.12612613,-4.35835351,-18.1,-27.33370598,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00262943-01,Tocanfil,170466061,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),5634-42-4,Tocamphylum;Tocanfil;Tocamphyl,21.19226141,0,-4.673822698,-1.960822452,-2.4,7,,-30.49552823,-26.66294019,0.003290051,0.975660063,,,CC1(CCC(C(=O)O)C1(C)C)C(=O)OC(C)c2ccc(C)cc2.OCCNCCO,GVK,FFS-11-286-NCI-206,1.24368441,0,4.1573536,1.62162162,4.93946731,-1.8,-26.66294019,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00178860-06,Ethopropazine hydrochloride,170465065,Butyrylcholinesterase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1094-08-2,,11.91728437,0,-4.923822698,-53.81603548,-2.2,7,,-68.24315259,-64.11403018,0.000835854,0.987962784,,,Cl.CCN(CC)C(C)CN1c3ccccc3Sc2ccccc12,Microsource,1500293,1.32141469,0,2.05632544,-6.66666667,-7.84503632,-34.2,-64.11403018,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00261967-01,Prednisolone farnesylate,170466045,Glucocorticoid and meneralocorticoid receptor agonists/antagonists Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),118244-44-3,No2-cbl;Nitritocobalamin;Nitrocobalamin,9.466235454,1,-5.023822698,-34.40343262,-2.2,7,,-33.50614869,-34.26495249,0.041595135,0.90303323,,,C/C(C)=C\CCC(\C)=C\CCC(/C)=C/C(=O)OCC(=O)[C@@]4(O)CC[C@@H]3[C@]4(C)C[C@H](O)[C@H]2[C@H]3CCC1=CC(=O)C=C[C@@]12C,GVK,FFS-11-286-NCI-185,-1.24368441,1.03007829,0.53643272,-10.81081081,3.38983051,-24.6,-34.26495249,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00095175-08,Cefditoren (Pivoxil),405558969,Cephalosporin Antibiotic,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),117467-28-4,,11.91728437,0,-4.923822698,-90.93481052,-2.1,7,,-101.4318055,-91.16825042,0.002879892,0.977259647,,,[H][C@]12SCC(\C=C/C3=C(C)N=CS3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C4=CSC(N)=N4)C(=O)OCOC(=O)C(C)(C)C,MedChem Express,HY-17452A,-8.00621842,2.67820354,0,-5.04504505,-24.89104116,-46.8,-91.16825042,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00356592-02,Ergotamine tartrate,405559037,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),379-79-3,,2.667947643,1,-5.573822698,-126.5465235,-1.1,7,,-95.8112,-96.42258245,0.000311223,0.992710809,,,CN1C[C@@H](\C=C2/[C@H]1CC3=C[NH]C4=C3C2=CC=C4)C(=O)N[C@]5(C)O[C@@]6(O)[C@@H]7CCCN7C(=O)[C@H](CC8=CC=CC=C8)N6C5=O,Prestwick,Prestw-NAT-0314,0,4.65595385,0,-8.46846847,-31.86440678,-97.2,-96.42258245,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00017030-10,Fusidic Acid (sodium salt),405558530,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),751-94-0,,8.436791229,1,-5.073822698,-39.97646769,-2.2,7,,-36.64030185,-37.84237004,0.033910143,0.913854156,,,C[C@@H]1[C@H](O)CC[C@@]2(C)[C@H]1CC[C@@]3(C)[C@H]2[C@H](O)C[C@H]4\C([C@H](CC34C)OC(C)=O)=C(CCC=C(C)C)/C([O-])=O,Cayman,14825,2.64282938,0,0,-11.89189189,-2.22760291,-27.6,-37.84237004,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00160431-02,2-[(4-Chloro-3-methylphenyl)amino]benzoic acid,405558671,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,21.19226141,0,-4.673822698,-61.70375078,-2.1,7,,-121.0050866,-93.85131358,3.11592E-05,0.997712751,,,CC1=CC(=CC=C1Cl)NC2=CC=CC=C2C(O)=O,Scientific Exchange,F-137102,0.77730276,3.37865678,0,-1.89189189,-8.13559322,-35.7,-93.85131358,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00179642-03,Isoconazole nitrate,170466012,Antifungal Agent,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),27523-40-6,;Isoconazole; Isoconazol; Travocort; Adestan-G;Isoconazole nitrate (Travogen),10.62129087,0,-4.973822698,-66.16730786,-2.1,7,,-99.74734489,-93.62772499,2.30564E-05,0.998033512,,,Clc3ccc(C(OCc1c(Cl)cccc1Cl)Cn2ccnc2)c(Cl)c3,"Prestwick Chemical, Inc.",Prestw-127,0,0,2.05632544,4.68468468,-3.48668281,-51.1,-93.62772499,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00159504-04,Thymol iodide,170465466,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),552-22-7,,37.68576212,0,-4.423822698,-25.0108494,-3,7,,-31.47756789,-30.81463991,0.108760901,0.824558288,,,IOc1cc(C)c(cc1C(C)C)c2cc(C(C)C)c(OI)cc2C,SIGMA,T2763,-3.36336336,2.49017038,0,-5.42118432,-12.37579042,-0.66287879,-30.81463991,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016255-10,SULFINPYRAZONE,170464677,Canalicular Multispecific Organic Anion Transporter 1 Modulator,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),57-96-5,,37.68576212,0,-4.423822698,-30.92814786,-3,7,,-44.35714286,-42.85714286,0.087556027,0.847467318,,,O=C1C(CCS(=O)C2=CC=CC=C2)C(=O)N(N1C1=CC=CC=C1)C1=CC=CC=C1,Microsource,1500554,-4.08408408,0,-0.21978022,0,-17.2538392,0,-42.85714286,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00164555-03,Entacapone,170464850,NCI-H1299 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),130929-57-6,,18.88762287,0,-4.723822698,-46.00066489,-2.2,7,,-87.13636363,-78.51239669,0.00024428,0.993551846,,,Oc1cc(\C=C(/C#N)C(=O)N(CC)CC)cc([N+]([O-])=O)c1O,Sequoia,SRP10885e,-4.68468468,0,3.07692308,0,0.09033424,-23.57954545,-78.51239669,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00253593-01,Bitolterol,170465239,Beta-2 adrenergic receptor Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),30392-40-6,,23.7781084,0,-4.623822698,-44.07640832,-2.2,7,,-83.16528925,-74.73435655,0.007031875,0.96368262,,,O=C(Oc2cc(ccc2OC(=O)c1ccc(C)cc1)C(O)CNC(C)(C)C)c3ccc(C)cc3,GVK,FFS-11-286-NCI-028,0,-13.23722149,0,3.00250209,0,-15.43560606,-74.73435655,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00015452-20,Flutamide,170464921,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),13311-84-7,Flutamide; ; Eulexin; 2-Methyl-N-(4-nitro-3-;FLUTAMIDE; Flutamide; Flutamida,10.62129087,0,-4.973822698,-18.75416436,-2.4,7,,-28.79397875,-27.74498229,0.001201276,0.985525948,374,AR,O=C(Nc1cc(c(cc1)[N+]([O-])=O)C(F)(F)F)C(C)C,Microsource,1500995,0,-1.04849279,0,3.33611343,0,-15.24621212,-27.74498229,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00263572-01,Deferasirox,170464723,Iron Chelating Agent,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),201530-41-8,,9.466235454,1,-5.023822698,-13.66507505,-2.4,7,,-25.19362456,-23.49468713,0.004030385,0.97294795,,CAT,O=C(O)c1ccc(cc1)n3nc(nc3c2ccccc2O)c4ccccc4O,Sequoia,201530-41-8,4.68468468,0,0,0,0,-13.92045455,-23.49468713,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00168785-03,Diclazuril,405559143,antiprotozoal agent,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),101831-37-2, ; Diclazuril;Diclazuril;DICLAZURIL,13.37141299,0,-4.873822698,-50.52387879,-2.2,7,,-86.32467533,-78.27626919,4.58626E-05,0.997222944,,,ClC1=CC=C(C=C1)C(C#N)C2=C(Cl)C=C(C=C2Cl)N3\N=C/C(=O)NC3=O,FLUKA,34057,0,0,3.51648352,0,0,-36.64772727,-78.27626919,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00024622-05,Dantrolene sodium,170464793,Ryanodine receptor 1 Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),14663-23-1,,18.88762287,0,-4.723822698,-45.54365877,-2.2,7,,-65.44805195,-60.56670602,0.021808011,0.932876709,6261,RYR1,[Na+].[O-][N+](=O)c1ccc(cc1)c3ccc(/C=N/N2CC(=O)[N-]C2=O)o3,Enzo,AC100,0,-1.04849279,3.003663,-14.92910759,0,-21.875,-60.56670602,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00164543-02,Lomerizine dihydrochloride,170466010,Ca channel blocker - benzhydryl class,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),101477-54-7, ; Terranas; Lomerizine HCl; LOMERIZINE DiHCl;Lomerizine; Lomerizine,37.68576212,0,-4.423822698,-11.24763146,-2.4,7,,-25.97697757,-23.73081464,0.019912546,0.936298545,,,Cl.Cl.Fc1ccc(cc1)C(c2ccc(F)cc2)N3CCN(CC3)Cc4ccc(OC)c(OC)c4OC,Sequoia,SRP01568l,0,2.88335518,0,-3.75312761,-3.34236676,0,-23.73081464,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00090757-06,Melphalan,170464727,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),148-82-3,"; Mustard, Phenylalanin; Melfalano;Melphalan; ; Sarcolisina; L-Phenylalanine mustard;MELPHALAN; Melphalan",23.7781084,0,-4.623822698,-38.83651092,-3,7,,-76.74793388,-75.20661157,0.000256634,0.99338921,,H2AFX,O=C(O)[C@@H](N)Cc1ccc(cc1)N(CCCl)CCCl,Microsource,1500382,-3.6036036,0,0,-5.92160133,0,-7.29166667,-75.20661157,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167533-02,Vardenafil,170465607,Phosphodiesterase V (PDE5) Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1193386-64-9, ;Levitra;Vardenafil citrate; Vardenafil citrate; Vardenafil Hcl; Vardenafil HCLTrihydrate;Vardenafil Hydrochloride Trihydrate (Vivanza,29.9348649,0,-4.523822698,-38.44938322,-2.2,7,,-82.73966943,-67.65053129,0.007542891,0.962305019,8654,PDE5A,O=C(O)C(O)(CC(=O)O)CC(=O)O.CCN1CCN(CC1)S(=O)(=O)c4cc(C2=NC(=O)c3c(C)nc(CCC)n3N2)c(OCC)cc4,Sequoia,SRP01005v,0.72072072,2.88335518,0,-1.91826522,-12.5564589,-10.51136364,-67.65053129,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00091455-09,Celecoxib,170464693,Cyclooxygenase-2 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),169590-42-5,; 5   Celecoxib (Celebrex);Celecoxib; Celecoxib; Celebrex;CELECOXIB,18.88762287,0,-4.723822698,-27.41195355,-2.2,7,,-64.33116883,-58.20543093,1.19015E-05,0.998588768,5743,PTGS2,NS(=O)(=O)c1ccc(cc1)n3nc(cc3c2ccc(C)cc2)C(F)(F)F,Microsource,1503678,1.68168168,0,2.1978022,0,0,-14.48863636,-58.20543093,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00179526-05,Demecarium bromide,405558429,Acetylcholinesterase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),56-94-0,,29.9348649,0,-4.523822698,-22.05387523,-3,7,,-35.54471772,-33.3705981,0.005978242,0.966705142,,,CN(CCCCCCCCCCN(C)C(=O)OC1=CC(=CC=C1)[N+](C)(C)C)C(=O)OC2=CC(=CC=C2)[N+](C)(C)C,Prestwick,Prestw-616,-5.20792849,0,0,0,-4.55205811,-3.5,-33.3705981,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00378920-01,Falecalcitriol,405558573,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),83805-11-2,,21.19226141,0,-4.673822698,-40.69092127,-2.4,7,,-96.36305199,-76.41140302,0.143553122,0.997101146,,,C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C3\C[C@@H](O)C[C@H](O)C3=C,MedChem Express,HY-32342,0,-30.44911413,4.42556996,-0.27027027,-1.3559322,-25,-76.41140302,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00263138-19,Regorafenib,405558722,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),835621-07-3,,23.7781084,0,-4.623822698,-40.66266733,-2.2,7,,-81.74287312,-74.39910565,0.001205834,0.985482424,,KDR,CNC(=O)C1=CC(=CC=N1)OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C(=C2)F,MedChem Express,HY-13308,1.39914497,0,0,-8.46846847,0,-14.3,-74.39910565,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00346565-04,Elvitegravir,405558598,HIV Integrase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),697761-98-1,,4.228412057,1,-5.373822698,-92.75380943,-1.1,7,,-79.18,-80.54779206,0.000255793,0.993399464,,,COC1=CC2=C(C=C1CC3=C(F)C(=CC=C3)Cl)C(=O)\C(=C/N2[C@H](CO)C(C)C)C(O)=O,MedChem Express,HY-14740,4.66381656,-2.84301607,-3.17389361,-5.31531532,-5.81113801,-81.4,-80.54779206,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00181136-01,Pyrrolnitrin,144206296,respiratory electron transport chain Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1018-71-9,Pyrrolnitrin; Pyrrolnitrin Microbial; Pirrolnitrina; ,7.519298098,1,-5.123822698,-88.91321997,-2.1,7,"3-Chloro-4-(3-chloro-2-nitrophenyl)pyrrole;Pirrolnitrina;pyrrolnitrine;LS-136879;Pyrrolnitrine;Pyrrolnitrinum;Pyrrolnitrin Microbial;PYRROLNITRIN;CIPLUS_157237;Pyrrolnitrin;pyrrolnitrinum;1H-Pyrrole, 3-chloro-4-(3-chloro-2-nitrophenyl)-;",-101.3351034,-88.03801006,8.34287E-05,0.996248241,,,Clc2cncc2c1cccc(Cl)c1[N+]([O-])=O,NCI,NSC-107654,0,0,0,0,-24.50363196,-58.7,-88.03801006,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00181300-01,Riboflavin tetrabutyrate,144206329,platelet aggregation Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),752-56-7,CIPLUS_668986; Hibon; vitamin B2 tetrabutyrate; ,8.436791229,1,-5.073822698,-73.5088419,-2.2,7,"Hibon;Riboflavin butyrate;Riboflavin Butyrate;riboflavin tetrabutyrate, riboflavin-2-14C-labeled;vitamin B2 tetrabutyrate;RIBOFLAVIN BUTYRATE;riboflavin tetrabutyrate;CIPLUS_668986;",-79.38345444,-77.529346,4.72664E-05,0.997180564,,,CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)CN2C3=NC(=O)NC(=O)C3=Nc1cc(C)c(C)cc12,ACC,riboflavin butyrate,0,0,-1.11756817,-5.4954955,-9.49152542,-50.3,-77.529346,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00241101-09,Neratinib,405558751,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),698387-09-6,,1.935088591,1,-5.713299148,-56.53585023,-2.4,7,,-38.30072666,-31.91727222,0.069350266,0.868268276,,EGFR,CCOC1=CC2=C(C=C1NC(=O)\C=C\CN(C)C)C(=C(C=N2)C#N)NC3=CC=C(OCC4=CC=CC=N4)C(=C3)Cl,Glixx,GLXC-90246,0,-3.41985991,0,0,-17.62711864,-14.6,-31.91727222,,,,,,,,,7.31E-10,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,,,,,,,,
NCGC00017253-03,Ergobasine,124882896,Serotonin (5-HT) receptor Partial Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),129-51-1,,29.9348649,0,-4.523822698,-18.61963436,-3,7,ERGONOVINE MALEATE,-44.58216881,-34.15315819,0.000112828,0.995636544,,,C[C@@H](CO)NC(=O)[C@H]\1CN(C)[C@@H]\2CC3=C[NH]C4=CC=CC(=C34)C2=C1,BIOMOL,AC824,0,0.61804697,0,-0.45045045,-2.51815981,-7.2,-34.15315819,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00183040-01,NCGC00183040-01,124894246,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,Betamethasone benzoate; Uticort; ,6.701581484,1,-5.173822698,-43.61852636,-2.2,7,"LS-118426;betamethasone 17-benzoate;9-FLUORO-11.BETA.,17,21-TRIHYDROXY-16.BETA.-METHYLPREGNA-1,4-DIENE-3,20-DIONE 17-BENZOATE;BETAMETHASONE 17-BENZOATE;BETAMETHASONE BENZOATE;W 5975;Betamethasone benzoate;CIPLUS_173148;PREGNA-1,4-DIENE-3,20-DIONE, 17-(BENZOYLOXY)-9-FLUORO-11,21-DIHYDROXY-16-METHYL-, (11.BETA.,16.BETA.)-;Betamethasone Benzoate;Uticort;Pregna-1,4-diene-3,20-dione, 17-(benzoyloxy)-9-fluoro-11,21-dihydroxy-16-methyl-,(11-beta,16-beta)-;",-49.49273337,-48.2392398,0.001395492,0.984356285,,,C[C@H]1C[C@H]2[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)C5=CC=CC=C5)C(=O)CO,USP,1067307,0,-3.41985991,1.78810907,4.5045045,-7.16707022,-34,-48.2392398,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00181297-01,Mebrofenin,144206328,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),78266-06-5,Mebrofenin; Mebrofenino; ,2.667947643,1,-5.573822698,-67.33336972,-1.2,7,"Technetium (99mTc) mebrofenin;TECHNETIUM TC-99M MEBROFENIN KIT;mebrofeninum;Mebrofenin;Mebrofenine;CIPLUS_191790;technetium Tc 99m mebrofenin;MEBROFENIN;Technetium Tc 99m Mebrofenin;2,2'-((2-((3-BROMO-2,4,6-TRIMETHYLPHENYL)-AMINO)-2-OXOETHYL)IMINO)DIACETIC ACID;Mebrofenin ((3-Bromo-2,4,6-trimethylphenylcarbamoyl) methyliminodiacetic acid);Mebrofeninum;mebrofenine;Mebrofenino;SQ-26962;",-49.66,-40.7490218,0.011191817,0.953433013,,,Cc1cc(C)c(Br)c(C)c1NC(=O)CN(CC(=O)O)CC(=O)O,ACC,mebrofenin,0,0.90646889,0,0,-18.40193705,-58.5,-40.7490218,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00021123-03,Diatrizoic acid dihydrate,170464638,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),50978-11-5,,37.68576212,0,-4.423822698,-7.539314785,-2.4,7,,-24.71015348,-21.84179457,3.44E-08,0.999924496,,,O.O.O=C(C)Nc1c(I)c(c(I)c(NC(C)=O)c1I)C(=O)O,Bosche,D0803,0,0,0.14652015,0,0,0,-21.84179457,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167472-03,Amlexanox,170465365,Mediator Release Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),68302-57-8, 3   Amlexanox; ; Solfa;Amlexanox; Aphthasol; Amlenanox,8.436791229,1,-5.073822698,-32.04129937,-2.2,7,,-37.42030696,-37.42621015,1.6145E-06,0.999481145,,IL3,CC(C)c1cc2C(=O)c3cc(c(N)nc3Oc2cc1)C(=O)O,Bosche,A2169,0,0,0.80586081,0,0,-27.93560606,-37.42621015,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00522453-01,MLN9708,405559125,Proteasome subunit beta type-5 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1239908-20-3,,11.91728437,0,-4.923822698,-25.00144797,-2.2,7,,-41.38680828,-37.39519285,0.000522869,0.990523975,5693,PSMB5,CC(C)C[C@H](NC(=O)CNC(=O)C1=CC(=CC=C1Cl)Cl)B2OC(=O)C(CC(O)=O)(CC(O)=O)O2,MedChem Express,HY-10452,-0.46638166,1.23609394,3.17389361,1.89189189,-4.26150121,-18.5,-37.39519285,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00378997-07,Micafunginsodium,405558539,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),208538-73-2,,14.61979583,0,-4.835058692,-55.9450458,-3,7,,-43.44326439,-35.94186696,0.301853582,0.624041341,,,CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@@H](O)[C@@H](O)NC(=O)C5[C@@H](O)[C@@H](C)CN5C(=O)C(NC(=O)C(NC(=O)C6C[C@@H](O)CN6C(=O)C(NC4=O)[C@@H](C)O)[C@H](O)[C@@H](O)C7=CC=C(O)C(=C7)O[S+](O)([O-])=O)[C@H](O)CC(N)=O,Bio Vision,2585,-4.74154683,-3.41985991,-15.86946804,0,-17.53026634,-8.6,-35.94186696,,,,,,,,,1.83E-09,9.14E-09,4.57E-08,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,
NCGC00344134-02,Limaprost,405559048,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),74397-12-9,,7.519298098,1,-5.123822698,-29.64880072,-2.4,7,,-34.75181666,-29.79318055,0.007449647,0.962584137,,,CCCC[C@H](C)C[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O,MedChem Express,HY-B0683,3.49786242,-3.6670787,2.5033527,-3.06306306,-7.16707022,-20.7,-29.79318055,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00253607-01,Watanidipine,170465844,calcium ion transmembrane transport Blocker,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),116308-55-5,,1.68336116,1,-5.773822698,-138.2636816,-1.1,7,,-93.50920897,-98.11097993,0.002653985,0.978201897,,,[O-][N+](=O)c1cccc(c1)C2C(C(=O)OC)=C(C)NC(C)=C2C(=O)OCCc3ccc(cc3)N4CCN(CC4)C(c5ccccc5)c6ccccc6,GVK,FFS-11-286-NCI-247,2.52252252,-8.12581913,0,2.58548791,-63.14363144,-83.4280303,-98.11097993,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00263575-01,Ezetimibe,170465013,NPC1L1 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),163222-33-1,,37.68576212,0,-4.423822698,-2.94097734,-2.4,7,,-26.27685951,-22.31404959,0.00638229,0.965564185,,NPC1L1,Fc1ccc(cc1)[C@@H](O)CC[C@H]3C(=O)N(c2ccc(F)cc2)[C@@H]3c4ccc(O)cc4,Sequoia,163222-33-1,0,0,0,3.83653044,0,3.125,-22.31404959,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00017245-10,Ellagic acid,170466649,Aldose Reductase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),476-66-4,"; Elagostasine; Acid, Ellagi; Acido elagico;ELLAGIC ACID; Acid, Benzoari;Ellagic Acid; EADME cpd;Ellagic acid; Ellagic acid hydrate",9.224467556,1,-5.035058692,-20.67030539,-2.4,7,,-26.69362456,-23.49468713,0.017046593,0.941539166,231,AKR1B1,Oc1c4OC(=O)c2cc(O)c(O)c3OC(=O)c(cc1O)c4c23,Vitas,STK801964,3.003003,0,0,-4.42035029,0,-7.85984848,-23.49468713,,,,,,,,,1.83E-09,9.14E-09,4.57E-08,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,
NCGC00015467-20,Glybenclamide,170464964,Sulfonylurea receptor 2 Modulator,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),10238-21-8,,7.519298098,1,-5.123822698,-24.65212568,-1.4,7,,-27.79397875,-27.74498229,0.004211621,0.97230274,,,O=C(NC1CCCCC1)NS(=O)(=O)c3ccc(CCNC(=O)c2cc(Cl)ccc2OC)cc3,Enzo,KC120,0,-2.09698558,-1.39194139,4.42035029,-0.27100271,-22.06439394,-27.74498229,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00095133-06,Famciclovir,170464774,antiviral,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),104227-87-4,; ; Famciclovir; FAMCICLOVIR;FAMCICLOVIR;Famciclovir,6.701581484,1,-5.173822698,-8.26060596,-2.4,7,,-33.43181818,0,0.001801733,0.99338516,,,CC(=O)OCC(COC(C)=O)CCn2cnc1cnc(N)nc12,Microsource,1505201,0,2.49017038,0,0,0,-28.69318182,0,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00095086-04,PERICIAZINE,405558569,Dopamine D2 receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),2622-26-6,,15.00297213,0,-4.823822698,-35.23894287,-2.2,7,,-64.89966462,-58.63610956,0.000221475,0.993864129,,,OC1CCN(CCCN2C3=CC=CC=C3SC4=CC=C(C=C24)C#N)CC1,Microsource,MS-01503936,-1.24368441,0,0.49173,3.96396396,0.5811138,-24.5,-58.63610956,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00165846-04,Nefazodone hydrochloride,170465078,Serotonin transporter Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),82752-99-6,,37.68576212,0,-4.423822698,-8.322672965,-3,7,,-51.53214086,-44.32643935,0.001361419,0.984555694,,,Cl.Clc1cccc(c1)N4CCN(CCCN3N=C(CC)N(CCOc2ccccc2)C3=O)CC4,Prestwick,Prestw-1152,3.57559269,0,1.1622709,3.87387387,-2.22760291,2.8,-44.32643935,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00538141-01,NCGC00538141-01,405558747,Microsomal triglyceride transfer protein Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,13.37141299,0,-4.873822698,-61.7123159,-2.1,7,,-92.71928451,-84.9077697,1.45E-08,0.999950819,,,CN(CC1=CC=CC=C1)C(=O)[C@H](NC(=O)C2=CC3=C(C=CC(=C3)NC(=O)C4=CC=CC=C4C5=CC=C(C=C5)C(F)(F)F)[N]2C)C6=CC=CC=C6,Pharmaron,PH-NIH-2017-009-L1-1-0,0,0,0,0,-5.32687651,-40.5,-84.9077697,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00014482-03,Methdilazine hydrochloride,124878446,ion channel,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,10.62129087,0,-4.973822698,-36.0101462,-2.2,7,Methdilazine hydrochloride,-45.29709335,-39.29569592,0.031676586,0.917157944,,,CN1CC[C@@H](C1)CN2C3=C(SC4=C2C=CC=C4)C=CC=C3,NCGC,NSC-169091,-3.03148076,0,0.35762181,4.95495495,-14.43099274,-18.8,-39.29569592,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00179332-03,Naftifine hydrochloride,170464903,Squalene monooxygenase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),65473-14-5,,21.19226141,0,-4.673822698,-58.74849833,-2.1,7,,-96.49435438,-91.61542761,0.001670358,0.982838112,3646509,,Cl.CN(C\C=C\c1ccccc1)Cc3cccc2ccccc23,Prestwick,Prestw-1063,-11.34862029,-4.3263288,-0.84935181,-0.54054054,2.13075061,-19.8,-91.61542761,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00344561-01,Norgestimate,170464733,Progesterone receptor Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),35189-28-7,,9.466235454,1,-5.023822698,-62.06413836,-2.2,7,,-81.43907211,-78.64728899,7.9137E-06,0.998849524,,,CC(=O)O[C@@]3(C#C)CC[C@H]2[C@@H]4CCC1=CC(\CC[C@@H]1[C@H]4CC[C@@]23CC)=N\O,Prestwick,Prestw-1452,0,0,2.90567725,0,-3.87409201,-48.5,-78.64728899,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00178831-03,Acriflavine hydrochloride,170465670,Hypoxia-inducible factor 1 alpha Interacts,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),69235-50-3,,21.19226141,0,-4.673822698,-70.65228675,-2.1,7,,-110.0125148,-90.55489965,0.001246043,0.985235361,,,[Cl-].C[n+]1c3cc(N)ccc3cc2ccc(N)cc12.Nc1cc2nc3cc(N)ccc3cc2cc1,Microsource,1500618,0,-11.14023591,0,0,-8.76242096,-35.89015152,-90.55489965,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00015735-11,Niclosamide,170465184,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),50-65-7, Yomesan;Niclosamide; Niclosamida;NICOLSAMIDE; ; Bayluscide;NICLOSAMIDE; Niclocide; Phenasal; Fenasal; Niclosamid; Radewerm; Bayer 73; Bayer 2353; Niclosamide; Clonitralide; Niclosamidel; Devermine; Niclosamide-olamine; Tr??d??mine,1.461979583,1,-5.835058692,-48.0441009,-1.2,7,,-38.94886363,-30.34238489,0.010014155,0.956147769,6774,STAT3,Clc2cc(ccc2NC(=O)c1cc(Cl)ccc1O)[N+]([O-])=O,Vitas,STK396676,0,3.93184797,2.85714286,1.00083403,-7.67841012,-43.08712121,-30.34238489,,,,,,,,,1.83E-09,9.14E-09,4.57E-08,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,
NCGC00274063-01,Pimobendan,174007050,Phosphodiesterase III (PDE3) Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),77469-98-8,Pimobendan(Vetmedin),37.68576212,0,-4.423822698,-16.71157387,-3,7,,-49.20306966,-44.0377804,0.000786283,0.988336126,5139,PDE3A,Cl.COc1ccc(cc1)c2nc3ccc(cc3n2)C4=NNC(=O)CC4C,Selleck,S1550,-0.24024024,0.3931848,1.97802198,-3.91993328,0,0,-44.0377804,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016855-10,Fenbendazole,170465647,antiparasitic agent,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),43210-67-9,; ; Phenbendasol; Fenbendazole; Panacur;FENBENDAZOLE; Fenbendazol;Fenbendazole,15.00297213,0,-4.823822698,-51.83991225,-2.1,7,,-92.6661157,-83.9433294,0.000026934,0.997874093,,CYP3A4,O=C(OC)Nc1nc2cc(ccc2n1)Sc3ccccc3,Vitas,STK378581,0,3.14547837,0,0,0,-35.3219697,-83.9433294,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00183046-03,Mequitazine,170465794,Histamine H1 receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),29216-28-2,,5.32325539,1,-5.273822698,-24.12634437,-2.4,7,,-23.51003542,-20.42502952,0.010985475,0.953999414,,,c3ccc4Sc5ccccc5N(CC2CN1CCC2CC1)c4c3,Vitas,STK324459,0,-1.31061599,0,0,-10.02710027,-12.97348485,-20.42502952,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00095264-04,Chloroxine,170465084,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),773-76-2,; ; Capitrol; CHLOROXINE;CHLOROXINE; Chloroxine;Chloroxine,2.37781084,1,-5.623822698,-129.4744296,-1.1,7,,-86.20681818,-76.85950413,0.00454302,0.971153579,,,Oc1c(Cl)cc(Cl)c2cccnc12,Vitas,STK075368,-7.20720721,3.27653997,0,-1.58465388,-40.37940379,-98.76893939,-76.85950413,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00166079-02,C.I. Solvent Red 24,170465710,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),85-83-6,,5.972790784,1,-5.223822698,-74.7781149,-2.2,7,,-79.86975964,-75.29346003,6.99E-07,0.999658585,,,Cc4ccccc4/N=N/c3ccc(/N=N/c1c2ccccc2ccc1O)c(C)c3,SIGMA,198102,1.32141469,1.77173465,0,-1.98198198,-16.46489104,-54.4,-75.29346003,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00183597-01,Betamethasone butyrate propionate,144206581,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),5534/2/1,,9.466235454,1,-5.023822698,-36.70300866,-2.2,7,Betamethasone butyrate propionate;BETAMETHASONE BUTYRATE PROPIONATE;Antebate;Betamethasone Butyrate Propionate;CIPLUS_213705;,-47.64980436,-43.99105646,1.0277E-06,0.99958607,,,CCC(=O)OCC(=O)[C@@]4(OC(=O)CCC)[C@@H](C)C[C@@H]3[C@]4(C)C[C@H](O)[C@@]2(F)[C@H]3CCC1=CC(=O)C=C[C@@]12C,APAC,877861,0,0.61804697,0,0,-5.13317191,-26,-43.99105646,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00532512-01,HYDROCORTISONE ACEPONATE,405558972,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,8.436791229,1,-5.073822698,-15.60383816,-2.4,7,,-20.71464506,-20.17887088,0.002093412,0.980761166,,,CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CC\C4=C\C(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)COC(C)=O,BOC Sciences,74050-20-7,-1.63233579,0.94767202,0,2.34234234,-0.1937046,-13.2,-20.17887088,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00386281-05,Fidaxomicin,405558974,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),873857-62-6,,9.466235454,1,-5.023822698,-47.64861935,-2.2,7,,-69.74455003,-67.35606484,0.000060424,0.996810356,,,CC[C@H]1\C=C(C)/[C@@H](O)C\C=C\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)C3=C(CC)C(=C(O)C(=C3O)Cl)Cl)[C@H](O)[C@@H]2OC)\C(=O)O[C@@H](C\C=C(C)\C=C(C)\[C@@H]1O[C@@H]4OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]4O)[C@@H](C)O,Glixx,GLXC-90140,4.58608628,0,0,0.72072072,0,-41.2,-67.35606484,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00386241-01,Avanafil,405558527,Phosphodiesterase 5A Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),330784-47-9,,9.466235454,1,-5.023822698,-15.63485518,-2.4,7,,-31.75181666,-29.79318055,0.001617895,0.983131616,,,COC1=C(Cl)C=C(CNC2=C(C=NC(=N2)N3CCC[C@H]3CO)C(=O)NCC4=NC=CC=N4)C=C1,Selleck,S4019,0,4.61475072,0,2.88288288,2.03389831,-17,-29.79318055,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167435-07,Nilvadipine,405558817,Voltage-gated L-type calcium channel alpha-1C subunit Blocker,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),75530-68-6,,11.91728437,0,-4.923822698,-61.65769708,-2.2,7,,-77.43683622,-64.11403018,0.00212542,0.980571829,,,COC(=O)C\1=C(\N\C(=C(/C1C2=CC(=CC=C2)[N+]([O-])=O)C(=O)OC(C)C)C)C#N,MedChem Express,HY-14284,0,0,2.36924452,-8.28828829,-17.43341404,-32.8,-64.11403018,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00181111-02,Tamibarotene,170465883,Retinoid RAR Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),94497-51-5, ; Am80; Am 80;AM 80; Tamibarotene;tamibarotene; Amnoid,10.62129087,0,-4.973822698,-24.06041036,-2.2,7,,-38.88680828,-37.39519285,0.000492567,0.990806864,5915,RARB,O=C(O)c1ccc(cc1)C(=O)Nc2ccc3c(c2)C(C)(C)CCC3(C)C,Tocris,3507,2.48736883,0,-1.74340635,2.07207207,0,-19.3,-37.39519285,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00181120-02,Acetophenazine Maleate,405558986,Sigma opioid receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),5714-00-1,,29.9348649,0,-4.523822698,-24.72448557,-3,7,,-53.2314142,-41.0844047,0.025872331,0.926152965,,,[CH3][C](=[O])C1=CC=C2[S]C3=C(C=CC=C3)[N]([CH2][CH2][CH2][N]4[CH2][CH2][N]([CH2][CH2][OH])[CH2][CH2]4)C2=C1,USP,1007000,4.27516518,-0.7828595,1.47518999,-9.45945946,-2.22760291,-9.4,-41.0844047,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00386298-01,Rifapentine,405559051,DNA-Directed RNA Polymerase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),61379-65-5,,21.19226141,0,-4.673822698,-61.86058662,-2.1,7,,-113.1685299,-85.3549469,0.000649326,0.989414719,,PRKDC,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C4=C(O)C(=C(NC(=O)\C(=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C)C(=C4C(=C3C)O)O)\C=N\N5CCN(CC5)C6CCCC6,Selleck,S1760,0,-1.03007829,4.78319177,-0.63063063,-14.23728814,-34.7,-85.3549469,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00015959-09,Sanguinarine,170466353,Serine/threonine-protein phosphatase PP1-alpha catalytic subunit Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),2447-54-3,,10.35002283,0,-4.985058692,-53.92579875,-2.1,7,,-87.88807556,-83.70720189,3.77079E-05,0.997482976,100009298,PPP1CA,C[n+]2cc1c6OCOc6ccc1c3ccc4cc5OCOc5cc4c23,Tocris,2302,0,0,4.32234432,0,0,-10.51136364,-83.70720189,,,,,,,,,1.83E-09,9.14E-09,4.57E-08,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,
NCGC00015714-16,Nimodipine,170466561,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),66085-59-4,,15.00297213,0,-4.823822698,-60.84875471,-2.4,7,,-54.79574971,-48.99645809,0.112878755,0.820057454,,,CC=1NC(C)=C(C(C=1C(=O)OC(C)C)c2cccc(c2)[N+]([O-])=O)C(=O)OCCOC,SigmaAldrich,N149,-4.2042042,-14.54783748,2.27106227,-0.25020851,-22.67389341,-21.875,-48.99645809,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00183008-01,Israpafant,144206851,Interleukin-5 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),117279-73-9,ISRAPAFANT; ,13.37141299,0,-4.873822698,-45.78414152,-2.2,7,"6H-Thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine, 4-(2-chlorophenyl)-6,9-dimethyl-2-(2-(4-(2-methylpropyl)phenyl)ethyl)-;4-(2-chlorophenyl)-2-(2-(4-isobutylphenyl)ethyl)-6,9-dimethyl-6H-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine;Y 24180;CIPLUS_695838;(+/-)-4-(O-CHLOROPHENYL)-2-(P-ISOBUTYLPHENETHYL)-6,9-DIMETHYL-6H-THIENO(3,2-F)-S-TRIAZOLO(4,3-A)(1,4)DIAZEPINE;israpafant;ISRAPAFANT;Israpafant;Y-24180;israpafantum;",-79.0974026,-71.66469894,7.68245E-05,0.996400972,,,CC(C)Cc1ccc(cc1)CCc2cc5c(s2)n3c(C)nnc3C(C)N=C5c4ccccc4Cl,Pharmaron,PH-NIH-155125,0,0,3.88278388,0.83402836,0,-34.375,-71.66469894,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00263955-02,TYLOSIN TARTRATE,405559071,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),74610-55-2,,16.8336116,0,-4.773822698,-21.13006187,-2.2,7,,-39.03246753,-36.0094451,2.0127E-06,0.999420776,,,CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)/C=C/C(=C/[C@@H]1CO[C@@H]4O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]4OC)C,FLUKA,33847,0,0,0,0,0,-12.21590909,-36.0094451,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016258-06,Menadione,170464997,CDC25 Phosphatase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),58-27-5," ; Menadione (K3);Menadione / vitamin K3;MENADIONE; Kappaxin; Kipca, oil soluble;Menadione; Menadione; Vitamin- K3",16.8336116,0,-4.773822698,-21.88278122,-2.2,7,,-38.59740259,-35.30106257,0.003623224,0.974393143,5923,CDC25,O=C2C=C(C)C(=O)c1ccccc12,Specs,AE-562/J257372,-3.36336336,0,0,0,3.34236676,-12.59469697,-35.30106257,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00091330-07,Anthralin,170466655,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1143-38-0,,2.37781084,1,-5.623822698,-121.5515128,-1.1,7,,-90.24261364,-88.42975207,2.17707E-05,0.998089254,,,Oc2cccc1Cc3cccc(O)c3C(=O)c12,Microsource,1500127,1.32132132,3.14547837,-1.24542125,-1.58465388,-40.01806685,-91.76136364,-88.42975207,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00346442-02,Phenprocoumon,405558576,Cytochrome P450 3A4 Substrate,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),435-97-2,,7.519298098,1,-5.123822698,-19.98999477,-1.4,7,,-23.03186138,-22.52655115,0.005719449,0.967482512,,,CCC(C1=CC=CC=C1)C/2=C(\O)C3=CC=CC=C3OC2=O,Adooq,A10656,3.49786242,0,-2.63746089,-0.81081081,1.8401937,-20.3,-22.52655115,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00509905-01,Eliglustat (Tartrate),405558462,Ceramide glucosyltransferase Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),491833-29-5,,23.7781084,0,-4.623822698,-6.833972706,-3,7,,-32.32504193,-30.68753494,0.011021638,0.95385498,7357,UGCG,CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)C2=CC=C3OCCOC3=C2,Selleck,S7852,3.18694131,-3.41985991,0,0,4.84261501,0,-30.68753494,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00177980-03,Oxiconazole nitrate,170465226,Steroid biosynthesis Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),64211-46-7,,7.519298098,1,-5.123822698,-69.37563385,-2.2,7,,-82.03046395,-78.53549469,6.7222E-06,0.998939819,,,[O-][N+](=O)O.Clc3ccc(C(=N\OCc1ccc(Cl)cc1Cl)\Cn2ccnc2)c(Cl)c3,Microsource,1505330,0,3.04903173,0,0,-7.94188862,-55.1,-78.53549469,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00249613-11,Carfilzomib,405558759,Proteasome Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),868540-17-4,,26.67947643,0,-4.573822698,-30.54330636,-3,7,,-77.60899944,-76.41140302,0.001189676,0.985582086,,PSMD1,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,Selleck,S2853_CM1,0,-7.62257932,0,0,3.97094431,-1.8,-76.41140302,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00532515-01,ROBENACOXIB,405558760,Cyclooxygenase-2 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,8.436791229,1,-5.073822698,-12.90820588,-2.4,7,,-23.42202347,-21.18501956,0.002128397,0.980587517,,,CCC1=CC=C(NC2=C(F)C(=CC(=C2F)F)F)C(=C1)CC(O)=O,J&W Pharm,99R0028,0,0,3.53151542,2.79279279,0,-14.2,-21.18501956,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00014925-06,Topotecan hydrochloride,170465137,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),119413-54-6,; Hycamtamine; Topotecane; Nogitecan hydrochloride;Nogitecan hydrochloride/NSC-609699;Topotecan hydrochloride; Topotecan hydrochloride;TOPOTECAN HYDROCHLORIDE; Nogitecan Hydrochloride; Hycamtin,26.67947643,0,-4.573822698,-29.23443949,-3,7,,-71.79693034,-63.16410862,0.001044483,0.986512391,7150,TOP1,Cl.CN(C)Cc1c2cc3CN4C(=O)C=5COC(=O)[C@](O)(CC)C=5C=C4c3nc2ccc1O,Prestwick,Prestw-1196,-5.88588589,2.49017038,0,2.08507089,0,-7.10227273,-63.16410862,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00017323-08,Tetracycline hydrochloride,170464838,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),64-75-5, Achromycin;; Tetraciclina; Tetracycline Hcl; Bristacycline; Tetrabid; Hostacyclin; Contramibial; Sustamycin;Tetracycline hydrochloride; Tetracycline hydrate; Ulcrux powder;Tetracycline;TETRACYCLINE HYDROCHLORIDE; Achromycin V; 4 Epitetracyclin; 4-Epitetracycline; Topicycline,37.68576212,0,-4.423822698,-20.02563033,-3,7,,-50.04899646,-45.21841795,0.019135423,0.937595252,,PADI1,Cl.NC(=O)C1=C(O)[C@@H](N(C)C)[C@@H]2C[C@H]4C(=C(O)[C@]2(O)C1=O)C(=O)c3c(O)cccc3[C@@]4(C)O,Microsource,1500566,0,0.5242464,0,-9.92493745,4.24570912,-0.85227273,-45.21841795,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00015718-12,Naftopidil,170466026,alpha1-Adrenoceptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),57149-07-2,;Naftopidil;Naftopidil dihydrochloride; Flivas; KT-611 dihydrochloride; Naftopidil,37.68576212,0,-4.423822698,-13.64289098,-2.4,7,,-27.46044864,-25.3837072,0.024587815,0.928321601,148,ADRA1A,OC(CN1CCN(CC1)c2ccccc2OC)COc4cccc3ccccc34,Tocris,597,0,-6.81520315,0,0,0,0,-25.3837072,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00274067-01,Eltrombopag olamine,174006931,Thrombopoietin Receptor (TpoR) Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),496775-61-2,Eltrombopag,2.667947643,1,-5.573822698,-117.3427296,-1.1,7,,-89.10602126,-90.55489965,5.87911E-05,0.996853635,4352,MPL,O=C(O)c1cccc(c1)c4cccc(N\N=C2\C(=O)N(N=C2C)c3ccc(C)c(C)c3)c4O,Selleck,S2229,0,0,-3.2967033,0,-38.57271906,-80.77651515,-90.55489965,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016511-08,Chlorotrianisene,170465394,Estrogen receptor Modulator,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),569-57-3,,4.228412057,1,-5.373822698,-51.59848401,-2.2,7,,-50.18831169,-45.21841795,0.000127777,0.995351439,,,COc1ccc(cc1)C(\Cl)=C(/c2ccc(OC)cc2)c3ccc(OC)cc3,Prestwick,Prestw-757,0,1.04849279,0,0,-15.62782294,-36.64772727,-45.21841795,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016600-08,Clofazimine,387065713,DNA Binding Agent,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),2030-63-9,,2.119226141,1,-5.673822698,-137.9841623,-1.1,7,,-100.5970484,-100.7083825,3.6061E-06,0.999223803,,,CC(C)\N=C\1/C=C\2N(C3=CC=C(Cl)C=C3)C4=C(C=CC=C4)\N=C2\C=C1NC5=CC=C(Cl)C=C5,SIGMA,C8895,0,1.83486239,0,0.41701418,-52.30352304,-97.06439394,-100.7083825,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00253588-01,Gimatecan,170465615,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),292618-32-7,,13.37141299,0,-4.873822698,-49.56971451,-2.2,7,,-66.47428731,-62.10173281,0.002440778,0.979131625,,,CC(C)(C)O\N=C\c1c3CN4C(=O)C=5COC(=O)[C@](O)(CC)C=5C=C4c3nc2ccccc12,GVK,FFS-11-286-NCI-141,-4.11970462,-4.07911001,-4.1573536,2.7027027,1.4527845,-30.4,-62.10173281,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00274272-01,Iobenzamic acid,170465948,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),3115/5/7,,23.7781084,0,-4.623822698,-7.348150789,-3,7,,-40.47343566,-38.13459268,0.001616662,0.983133907,,,Ic1cc(I)c(N)c(I)c1C(=O)N(CCC(=O)O)c2ccccc2,GVK,FFS-11-286-NCI-258,0,3.66972477,4.90842491,0,0,0,-38.13459268,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00025349-05,Apomorphine,170465297,D2-like dopamine receptor Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),58-00-4,,16.8336116,0,-4.773822698,-44.22466302,-2.1,7,,-88.75324675,-80.87367178,9.6927E-06,0.998726524,,,Oc3ccc2C[C@@H]1c4c(CCN1C)cccc4c2c3O,Specs,AE-562/J258166,2.76276276,0,0,0,0,-26.42045455,-80.87367178,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167489-03,Sarpogrelate hydrochloride,174006666,5HT(2A) and 5HT(2B) inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),135159-51-2, ; Sarpogrelate;Sarpogrelate; Anplag; Sarpogrelate HCl,13.37141299,0,-4.873822698,-15.82566871,-2.4,7,,-25.19362456,-23.49468713,2.13439E-05,0.998111727,,,Cl.O=C(O)CCC(=O)OC(COc2ccccc2CCc1cccc(OC)c1)CN(C)C,Tocris,3739,0,0,0,0,0,-10.89015152,-23.49468713,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00263960-01,OXANTEL PAMOATE,405558714,antiparasitic agent,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,8.436791229,1,-5.073822698,-69.38215613,-2.2,7,,-74.63862493,-72.05142538,1.62279E-05,0.998351228,,,CN1CCC/N=C1/C=C/C2=CC=CC(=C2)O.OC(=O)C3=CC4=CC=CC=C4C(=C3O)CC5=C(O)C(=CC6=CC=CC=C56)C(O)=O,Microsource,MS-01505982,-3.26467159,0,0,-1.62162162,-10.55690073,-46.8,-72.05142538,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00179247-04,Nomegestrol acetate,405558605,Androgen Receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),58652-20-3,,18.88762287,0,-4.723822698,-22.40217784,-2.4,7,,-31.98351034,-29.56959195,0.013926184,0.947630197,,,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3\C=C(C)/C4=C/C(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O,SIGMA,SML0133,-6.37388263,0,0,0,0.968523,-9.9,-29.56959195,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00481544-01,Cetrorelix,405558930,Gonadotropin-releasing hormone receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,10.35002283,0,-4.985058692,-76.43743919,-2.2,7,,-101.067915,-76.18781442,0.000108511,0.995717806,,,CC(C)C[C@H](\N=C(/O)[C@@H](CCCNC(O)=N)\N=C(/O)[C@H](CC1=CC=C(O)C=C1)\N=C(/O)[C@H](CO)\N=C(/O)[C@@H](CC2=CN=CC=C2)\N=C(/O)[C@@H](CC3=CC=C(Cl)C=C3)\N=C(/O)[C@@H](CC4=CC5=CC=CC=C5C=C4)\N=C(\C)O)/C(O)=N/[C@@H](CCCNC(N)=N)C(=O)N6CCC[C@H]6\C(O)=N\[C@H](C)C(O)=N,APExBIO,B4975,0.85503304,0,0,0,-12.30024213,-33.2,-76.18781442,,,,,,,,,1.83E-09,9.14E-09,4.57E-08,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,
NCGC00378902-03,Toceranib,405558487,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),[356068-94-5],,8.221315363,1,-5.085058692,-53.54651946,-2.2,7,,-72.69647848,-65.67915036,0.000157848,0.994827938,,FLT1,CC1=C(C(=C([NH]1)\C=C2/C(=O)NC3=C2C=C(F)C=C3)C)C(=O)NCCN4CCCC4,Tocris,3909,0,0,0,0,3.29297821,-24.2,-65.67915036,,,,,,,,,1.83E-09,9.14E-09,4.57E-08,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,
NCGC00167457-02,Gestrinone,170466364,Progesterone receptor Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),16320-04-0,,16.8336116,0,-4.773822698,-55.4901946,-2.2,7,,-94.36305199,-76.41140302,1.1679E-06,0.999558578,5241,PGR,O=C3C=C4CC[C@@H]2C(C=C[C@@]1(CC)[C@H]2CC[C@@]1(O)C#C)=C4CC3,Bosche,G6427,0,1.68932839,0,0,-7.26392252,-35.6,-76.41140302,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00015619-13,Loratadine,170464867,Histamine H1 Receptor Antagonists,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),79794-75-5, Sch2985; ; Claritin; Sch-434;LORATADINE; Wyeth Brand of Loratadine; Clarium; Sch 2985;Loratidine; Alavert; Loratadine Hydrochloride; Sch 434; Loratidine; Loratadine Wyeth Bran; Loratadine W/Pseudo; Loratadine;Loratadine;,37.68576212,0,-4.423822698,-16.811725,-3,7,,-54.27922078,-48.05194805,1.20E-09,0.999985765,9704,HRH1,Clc3cc4CCc1cccnc1C(=C2/CCN(CC2)C(=O)OCC)\c4cc3,Vitas,STK574925,0,0,0,0,0,0,-48.05194805,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00159423-03,Phytonadione,170464798,Vitamin K epoxide reductase complex subunit 1 Substrate,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),84-80-0,,9.466235454,1,-5.023822698,-72.1347115,-2.1,7,,-88.99409681,-87.24911452,0.000137006,0.995183669,79001,VKORC1,CC(C)CCC[C@@H](C)CCC[C@@H](C)CCCC(\C)=C\CC2=C(C)C(=O)c1ccccc1C2=O,Labotest,LT00452032,0,-4.84927916,2.56410256,0,0,-57.29166667,-87.24911452,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016978-04,Repaglinide,225144184,Insulin Secretagogues,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),135062-02-1,; ; Prandin; Repaglinide;Repaglinide; Repaglinida; Novonorm,13.37141299,0,-4.873822698,-43.66502289,-2.4,7,,-42.55076741,-43.56552538,0.081542672,0.854186302,,INS,CCOC1=C(C=CC(=C1)CC(=O)N[C@@H](CC(C)C)C2=C(C=CC=C2)N3CCCCC3)C(O)=O,Prestwick,Prestw-1046,-1.32132132,0,0.95238095,-17.26438699,0,-22.63257576,-43.56552538,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00250399-08,Vemurafenib,405559058,Raf kinase B Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1029872-54-5,,21.19226141,0,-4.673822698,-59.40909586,-2.1,7,,-106.4405254,-83.67803242,0.000104044,0.995807375,,BRAF,CCC[S+]([O-])(=O)NC1=CC=C(F)C(=C1F)C(=O)C2=C[NH]C3=NC=C(C=C23)C4=CC=C(Cl)C=C4,Bio Vision,2235,0,0,0,0,-10.94430993,-32.2,-83.67803242,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00179370-05,Methotrimeprazine maleat salt,405559100,Serotonin 2 (5-HT2) receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),7104-38-3,,9.466235454,1,-5.023822698,-61.00205882,-2.2,7,,-54.66880939,-56.28842929,0.005289792,0.968760313,,,COC1=CC2=C(SC3=C(C=CC=C3)N2C[C@H](C)CN(C)C)C=C1,Prestwick,Prestw-797,-9.63855422,-5.80964153,1.51989271,0.81081081,-7.16707022,-35.9,-56.28842929,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167502-01,NCGC00167502-01,50112755,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,CIPLUS_205233; Santeson; ,8.436791229,1,-5.073822698,-39.44687501,-2.2,7,Santeson;CIPLUS_684703;Dexamethasone Metasulfobenzoate Sodium;Dexamethasone metasulfobenzoate sodium;CIPLUS_205233;DEXAMETHASONE METASULFOBENZOATE SODIUM;,-29.30072666,-31.91727222,0.003019265,0.976718179,,,CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)COC(=O)C5=CC=CC(=C5)S([O-])(=O)=O,Pharmeks,PHAR046594,-5.20792849,0,-5.14081359,-3.24324324,-3.29297821,-22,-31.91727222,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00181168-01,Trifluomeprazine 2-butenedioate,144206322,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),71609-19-3,Trifluomeprazine; Trifluomeprazina; ,23.7781084,0,-4.623822698,-19.25778481,-2.2,7,Trifluomeprazinum;Trifluomeprazine;CIPLUS_214394;trifluomeprazine;TRIFLUOMEPRAZINE;trifluomeprazinum;Trifluomeprazina;TRIFLUOMEPRAZINE MALEATE;,-52.13247625,-38.73672443,0.000788297,0.988322428,,,O=C(O)C=CC(=O)O.FC(F)(F)c1cc2N(CC(C)CN(C)C)c3ccccc3Sc2cc1,NCI,NSC-170991,4.66381656,0,0,0,-1.0653753,-13.2,-38.73672443,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00160504-01,Testosterone 17-phenylpropionate,144206667,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1255-49-8,testosterone 17-phenylpropionate; Retandrol; Mixogen; ,37.68576212,0,-4.423822698,-8.748235472,-2.4,7,TESTOSTERONE PHENYL PROPIONATE;CIPLUS_3882657;testosterone phenylpropionate;Retandrol;Testosterone Phenylpropionate;CIPLUS_157987;Testosterone 17-phenylpropionate;testosterone 17-phenylpropionate;estandron prolongatum;4-Androsten-17beta-ol-3-one 17-phenylpropionate;Testosterone phenylpropionate;Mixogen;Testosterone hydrocinnamate;,-25.76355506,-22.30296255,0.000113931,0.995620947,,,O=C5CC[C@@]4(C)C(CC[C@@H]2[C@@H]4CC[C@]3(C)[C@@H](OC(=O)CCc1ccccc1)CC[C@@H]23)=C5,InterBioScreen,STOCK1N-42343,0,0,0,-1.35135135,0,0,-22.30296255,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00509862-02,Fluralaner,405558651,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),864731-61-3,,16.8336116,0,-4.773822698,-20.01605919,-2.2,7,,-48.74007826,-42.98490777,0.009813482,0.956625861,,,CC1=C(C=CC(=C1)\C2=N\OC(C2)(C3=CC(=CC(=C3)Cl)Cl)C(F)(F)F)C(=O)NCC(=O)NCC(F)(F)F,MedChem Express,HY-16973,3.73105325,2.43098475,4.24675905,-6.30630631,2.13075061,-14.5,-42.98490777,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00378682-03,Pasireotide (ditrifluoroacetate),405558784,Somatostatin receptor 5 Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,3.672326679,1,-5.435058692,-78.26388416,-2.2,7,,-74.18474008,-61.65455562,0.00017538,0.994545707,,,NCCCC[C@@H]1NC(=O)[C@@H](CC2=C[NH]C3=C2C=CC=C3)NC(=O)[C@@H](NC(=O)[C@@H]4C[C@H](CN4C(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC6=CC=C(OCC7=CC=CC=C7)C=C6)NC1=O)OC(=O)NCCN)C8=CC=CC=C8,MedChem Express,HY-79135,0,0.53564071,4.42556996,-4.23423423,-18.11138015,-42.3,-61.65455562,,,,,,,,,1.83E-09,9.14E-09,4.57E-08,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,
NCGC00344330-02,Elaidic Acid,405558971,SiHa Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),112-79-8,,15.00297213,0,-4.823822698,-56.73373492,-2.1,7,,-96.23068753,-88.14980436,0.00012881,0.995331187,,,CCCCCCCC/C=C/CCCCCCCC(O)=O,Cayman,90250,-3.96424407,2.2249691,0,0,0.5811138,-34.7,-88.14980436,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00390666-01,Opicapone,405559022,Catechol O-methyltransferase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),923287-50-7,,9.466235454,1,-5.023822698,-90.14159629,-2.2,7,,-87.78591392,-79.98882057,0.001839144,0.981966732,,,CC1=C(Cl)C(=[N+]([O-])C(=C1C2=NOC(=N2)C3=CC(=C(O)C(=C3)O)[N+]([O-])=O)Cl)C,MedChem Express,HY-14896,0,-4.24392254,-1.74340635,-14.77477477,-15.10895884,-53.1,-79.98882057,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00179625-03,Thioproperazine dimethanesulfonate,170465871,Serotonin 2a (5-HT2a) receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),2347-80-0,,9.466235454,1,-5.023822698,-46.76109246,-2.2,7,,-61.7177194,-58.52431526,0.000003022,0.99928967,,,CS(=O)(=O)O.CS(=O)(=O)O.CN(C)S(=O)(=O)c2cc3N(CCCN1CCN(C)CC1)c4ccccc4Sc3cc2,Prestwick,Prestw-149,0,0,1.74340635,0,-3.68038741,-35.7,-58.52431526,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00379027-01,"(24S)-24,25-Dihydroxyvitamin D3",405558665,Vitamin D3 receptor Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),55700-58-8,,23.7781084,0,-4.623822698,-45.63370018,-2.2,7,,-47.28172163,-45.66797093,0.024144233,0.928970588,7421,VDR,C[C@H](CC[C@H](O)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C/3C[C@@H](O)CCC3=C,MedChem Express,HY-15439,-6.52934318,-6.96332921,0,-12.25225225,-3.38983051,-11.3,-45.66797093,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00386194-01,Clindamycin palmitate HCl,405558990,Antibacterial,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),25507-04-4,,4.74435636,1,-5.323822698,-50.26773154,-1.2,7,,-49.15455562,-47.34488541,2.2721E-06,0.999384241,,,CCCCCCCCCCCCCCCC(=O)OC1C(O)C(O)C(OC1SC)C(NC(=O)C2CC(CCC)CN2C)C(C)Cl,Selleck,S2596,0.62184221,0,0,0,-10.16949153,-38.9,-47.34488541,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00183830-01,Lemildipine,144206840,Voltage-gated calcium channel Blocker,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),94739-29-4,,21.19226141,0,-4.673822698,-55.43590885,-2.2,7,"CIPLUS_208006;NPK 1886;isopropyl methyl 2-carbamoyloxymethyl-6-methyl-4-(2,3-dichlorophenyl)-1,4-dihydropyridine-3,5-dicarboxylate;lemildipine;Lemidipine;Lemildipine;LS-131203;LEMILDIPINE;NB-818;NPK-1886;CIPLUS_701996;NB 818;lemildipinum;",-106.3831169,-79.45690673,0.000652546,0.989388261,,,O=C(OC)C1=C(C)NC(COC(N)=O)=C(C1c2cccc(Cl)c2Cl)C(=O)OC(C)C,Pharmaron,PH-NIH-152804,4.08408408,2.09698558,-1.0989011,0.58381985,-13.82113821,-32.67045455,-79.45690673,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00386547-01,Difluprednate,405558562,Glucocorticoid receptor Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),23674-86-4,,1.500297213,1,-5.823822698,-26.72583678,-1.4,7,,-23.22722191,-26.43935159,0.029926319,0.91983245,,,CCCC(=O)O[C@@]1(CC[C@H]2C3C[C@H](F)C\4=C\C(=O)\C=C/[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)COC(C)=O,Axon Medchem,1428,1.16595414,4.65595385,0,2.88288288,-18.78934625,-15.3,-26.43935159,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00344565-01,Mizolastine,170465604,Histamine H1 Receptor Antagonists,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),108612-45-9,,15.00297213,0,-4.823822698,-48.71465795,-2.2,7,,-53.52207937,-49.58077138,0.00033863,0.992395955,,HRH1,O=C1C=CN=C(N1)N(C)C2CCN(CC2)c4nc5ccccc5n4Cc3ccc(F)cc3,Prestwick,Prestw-1506,0,-3.00782859,-3.26329906,-5.58558559,-7.84503632,-25.2,-49.58077138,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00025212-08,Cantharidin,170465704,PP-1 Inhibitors;PP-2A Inhibitors,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),56-25-7,,26.67947643,0,-4.573822698,-6.705957445,-3,7,,-39.24321133,-35.30106257,0.000932365,0.987279942,,PPP1CA,O=C2OC(=O)[C@]3(C)C1CCC(O1)[C@]23C,Enzo,PR105,3.6036036,0,3.36996337,0,0,0,-35.30106257,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00023699-09,Cephalothin,170465101,Solute carrier family 22 member 7 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),153-61-7,,26.67947643,0,-4.573822698,-26.80273097,-3,7,,-32.47756789,-30.81463991,0.110262937,0.822961395,10864,SLC22A7,O=C(O)C=2N3C(=O)[C@@H](NC(=O)Cc1cccs1)[C@H]3SCC=2COC(C)=O,Microsource,1500166,-5.52552553,0,0,-11.75979983,3.16169828,-7.10227273,-30.81463991,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00164385-05,Clomifene citrate,170464951,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),911-45-5,"; Zuclomifeno; Clomifeno; Clomiphene citrate (Z,E);CLOMIPHENE CITRATE; Clomifene Citrate; ; Clomiphene Hydrochloride; Clomid; Clomiphene citrate salt; (E)-isomer, HCl; Clomifen; cis-Clomiphene citrate; Clomifene citrate; Enclomifeno; (Z)-isomer, citrate; Clomiphene citrate",8.436791229,1,-5.073822698,-94.22614324,-2.1,7,,-97.8394333,-92.44391972,0.000317867,0.992632791,2099,ESR1,CCN(CCOc1ccc(cc1)C(c2ccccc2)=C(Cl)c3ccccc3)CC,Microsource,1500196,0,2.49017038,-7.69230769,-5.75479566,-15.98915989,-61.64772727,-92.44391972,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00262961-01,Cromoglicate lisetil,170465975,mast cell activation Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),110816-79-0,O,21.19226141,0,-4.673822698,-12.02086796,-3,7,,-31.82762692,-31.52302243,2.00E-10,0.999993695,,,O=C(OCC)C=4Oc3cccc(OCC(OC(=O)[C@@H](N)CCCCN)COc1cccc2OC(=CC(=O)c12)C(=O)OCC)c3C(=O)C=4,GVK,FFS-11-286-NCI-234,0,0,0,0,0,-1.42045455,-31.52302243,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00344528-01,TRYPAN BLUE,225144379,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),72-57-1,,9.466235454,1,-5.023822698,-74.02912979,-2.1,7,,-101.3094451,-84.88783943,4.94384E-05,0.997116105,,,CC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=C(O)C4=C(C=C(C=C4N)[S]([O-])(=O)=O)C=C3[S]([O-])(=O)=O)C)N=NC5=C(O)C6=C(C=C(C=C6N)[S]([O-])(=O)=O)C=C5[S]([O-])(=O)=O,SIGMA,302643,3.84384384,0,1.61172161,0.75062552,-19.06052394,-51.79924242,-84.88783943,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00183049-01,Zelandopam,144206852,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),139233-53-7,ZELANDOPAM; ,23.7781084,0,-4.623822698,-41.46058916,-2.2,7,ZELANDOPAM;CIPLUS_3879393;zelandopamum;,-75.23966943,-67.65053129,0.001924518,0.981541858,,,Cl.Oc1ccc(cc1O)[C@H]3CNCc2c3ccc(O)c2O,Pharmaron,PH-NIH-155132,0,-6.55307995,2.27106227,-6.42201835,-0.27100271,-14.48863636,-67.65053129,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00181775-02,Toluidine blue,170466390,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),92-31-9,,7.519298098,1,-5.123822698,-87.95031226,-2.1,7,,-97.84527669,-91.61542761,0.0000178,0.998272844,,,[Cl-].CN(C)c1ccc2nc3cc(C)c(N)cc3[s+]c2c1,Labotest,LT00451843,1.47687524,0.61804697,-2.54805543,0,-17.43341404,-62.6,-91.61542761,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00166309-02,Altrenogest,170465646,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),850-52-2,,23.7781084,0,-4.623822698,-35.65240098,-2.2,7,,-60.6098379,-46.67411962,0.000543881,0.990330783,,,O=C3C=C4CC[C@@H]2C(C=C[C@@]1(C)[C@H]2CC[C@@]1(O)CC=C)=C4CC3,SIGMA,33994,-3.42013214,0,0,0,-6.29539952,-16.9,-46.67411962,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00262537-04,Thiethylperazine dimalate ,405558764,Dopamine receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),52239-63-1,,6.701581484,1,-5.173822698,-109.4340507,-2.1,7,,-106.4335383,-95.75181666,0.000133273,0.995250212,,,CCSC1=CC2=C(SC3=CC=CC=C3N2CCCN4CCN(C)CC4)C=C1,Prestwick,Prestw-1068,0,-0.94767202,-0.6705409,-12.79279279,-24.89104116,-69.4,-95.75181666,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00263117-05,Panobinostat,405558944,HDAC Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),404950-80-7,,18.88762287,0,-4.723822698,-59.76377659,-2.2,7,,-97.83007267,-75.62884293,1.0363E-06,0.999584198,,HDAC1,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=CC=CC=C3[NH]1,Selleck,S1030,0,0,0,-2.97297297,-9.00726392,-35.7,-75.62884293,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00015321-11,Dobutamine,170465050,beta1-Adrenoceptor Antagonists,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),34368-04-2," ; Dobutamine, (-)-Isomer;Dobutamine hydrochloride; Dobutamine hydrochloride;Dobutamine; Dobutamina; Dobutaminum; Dobutamine HCl; Dobutamine (+)-Isomer",13.37141299,0,-4.873822698,-23.50359845,-2.2,7,,-42.64935065,-38.37072019,0.001684963,0.982770805,153,ADRB1,Oc2ccc(CCNC(C)CCc1ccc(O)cc1)cc2O,Tocris,515,0,-2.09698558,2.56410256,0,2.61969286,-17.51893939,-38.37072019,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00344531-01,Droxidopa,170465890,Adrenergic receptor Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),23651-95-8,,37.68576212,0,-4.423822698,-30.30579695,-3,7,,-48.57126887,-46.11514813,0.064977776,0.873368197,,,Oc1ccc(cc1O)[C@H](O)[C@H](N)C(=O)O,SIGMA,D2384,-7.38437621,-4.49114133,2.01162271,2.79279279,-13.75302663,2.8,-46.11514813,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00182998-01,Bisoxatin acetate,144206872,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),14008-48-1,Bisoxatin acetate; ,11.91728437,0,-4.923822698,-19.21147355,-2.2,7,"LS-41817;2H-1,4-Benzoxazin-3-(4H)-one, 2,2-bis(p-hydroxyphenyl)-, diacetate;BISOXATIN ACETATE;bisoxatin diacetate;Bisoxatin Acetate;bisoxatin acetate;CIPLUS_169129;laxonalin;Bisoxatin acetate;",-37.14225824,-33.0352152,0.002803956,0.977590061,,,CC(=O)Oc1ccc(cc1)C2(Oc3ccccc3NC2=O)c4ccc(OC(C)=O)cc4,Pharmaron,PH-NIH-183223,0,3.87309436,0,4.14414414,-3.58353511,-15.4,-33.0352152,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00183096-01,Cefcapene pivoxil hydrochloride,144206464,Penicillin-binding protein Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),147816-23-7,"5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-7-((2-(2-amino-4-thiazolyl)-1-oxo-2-pentenyl)amino)-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, (6R-(6alpha,7beta(Z)))-; Flomox; ",18.88762287,0,-4.723822698,-52.25232974,-2.1,7,"Cefcapene pivoxil hydrochloride;S-1108;CIPLUS_3875022;CEFCAPENE PIVOXIL HYDROCHLORIDE;LS-171990;5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-7-((2-(2-amino-4-thiazolyl)-1-oxo-2-pentenyl)amino)-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, (6R-(6alpha,7beta(Z)))-;Flomox;Cefcapene Pivoxil Hydrochloride;S 1108;CIPLUS_695832;",-111.166853,-96.19899385,2.11586E-05,0.998116455,,,Cl.Nc1scc(n1)\C(=C\CC)C(=O)N[C@@H]3C(=O)N2C(=C(COC(N)=O)CS[C@@H]23)C(=O)OCOC(=O)C(C)(C)C,ACC,API-04911,0,4.4499382,0,0,-0.6779661,-30.4,-96.19899385,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00351603-13,Ceritinib,405558669,ALK Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1032900-25-6,,6.701581484,1,-5.173822698,-102.7471275,-2.1,7,,-86.80324204,-87.47903857,0.000448528,0.991228471,,ALK,CC(C)OC1=CC(=C(C)C=C1NC2=NC=C(Cl)C(=N2)NC3=C(C=CC=C3)[S+]([O-])(=O)C(C)C)C4CCNCC4,MedChem Express,HY-15656,-10.18266615,0,-3.53151542,-3.6036036,-20.33898305,-62.5,-87.47903857,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00386364-01,Lomitapide,405558897,Microsomal triglyceride transfer protein large subunit Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),182431-12-5,,16.8336116,0,-4.773822698,-26.03798442,-2.2,7,,-52.58552263,-47.7920626,2.71025E-05,0.997868184,4547,MTTP,FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)C3=C(C=CC=C3)C4=CC=C(C=C4)C(F)(F)F)C5=C(C=CC=C5)C6=C1C=CC=C6,Selleck,S7635,0,0,0,0,1.2590799,-14.6,-47.7920626,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00182027-01,Amogastrin,144206458,Cholecystokinin receptor Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),16870-37-4,Amogastrin; Amogastrina; ,10.62129087,0,-4.973822698,-38.58404899,-2.2,7,AMOGASTRIN;amogastrin;CIPLUS_214157;Amogastrina;tert-amyloxycarbonyltetragastrin;Amogastrinum;Amogastrin;Amogastrine;amogastrine;amogastrinum;,-50.52878703,-46.78591392,5.6715E-06,0.999026664,,,NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](NC(=O)OC(C)(C)CC)Cc3cnc2ccccc23,ACC,AMOGASTRIN,0,0,0,0,-5.90799031,-25.9,-46.78591392,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00263539-01,Ziprasidone,170465342,5-HT2A Antagonists?,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),146939-27-7,Ziprasidone hydrochloride;Ziprasidone  Hydrochloride,26.67947643,0,-4.573822698,-55.79305674,-2.1,7,,-114.8926216,-91.50363331,9.5619E-06,0.998735124,3356,HTR2A,O=C4Cc5cc(CCN1CCN(CC1)c3nsc2ccccc23)c(Cl)cc5N4,"Prestwick Chemical, Inc.",Prestw-1188,-0.77730276,0,-3.26329906,-3.15315315,-2.80871671,-23.8,-91.50363331,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00378796-01,Tacalcitol,405558914,Vitamin D receptor Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),57333-96-7,,26.67947643,0,-4.573822698,-44.26693218,-3,7,,-86.18166574,-79.31805478,0.006448524,0.965311337,,,CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C/3C[C@@H](O)C[C@H](O)C3=C,MedChem Express,HY-32337,-12.5923047,1.27729707,4.87259723,-4.23423423,0,-9.1,-79.31805478,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00378907-01,Edoxaban tosylate monohydrate,405559062,Coagulation Factor X Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1229194-11-9,,21.19226141,0,-4.673822698,-15.38370911,-2.4,7,,-27.86137507,-26.55114589,0.000255654,0.993412229,,,CN1CCC2=C(C1)SC(=N2)C(=O)N[C@@H]3C[C@H](CC[C@@H]3NC(=O)C(=O)NC4=NC=C(Cl)C=C4)C(=O)N(C)C,MedChem Express,HY-10264B,-2.09871745,0,0,-1.08108108,0,-4.9,-26.55114589,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00095787-05,(-)-Inosine,405559132,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),58-63-9,,15.00297213,0,-4.823822698,-39.2966549,-2.4,7,,-28.69421488,-30.5785124,0.289815994,0.637086734,,,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=NC3=C2N=CNC3=O,Bosche,I0819,-16.21621622,-11.66448231,4.46886447,2.50208507,0,-15.05681818,-30.5785124,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00162150-04,Cilnidipine,170465867,Voltage-gated N-type calcium channel alpha-1B subunit Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),132203-70-4,,2.37781084,1,-5.623822698,-88.96826143,-1.2,7,,-61.19657615,-58.91381346,0.000357543,0.992181923,,,CC=1NC(C)=C(C(C=1C(=O)OCCOC)c2cccc(c2)[N+]([O-])=O)C(=O)OC/C=C/c3ccccc3,Prestwick,Prestw-1376,0,-4.32503277,0,-13.76146789,-30.80397471,-48.95833333,-58.91381346,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00262928-01,Clevidipine,170466066,Voltage-gated L-type calcium channel Blocker,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),167221-71-8,"Butyroxymethyl methyl 4-(2 ,3 -dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate;Clevidipinum;Clevidipine",6.701581484,1,-5.173822698,-34.64734756,-1.2,7,,-37.62750886,-36.95395514,0.00096578,0.987044823,,,CC=1NC(C)=C(C(C=1C(=O)OCOC(=O)CCC)c2cccc(Cl)c2Cl)C(=O)OC,GVK,FFS-12-73-NCI-1401,4.32432432,-2.49017038,-0.07326007,0,0,-34.18560606,-36.95395514,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016961-06,Atovaquone,170464681,"Synergistic with proguanil, mitochondrial sensitizer (cytochrome bc1 complex)",Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),95233-18-4, ; Atovaquone;Atovaquone; Mepron,4.228412057,1,-5.373822698,-94.15619737,-1.2,7,,-73.98819362,-74.49822904,0.003854151,0.973534487,,PFF0160c,Clc1ccc(cc1)[C@H]2CC[C@@H](CC2)C=4C(=O)c3ccccc3C(=O)C=4O,Bosche,A2953,0,-10.48492792,0,0,-29.90063234,-57.10227273,-74.49822904,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00018218-10,Edaravone,170465935,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),89-25-8,;MCI-186; Developer Z; N-demethylantipyrine; Radicut;1-Phenyl-3-methyl-5-pyrazolone,37.68576212,0,-4.423822698,-14.20864869,-3,7,,-41.12750886,-36.95395514,4.41576E-05,0.99727717,,NT5E,O=C2CC(C)=NN2c1ccccc1,Vitas,STK201315,0,0,-1.83150183,0,0,0,-36.95395514,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016799-08,Suxibuzone,170465972,Prostaglandin G/H synthase 2 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),27470-51-5,,8.436791229,1,-5.073822698,-28.38171496,-2.2,7,,-33.59504132,-33.88429752,0.000594251,0.989887947,791253,PTGS2,O=C(O)CCC(=O)OCC2(CCCC)C(=O)N(c1ccccc1)N(C2=O)c3ccccc3,"Prestwick Chemical, Inc.",Prestw-658,2.04204204,-2.75229358,0,0,0,-23.57954545,-33.88429752,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00274280-01,Pixantronemaleate,225144373,DNA Modulator,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,7.519298098,1,-5.123822698,-81.76042358,-2.1,7,,-91.11570247,-86.7768595,0.000938637,0.987226972,,,NCCNC1=C2C(=O)C3=C(C=NC=C3)C(=O)C2=C(NCCN)C=C1,GVK,FFS-12-73-NCI-2833,4.92492492,-0.1310616,0,-9.59132611,-11.11111111,-59.18560606,-86.7768595,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00094874-05,Esculin hydrate,225144214,tumor necrosis factor production Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),66778-17-4,,37.68576212,0,-4.423822698,-6.61054524,-2.4,7,,-28.96044864,-25.3837072,0.025375894,0.92702103,,,OC[C@H]1O[C@@H](OC2=C(O)C=C3OC(=O)\C=C/C3=C2)[C@H](O)[C@@H](O)[C@@H]1O,SIGMA,E8250,0,0,-4.46886447,4.75396163,1.44534779,1.51515152,-25.3837072,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00091585-05,Octocrylene,170464719,photosensitizer,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),6197-30-4,"2-Ethylhexyl-2-cyano-3,3-diphenylacrylate; ; 2-Ethylhexyl-2-cyano-3,3-diphenylacrylate; ""2-Ethylhexyl-2-cyano-3; Octocrileno;OCTOCRYLENE",8.436791229,1,-5.073822698,-58.86480515,-2.2,7,,-76.62042503,-73.78984652,3.88067E-05,0.997446397,,CAT,CCC(CCCC)COC(=O)C(\C#N)=C(\c1ccccc1)c2ccccc2,Labotest,LT00159303,4.08408408,0.65530799,0,0,0,-53.31439394,-73.78984652,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00182054-03,Aranidipine,170465977,Voltage-gated calcium channel Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),86780-90-7,,21.19226141,0,-4.673822698,-106.3357016,-2.1,7,,-102.6855491,-85.91391839,0.000927025,0.987308872,,,CC=1NC(C)=C(C(C=1C(=O)OCC(C)=O)c2ccccc2[N+]([O-])=O)C(=O)OC,APAC,826079,-4.74154683,-12.15492377,-12.91908806,-14.59459459,-21.11380145,-42.2,-85.91391839,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00345812-02,Ingenol mebutate,405558836,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),75567-37-2,,29.9348649,0,-4.523822698,-42.91391581,-2.4,7,,-37.49580772,-31.24650643,0.119202805,0.813598682,,PRKCA,C\C=C(C)/C(=O)O[C@H]1C(=C/C23[C@H](C)C[C@@H]4[C@H](C(\C=C(CO)/[C@@H](O)[C@]12O)C3=O)C4(C)C)\C,MedChem Express,HY-B0719,-9.94947532,-10.01236094,0.6705409,-3.33333333,-9.20096852,-10.9,-31.24650643,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00263120-06,Enzalutamide,384568604,Androgen Receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),915087-33-1,,15.00297213,0,-4.823822698,-24.43899511,-2.2,7,,-43.37031861,-39.29569592,1.31167E-05,0.998518864,,AR,CNC(=O)C1=CC=C(C=C1F)N2C(=S)N(C(=O)C2(C)C)C3=CC(=C(C=C3)C#N)C(F)(F)F,MedChem Express,HY-70002,0,0,0,0.99099099,0,-16.3,-39.29569592,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00532496-01,P-T-BUTYL-M-CRESOL,405558633,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,26.67947643,0,-4.573822698,-51.99803235,-2.2,7,,-58.49524874,-47.34488541,0.01962324,0.936724543,,,CC1=CC(=CC=C1C(C)(C)C)O,SIGMA,A000011660,-8.93898173,-6.79851669,0,-2.16216216,-12.88135593,-17.2,-47.34488541,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00094748-07,Oxyphenbutazone,170465310,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),129-20-4,,37.68576212,0,-4.423822698,-20.98180524,-3,7,,-61.58559622,-54.89964581,0.001515719,0.983678004,,,Oc1ccc(cc1)N3C(=O)C(CCCC)C(=O)N3c2ccccc2,Microsource,1500455,0,0,2.85714286,0,-5.87172538,0.47348485,-54.89964581,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00091533-10,Ethinylestradiol,170464983,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),57-63-6,;ETHINYL ESTRADIOL; Minulet; Ovulen 50; Conova 30; Oviol; Ovoresta M; Ovostat; Serial C; Varnoline;Ethinyl Estradiol; ; Trikvilar; Desogen (contraceptive); Practil 21; Yermonil (CIBA); Ministat; Oraconal; Mircette; Modicon; Valdys;17alpha-Ethinylestradiol; 17alpha-Ethinylestradiol; Cilest; Novacyclin 22;Ethinylestradiol; Ethinyl estradiol;Ethinyl estradiol; Ortho-Cept; Fisioquens; Femovan; Diane-35; Etinilestradiol; Ethynyl estradiol; Femodene; Gynatrol; Diane; Lestrin; Tri-Ervonum; Bisecurin II; Ovulen-50; Ovidol;17alpha-Ethynylestradiol; Estinyl; Oracon; Demulen; Triregol,26.67947643,0,-4.573822698,-11.76106085,-3,7,,-39.19421488,-30.5785124,0.000204652,0.994109363,2099,ESR1,Oc3cc4CC[C@@H]2[C@H](CC[C@@]1(C)[C@H]2CC[C@@]1(O)C#C)c4cc3,Prestwick,Prestw-1405,0,1.57273919,2.49084249,0,0,-5.58712121,-30.5785124,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00018187-09,Cinnarizine,170465920,Voltage-gated calcium channel Blocker,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),298-57-7,,23.7781084,0,-4.623822698,-41.78254509,-2.2,7,,-90.03246753,-72.37308146,3.67E-08,0.99992184,,,c1ccccc1C(c2ccccc2)N3CCN(CC3)C/C=C/c4ccccc4,Prestwick,Prestw-278,0,0,-0.36630037,0,-1.89701897,-21.30681818,-72.37308146,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00092377-04,Apafant,170466052,Platelet activating factor receptor Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),105219-56-5,,26.67947643,0,-4.573822698,-27.69048803,-2.2,7,,-74.71428571,-55.84415584,0.001140899,0.985890171,,,Clc1ccccc1C4=NCc2nnc(C)n2c3sc(cc34)CCC(=O)N5CCOCC5,Tocris,2339,2.64264264,2.49017038,2.1978022,-4.75396163,0,-15.05681818,-55.84415584,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00162179-08,cis-Flupentixol,170465964,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),53772-82-0,,8.436791229,1,-5.073822698,-66.82003438,-2.2,7,,-71.15938607,-71.19244392,2.46764E-05,0.997965541,,,FC(F)(F)c2cc3C(=C\CCN1CCN(CCO)CC1)/c4ccccc4Sc3cc2,Tocris,4057,0,-3.27653997,-2.85714286,0,-6.05239386,-47.8219697,-71.19244392,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016916-11,Norfloxacin,170464769,DNA Topoisomerase IV Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),70458-96-7,; ; Norfloxacin-d5;NORFLOXACIN; Norfloxacino; Noroxin; Norfloxacin;Norfloxacin; Norfloxacin Glutamate,6.701581484,1,-5.173822698,-5.603754782,-2.4,7,,-24.84090909,-1.53482881,0.000991494,0.995578478,7155,TOP2B,O=C(O)C2=CN(CC)c1cc(c(F)cc1C2=O)N3CCNCC3,Vitas,STK177250,0,1.04849279,1.46520147,0,0,-21.11742424,-1.53482881,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00183332-01,Dihydroergocriptine,144206629,D(1A) dopamine receptor Partial Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),25447-66-9,,11.91728437,0,-4.923822698,-42.71564573,-2.2,7,"CIPLUS_752814;Vasobral;LS-174243;CIPLUS_746395;Dihydroergocryptine Mesylate;CIPLUS_691892;CIPLUS_737198;CIPLUS_3861508;Ergotaman-3',6',18-trione, 9,10alpha-dihydro-12'-hydroxy-5'alpha-isobutyl-2'-isopropyl;Dihydroergocryptine;DIHYDROERGOCRYPTINE MESYLATE;",-67.63946339,-63.55505869,1.33249E-05,0.998506435,1812,DRD1,CN1C[C@@H](C[C@@H]2c3cccc4ncc(C[C@@H]12)c34)C(=O)N[C@@]7(O[C@]6(O)N([C@@H](CC(C)C)C(=O)N5CCC[C@H]56)C7=O)C(C)C,Chemical Block,A4425/0188924,1.01049359,1.85414091,0,0,0,-32.5,-63.55505869,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00507976-02,Derquantel,405558509,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),187865-22-1,,18.88762287,0,-4.723822698,-23.29542169,-2.2,7,,-50.28172163,-45.66797093,5.08623E-05,0.997075902,,,CN1C(=O)[C@]23C[C@H]4C(C)(C)[C@]5(CNC6=C7O\C=C/C(C)(C)OC7=CC=C56)C[C@]14CN2CC[C@@]3(C)O,SantaCruz Bio,sc-391516,0,-0.61804697,0,0,1.8401937,-11.7,-45.66797093,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00182606-01,Physalien,144206657,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),144-67-2,Helenien; Palmitato de xantofila; ,4.228412057,1,-5.373822698,-55.37463068,-1.2,7,xanthophyll dipalmitate;Xantofyl palmitate;Helenien;Palmitate de xantofyle;heleniene;CIPLUS_214390;palmitate de xantofyle;xantofyle palmitate;Xantofyli palmitas;helenien;Palmitato de xantofila;xantofyli palmitas;XANTOFYL PALMITATE;HELENIEN;,-39.75768586,-43.20849637,0.003866027,0.973499147,,,O=C(O[C@@H]2CC(C)=C(/C=CC(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C[C@@H](OC(=O)CCCCCCCCCCCCCCC)CC1(C)C)C(C)(C)C2)CCCCCCCCCCCCCCC,INDOFINE,020309S,-8.78352118,-0.53564071,0,0,-5.42372881,-40.2,-43.20849637,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00378657-01,Simeprevir,405558913,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),923604-59-5,,9.466235454,1,-5.023822698,-62.67218072,-2.1,7,,-86.02711012,-82.89547233,0.000780303,0.988376024,,,COC1=C(C)C2=C(C=C1)C(=CC(=N2)C3=NC(=CS3)C(C)C)O[C@@H]4C[C@@H]5C(C4)C(=O)N(C)CCCC\C=C/[C@@H]6C[C@]6(NC5=O)C(=O)N[S+]([O-])(=O)C7CC7,MedChem Express,HY-10241,3.34240187,2.55459415,4.64908359,-6.57657658,0,-53.2,-82.89547233,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00178737-05,Trimeprazine tartrate,170465278,Histamine H1 receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),4330-99-8,,6.701581484,1,-5.173822698,-26.93201095,-1.4,7,,-20.92680047,-21.60566706,0.030404468,0.919149409,,,O=C(O)[C@H](O)[C@H](O)C(=O)O.CN(C)C[C@H](C)CN1c3ccccc3Sc2ccccc12.CN(C)C[C@H](C)CN1c3ccccc3Sc2ccccc12,Microsource,1500593,-4.68468468,-4.58715596,0,0,3.52303523,-20.54924242,-21.60566706,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00160456-03,2-Iodohippuric acid,170465302,renal filtration Interacts,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),147-58-0,,8.436791229,1,-5.073822698,-11.01860961,-2.4,7,,-30.97727272,3.65997639,0.045268934,0.938259092,,,O=C(NCC(=O)O)c1ccccc1I,SIGMA,106577,-4.92492492,0,2.71062271,0,0,-24.14772727,3.65997639,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00090903-11,Sulfasalazine,170464716,NFKB Activation Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),599-79-1,"; Sulfasalazine; Azulfidine;Sulfasalazine; Sulfasalazina;Azulfidine; Salazosulfapyridinum; Salicylazosulfapyridine; Sulphasalazine, N-; Sulfasalazine DR; Salazosulfapiridina; Salazopyrine",11.91728437,0,-4.923822698,-36.42803007,-2.2,7,,-54.44628099,-50.41322314,0.000461985,0.991098476,4790,NFKB1,O=S(=O)(Nc1ccccn1)c3ccc(/N=N/c2cc(C(=O)O)c(O)cc2)cc3,Microsource,1500552,0,-1.83486239,3.88278388,0,-4.4263776,-24.52651515,-50.41322314,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00249925-01,Tilmacoxib,170466033,Cyclooxygenase-2 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),180200-68-4,,26.67947643,0,-4.573822698,-9.260928662,-2.4,7,,-24.86009445,-21.13341204,4.13E-07,0.999738129,,,Cc2nc(C1CCCCC1)c(o2)c3ccc(c(F)c3)S(N)(=O)=O,GVK,FFS-11-286-NCI-214,0,0.2621232,0,0,0,-2.93560606,-21.13341204,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167456-02,Bisibutiamine,170466019,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),3286-46-2,,29.9348649,0,-4.523822698,-8.217241465,-3,7,,-39.74321133,-35.30106257,0.00010962,0.995698743,,,Nc2nc(C)ncc2CN(C=O)C(/C)=C(/CCOC(=O)C(C)C)SSC(/CCOC(=O)C(C)C)=C(/C)N(C=O)Cc1cnc(C)nc1N,Bosche,B6282,0,1.83486239,0,2.00166806,2.07768744,0,-35.30106257,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00094561-06,Phenothrin,170465585,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),26002-80-2,,26.67947643,0,-4.573822698,-19.42399474,-3,7,,-65.50708383,-63.16410862,0.000141074,0.995112892,,,C/C(C)=C/C3C(C(=O)OCc2cccc(Oc1ccccc1)c2)C3(C)C,Microsource,1504098,-0.48048048,4.45609436,0,0,0,0,-63.16410862,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016542-06,Levonordefrin,170464794,Adrenergic receptor alpha-2 Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),829-74-3,,21.19226141,0,-4.673822698,-60.02063149,-2.1,7,,-106.7532467,-80.87367178,0.000308573,0.992743012,,,Oc1ccc(cc1O)[C@@H](O)[C@H](C)N,Enzo,AC1038,0,4.06290957,0,-4.75396163,-11.11111111,-33.61742424,-80.87367178,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00181770-02,Garenoxacin mesylate hydrate,170465937,Topoisomerase IV Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),223652-90-2,,10.35002283,0,-4.985058692,-86.91371211,-2.1,7,,-114.2987013,-85.83234947,0.009701117,0.956875593,,,O.CS(=O)(=O)O.C[C@H]1NCc2cc(ccc12)c3ccc4c(c3OC(F)F)N(C=C(C4=O)C(=O)O)C5CC5,APAC,816272,0.96096096,3.40760157,0,0.75062552,-24.66124661,-31.91287879,-85.83234947,,,,,,,,,1.83E-09,9.14E-09,4.57E-08,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,
NCGC00346667-02,Lornoxicam,405558606,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),70374-39-9,,26.67947643,0,-4.573822698,-29.91538149,-2.2,7,,-65.38932365,-49.91615428,0.000120385,0.995489141,,PTGS1,CN1\C(=C(O)/C2=C(C=C(Cl)S2)[S+]1([O-])=O)C(=O)NC3=NC=CC=C3,Selleck,S2047,1.16595414,0,0,0,-4.55205811,-14.8,-49.91615428,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00241107-02,Bosutinib,170466788,Bcr-Abl Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),918639-10-8, Bosutinib;Bosutinib;PF-5208763/SKI-606,6.701581484,1,-5.173822698,-71.81380152,-2.2,7,,-63.51593069,-63.1078815,0.003221283,0.975898869,25,ABL1,CO.COc4cc(Nc3c(C#N)cnc2cc(OCCCN1CCN(C)CC1)c(OC)cc23)c(Cl)cc4Cl,Sequoia,380843-75-4,1.47687524,-4.24392254,0,-11.08108108,-9.29782082,-48.5,-63.1078815,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00181132-01,Halofuginone hydrochloride,144206292,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1217623-74-9,halofuginone; Halofuginona; Stenorol; ,9.466235454,1,-5.023822698,-78.21263348,-2.1,7,"halofunginone;LS-176413;Halofuginone hydrobromide;halofuginone;LS-140372;HALOFUGINONE;RU-19110;Halofuginonum;4(3H)-Quinazolinone, 7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidinyl)-2-oxopropyl)-, trans-;7-bromo-6-chlorofebrifugine;Halofuginone Hydrobromide;HALOFUGINONE HYDROBROMIDE;CIPLUS_205078;7-bromo-6-chloro- 3-(3-(3-hydroxy-2-piperidinyl)-2-oxopropyl)-4(3H)- quinazolinone;CIPLUS_205079;Halofuginona;halofuginone lactate;LS-173665;Stenorol;halofuginonum;7-bromo-6-chloro-3,3-(3-hydroxy-2-piperidyl)acetonyl-4(3H)-quinazolinone-hydrolactate;Halofuginone;CIPLUS_205081;CIPLUS_205080;",-102.084796,-98.43487982,5.6306E-06,0.999029807,,,Cl.O[C@@H]3CCCN[C@H]3CC(=O)CN2C=Nc1cc(Br)c(Cl)cc1C2=O,Toronto Research,H102500,2.56509911,-1.27729707,0,1.35135135,-6.00484262,-60.1,-98.43487982,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00090762-11,Rifabutin,405558775,Cytochrome P450 3a4 Substrate,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),72559-06-9,,6.701581484,1,-5.173822698,-98.68827088,-2.1,7,,-103.275014,-89.71492454,2.42442E-05,0.997983351,,PRKDC,[H][C@]1(C)\C=C\C=C(C)\C(=O)NC2=C3NC4(CCN(CC(C)C)CC4)N=C3C5=C(C2=O)C(O)=C(C)C6=C5C(=O)[C@](C)(O6)O\C=C\[C@]([H])(OC)[C@@]([H])(C)[C@@]([H])(OC(C)=O)[C@]([H])(C)[C@]([H])(O)[C@]([H])(C)[C@@]1([H])O,MedChem Express,HY-17025,0,-0.61804697,2.14573089,-8.28828829,-28.08716707,-61.5,-89.71492454,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00015810-12,Papaverine hydrochloride,170465687,Phosphodiesterase X (PDE10) Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),61-25-6,"; ;Papaverine?HCl;PAPAVERINE HYDROCHLORIDE; Pavatym; Cerespan;Papaverine hydrochloride; Albatran; Omnopon-Scopolamine; Hydrochloride, Papaverin; Cepaverin; Papaverine hydrochloride; Papaverine Hcl; Pavabid",15.00297213,0,-4.823822698,-20.83141462,-2.2,7,,-32.91086187,-30.34238489,0.001182372,0.985642411,10846,PDE10A,Cl.COc1ccc(cc1OC)Cc3nccc2cc(OC)c(cc23)OC,Vitas,STK039035,0,-3.01441678,1.17216117,0,0,-12.78409091,-30.34238489,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016000-18,Disulfiram,170464767,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),97-77-8, ;Tetraethylthiuram disulfide; Disulfiram; Tetraethylthiuram disulfide; Disulfiramo; Teturam; Antabuse;Disulfiram;DISULFIRAM,7.519298098,1,-5.123822698,-41.7941326,-2.2,7,,-49.93329398,-46.87131051,0.003704159,0.974083616,217,ALDH2,CCN(CC)C(=S)SSC(=S)N(CC)CC,Microsource,1500262,3.72372372,3.40760157,0,-6.42201835,-4.96838302,-33.23863636,-46.87131051,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167493-04,Manidipine,174006297,Calcium Channel Blocker,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),89226-75-5,; Manidipine 6300;Manidipine; Manidipine; Mandipine 6300; Calslot;manidipine dihydrochloride,6.701581484,1,-5.173822698,-85.51283746,-2.1,7,,-99.17249115,-94.09681228,1.19545E-05,0.998585286,,,Cl.Cl.[O-][N+](=O)c1cccc(c1)C2C(C(=O)OC)=C(C)NC(C)=C2C(=O)OCCN3CCN(CC3)C(c4ccccc4)c5ccccc5,Selleck,S2481,4.8048048,1.04849279,0,0,-14.5438121,-68.08712121,-94.09681228,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00531794-01,Cimicoxib,405559129,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),265114-23-6,,9.466235454,1,-5.023822698,-32.48900473,-2.2,7,,-43.44074903,-42.53773058,8.8934E-06,0.998780734,,,COC1=CC=C(C=C1F)C2=C(Cl)N=C[N]2C3=CC=C(C=C3)[S+](N)([O-])=O,Toronto Research,C441690,0,0,0,0.09009009,0,-25.3,-42.53773058,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00386239-01,Mirabegron,405558549,Beta-3 adrenergic receptor Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),223673-61-8,,21.19226141,0,-4.673822698,-42.88853662,-2.1,7,,-106.3397429,-95.41643376,8.3611E-06,0.998817347,,,NC1=NC(=CS1)CC(=O)NC2=CC=C(CCNC[C@H](O)C3=CC=CC=C3)C=C2,Selleck,S4009,1.9432569,0,0,1.53153153,2.61501211,-20.3,-95.41643376,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00181306-04,Docetaxel,170464919,Tubulin depolymerization Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),114977-28-5, Docetaxolum; Docetaxel Hydrate; ; AE-docetaxel;DOCETAXEL; 5   Docetaxel; Docetaxel hydrate; Docetaxel Anhydrous; Docetaxel Trihydrate; Docetaxel;Docetaxel; Taxoltere metro,9.466235454,1,-5.023822698,-65.87506439,-2.2,7,,-59.67831191,-62.43711571,0.000748068,0.988625186,203068,TUBB,CC(C)(C)OC(=O)N[C@@H](c1ccccc1)[C@@H](O)C(=O)O[C@H]5C[C@@]6(O)[C@@H](OC(=O)c2ccccc2)[C@H]4[C@@](C)([C@@H](O)C[C@H]3OC[C@]34OC(C)=O)C(=O)[C@H](O)C(=C5C)C6(C)C,Alfa Aesar,J60174,0,-7.29295426,-6.21367903,-5.40540541,-5.61743341,-38.5,-62.43711571,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00507682-01,Emodepside,405558968,synaptic transmission Modulator,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),155030-63-0,,21.19226141,0,-4.673822698,-61.97002593,-2.1,7,,-122.9210732,-94.07490218,0.000276224,0.993138058,174419,,CC(C)C[C@@H]1N(C)C(=O)[C@@H](C)OC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](CC2=CC=C(C=C2)N3CCOCC3)OC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)OC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](CC4=CC=C(C=C4)N5CCOCC5)OC1=O,AdvChemBlocks,M15352,0,4.16151628,4.02324542,-5.67567568,-5.90799031,-38.2,-94.07490218,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00159390-14,PERMETHRIN,405558899,Voltage-sensitive sodium channel Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),"52341-33-0, 52645-53-1",,15.00297213,0,-4.823822698,-36.81417565,-2.2,7,,-65.6704863,-59.97764114,1.13706E-05,0.998620633,,,CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC2=CC=CC(=C2)OC3=CC=CC=C3,Microsource,1504932,1.63233579,0,0,0,0,-24.8,-59.97764114,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00181159-03,Trabectedin,384568393,DNA-Damaging Drug,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),114899-77-3,,3.861009342,1,-5.413299148,-70.73351114,-2.2,7,,-72.02124092,-66.68529905,6.53277E-05,0.996682892,,H2AFX,COC1=CC2=C(CCN[C@]23CS[C@H]4[C@H]5[C@@H]6N(C)[C@@H](CC7=C6C(=C(OC)C(=C7)C)O)[C@H](O)N5[C@@H](COC3=O)C8=C4C(=C(C)C9=C8OCO9)OC(C)=O)C=C1O,MedChem Express,HY-50936,3.96424407,0.20601566,3.35270451,1.26126126,0,-13.5,-66.68529905,,,,,,,,,7.31E-10,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,,,,,,,,
NCGC00015680-18,Melatonin,170465589,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),73-31-4,; ;Melatonin;MELATONIN; Melatonin,8.436791229,1,-5.073822698,-8.020258366,-2.4,7,,-30.11363637,0,3.6074E-06,0.999896097,,MTNR1B,CC(=O)NCCc2cnc1ccc(cc12)OC,Specs,AN-153/I149495,0,0,0,0,0,-23.01136364,0,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00091469-04,Saquinavir,225144210,protease inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),149845-06-7,Saquinavir mesylate;Saquinavir mesylate; Fortovase; Ro 31-8959; Ro 31 895; Saquinivir; Ro 31895; ; Saquinavir mesylate;Saquinavir mesylate; Fortovase; Ro 31-8959; Ro 31 895; Saquinivir; Ro 31895; ;saquinavir,10.62129087,0,-4.973822698,-47.43478913,-2.2,7,,-67.55844155,-66.23376623,3.4796E-06,0.999237683,,,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(N)=O)NC(=O)C4=NC5=C(C=CC=C5)C=C4,Prestwick,Prestw-1114,0,0.3931848,0,0,0,-35.13257576,-66.23376623,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016809-07,Moricizine hydrochloride,174006664,"class 1c antiarrhythmic, Na(v)1.5 channel blocker",Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),29560-58-5," Moracizina;Moricizine hydrochloride; Ethmozine; Moracizine;Moracizine; ; Ethmozin; Hydrochloride, Moricizin; Etmozin",29.9348649,0,-4.523822698,-12.5573953,-3,7,,-34.62750886,-30.10625738,5.3766E-06,0.999053129,,,Cl.O=C(OCC)Nc1cc2N(c3ccccc3Sc2cc1)C(=O)CCN4CCOCC4,Prestwick,Prestw-1051,-0.84084084,0,0,0,0,-1.79924242,-30.10625738,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00319019-01,Nemorubicin,170465590,DNA Topoisomerase II Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),108852-90-0,,15.00297213,0,-4.823822698,-57.24353674,-2.2,7,,-79.46103896,-74.97048406,0.000439552,0.991318585,,TOP2A,COC1CN(CCO1)C6CC(OC5C[C@@](O)(Cc4c5c(O)c3C(=O)c2c(OC)cccc2C(=O)c3c4O)C(=O)CO)OC(C)C6O,GVK,FFS-11-286-NCI-135,0,-7.60157274,-0.95238095,-0.58381985,-3.16169828,-32.10227273,-74.97048406,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00015238-13,Chlorzoxazone,170464957,Intermediate conductance calcium-activated potassium channel protein 4 Activator,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),95-25-0,,9.466235454,1,-5.023822698,-29.77770349,-2.2,7,,-35.88016529,-35.53719008,0.004874981,0.970085927,,,Clc1cc2NC(=O)Oc2cc1,Vitas,STK071582,-5.16516517,0,0.07326007,2.91909925,1.17434508,-22.25378788,-35.53719008,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00253595-01,Clocapramine,170465785,Serotonin 2a (5-HT2a) receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),47739-98-0,,16.8336116,0,-4.773822698,-42.69553422,-2.2,7,,-57.34415584,-54.42739079,0.026784303,0.924671411,,,Clc4ccc5CCc1ccccc1N(CCCN2CCC(CC2)(C(N)=O)N3CCCCC3)c5c4,GVK,FFS-11-286-NCI-179,0,-14.28571429,0,2.91909925,-0.81300813,-21.68560606,-54.42739079,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00160408-06,Benziodarone,405558418,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,13.37141299,0,-4.873822698,-47.06811514,-2.1,7,,-91.32308552,-80.54779206,0.000024792,0.997960683,,,CCC1=C(C(=O)C2=CC(=C(O)C(=C2)I)I)C3=CC=CC=C3O1,Bionet,KS-1133_CM2,3.73105325,0,4.60438087,2.7027027,-2.03389831,-37.2,-80.54779206,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00182049-02,Nitroscanate,225144331,ATP biosynthetic process Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,15.00297213,0,-4.823822698,-38.82748887,-2.2,7,,-75.82839575,-68.80939072,0.00041334,0.99158529,,,[O-][N+](=O)C1=CC=C(OC2=CC=C(C=C2)N=C=S)C=C1,Oakwood,8991,0,3.50226617,-2.01162271,0,3.58353511,-26.2,-68.80939072,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00378604-01,ABT-333,405558941,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1132935-63-7,,8.436791229,1,-5.073822698,-83.23643113,-2.1,7,,-104.0017328,-95.97540525,2.40991E-05,0.99798937,,,COC1=C(C=C(C=C1C2=CC3=CC=C(N[S+](C)([O-])=O)C=C3C=C2)N4\C=C/C(=O)NC4=O)C(C)(C)C,MedChem Express,HY-13998,-1.63233579,3.91429749,1.65400089,0,-11.13801453,-63.4,-95.97540525,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00090782-06,Nelfinavir mesylate,170465351,HIV Protease Inhibitors,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),159989-65-8," Mesylate, Nelfinavi;; ; Viracept; Nelfinavir mesylate;Nelfinavir mesylate;Nelfinavir; Viracept 250mg; Nelfinavir mesilate; Nelfinavir Mesilate",18.88762287,0,-4.723822698,-48.08456351,-2.1,7,,-97.34439197,-87.72136954,3.51E-07,0.999758075,,,CS(=O)(=O)O.Oc1cccc(c1C)C(=O)N[C@@H](CSc2ccccc2)[C@H](O)CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C,Tocris,3766,0,0,0,0,0,-24.90530303,-87.72136954,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00181774-02,Chrysarobin,170465659,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),491-59-8,,15.00297213,0,-4.823822698,-69.01918368,-2.1,7,,-109.2157025,-100.472255,0.000164439,0.994719336,,,Oc2c3c(cc1cccc(O)c12)cc(C)cc3O,Sequoia,491-59-8,0,-5.89777195,-0.07326007,0,0,-42.51893939,-100.472255,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016311-19,Phentolamine mesilate,170464866,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),50-60-2, Regitine;Phentolamine mesylate;Phentolamine;PHENTOLAMINE; ; Regitin;Phentolamine hydrochloride; Regitin mesylate; Vasomax;PHENTOLAMINE HYDROCHLORIDE; Phentolamine hydrochloride; Fentolamina;,11.91728437,0,-4.923822698,-28.1953623,-2.2,7,,-55.10743801,-52.0661157,0.000605128,0.9897897,148,ADRA1A,Cc1ccc(cc1)N(CC2=NCCN2)c3cc(O)ccc3,Vitas,STK802099,0,0,1.39194139,4.42035029,4.60704607,-24.71590909,-52.0661157,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00179867-02,NCGC00179867-02,405559098,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,5.32325539,1,-5.273822698,-99.64559166,-2.1,7,,-98.13951928,-83.45444382,3.42404E-05,0.997601914,,,O[C@@H]1[C@@H](COC(=O)C2=CC(=C(O)C(=C2)O)O)O[C@@H](OC(=O)C3=CC(=C(O)C(=C3)O)O)[C@H](O)[C@H]1OC(=O)C4=CC(=C(O)C(=C4)O)O,Analyticon,NP-005114,0,1.4421096,0,-8.28828829,-33.60774818,-60.4,-83.45444382,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00182036-01,Peplomycin sulfate,144206501,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),70384-29-1,"Peplomycin sulfate; Peplomycin Sulfate (1:1); Peplomycina; Sulfate, Peplomyci; Pepleo; ",1.888762287,1,-5.723822698,-29.38594193,-2.2,7,"nk 631;Peplomycin;Sulfate, Peplomyci;Pepleo;Peplomycine;bleomycin pep;Peplomycina;NK63;Peplomycin Sulfate;CIPLUS_188638;LS-177021;PEPLOMYCIN SULFATE;Peplomycinum;LS-44906;Bleomycinamide, N1-(3-((1-phenylethyl)amino)propyl)-, (S)-;NK-631;peplomycinum;LS-102345;CIPLUS_699356;Peplomycin Sulfate (1:1);Peplomycin sulfate;NK 63;PEPLOMYCIN;peplomycine;",-45.984,-15.14812745,0.004172941,0.988321439,,,O=C(N)C(N)CNC(CC(=O)N)c1nc(N)c(C)c(n1)C(=O)NC(C(O[C@@H]3O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]3O[C@H]2O[C@H](CO)[C@@H](O)[C@H](OC(=O)N)[C@@H]2O)c4cncn4)C(=O)NC(C)C(O)C(C)C(=O)NC(C(=O)NCCc5nc(cs5)c6nc(cs6)C(=O)NCCCN[C@@H](C)c7ccccc7)C(C)O.O=S(=O)(O)O,ACC,PEPLOMYCIN SULFATE,2.79828993,3.50226617,-3.35270451,-6.48648649,-22.56658596,-33.7,-15.14812745,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00249415-01,Fabesetron,144206751,5-hydroxytryptamine receptor 4 Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),129300-27-2,,23.7781084,0,-4.623822698,-88.97931408,-2.1,7,,-107.275014,-84.68418111,0.014086828,0.947239915,3360,HTR4,Cc4ncnc4C[C@H]3CCc2c(C)c1ccccc1n2C3=O,NCGCChem,DJM10-012,-13.36960746,-12.9789864,0.58113545,-12.97297297,-9.00726392,-33.1,-84.68418111,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00164789-04,Fulvestrant,170464917,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),129453-61-8,; Faslodex;Fulvestrant;Fulvestrant (Faslodex),15.00297213,0,-4.823822698,-21.0997656,-2.2,7,,-43.72275014,-39.18390162,0.000430256,0.991416388,2099,ESR1,FC(F)(F)C(F)(F)CCCS(=O)CCCCCCCCC[C@@H]2Cc1cc(O)ccc1[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@H]23,Prestwick,Prestw-1424,0,2.1013597,0,0,2.61501211,-15.3,-39.18390162,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167519-02,Ramatroban,170465980,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),116649-85-5,BAY u-3405; ; Ramatroban;Ramatroban; Baynas; BAY u3405;BAY-u3405; BAY u 3405; BAY u 3406,18.88762287,0,-4.723822698,-25.63770061,-2.2,7,,-43.51788709,-39.40749022,0.008301224,0.960349555,11251,PTGDR2,Fc1ccc(cc1)S(=O)(=O)N[C@H]3Cc4c2ccccc2n(CCC(=O)O)c4CC3,Sequoia,SRP0101165r,-6.29615235,1.89534405,0.04470273,0,2.42130751,-13.1,-39.40749022,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00166241-02,"2,6-DIIODO-4-NITROPHENOL",225144276,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),305-85-1,,0.843679123,1,-6.073822698,-53.0796063,-1.4,7,,-30.64,-26.77473449,0.004844952,0.97019216,,,OC1=C(I)C=C(C=C1I)[N+]([O-])=O,SIGMA,145416,-0.07773028,0,-2.90567725,-12.52252252,-17.33656174,-29.7,-26.77473449,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00390731-01,Tafamidis,405558810,Transthyretin Modulator,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),594839-88-0,,26.67947643,0,-4.573822698,-18.95409174,-3,7,,-47.27138066,-36.94801565,0.004132143,0.972571724,,,OC(=O)C1=CC=C2N=C(OC2=C1)C3=CC(=CC(=C3)Cl)Cl,MedChem Express,HY-14852,3.80878352,-1.4421096,1.20697363,-3.78378378,-0.4842615,-9.1,-36.94801565,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00263875-02,SELAMECTIN,405558820,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),165108-07-6,,13.37141299,0,-4.873822698,-71.59496743,-2.1,7,,-107.0994969,-97.54052543,1.63992E-05,0.998342387,,,CO[C@H]1C[C@H](O[C@@H](C)[C@H]1O)O[C@H]\2[C@@H](C)\C=C\C=C\3CO[C@@H]4C(=N/O)\C(=C/[C@@H](C(=O)O[C@H]5C[C@@H](C/C=C2C)O[C@@]6(CC[C@H](C)[C@H](O6)C7CCCCC7)C5)[C@]34O)C,Microsource,1503720,-0.3109211,0.28842192,1.25167635,-3.51351351,-4.16464891,-47.1,-97.54052543,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00509859-03,ABT-450,,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1221573-85-8,,37.68576212,0,-4.423822698,-11.98812914,-3,7,,-38.56204584,-34.26495249,1.30E-09,0.999985112,,,CC1=CN=C(C=N1)C(=O)N[C@H]2CCCCCC=C[C@@H]3C[C@]3(NC(=O)[C@@H]4C[C@H](CN4C2=O)OC5=NC6=C(C=CC=C6)C7=C5C=CC=C7)C(=O)N[S+]([O-])(=O)C8CC8,Glixx,GLXC-90367,0,0,0,0,0,0,-34.26495249,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00017134-08,Meclocycline sulfosalicylate,405559138,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),73816-42-9,,5.32325539,1,-5.273822698,-110.321804,-2.1,7,,-94.04096813,-86.540732,0.000237672,0.993640278,,,CN(C)[C@H]\1[C@@H]2[C@@H](O)[C@@H]\3C(=C)C4=C(Cl)C=CC(=C4C(=O)C3=C(\O)[C@@]2(O)C(=O)\C(=C1O)C(N)=O)O.OC(=O)C5=C(O)C=CC(=C5)[S+](O)([O-])=O,SIGMA,M1388,-6.48648649,0.1310616,-1.39194139,-8.92410342,-33.33333333,-62.59469697,-86.540732,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00164034-05,Triclocarban,170465481,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),101-20-2,,37.68576212,0,-4.423822698,-21.17889913,-3,7,,-36.12809917,-33.88429752,0.03785302,0.908240083,,,Clc2ccc(NC(=O)Nc1ccc(Cl)cc1)cc2Cl,Specs,AN-153/I101902,0,-3.01441678,-10.32967033,0,0,0,-33.88429752,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00015970-11,Sulindac,170464648,ABCC1 Expression Enhancer,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),38194-50-2, ; Sulindac;Sulindac; Sulindaco; Clinoril; Sulindac sulfide; Sulindac sulfone;SULINDAC; Suldinac,26.67947643,0,-4.573822698,-16.02359057,-3,7,,-35.35891381,-33.64817001,0.001180585,0.985650994,,ABCC1,CS(=O)c1ccc(cc1)/C=C3\c2ccc(F)cc2C(CC(=O)O)=C3C,Microsource,1500556,-3.72372372,1.04849279,0,0,-0.09033424,-2.1780303,-33.64817001,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00015436-11,Fluphenazine hydrochloride,170465375,Nicotinic alpha7 Receptor Ligands,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),69-23-8, Motipress; Liogen;Fluphenazine; Flumezin;; ; Fluphenazine dihydrochloride;Fluphenazine di?HCl; Flufenazine; Prolixin; Lyogen; Motival;Fluphenazine dihydrochloride; Fluphenazine Hcl; prolixin S,15.00297213,0,-4.823822698,-33.06540348,-2.2,7,,-58.5974026,-53.48288076,0.000754256,0.988578354,1813,DRD2,FC(F)(F)c2cc3N(CCCN1CCN(CCO)CC1)c4ccccc4Sc3cc2,Vitas,STK050763,0,-2.49017038,-1.39194139,4.25354462,0,-20.9280303,-53.48288076,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00262940-01,Iodoxamic Acid,170465432,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),31127-82-9,Acide iodoxamique;Iodoxamate meglumine;Iodoxamic acid,23.7781084,0,-4.623822698,-7.493175253,-3,7,,-32.19421488,-30.5785124,0.002169678,0.980381152,,,O=C(Nc1c(I)c(c(I)cc1I)C(=O)O)CCOCCOCCOCCOCCC(=O)Nc2c(I)c(C(=O)O)c(I)cc2I,GVK,FFS-11-286-NCI-61,0,4.58715596,0,0,0,0,-30.5785124,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00159391-03,Sulfobromophthalein,170465816,Solute carrier organic anion transporter family member 1B1 Substrate,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),71-67-0,,9.466235454,1,-5.023822698,-60.27365358,-2.2,7,,-70.10271547,-69.53955136,0.004065472,0.972786052,,,[Na+].[Na+].[O-]S(=O)(=O)c1cc(ccc1O)C3(OC(=O)c2c(Br)c(Br)c(Br)c(Br)c23)c4ccc(O)c(c4)S([O-])(=O)=O,Labotest,LT03378988,4.8048048,-5.11140236,0,-8.09007506,4.4263776,-48.95833333,-69.53955136,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00263583-01,Temocapril hydrochloride,170465944,Angiotensin-I Converting Enzyme Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),110221-44-8,,37.68576212,0,-4.423822698,-3.807462049,-2.4,7,,-29.67709563,-25.14757969,0.007579777,0.962258682,,ACE,Cl.O=C(OCC)[C@@H](N[C@H]1CS[C@@H](CN(CC(=O)O)C1=O)c2cccs2)CCc3ccccc3,Sequoia,110221-44-8,2.76276276,-2.22804718,2.63736264,0,0,3.125,-25.14757969,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00159437-03,Clobutinol hydrochloride,170466051,HERG Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1215-83-4,,37.68576212,0,-4.423822698,-14.58820636,-3,7,,-47.28040141,-41.91263282,0.000108879,0.995712461,,,Cl.Clc1ccc(CC(C)(O)C(C)CN(C)C)cc1,Prestwick,Prestw-1380,0,-1.83486239,0,0.33361134,0,1.60984848,-41.91263282,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00165966-06,Vinorelbine tartrate ,,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),125317-39-7,,8.436791229,1,-5.073822698,-43.8700385,-2.4,7,,-49.72077922,-35.77331759,0.077840408,0.858412803,,,[H][C@@]12N3CC[C@@]14C5=CC(=C(OC)C=C5N(C)[C@@]4([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC)[C@]6(C[C@@]7([H])CN(CC(CC)=C7)CC8=C6NC9=C8C=CC=C9)C(=O)OC,Bosche,V5183,0.84084084,0,3.58974359,-17.43119266,-9.30442638,-22.8219697,-35.77331759,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167437-02,Ramosetron hydrochloride,170465928,Serotonin 3a (5-HT3a) receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),132907-72-3,,11.91728437,0,-4.923822698,-45.11958546,-2.2,7,,-40.7588038,-37.50698714,0.031289213,0.917751108,,,Cl.O=C(c2cn(C)c1ccccc12)[C@H]3Cc4ncnc4CC3,Bosche,R2999,-1.86552662,-8.11701689,3.88913724,-8.37837838,-7.55447942,-23.2,-37.50698714,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00386545-01,Ciclesonide,405558718,Glucocorticoid receptor Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),126544-47-6,,26.67947643,0,-4.573822698,-47.25402707,-2.2,7,,-89.32839575,-68.80939072,0.00725648,0.963072543,,NR3C1,CC(C)C(=O)OCC(=O)[C@@]12OC(O[C@@H]1C[C@H]3[C@@H]4CCC\5=C\C(=O)\C=C/[C@]5(C)[C@H]4[C@@H](O)C[C@]23C)C6CCCCC6,Axon Medchem,1426,1.71006607,4.16151628,0,-6.3963964,-12.88135593,-20.3,-68.80939072,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00507775-01,Midecamycin Acetate,405558744,Ribosome Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),55881-07-7,,29.9348649,0,-4.523822698,-18.5392042,-3,7,,-37.28842929,-30.24035774,0.008914605,0.958835597,,,CCC(=O)O[C@@H]1CC(=O)O[C@H](C)C/C=C/C=C/[C@H](OC(C)=O)[C@H](C)C[C@H](CC=O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@](C)(OC(C)=O)[C@H](OC(=O)CC)[C@@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@H]1OC,AvaChem,2845,0,0,0,0,-6.29539952,-5.1,-30.24035774,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00186637-01,Chromomycin A<SUB>3</SUB> from Streptomyces griseus,124897824,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),7059-24-7,,13.37141299,0,-4.873822698,-37.64401695,-2.4,7,CHROMOMYCIN A3,-53.75265511,-43.54387926,0.059905095,0.879496768,,,CO[C@H]1[C@@H](O)CC(O[C@H]1C)O[C@H]2CC(O[C@@H](C)[C@H]2OC(C)=O)OC3=CC4=CC5=C(C(=C4C(=C3C)O)O)C(=O)[C@@H](OC6C[C@@H](OC7C[C@H](OC8C[C@](C)(O)[C@@H](OC(C)=O)[C@H](C)O8)[C@@H](O)[C@H](C)O7)[C@H](O)[C@@H](C)O6)[C@@H](C5)[C@@H](OC)C(=O)[C@@H](O)[C@H](C)O,BIOMOL,GR302,0.38865138,-0.28842192,3.97854269,-3.96396396,-18.01452784,-14.3,-43.54387926,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00022678-23,Rifampicin,,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),[13292-46-1],,11.91728437,0,-4.923822698,-52.99610956,-2.2,7,,-70.09782001,-69.70374511,0.000105233,0.99578355,,,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C4=C(O)C(\C=N\N5CCN(C)CC5)=C(NC(=O)C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C4C(O)=C3C,Tocris,4121,0,0,0,-4.59459459,-1.1622276,-35.2,-69.70374511,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00183879-01,Bisbentiamine,144206468,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),2667-89-2,,9.466235454,1,-5.023822698,-31.37518334,-2.2,7,BISBENTIAMINE;Bisbentiamina;Beston;CIPLUS_213921;bisbentiaminum;Bisbentiamine;bisbentiamine;Bisbentiaminum;,-51.42649525,-49.46897708,0.000847695,0.987877375,,,Nc4nc(C)ncc4CN(C=O)C(/C)=C(/CCOC(=O)c1ccccc1)SSC(/CCOC(=O)c2ccccc2)=C(/C)N(C=O)Cc3cnc(C)nc3N,ACC,Bisbentiamine,0,0,0,4.59459459,4.45520581,-29.2,-49.46897708,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00319175-03,Rilpivirine,405558769,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),500287-72-9,,8.436791229,1,-5.073822698,-82.84638291,-2.1,7,,-98.02498602,-88.82057015,2.0503E-06,0.999414937,,,CC1=C(NC2=CC=NC(=N2)NC3=CC=C(C=C3)C#N)C(=CC(=C1)\C=C\C#N)C,APExBIO,A3765,0,2.1013597,0,-3.33333333,-15.69007264,-57.2,-88.82057015,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00379087-02,Tipranavir,405558770,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),174484-41-4,,16.8336116,0,-4.773822698,-56.39731095,-2.1,7,,-93.36159866,-85.019564,0.000239027,0.993622102,,,CCC[C@@]1(CCC2=CC=CC=C2)CC(=C([C@H](CC)C3=CC=CC(=C3)N[S+]([O-])(=O)C4=CC=C(C=N4)C(F)(F)F)/C(=O)O1)\O,MedChem Express,HY-15148,-5.51884959,-0.37082818,0,1.62162162,0,-32.2,-85.019564,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00179357-05,PREDNICARBATE,405558774,Glucocorticoid Receptor Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),73771-04-7,,13.37141299,0,-4.873822698,-37.94852879,-2.2,7,,-51.14281722,-42.20234768,0.017239296,0.941094464,,,CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)COC(=O)CC,Microsource,1503876,-1.71006607,2.34857849,-0.49173,0,-14.91525424,-17.9,-42.20234768,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016868-12,Acemetacin,170466043,Cyclooxygenase-1/2/3 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),53164-05-9,; ; Acemetacina; Rantudil;ACEMETACIN; Acemetacin;Acemetacin,18.88762287,0,-4.723822698,-34.36308448,-2.2,7,,-58.46753247,-54.89964581,0.000414031,0.991579629,5742,PTGS1,Clc1ccc(cc1)C(=O)n3c2ccc(cc2c(CC(=O)OCC(=O)O)c3C)OC,Microsource,1500666,-3.48348348,-3.40760157,1.31868132,0,0,-15.05681818,-54.89964581,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00263918-08,Epirubicin hydrochloride,405559095,DNA Topoisomerase II Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),56390-09-1,,23.7781084,0,-4.623822698,-42.57258827,-2.2,7,,-84.57322527,-64.44941308,0.000104672,0.995795154,,TOP2A,COC1=C2C(=O)C3=C(C(=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)C4=C3O)C(=O)CO)O)C(=O)C2=CC=C1,MedChem Express,HY-13624A,0,0,0,0,-7.07021792,-21.6,-64.44941308,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00181039-02,Ethyl linoleate,170466006,regulation of prostaglandin secretion Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),6114-21-2,,29.9348649,0,-4.523822698,-11.22571153,-3,7,,-38.60117384,-36.05366126,0.003961769,0.9731691,,,O=C(CCCCCCC/C=C\C/C=C\CCCCC)OCC,SIGMA,L6253,0,0,4.87259723,-2.88288288,0,0,-36.05366126,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00390559-05,Azilsartan Medoxomil,405558503,Type-1 angiotensin II receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),863031-21-4,,23.7781084,0,-4.623822698,-53.27946862,-2.2,7,,-95.2884293,-72.94577977,0.000414582,0.991572457,185,AGTR1,CCOC1=NC2=CC=CC(=C2[N]1CC3=CC=C(C=C3)C4=CC=CC=C4\C5=N\C(=O)O[N-]5)C(=O)OC\C6=C(/C)OC(=O)O6,APExBIO,B2218,0,-4.9855789,1.47518999,-0.72072072,-8.91041162,-26.6,-72.94577977,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00181334-04,DIBUNATE SODIUM,225144323,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,21.19226141,0,-4.673822698,-22.0311345,-3,7,,-48.82336501,-45.89155953,0.000574246,0.990060025,,,CC(C)(C)C1=CC=C2C(=C1)C=CC(=C2[S]([O-])(=O)=O)C(C)(C)C,Bosche,D6477,-2.40963855,0,0,-0.9009009,3.19612591,-7.7,-45.89155953,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00379034-03,Caspofungin Acetate,,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),179463-17-3,,2.917032768,1,-5.535058692,-111.5163743,-1.1,7,,-85.59390721,-86.92006708,0.001207897,0.985468267,,,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@@H](O)[C@H](O)C4=CC=C(O)C=C4)[C@H](O)CCN,Selleck,S3073,-10.10493587,0,-0.13410818,4.05405405,-12.97820823,-67.9,-86.92006708,,,,,,,,,1.83E-09,9.14E-09,4.57E-08,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,
NCGC00167518-09,Temsirolimus,405559026,mTOR Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),162635-04-3,,13.02990675,0,-4.885058692,-27.86792308,-3,7,,-34.96394634,-35.49468977,0.009387813,0.957662836,,MTOR,CO[C@@H]1C[C@@H](CC[C@H]1OC(=O)C(C)(CO)CO)C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC,Adooq,A10906,0,0,-7.37594993,0,0,-2.4,-35.49468977,,,,,,,,,1.83E-09,9.14E-09,4.57E-08,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,
NCGC00483046-01,SCE 2174,405559041,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),95789-30-3,,3.358747085,1,-5.473822698,-61.4894895,-1.2,7,,-55.094,-51.92845165,0.000122969,0.99543951,,,CC(OC(=O)OC1CCCCC1)OC(=O)\C2=C(CS[C@@H]3[C@H](NC(=O)CC4=CSC(=N4)N)C(=O)N23)/CSC5=NN=N[N]5CCN(C)C,DC Chemicals,DC9200,0,2.43098475,0,0,-7.36077482,-57.1,-51.92845165,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167510-02,Doripenem,170465085,Carbapenem Antibiotic,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),148016-81-3,,16.8336116,0,-4.773822698,-36.27884544,-2.2,7,,-73.72945779,-66.46171045,7.67833E-05,0.996402117,,DPEP1,O[C@H](C)[C@H]3C(=O)N2C(=C(S[C@H]1C[C@@H](CNS(N)(=O)=O)NC1)[C@H](C)[C@@H]23)C(=O)O,Sequoia,148016-81-3,0,1.03007829,0,0.81081081,2.90556901,-23.4,-66.46171045,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00386699-01,Fluphenazine decanoate dihydrochloride,405558673,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),2376-65-0,,7.519298098,1,-5.123822698,-71.50492046,-1.2,7,,-69.73672442,-70.82168809,0.00051241,0.990615319,,,CCCCCCCCCC(=O)OCCN1CCN(CCCN2C3=C(SC4=CC=C(C=C24)C(F)(F)F)C=CC=C3)CC1,Axon Medchem,2127,0,-7.62257932,-0.04470273,2.16216216,0,-61.4,-70.82168809,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00346533-09,Daclatasvir dihydrochloride,405558621,HCV NS5A Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1009119-65-6,,5.972790784,1,-5.223822698,-74.52790257,-1.2,7,,-73.18753494,-74.28731135,4.4557E-06,0.999137141,,,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C2=NC=C([NH]2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C([NH]5)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)C(C)C,Glixx,GLXC-90137,-0.07773028,0,0,0,-6.29539952,-63.1,-74.28731135,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00181782-03,Sertindole,170465613,Serotonin 2c (5-HT2c) receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),106516-24-9,,21.19226141,0,-4.673822698,-73.56722061,-2.1,7,,-107.8074343,-83.56623812,0.005677382,0.96756864,,,Fc1ccc(cc1)n5cc(C3CCN(CCN2CCNC2=O)CC3)c4cc(Cl)ccc45,Prestwick,Prestw-1341,-1.01049359,-7.37536053,2.36924452,-1.44144144,-21.59806295,-34.1,-83.56623812,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167561-03,D-alpha-Tocopherol succinate,225144294,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),4345/3/3,,5.972790784,1,-5.223822698,-94.56068492,-2.1,7,,-85.23007266,-85.019564,7.77172E-05,0.996379744,,,CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCC2=C(C)C(=C(C)C(=C2O1)C)OC(=O)CCC(O)=O,SIGMA,T3126,-6.21842208,-1.27729707,0,-1.35135135,-17.14285714,-64.9,-85.019564,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00510940-01,Kebuzone,405558634,Cyclooxygenase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),853-34-9,,37.68576212,0,-4.423822698,-21.76681317,-3,7,,-43.58133035,-40.8608161,0.061088668,0.878064132,,,CC(=O)CCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,SantaCruz Bio,sc-488996,1.9432569,-8.28182942,2.72686634,-2.88288288,-9.49152542,4.7,-40.8608161,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00165993-02,Picolinic acid,170466822,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),98-98-6,,18.88762287,0,-4.723822698,-47.55417206,-2.2,7,,-72.9935065,-65.52538371,0.002960883,0.976933025,,,O=C(O)c1ccccn1,Bosche,P0843,0,-9.56749672,0,1.75145955,-4.24570912,-23.20075758,-65.52538371,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00095303-04,Cloxyquin,170465523,Mycobacterium tuberculosis Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),130-16-5,,3.358747085,1,-5.473822698,-89.31422105,-1.2,7,,-74.58579546,-64.58087367,0.003979696,0.973086114,,,Oc1ccc(Cl)c2cccnc12,Vitas,STK015543,-0.96096096,0,0.80586081,-1.75145955,-8.76242096,-84.56439394,-64.58087367,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016344-07,5-Aminosalicylic acid,170464840,reactive oxygen species biosynthetic process Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),89-57-6,,10.62129087,0,-4.973822698,-65.29470667,-2.1,7,,-95.45914994,-87.48524203,6.6286E-06,0.998947224,16534,,OC(=O)c1cc(N)ccc1O,Vitas,STK301678,1.44144144,3.40760157,0,0,-7.1364047,-47.8219697,-87.48524203,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00094887-05,Fenoprofen calcium salt dihydrate,170465299,Cyclooxygenase-2 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),71720-56-4,,37.68576212,0,-4.423822698,-13.67632338,-3,7,,-50.20306966,-44.0377804,1.28136E-05,0.998535923,,,[Ca+2].O.O.[O-]C(=O)[C@@H](C)c2cc(Oc1ccccc1)ccc2.[O-]C(=O)[C@@H](C)c2cc(Oc1ccccc1)ccc2,Microsource,1501011,0.6006006,0,0,0.08340284,0,1.60984848,-44.0377804,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00095836-05,Guaiazulene,170465862,lipid oxidation Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),489-84-9,,6.701581484,1,-5.173822698,-104.9129683,-2.1,7,,-103.4057851,-101.6528926,1.48151E-05,0.998424666,,,CC(C)c1ccc(C)c2ccc(C)c2c1,Microsource,1502249,-2.88288288,0.2621232,0,-5.75479566,-18.33785005,-71.68560606,-101.6528926,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00532507-01,INOSITOL NIACINATE,405558892,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,1.791164342,1,-5.746864565,-28.75744451,-2.4,7,,-26.26355506,-22.30296255,0.00252423,0.978794611,,,O=C(O[C@@H]1[C@H](OC(=O)C2=CC=CN=C2)[C@H](OC(=O)C3=CC=CN=C3)[C@@H](OC(=O)C4=CN=CC=C4)[C@H](OC(=O)C5=CC=CN=C5)[C@H]1OC(=O)C6=CC=CN=C6)C7=CC=CN=C7,SIGMA,MFCD00006387,3.73105325,1.11248455,0,3.15315315,-4.26150121,-14.5,-22.30296255,,,,,,,,,9.14E-10,4.57E-09,2.29E-08,1.14E-07,5.71E-07,2.86E-06,0.0000143,,,,,,,,
NCGC00379082-01,Anidulafungin,405558984,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),166663-25-8,,4.120418304,1,-5.385058692,-105.7507328,-2.1,7,,-98.14471772,-96.86975964,3.59E-07,0.999755493,,,CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)NC4CC(O)C(O)NC(=O)C5C(O)C(C)CN5C(=O)C(NC(=O)C(NC(=O)C6CC(O)CN6C(=O)C(NC4=O)C(C)O)C(O)C(O)C7=CC=C(O)C=C7)C(C)O,MedChem Express,HY-13553,0,0,0,0,-2.61501211,-66.5,-96.86975964,,,,,,,,,1.83E-09,9.14E-09,4.57E-08,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,
NCGC00390569-01,Netupitant,363680908,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),290297-26-6,,29.9348649,0,-4.523822698,-37.99278596,-3,7,,-77.4980436,-67.91503633,0.006651828,0.964739003,,,CN1CCN(CC1)C2=CC(=C(C=N2)N(C)C(=O)C(C)(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C4=C(C)C=CC=C4,MedChem Express,HY-16346,2.72055966,0,0.62583818,-5.22522523,-11.52542373,-7.8,-67.91503633,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00091501-06,Resorcinol,170465462,leukotriene B4 biosynthetic process Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),108-46-3,,8.436791229,1,-5.073822698,-7.096113366,-2.4,7,,-26.43181818,0,1.7991E-06,0.999934701,,,Oc1cccc(O)c1,Specs,AE-562/J255633,0,0,0,0,0,-20.35984848,0,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00015251-13,Clotrimazole,170464807,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),23593-75-1," ; Bay b 5097; Clotrimazole;Clotrimazole; b 5097, F; Clotrimazol; Kanesten; Baycuten; Canesten; Canesten HC; FB b 5097; b 5097, Ba; Baycuten SD; Lotrimin; Mycelex; Klotrimazole;CLOTRIMAZOLE; 5097, Bay",21.19226141,0,-4.673822698,-45.40552482,-2.2,7,,-83.26623376,-77.09563164,0.003807397,0.973703354,1595,CYP51A1,Clc1ccccc1C(c2ccccc2)(c3ccccc3)n4ccnc4,Vitas,STK700023,-1.44144144,-4.98034076,3.36996337,-9.25771476,3.7037037,-17.32954545,-77.09563164,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016069-13,Brimonidine,170464941,Alpha-2C adrenergic receptor Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),59803-98-4,,37.68576212,0,-4.423822698,-4.718326901,-2.4,7,,-33.64403778,-28.45336482,0.001068005,0.986371623,152,ADRA2C,Brc2c3nccnc3ccc2NC1=NCCN1,Enzo,AC155,0,0,2.41758242,3.08590492,0,1.98863636,-28.45336482,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00018153-10,Dienestrol,170465362,Estrogen Receptor (ER) Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),84-17-3," (E,E)-Dienestrol; Ortho Dienestrol; Dienestrol, (Z,E)-Isomer; Dienoestrol; Ortho Brand of Dienestrol; Dienestrol, (E,E)-Isomer; Dienestrol, (Z,Z)-Isomer; Oestrasid;DIENESTROL; Synestrol;Dienestrol;",8.436791229,1,-5.073822698,-23.57918175,-2.4,7,,-27.51062574,-27.50885478,5.19E-07,0.99970606,2099,ESR1,Oc1ccc(cc1)C(=C\C)/C(=C/C)c2ccc(O)cc2,Microsource,1500241,0,0,0,0,0,-19.98106061,-27.50885478,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00015252-12,Cyproheptadine hydrochloride,170465127,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),129-03-3,; ; Cyproheptadine hydrochloride;Cyproheptadine hydrochloride; Dihexazin; 1   Cyprohetadine;Cyproheptadine;CYPROHEPTADINE HYDROCHLORIDE; Viternum; 9   Cyproheptadine; Ciproheptadina; Periactin; Peritol; Antergan,16.8336116,0,-4.773822698,-16.31416451,-2.2,7,,-39.24439198,-32.70365998,0.000410148,0.991624594,9704,HRH1,CN1CC\C(CC1)=C2\c4ccccc4C=Cc3ccccc23,Vitas,STK802098,0,3.53866317,1.97802198,0,-0.09033424,-12.40530303,-32.70365998,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00183858-01,Blonanserin,144206818,Serotonin 2a (5-HT2a) receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),132810-10-7,,8.221315363,1,-5.085058692,-33.45255942,-2.2,7,"AD-5423;BLONANSERIN;blonanserin;AD 5423;2-(4-ETHYLPIPERAZIN-1-YL)-4-(4-FLUOROPHENYL)-5,6,7,8,9,10-HEXAHYDROCYCLOOCTA[B]PYRIDINE;blonanserinum;Blonanserin;blonanserine;Cycloocta(b)pyridine, 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydro-;2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta(b)pyridine;CIPLUS_702318;",-45.82467532,-41.91263282,0.005710314,0.967483987,,,CCN1CCN(CC1)c3cc(c2ccc(F)cc2)c4CCCCCCc4n3,Pharmaron,PH-NIH-148160,0,3.66972477,-5.05494505,3.75312761,0,-14.6780303,-41.91263282,,,,,,,,,1.83E-09,9.14E-09,4.57E-08,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,
NCGC00021152-06,Hydroxyzine,170464958,antiparasitic agent,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),68-88-2,,13.37141299,0,-4.873822698,-53.82886926,-2.2,7,,-81.14935065,-74.73435655,0.003429257,0.975099394,,,Clc1ccc(cc1)C(c2ccccc2)N3CCN(CC3)CCOCCO,Microsource,1500345,0,0,0,-7.75646372,4.96838302,-36.83712121,-74.73435655,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00249913-01,Isoniazid pyruvate,170465758,Isocitrate lyase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1081-50-1,,7.519298098,1,-5.123822698,-37.90059313,-2.2,7,,-47.16410862,-46.635183,7.71828E-05,0.996393252,,,O=C(N\N=C(\C)C(=O)O)c1ccncc1,GVK,FFS-11-286-NCI-164,0,0,0,3.08590492,0,-33.99621212,-46.635183,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00015748-17,Nifedipine,170465006,Voltage-gated L-type calcium channel alpha-1C subunit Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),21829-25-4,,10.62129087,0,-4.973822698,-53.46036752,-2.2,7,,-78.75324675,-76.62337662,6.0201E-06,0.998996824,,,CC=1NC(C)=C(C(C=1C(=O)OC)c2ccccc2[N+]([O-])=O)C(=O)OC,Specs,AN-153/I100964,0,0,0.58608059,2.25187656,0,-41.00378788,-76.62337662,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00090680-06,Carbaryl,170465695,Acetylcholinesterase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),63-25-2,,18.88762287,0,-4.723822698,-7.05395511,-2.4,7,,-24.91027154,-23.25855962,0.005002221,0.969714824,,,CNC(=O)Oc2cccc1ccccc12,Bosche,C1592,0.48048048,0,0,0,4.4263776,-3.50378788,-23.25855962,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00168290-05,Avermectin B1a,405558426,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),65195-55-3,,11.91728437,0,-4.923822698,-70.48597559,-2.2,7,,-81.28563443,-73.05757406,0.00858666,0.95960616,,,CC[C@H](C)[C@H]1O[C@@]2(C[C@@H]3C[C@@H](C/C=C(C)/[C@@H](O[C@H]4C[C@H](OC)[C@@H](O[C@H]5C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)[C@@H](C)/C=C/C=C/6CO[C@@H]7[C@H](O)\C(=C/[C@@H](C(=O)O3)[C@]67O)C)O2)\C=C/[C@@H]1C,MedChem Express,HY-15308,0,-11.08364236,3.35270451,0,-18.78934625,-37.8,-73.05757406,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00183853-01,Mosapramine,144206880,Dopamine D4 receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),89419-40-9,,18.88762287,0,-4.723822698,-36.75870559,-2.2,7,"MOSAPRAMINE HYDROCHLORIDE;LS-178090;Cremin;3-chloro-5-(3-(2-oxo-1,2,3,5,6,7,8,8a-octahydroimidazo(1,2-a)pyridine-3-spiro-4'-piperidino)propyl)-10,11-dihydro-5H-dibenz(b,f)azepine;Spiro(imidazo(1,2-a)pyridine-3(2H),4'-piperidin)-2-one, 1'-(3-(3-chloro-10,11-dihydro-5H-dibenz(b,f)azepin-5-yl)propyl)hexahydro-, dihydrochloride;CIPLUS_3853867;mosapraminum;CIPLUS_703731;Mosapramine hydrochloride;Y 516;(+/-)-1'-(3-(3-CHLORO-10,11-DIHYDRO-5H-DIBENZ(B,F]AZEPIN-5-YL)PROPYL)HEXAHYDROSPIRO(IMIDAZO(1,2-A)PYRIDINE-3(2H),4'-PIPERIDIN)-2-ONE;Mosapramine Hydrochloride;Mosapramine;mosapramine;Y-516;MOSAPRAMINE;",-77.78571429,-71.42857143,3.19E-07,0.999769344,,,Clc5ccc6CCc1ccccc1N(CCCN2CCC4(CC2)C(=O)NC3CCCCN34)c6c5,Pharmaron,PH-NIH-183543,-0.12012012,0.78636959,0,0.41701418,0,-17.89772727,-71.42857143,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00063561-03,"4,5-Diphenylimidazole",170465946,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),668-94-0,,16.8336116,0,-4.773822698,-39.60229467,-2.2,7,,-72.24025974,-66.46989374,0.001446192,0.984064935,,,c1ccc(cc1)c2ncnc2c3ccccc3,Labotest,LT03333454,-4.56456456,2.22804718,-1.24542125,-1.91826522,4.4263776,-20.9280303,-66.46989374,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00021274-04,ESTRADIOL BENZOATE,405559069,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),50-50-0,,21.19226141,0,-4.673822698,-19.11970107,-3,7,,-55.98701299,-49.2325856,0.000321387,0.992594113,,,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=CC=C34)OC(=O)C5=CC=CC=C5)[C@@H]1CC[C@@H]2O,SIGMA,E8515,0,3.14547837,0,0,3.7037037,-9.56439394,-49.2325856,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00091345-04,Hexanedioic acid,170465352,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),124-04-9,,37.68576212,0,-4.423822698,-13.52317887,-2.4,7,,-31.7107438,-28.92561983,0.008300986,0.96037686,,,OC(=O)CCCCC(=O)O,Specs,AE-562/J262759,-0.72072072,0,-5.34798535,1.41784821,0,0,-28.92561983,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00249910-01,Ibafloxacine,170466478,Bacterial DNA gyrase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),91618-36-9,,13.37141299,0,-4.873822698,-38.28732058,-2.4,7,,-28.67768595,-32.23140496,0.058685684,0.881064469,,,O=C(O)C3=CN1c2c(cc(F)c(C)c2CCC1C)C3=O,GVK,FFS-11-286-NCI-148,-3.48348348,-10.22280472,-1.39194139,-7.25604671,1.7163505,-16.95075758,-32.23140496,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00015829-12,Promazine hydrochloride,170464766,Serotonin 2a (5-HT2a) receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),53-60-1,,29.9348649,0,-4.523822698,-23.10415344,-3,7,,-52.10743802,-42.14876033,0.006936606,0.963961296,,,Cl.CN(C)CCCN1c3ccccc3Sc2ccccc12,Microsource,1500509,0,0,0,2.25187656,-7.49774164,-6.72348485,-42.14876033,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00094918-07,Saccharin,170465766,Taste receptor type 1 member 3 Binding Agent,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1981/7/2,,9.466235454,1,-5.023822698,-28.24817576,-2.4,7,,-25.3772137,-26.56434475,0.049039847,0.893217975,83756,TAS1R3,O=C2NS(=O)(=O)c1ccccc12,Vitas,STK803263,-9.00900901,1.96592398,0,0,0,-17.32954545,-26.56434475,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00021193-03,AMCINONIDE,405559147,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),51022-69-6,,21.19226141,0,-4.673822698,-42.50623298,-2.1,7,,-93.31818182,-80.16528926,3.9741E-06,0.999185199,,,CC(=O)OCC(=O)[C@@]12OC3(CCCC3)O[C@@H]1C[C@H]4[C@@H]5CCC/6=C/C(=O)/C=C\[C@]6(C)[C@@]5(F)[C@@H](O)C[C@]24C,FLUKA,A2428,0,-0.65530799,0.07326007,1.75145955,0,-21.875,-80.16528926,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00014648-04,Spiclomazine hydrochloride,405558575,Adrenergic receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,9.466235454,1,-5.023822698,-90.12331595,-2.1,7,,-90.71112353,-94.52207937,0.00085981,0.987786204,,,ClC1=CC2=C(SC3=C(C=CC=C3)N2CCCN4CCC5(CC4)NC(=O)CS5)C=C1,NCI,NSC-290956,0,-8.94107952,0,-9.90990991,-5.52058111,-57.3,-94.52207937,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00181104-04,Dithiazanine chloride,124893646,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,2.99348649,1,-5.523822698,-128.6555935,-1.1,7,,-95.70922303,-99.10564561,0.000111309,0.995662038,,,CCN1C(/SC2=C1C=CC=C2)=C/C=C/C=C/C3=[N+](CC)C4=C(S3)C=CC=C4,NCI,NSC-221154,-6.84026428,1.68932839,0,-5.76576577,-23.43825666,-98.1,-99.10564561,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00379045-01,Alfacalcidol-D6,405558455,Increase blood calcium level via a variety of mechanisms,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,29.9348649,0,-4.523822698,-53.50059297,-2.1,7,,-103.3230855,-80.54779206,0.012826011,0.949862967,,,C(C(C([2H])([2H])[2H])CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C/3C[C@@H](O)C[C@H](O)C3=C)([2H])([2H])[2H],MedChem Express,HY-15332,0.15546055,-2.01895344,0,3.15315315,-18.69249395,-18.9,-80.54779206,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00250406-02,Tipifarnib,405558726,Farnesyltransferase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),192185-72-1,,6.701581484,1,-5.173822698,-116.4394205,-2.1,7,,-97.88395751,-92.2861934,0.000330048,0.992491229,,COX10,C[N]1C=NC=C1[C@@](N)(C2=CC=C(Cl)C=C2)C3=CC=C4N(C)C(=O)\C=C(\C5=CC=CC(=C5)Cl)C4=C3,Selleck,S1453,-4.89700738,0,-9.25346446,-11.8018018,-24.30992736,-68.7,-92.2861934,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00482546-01,Ganirelix,405558835,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),123246-29-7,,11.91728437,0,-4.923822698,-60.2911635,-2.2,7,,-85.17775293,-73.84013415,9.44827E-05,0.996006088,,,CCNC(NCC)=NCCCC[C@@H](NC(=O)[C@@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](CO)NC(=O)[C@H](CC2=CN=CC=C2)NC(=O)[C@H](CC3=CC=C(Cl)C=C3)NC(=O)C(CC4=CC5=CC=CC=C5C=C4)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N6CCCC6C(=O)N[C@H](C)C(N)=O,DC Chemicals,DC8877,0,3.6670787,-0.84935181,-0.45045045,-12.20338983,-39.5,-73.84013415,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167503-02,Aclarubicin,174007366,DNA Topoisomerase II Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),57576-44-0,; Aclacin;Aclarubicin; Aclaplastin; Aclacinon; Aclarubicino;Aclacinomycin A,15.00297213,0,-4.823822698,-91.63063876,-2.1,7,,-103.117943,-93.96310788,0.003071485,0.976485945,7153,TOP2A,CC[C@@]1(O)C[C@H](O[C@H]2C[C@@H]([C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC(=O)[C@H](C)O4)[C@H](C)O3)[C@H](C)O2)N(C)C)C5=C(O)C6=C(C=C5[C@H]1C(=O)OC)C(=O)C7=CC=CC(=C7C6=O)O,Carbosynth,OA08264,-2.64282938,-4.16151628,0,-11.71171171,-22.17917676,-42.6,-93.96310788,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00185000-22,Afatinib (BIBW2992),,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),439081-18-2,,7.519298098,1,-5.123822698,-27.05220136,-2.2,7,,-41.42453885,-39.40749022,0.000126824,0.995369466,,,CN(C)C\C=C\C(=O)NC1=CC2=C(NC3=CC(Cl)=C(F)C=C3)N=CN=C2C=C1O[C@H]4CCOC4,APExBIO,A8247,2.64282938,3.91429749,0,1.8018018,-0.968523,-27.2,-39.40749022,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00024025-05,Dehydrocholic acid,170465502,bile acid secretion Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),81-23-2,,6.701581484,1,-5.173822698,-30.17565346,-1.2,7,,-30.12750886,-30.10625738,2.00E-09,0.999981666,1045,,O=C(O)CC[C@@H](C)[C@H]4CC[C@@H]3[C@]4(C)C(=O)C[C@H]2[C@H]3C(=O)C[C@@H]1CC(=O)CC[C@@]12C,Prestwick,Prestw-123,0,0,0,0,0,-28.125,-30.10625738,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00164140-07,Dioctyl sulfosuccinate sodium salt,225144252,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),577-11-7,,11.91728437,0,-4.923822698,-42.18612505,-2.4,7,,-33.71133412,-36.48170012,0.084130664,0.851318543,,,CCCCC(CC)COC(=O)CC(C(=O)OCC(CC)CCCC)[S]([O-])(=O)=O,SIGMA,323586,-13.21321321,0,-7.3992674,2.3352794,0,-19.79166667,-36.48170012,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016278-10,Mefenamic acid,170464813,Cyclooxygenase-2 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),61-68-7,,18.88762287,0,-4.723822698,-25.1030964,-2.2,7,,-69.27272727,-57.02479339,8.58777E-05,0.996193986,,,O=C(O)c2ccccc2Nc1cccc(C)c1C,Vitas,STK666691,2.28228228,0,4.32234432,3.58632193,0,-18.27651515,-57.02479339,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00018238-09,Oxibendazole,170465661,DNA Polymerase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),20559-55-1,OXIBENDAZOLE;Oxibendazole; Loditac; Oxibendazolo;,37.68576212,0,-4.423822698,-13.77116293,-3,7,,-50.20306966,-44.0377804,0.003441422,0.975062813,,POLB,O=C(OC)Nc1nc2cc(ccc2n1)OCCC,Microsource,1503373,-4.2042042,1.57273919,0,4.83736447,0,1.42045455,-44.0377804,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00249915-01,Bupranolol,170465802,Beta-3 adrenergic receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),14556-46-8,,8.436791229,1,-5.073822698,-7.037837505,-2.4,7,,-36.20454546,0,0.033224252,0.95066214,,,Clc1ccc(C)cc1OCC(O)CNC(C)(C)C,GVK,FFS-11-286-NCI-172,-1.32132132,-2.35910878,0,4.25354462,3.97470641,-28.50378788,0,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00065934-05,Oxcarbazepine,170464811,Sodium channel inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),28721-07-5,; Oxcarbazepina; Oxcarbazepine;Oxcarbazepine;OXCARBAZEPINE; Timox; Trileptal; Oxacarbazepine,18.88762287,0,-4.723822698,-13.108253,-2.4,7,,-26.89374262,-24.91145218,0.025314235,0.927131929,,,NC(=O)N3c1ccccc1C(=O)Cc2ccccc23,Vitas,STK594696,0,-4.32503277,0,4.75396163,0,-6.72348485,-24.91145218,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00159331-07,CHOLECALCIFEROL,405558699,Vitamin D receptor Binding Agent,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),67-97-0,,15.00297213,0,-4.823822698,-48.38528727,-2.2,7,,-82.46103896,-74.97048406,1.04134E-05,0.998679953,,,CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C/3C[C@@H](O)CCC3=C,SIGMA,C9756,0,0,0,0,0,-31.72348485,-74.97048406,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00163128-08,Pioglitazone hydrochloride,170465116,PPARgamma Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),112529-15-4,Pioglitazona; Pioglitazone HCl;AA-10090;Pioglitazone HCl;PIOGLITAZONE HYDROCHLORIDE; ;Zactos;Actos;U-72107A;Glustin,23.7781084,0,-4.623822698,-28.93438335,-3,7,,-59.51298701,-55.84415584,0.00172013,0.982581095,5468,PPARG,Cl.CCc1ccc(nc1)CCOc3ccc(CC2SC(=O)NC2=O)cc3,Microsource,1504401,0,-6.94626474,0,0,1.35501355,-7.85984848,-55.84415584,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00183097-01,Beraprost sodium,144206467,Thyroid hormone receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),88475-69-8,Beraprost sodium; Procylin; ,4.74435636,1,-5.323822698,-38.73149269,-2.2,7,"TRK-100;1H-Cyclopenta(b)benzofuran-5-butanoic acid, 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-, monosodium salt;beraprost;4-(1,2,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyloct-6-yne-1-enyl)-5-cyclopenta(b)benzofuranyl)butyrate;BERAPROST;CIPLUS_685106;beraprost sodium;Procylin;Beraprost sodium;TRK 100;Beraprost Sodium;CIPLUS_193198;Beraprostum;1H-Cyclopenta(b)benzofuran-5-butanoic acid, 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-;Beraprost;trk-100;BERAPROST SODIUM;ML-1129;2,3,3A,8B-TETRAHYDRO-2-HYDROXY-1((E)-(3S)-3-HYDROXY-4-METHYL-1-OCTEN-6-YNYL)-1H-CYCLOPENTA(B)BENZOFURAN-5-BUTYRIC ACID SODIUM SALT;LS-57735;beraprostum;LS-57736;",-36.78675237,-35.94186696,0.008891846,0.958865652,19222,,[Na+].CC(CC#CC)[C@H](O)/C=C/[C@H]2[C@H](O)C[C@@H]3Oc1c(cccc1CCCC([O-])=O)[C@H]23,ACC,BERAPROST SODIUM,1.24368441,-4.57354759,0,3.6036036,-12.00968523,-26.1,-35.94186696,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00181767-03,Tolcapone,170465081,catechol-O-methyltransferase (COMT),Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),134308-13-7, ; Roche brand of tolcapone; Tasmar;TOLCAPONE; Tolcapone;Tolcapone,9.466235454,1,-5.023822698,-50.88452083,-2.2,7,,-62.81134712,-62.32532141,0.000648312,0.989424044,1312,COMT,Oc1cc(cc([N+]([O-])=O)c1O)C(=O)c2ccc(C)cc2,Sequoia,134308-13-7,0,0,0,-4.5045045,3.87409201,-41,-62.32532141,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00179306-04,Zuclopenthixol (-)-10-Camphorsulfonic Acid Salt,405558792,Serotonin 2 (5-HT2) receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),53772-83-1,,37.68576212,0,-4.423822698,-29.5473931,-3,7,,-78.99161543,-71.04527669,0.00064262,0.989471288,,,OCCN1CCN(CC\C=C2\C3=C(SC4=C2C=C(Cl)C=C4)C=CC=C3)CC1,Toronto Research,Z701495,0,0,0,0.45045045,-7.16707022,0,-71.04527669,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167514-02,Ethylestrenol,170465211,Androgen Receptor Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),965-90-2,,4.228412057,1,-5.373822698,-37.76454281,-2.4,7,,-39.64225824,-33.0352152,0.058974993,0.880671398,,,C[C@]32CC[C@@H]1[C@H]4CCCC=C4CC[C@H]1[C@@H]3CC[C@@]2(O)CC,Sequoia,965-90-2,-1.39914497,4.57354759,0.17881091,-4.59459459,-20.14527845,-15.7,-33.0352152,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167301-02,Triptorelin,405558815,Gonadotropin-releasing hormone receptor Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),57773-63-4,,13.02990675,0,-4.885058692,-34.36029072,-2.2,7,,-56.64980437,-42.53773058,0.001448468,0.984057987,,,CC(C)C[C@H](NC(=O)[C@@H](CC1=C[NH]C2=C1C=CC=C2)NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=C[NH]C5=C4C=CC=C5)NC(=O)[C@H](CC6=CN=C[NH]6)NC(=O)[C@@H]7CCC(=O)N7)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N8CCC[C@H]8C(=O)NCC(N)=O,Enzo,DL310,0,0,3.84443451,0.9009009,-4.93946731,-12.9,-42.53773058,,,,,,,,,1.83E-09,9.14E-09,4.57E-08,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,
NCGC00179363-03,Ursodiol,225144303,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),128-13-2,; Urosiol; Ursodexycholic Acid; Antigall; Chenique Acid; Acido chenodeoxicholico;Urosiol; Sodium chenodeoxycholate; Litursol; Acido ursodeoxicolico; Urso;Ursodiol (Actigal Urso); UDCA-menthol; Ursodeoxy cholic acid; Chenodesoxycholic acid;URSODIOL; Ursometh; Acide chenodeoxycholique,9.466235454,1,-5.023822698,-17.54714209,-2.4,7,,-23.03186138,-22.52655115,0.013618543,0.948289834,,NR14H,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,Prestwick,Prestw-958,4.27516518,-2.51339102,-1.65400089,0,-1.2590799,-14,-22.52655115,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00166147-02,Dihydrotachysterol,144205894,Vitamin D receptor Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),67-96-9,"Dihydrotachysterol; Dihydrotachysterin; Dihidrotaquisterol; Calcamine; Tachysterol, dihydro-; Tachystin; Hytakerol; ",23.7781084,0,-4.623822698,-37.09797539,-2.2,7,"parterol;LS-148512;Tachystin;CIPLUS_149136;Dihydrotachysterin;AT 10;Calcamine;dihydrotachysterol;dihydrotachysterolum;Hytakerol;NCGC00166147-01;Tachysterol, dihydro-;DIHYDROTACHYSTEROL;Dihydrotachysterol;AT-10;Dihydrotachysterolum;Dihidrotaquisterol;9,10-Secoergosta-5,7,22-trien-3-ol, (3beta,5E,7E,10alpha,22E)-;VITAMIN D1;9,10-Secoergosta-5,7,22-trien-3beta-ol;NCGC_SIGMA_D9257;",-90.27836781,-76.41140302,6.95E-07,0.999659525,,,C[C@H]3CC[C@H](O)C/C3=C\C=C1/CCC[C@]2(C)[C@H](CC[C@@H]12)[C@H](C)/C=C/[C@H](C)C(C)C,SIGMA,D9257,0,0,0,1.26126126,0.0968523,-16.2,-76.41140302,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00160603-02,4-Styrylpyridine,144205483,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),103-31-1,"4-styrylpyridine; 4-stilbazole, (E)-isomer; 4-stilbazole, (Z)-isomer; ",39.81071706,0,-4.4,-7.333190586,-2.4,7,"CIPLUS_714835;4-stilbazole, (E)-isomer;STYRYLPYRIDINIUM CHLORIDE;CIPLUS_679001;4-STYRYLPYRIDINIUM CHLORIDE;4-stilbazole;4-styrylpyridine;4-stilbazole, (Z)-isomer;4-stilbazole monohydrochloride, (E)-isomer;4-stilbazole monohydrochloride;",-22.32448295,-21.52040246,0.000339149,0.992404863,,,C(=Cc1ccncc1)c2ccccc2,Maybridge,JFD 00085,0,0,0,0,1.937046,-1.7,-21.52040246,,,,,,,,,7.31E-09,3.66E-08,1.83E-07,9.14E-07,0.00000457,2.29E-05,0.000114,,,,,,,,
NCGC00159492-03,Perazine,29215457,Cytochrome P450 1A2 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,"Perazine; Perazine Maleate (1:1); Perazine Maleate (1:2); Maleate, Perazin; Taxilan; Dihydrochloride, Perazin; Perazine Dihydrochloride; Perazine Fendizoate; ",35.48133892,0,-4.45,-44.72244659,-2.2,7,"CIPLUS_744600;Perazine Fendizoate;LS-172810;CIPLUS_776815;PERAZINE DIMALONATE;Maleate, Perazin;10H-Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-;Perazine Dihydrochloride;Dihydrochloride, Perazin;CIPLUS_666528;10-(3-(4-Methyl-1-piperazinyl)propyl)phenothiazine dihydrochloride;Perazine Dimalonate;CIPLUS_660985;Perazine Maleate (1:1);Perazine Maleate;10h-phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-, (z)-2-butenedioate;CIPLUS_777988;PERAZINE MALEATE;LS-105591;LS-105593;pernazine;LS-173237;Perazine maleate;Pernazine;Perazine Maleate (1:2);Perazine;LS-105589;Perazine dimalonate;CIPLUS_149789;Cinchonan-9-ol, 6'-methoxy-, (9S)-, sulfate (2:1) (salt), mixt. with 5,5-diphenyl-2,4-imidazolidinedione and 10-(3-(4-methyl-1-piperazinyl)propyl)-10H-phenothiazine (Z)-2-butenedioate (1:2);Taxilan;CIPLUS_769544;phenrytmat;",-86.10620458,-65.23197317,5.29175E-05,0.997016192,,,CN1CCN(CCCN2C3=CC=CC=C3SC4=CC=CC=C24)CC1,AKos,AKJ-93711,0,4.07911001,0.71524363,1.71171171,-6.77966102,-31.2,-65.23197317,,,,,,,,,7.31E-09,3.66E-08,1.83E-07,9.14E-07,0.00000457,2.29E-05,0.000114,,,,,,,,
NCGC00181129-14,Dasatinib,405558859,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),302962-49-8,,11.91728437,0,-4.923822698,-42.03530516,-2.2,7,,-51.3529905,-51.81665735,0.001770268,0.982322028,,ABL1,CC1=NC(=CC(=N1)NC2=NC=C(S2)C(=O)NC3=C(Cl)C=CC=C3C)N4CCN(CCO)CC4,Adooq,A10290,0,-7.04573548,0,0,-0.5811138,-26.6,-51.81665735,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00015199-20,Chlorambucil,170464770,DNA Alkylating Agent,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),305-03-3,; ;CHLORAMBUCIL; Chlorambucil;Chlorambucil; Leukeran; Clorambucilo,26.67947643,0,-4.573822698,-6.724282574,-2.4,7,,-31.69362456,-23.49468713,0.002070933,0.980861463,,H2AFX,O=C(O)CCCc1ccc(cc1)N(CCCl)CCCl,Microsource,1500171,0,2.62123198,3.51648352,0,0.45167118,-4.45075758,-23.49468713,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00024595-08,Carbetapentane,170465562,Sigma-1 receptor Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),77-23-6,,11.91728437,0,-4.923822698,-19.63475925,-2.2,7,,-35.02774499,-32.93978749,0.000617229,0.989692203,,,CCN(CC)CCOCCOC(=O)C1(CCCC1)c2ccccc2,Enzo,NO103,0,0,0,3.75312761,0.63233966,-16.00378788,-32.93978749,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167471-02,Anethole trithione,170465669,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),532-11-6,,2.667947643,1,-5.573822698,-139.3271898,-1.1,7,,-92.74096812,-99.52774498,0.000869232,0.987717645,,,COc1ccc(cc1)C2=CC(=S)SS2,Prestwick,Prestw-1223,-0.48048048,0,-12.96703297,-7.75646372,-34.41734417,-93.84469697,-99.52774498,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00095227-06,Alizarin,170465641,Calcium Binding Agent,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),72-48-0,,6.701581484,1,-5.173822698,-85.22002749,-2.1,7,,-99.02786305,-94.5690673,0.000051576,0.997053999,,,O=C3c1ccccc1C(=O)c2c3ccc(O)c2O,Vitas,STK801841,0,-0.2621232,3.15018315,4.75396163,-13.64046974,-68.65530303,-94.5690673,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00249897-01,Nitromersol,170465514,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),133-58-4,,26.67947643,0,-4.573822698,-18.04815148,-3,7,,-35.67768595,-32.23140496,0.003867828,0.973512443,,,Cc1ccc(c2[Hg]Oc12)[N+]([O-])=O,GVK,FFS-11-286-NCI-74,0,-5.24246396,0,0,0,-4.45075758,-32.23140496,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00182996-01,Pamicogrel,144206832,platelet aggregation Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),101001-34-7,KBT-3022; ,13.37141299,0,-4.873822698,-55.77331491,-2.1,7,"KB-3022;KB 3022;pamicogrel;1H-Pyrrole-1-acetic acid, 2-(4,5-bis(4-methoxyphenyl)-2-thiazolyl)-, ethyl ester;LS-136537;CIPLUS_207912;PAMICOGREL;Pamicogrel;ETHYL 2-(4,5-BIS(P-METHOXYPHENYL)-2-THIAZOLYL)PYRROLE-1-ACETATE;pamicogrelum;ethyl 2-(4,5-bis(4-methoxyphenyl)thiazol-2-yl)pyrrol-1-ylacetate;KBT-3022;",-99.79929162,-90.55489965,6.93275E-05,0.996581857,,,O=C(OCC)Cn1cccc1c2nc(c(s2)c3ccc(OC)cc3)c4ccc(OC)cc4,Pharmaron,PH-NIH-151650,0,4.32503277,0,0.83402836,1.53568202,-41.19318182,-90.55489965,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00385183-01,NCGC00385183-01,405559009,Potassium-transporting ATPase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,0.732725503,1,-6.135058692,-189.0272703,-1.1,7,,-81.71565682,-81.55394075,0.002518708,0.978785466,,,OC[C@H]1O[C@@H](OC2=CC=CC3=C2C(=O)C4=C(C=C(C=C4O)C(O)=O)[C@@H]3[C@@H]5C6=C(C(=O)C7=C5C=C(C=C7O)C(O)=O)C(=CC=C6)O[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O)[C@H](O)[C@@H](O)[C@@H]1O,Analyticon,NP-010759,-5.44111932,-11.33086115,-8.18059902,-20.54054054,-59.95157385,-96.5,-81.55394075,,,,,,,,,1.83E-09,9.14E-09,4.57E-08,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,
NCGC00090708-11,OXYQUINOLINE HEMISULFATE,405558695,Trichophyton interdigitale Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),134-31-6,,4.228412057,1,-5.373822698,-47.42658682,-2.4,7,,-50.72861934,-49.35718278,0.234574299,0.992767329,,,OC1=CC=CC2=CC=CN=C12,Microsource,1500456,-0.69957248,0,-0.13410818,2.7027027,-13.46246973,-88.9,-49.35718278,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00507845-01,Netarsudil,384569326,ROCK Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1253952-02-1,,4.623185376,1,-5.335058692,-80.57313271,-2.2,7,,-75.22889883,-71.04527669,9.3401E-06,0.998749985,,ROCK1,CC1=CC(=C(C=C1)C(=O)OCC2=CC=C(C=C2)[C@@H](CN)C(=O)NC3=CC4=C(C=C3)C=NC=C4)C,Selleck,S8226,-2.254178,0,0,0,-8.03874092,-45,-71.04527669,,,,,,,,,1.83E-09,9.14E-09,4.57E-08,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,
NCGC00181016-04,Bexarotene,170465308,Retinoid RXR Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),153559-49-0, ; LG69 compound; Bexarotene;Bexarotene;Targretin; Elan brand of bexarotene; Bexarotene (Targretin); 3-methyl-TTNEB,8.436791229,1,-5.073822698,-76.64590302,-2.2,7,,-79.16769145,-79.09446618,0.000623792,0.989628688,6256,RXRA,O=C(O)c1ccc(cc1)C(=C)c2cc3c(cc2C)C(C)(C)CCC3(C)C,CiVentiChem,CV-1209,-3.18694131,-6.46889164,4.1573536,-3.33333333,-9.10411622,-51.2,-79.09446618,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00485883-01,Forodesine (hydrochloride),363681392,Purine nucleoside phosphorylase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),284490-13-7,,26.67947643,0,-4.573822698,-20.22955781,-3,7,,-64.88932365,-49.91615428,0.000205919,0.994086538,,,OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)C2=C[NH]C3=C2\N=C/NC3=O,MedChem Express,HY-16209,0,0,1.69870362,4.23423423,0,-9.9,-49.91615428,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00017366-08,Pergolide methanesulfonate,170465250,Dopamine D3 receptor Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),66104-23-2,,6.701581484,1,-5.173822698,-32.24682236,-2.4,7,,-37.59386069,-26.32821724,0.003656535,0.974285816,,,CS(=O)(=O)O.CSC[C@@H]1C[C@@H]2c3cccc4ncc(C[C@H]2N(C1)CCC)c34,Enzo,AC755,1.44144144,-0.5242464,1.24542125,-6.08840701,-12.91779584,-16.5719697,-26.32821724,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00159508-04,Rose Bengal disodium,225144230,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),632-69-9,"; Bengal Rose B sodium salt; Rose Bengal Sodium I 125; ; Rose Bengal sodium salt; Rose bengal sodium;Rose bengal; Rose bengal;Rose Bengal; Bengal, Ros;Rose Bengal disodium; Acid Red- 94",2.37781084,1,-5.623822698,-140.2200305,-1.1,7,,-96.66765053,-99.76387249,6.75367E-05,0.996626374,,,[O-]C(=O)C1=C(C(=C(Cl)C(=C1Cl)Cl)Cl)C/2=C/3\C=C(I)/C(=O)/C(=C3OC4=C2C=C(I)C(=C4I)[O-])I,SIGMA,R3877,-6.72672673,0,0,0.08340284,-46.34146341,-95.73863636,-99.76387249,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00181034-03,Liarozole,170465610,Cytochrome P450 CYP17A1 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),145858-50-0,,9.466235454,1,-5.023822698,-33.39806099,-2.2,7,,-49.16469893,-43.56552538,0.000609952,0.989749958,,CYP17A1,Cl.Clc1cc(ccc1)C(c2ccc3ncnc3c2)n4ccnc4,Tocris,2705,0,1.17955439,0.29304029,4.42035029,-6.23306233,-25.66287879,-43.56552538,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00042523-03,N-Oxydiethylenebenzothiazole-2-sulfenamide,170465568,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),102-77-2,,10.62129087,0,-4.973822698,-27.83843038,-2.4,7,,-28.34415584,-29.87012987,0.035404212,0.911736799,,,c1cccc2sc(nc12)SN3CCOCC3,Labotest,LT00078541,0,-9.04325033,0,0,0.72267389,-16.5719697,-29.87012987,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016032-11,alpha-Lipoic acid,170465713,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1077-28-7,,26.67947643,0,-4.573822698,-5.135972916,-2.4,7,,-22.07674144,-20.89728453,0.024015755,0.929303335,,,O=C(O)CCCCC1CCSS1,Vitas,STK801969,4.44444444,-3.14547837,0,0,0.45167118,0,-20.89728453,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00159387-03,Laureth 10s,170465561,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),13081-34-0,,29.9348649,0,-4.523822698,-9.013856973,-2.4,7,,-30.29397875,-27.74498229,0.009633325,0.957091633,,,OCCOCCSCCCCCCCCCCCC,Labotest,LT00000347,-2.88288288,0,0,4.75396163,0,0,-27.74498229,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016329-07,Phenindione,170465130,Vitamin k epoxide reductase complex subunit 1 isoform 1 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1983/12/5,,21.19226141,0,-4.673822698,-5.781461853,-2.4,7,,-26.74380165,-25.61983471,0.000751203,0.988616293,,,O=C2c1ccccc1C(=O)C2c3ccccc3,Specs,AN-153/I102301,0,2.75229358,0,0,1.89701897,-0.09469697,-25.61983471,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00390657-02,Lesinurad (sodium),405558615,Solute carrier family 22 member 12 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1151516-14-1,,11.91728437,0,-4.923822698,-8.960765383,-2.4,7,,-26.22694242,-21.85578535,0.007068882,0.96364011,,,[Na]OC(=O)CSC1=NN=C(Br)[N]1C2=C3C=CC=CC3=C(C=C2)C4CC4,MedChem Express,HY-15258A,0.38865138,4.90317264,0,3.87387387,-0.7748184,-10.4,-21.85578535,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00183095-01,Tigecycline,124894296,glycylcycline antibiotics,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),220620-09-7,Tigecycline; ; Tigecycline; Tygacil,29.9348649,0,-4.523822698,-53.40559635,-2.2,7,"Tigecycline;tigecycline;TIGECYCLINE;TetX protein, Bacillus fragilis;tigecycline 11a-hydroxylase, Bacillus fragilis;GAR-936;CL-346635;4,6-BIS(DIMETHYLAMINO)-9-((((DIMETHYLETHYL)AMINO)ACETYL)AMINO)-1,4,4A,5,5A,6,11,12A-OCTAHYDRO-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-2-NAPHTHACENECARBOXAMIDE;2-NAPHTHACENECARBOXAMIDE, 4,7-BIS(DIMETHYLAMINO)-9-((((1,1-DIMETHYLETHYL)AMINO)ACETYL)AMINO)-1,4,4A,5,5A,6,11,12A-OCTAHYDRO-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-, (4S,4AS,5AR,12AS)-;TBG-MINO;CIPLUS_736709;GAR 936;WAY-156936;9-(tert-butylglycylamido)minocycline;Tygacil;",-100.6095584,-78.87087759,0.010344702,0.955363045,,,CC(C)(C)NCC(=O)Nc1cc(N(C)C)c2C[C@H]3C[C@H]4[C@@H](C(O)=C(C(=O)[C@@]4(O)C(O)=C3C(=O)c2c1O)C(N)=O)N(C)C,ACC,API-03922,4.11970462,0,0,-8.91891892,-15.10895884,-18.3,-78.87087759,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00162116-04,Cephapirin sodium,170465306,Bacterial penicillin-binding protein Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),24356-60-3,,5.972790784,1,-5.223822698,-3.818767959,-2.4,7,,-23.20454546,0,0.021715168,0.963612489,,,[Na+].[O-]C(=O)C=2N3C(=O)[C@@H](NC(=O)CSc1ccncc1)[C@H]3SCC=2COC(C)=O,Microsource,1500167,0,4.32503277,0,0,0.27100271,-20.17045455,0,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00249903-01,Dexamethasone isonicotinate,170466851,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),2265-64-7,,6.701581484,1,-5.173822698,-35.32997954,-1.2,7,,-40.62691853,-40.02361275,0.000423727,0.991480665,,,O=C1C=C2CC[C@@H]5[C@@](F)([C@@]2(C)C=C1)[C@@H](O)C[C@@]4(C)[C@H]5C[C@@H](C)[C@]4(O)C(=O)COC(=O)c3ccncc3,GVK,FFS-11-286-NCI-109,-0.12012012,4.84927916,0,0,0.09033424,-35.3219697,-40.02361275,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167440-02,Bosentan,170465245,"Endothelin receptor, ET-A/ET-B Antagonist",Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),147536-97-8,,2.37781084,1,-5.623822698,-91.33787249,-1.2,7,,-54.21590909,-57.02479339,0.002025737,0.981046901,,,CC(C)(C)c1ccc(cc1)S(=O)(=O)Nc3nc(nc(OCCO)c3Oc2ccccc2OC)c4ncccn4,Prestwick,Prestw-1244,-9.96996997,0,-4.61538462,0,-25.56458898,-58.99621212,-57.02479339,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00090965-07,Propyl-4-hydroxybenzoate,405559148,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),94-13-3,,9.466235454,1,-5.023822698,-29.78804378,-2.4,7,,-27.49409681,-29.16174734,0.018796918,0.938246733,,,CCCOC(=O)C1=CC=C(O)C=C1,SigmaAldrich,P53357,-4.32432432,-5.76671035,0,0,2.98102981,-19.60227273,-29.16174734,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00168746-02,Methyldigoxin,99455400,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,12.58925412,0,-4.9,-28.75098117,-3,7,,-45.472,-18.5019564,0.084271477,0.901286681,,,CO[C@H]1[C@@H](O)CC(O[C@@H]1C)OC2[C@@H](O)CC(O[C@@H]2C)OC3[C@@H](O)C[C@@H](O[C@@H]3C)OC4CC[C@@]5(C)C(CCC6C5CC(O)[C@]7(C)[C@@H](CCC67O)C/8=C/C(=O)OC8)C4,Chemdiv,N001-0009,2.02098717,-6.38648537,-0.04470273,-10.72072072,-8.91041162,-37.1,-18.5019564,,,,,,,,,7.31E-09,3.66E-08,1.83E-07,9.14E-07,0.00000457,2.29E-05,0.000114,,,,,,,,
NCGC00163127-04,Acitretin,225144249,retinoid,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),55079-83-9,Acitretin; ; Acitretin; ACITRETIN; Soriatane,8.436791229,1,-5.073822698,-95.32047622,-2.1,7,,-106.2249115,-98.81936246,0.000627461,0.989597062,,RXRA,COC1=C(C)C(=C(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)C(=C1)C)C,Prestwick,Prestw-1165,-5.88588589,0,-1.53846154,4.42035029,-20.14453478,-62.02651515,-98.81936246,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00095125-05,Losartan,170465135,Angiotensin II receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),114798-26-4,,11.91728437,0,-4.923822698,-24.18340131,-2.2,7,,-44.49173554,-42.14876033,0.000141318,0.995110059,,,OCc4c(Cl)nc(CCCC)n4Cc1ccc(cc1)c2ccccc2c3nnnn3,Microsource,1504268,3.24324324,2.22804718,0,0,0,-19.98106061,-42.14876033,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00094937-04,Carprofen,170464799,Cyclooxygenase-2 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),53716-49-7,,4.228412057,1,-5.373822698,-26.06639095,-1.4,7,,-22.70454546,-19.00826446,0.020775247,0.934730395,,,O=C(O)C(C)c1ccc2c3cc(Cl)ccc3nc2c1,Microsource,1502006,0,-3.80078637,0,2.41868224,0,-26.42045455,-19.00826446,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00532510-01,PREDNISOLONE VALERATE ACETATE,405558610,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,29.9348649,0,-4.523822698,-18.18290379,-3,7,,-40.5570151,-35.04751258,0.000844868,0.987905647,,,CCCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CC\C4=C\C(=O)\C=C/[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)COC(C)=O,Biosynth,Q-101384,-0.3109211,0,0,0,-3.97094431,-4.1,-35.04751258,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00159502-03,N-Cyclohexyl-2-benzothiazolesulfenamide,29215472,Aryl hydrocarbon receptor Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,N-cyclohexyl-2-benzothiazylsulfenamide; ,70.79457844,0,-4.15,-18.1417454,-3,7,N-Cyclohexyl-2-benzothiazolesulfenamide;N-CYCLOHEXYLBENZOTHIAZYLSULFENAMIDE;N-cyclohexyl-2-benzothiazylsulfenamide;CIPLUS_150281;N-cyclohexyl-2-benzothiazyl sulfenamide;N-cyclohexyl-2-benzothiazolesulfenamide;thiohexam;,-38.04164338,-36.61263276,0.011862634,0.951973892,,,C1CCC(CC1)NSC2=NC3=CC=CC=C3S2,SigmaAldrich,S365971,0,0,0,-1.44144144,-7.65133172,1.4,-36.61263276,,,,,,,,,7.31E-09,3.66E-08,1.83E-07,9.14E-07,0.00000457,2.29E-05,0.000114,,,,,,,,
NCGC00522040-01,Carpipramine Dihydrochloride,405558850,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),7075/3/8,,37.68576212,0,-4.423822698,-24.56479978,-3,7,,-48.29681386,-44.99720514,0.028400432,0.922144815,,,NC(=O)C1(CCN(CCCN2C3=CC=CC=C3CCC4=C2C=CC=C4)CC1)N5CCCCC5,Toronto Research,C184320,0,0,0,-12.61261261,0,0,-44.99720514,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00480770-01,MK-3102,405558938,Dipeptidyl peptidase IV Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1226781-44-7,,23.7781084,0,-4.623822698,-56.89555235,-2.1,7,,-103.9793181,-82.56008944,0.000718617,0.988854187,,,C[S+]([O-])(=O)[N]1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(=C4)F,Adooq,A13310,1.86552662,-6.13926658,2.5033527,-2.97297297,-8.32929782,-27.6,-82.56008944,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00183104-02,Nizofenone,170466022,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),54533-86-7,,29.9348649,0,-4.523822698,-20.64180642,-3,7,,-46.05785354,-35.27110117,0.003981189,0.973103727,,,Clc1ccccc1C(=O)c2cc(ccc2n3ccnc3CN(CC)CC)[N+]([O-])=O,APAC,556416,0,1.52451586,0,0,-5.81113801,-7.6,-35.27110117,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00522503-01,Velpatasvir,405558874,Nonstructural protein 5A Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1377049-84-7,,5.32325539,1,-5.273822698,-106.9548625,-2.1,7,,-105.4721073,-96.19899385,1.90939E-05,0.998210951,,,COC[C@H]1C[C@H](N(C1)C(=O)[C@H](NC(=O)OC)C2=CC=CC=C2)C3=NC=C([NH]3)C4=CC=C5C(=C4)COC6=CC7=C(C=CC8=C7[NH]C(=N8)[C@@H]9CC[C@H](C)N9C(=O)[C@@H](NC(=O)OC)C(C)C)C=C56,MedChem Express,HY-12530,-0.07773028,0,2.36924452,-3.24324324,-28.66828087,-75.3,-96.19899385,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00165810-02,Indoramin hydrochloride,170466233,Alpha-1d adrenergic receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),38821-52-2,,37.68576212,0,-4.423822698,-1.609338032,-2.4,7,,-31.24380165,-25.61983471,0.006175944,0.966139429,,,Cl.O=C(NC3CCN(CCc1cnc2ccccc12)CC3)c4ccccc4,SigmaAldrich,I2909,0,4.98034076,0,2.41868224,0,3.125,-25.61983471,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00015747-09,Nicardipine,170465173,Ca channel blocker - DHP class,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),55985-32-5, ;Nicardipine hydrochloride; YC-93 hydrochloride; Dagan;Nicardipine?HCl;Nicardipine; Nicardipine; Cardene/SR; Nicardipino,9.466235454,1,-5.023822698,-62.92501877,-2.1,7,,-84.08854781,-80.63754427,6.50061E-05,0.996690766,,,CC=2NC(C)=C(C(C=2C(=O)OCCN(C)Cc1ccccc1)c3cccc(c3)[N+]([O-])=O)C(=O)OC,Enzo,AC108,0,0,0,4.83736447,-3.88437218,-50.66287879,-80.63754427,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00348371-01,Chloramphenicol palmitate,405558999,Antibiotic,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),530-43-8,,18.88762287,0,-4.723822698,-41.91171609,-2.1,7,,-94.72680048,-86.30460449,9.60E-07,0.999599747,,,CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O,FLUKA,46109,0,1.83486239,1.31868132,1.75145955,0,-21.68560606,-86.30460449,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00024928-23,Tamoxifen,170465425,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),54965-24-1,"Soltamox; ""Tamoxifen; ; Novaldex; Tamoxifen; Tomaxithen; Tamoxifen citrate salt; Tamoxifen, citrate salt; Nolvadex; Tamoxifeno;ICI-46474;ICI-46474?;Tamoxifen citrate;Tamoxifen; Zitazonium; Citrate, Tamoxife",9.466235454,1,-5.023822698,-87.82289402,-2.1,7,,-95.09020071,-95.74970484,0.003054197,0.97655392,2099,ESR1,O=C(O)C(O)(CC(=O)O)CC(=O)O.CN(C)CCOc1ccc(cc1)/C(c2ccccc2)=C(/CC)c3ccccc3,Microsource,1500557,-14.53453453,0.65530799,3.44322344,0,0.09033424,-62.97348485,-95.74970484,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016957-05,Aceclofenac,170465979,Cyclooxygenase-2 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),89796-99-6,,26.67947643,0,-4.573822698,-43.08388345,-3,7,,-36.1038961,-33.4120425,0.268320013,0.660057379,,,Clc2cccc(Cl)c2Nc1ccccc1CC(=O)OCC(=O)O,Vitas,STK594349,-19.93993994,-8.38794233,0.07326007,0,-0.81300813,-9.75378788,-33.4120425,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00378990-02,Ledipasvir (GS 5885),405559115,Nonstructural protein 5A Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1256388-51-8,,4.120418304,1,-5.385058692,-107.7127267,-1.1,7,,-94.2117943,-93.40413639,0.000151233,0.994937578,,,COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1C3=NC=C([NH]3)C4=CC5=C(C=C4)C6=C(C=C(C=C6)C7=CC=C8N=C([NH]C8=C7)[C@@H]9[C@H]%10CC[C@H](C%10)N9C(=O)[C@@H](NC(=O)OC)C(C)C)C5(F)F,Adooq,A13155,-5.59657987,3.74948496,0,0,0,-73.7,-93.40413639,,,,,,,,,1.83E-09,9.14E-09,4.57E-08,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,
NCGC00183107-01,NCGC00183107-01,124894307,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,Carbetocin; Depotocin; Carbetocino; ,18.88762287,0,-4.723822698,-28.26958987,-2.2,7,"carbetocin;1-BUTYRIC ACID-2-(3-(4-METHOXYPHENYL)-ALANINE)OXYTOCIN;oxytocin, 1-desamino-1-monocarba-(Tyr(OMe))(2)-;1-Carbaoxytocin, 1-butanoic acid-2-(O-methyl-L-tyrosine)-;Carbetocino;Depotocin;dcomot;oxytocin, 1-desamino-1-monocarba-(tyrosine(O-methyl))(2)-;LS-174644;carbetocinum;Carbetocinum;1-deamino-1-monocarba-2-(Tyr(OMe))-oxytocin;CIPLUS_213985;carbetocine;Carbetocin;CARBETOCIN;",-31.69088877,-30.57574064,0.022216239,0.932252194,,,CC[C@H](C)[C@@H]1NC(=O)[C@H](CC2=CC=C(O)C=C2)N(C)C(=O)CCCSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O,APAC,877872,0,-8.36423568,0,-3.06306306,-2.32445521,-11.4,-30.57574064,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00484900-01,Estramustine PhosphateNa,405558512,Dna Alkylating Agent,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),52205-73-9,,6.701581484,1,-5.173822698,-64.77142357,-2.2,7,,-69.55897149,-67.13247624,9.5939E-06,0.998733093,,H2AFX,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=CC=C34)OC(=O)N(CCCl)CCCl)[C@@H]1CC[C@@H]2O[P](O)(O)=O,Enzo,AC1524,1.78779635,0,0,-2.7027027,-11.04116223,-47.7,-67.13247624,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00166301-04,SODIUM TETRADECYL SULFATE,405558515,Vitamin K-dependent protein S Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),139-88-8,,9.466235454,1,-5.023822698,-30.8708882,-2.2,7,,-40.90525433,-40.19005031,7.14519E-05,0.996531149,5627,PROS1,CCCCC(CC)CCC(CC(C)C)O[S]([O-])(=O)=O,Microsource,1300042,0,0,0,0,2.13075061,-26.2,-40.19005031,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00021305-19,Sirolimus,405558660,mTOR Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),(53123-88-9),,8.436791229,1,-5.073822698,-36.51338621,-2.2,7,,-43.14812744,-43.65567356,1.05726E-05,0.998670278,,MTOR,CO[C@@H]1C[C@@H](CC[C@H]1O)C[C@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C(C)/[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC,SynKinase,SYN-1185,0,0,0,-0.81081081,0,-29.6,-43.65567356,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00378574-01,Brexpiprazole,405558789,Dopamine D3 receptor Partial Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),913611-97-9,,18.88762287,0,-4.723822698,-38.2877804,-2.2,7,,-88.5765791,-78.0883175,1.57628E-05,0.998375067,,,O=C\1NC2=C(\C=C1)C=CC(=C2)OCCCCN3CCN(CC3)C4=C5C=CSC5=CC=C4,MedChem Express,HY-15780,2.48736883,0,0.62583818,3.51351351,0,-23.1,-78.0883175,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167430-04,Tioconazole,170465343,Antifungal Agent,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),65899-73-2, ; Vagistat-1;Tioconazole; Tioconazol;TIOCONAZOLE; Tioconazole,8.436791229,1,-5.073822698,-96.62672059,-2.1,7,,-94.59748463,-93.96310788,0.00117025,0.985702023,,,Clc3sccc3COC(Cn1ccnc1)c2ccc(Cl)cc2Cl,Microsource,1505581,0,-12.64936135,0,-2.52252252,-15.39951574,-60.7,-93.96310788,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00163953-03,Allethrin,144214035,Testis-specific androgen-binding protein Binding Agent,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),584-79-2,,63.09573445,0,-4.2,-20.43671795,-3,7,Allethrin,-61.82699832,-58.63610956,1.94E-08,0.999943168,,,O=C2CC(OC(=O)C1C(/C=C(\C)C)C1(C)C)C(C)=C2CC=C,LightBiologicals,MOP-20453,0,0,0,0,0,0,-58.63610956,,,,,,,,,7.31E-09,3.66E-08,1.83E-07,9.14E-07,0.00000457,2.29E-05,0.000114,,,,,,,,
NCGC00179305-04,Lymecycline,405558898,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),992-21-2,,26.67947643,0,-4.573822698,-43.62660202,-2.2,7,,-85.54891,-65.56735606,0.004547706,0.971143319,,,CN(C)[C@H]\1[C@@H]2C[C@H]3\C(=C(\O)[C@]2(O)C(=O)\C(=C1O)C(=O)NCNC(CCCCN)C(O)=O)C(=O)C4=C(C=CC=C4O)[C@@]3(C)O,Prestwick,Prestw-1000,0,4.90317264,0,-3.78378378,-11.23486683,-19.5,-65.56735606,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00346688-03,Alectinib (CH5424802),405559044,ALK Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1256580-46-7,,7.32725503,1,-5.135058692,-20.81520265,-2.2,7,,-36.26411404,-31.47009503,0.001653797,0.982940135,,ALK,CCC1=CC2=C(C=C1N3CCC(CC3)N4CCOCC4)C(C)(C)C5=C(C2=O)C6=CC=C(C=C6[NH]5)C#N,Axon Medchem,1884,3.10921104,0,4.64908359,0,1.937046,-12.4,-31.47009503,,,,,,,,,1.83E-09,9.14E-09,4.57E-08,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,
NCGC00015385-18,Dipyridamole,170464694,Phosphodiesterase PDE3 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),58-32-2,; ; Prandiol; Dipyridamole;DIPYRIDAMOLE; Asasantin; Dipiridamol;Dipyridamole; Persantine,37.68576212,0,-4.423822698,-28.55730301,-3,7,,-81.81286895,-73.08146399,0.003442819,0.975048716,8654,PDE5A,OCCN(CCO)c2nc1c(nc(nc1c(n2)N3CCCCC3)N(CCO)CCO)N4CCCCC4,Enzo,EI127,0,-9.69855832,0,4.75396163,0,0.66287879,-73.08146399,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00263574-01,Diflucortolone valerate,170465700,Annexin A1 Activator,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),59198-70-8,,37.68576212,0,-4.423822698,-7.996955152,-3,7,,-40.47402597,-35.06493506,0.000694058,0.989057549,301,ANXA1,CCCCC(=O)OCC(=O)[C@H]4[C@H](C)C[C@@H]3[C@]4(C)C[C@H](O)[C@@]2(F)[C@H]3C[C@H](F)C1=CC(=O)C=C[C@@]12C,Sequoia,59198-70-8,0,0.2621232,0,3.66972477,0,2.1780303,-35.06493506,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00159346-04,Terbinafine,170465174,Fungal Squalene Monooxygenase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),91161-71-6," ;Terbinafine; terbinafine, (Z)-isomer; Lamasil;TERBINAFINE HYDROCHLORIDE; Terbinafine; TERBINAFINE HCl;Terbinafine?HCl; Terbinafine HCl",37.68576212,0,-4.423822698,-16.37183598,-3,7,,-52.39492326,-46.39905549,0.011990244,0.951676931,,,CC(C)(C)C#C\C=C\CN(C)Cc2cccc1ccccc12,Vitas,STK802069,0,3.53866317,-7.98534799,0,4.15537489,0.09469697,-46.39905549,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00164581-02,Estramustine,170466403,Estrogen receptor beta Modulator,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),2998-57-4,,9.466235454,1,-5.023822698,-78.31985465,-2.1,7,,-85.73435655,-81.3459268,0.000273698,0.993170104,4130,,ClCCN(CCCl)C(=O)Oc3cc4CC[C@@H]1[C@H](CC[C@]2(C)[C@@H](O)CC[C@@H]12)c4cc3,Sequoia,SRP01725e,-0.72072072,2.35910878,-6.66666667,-3.08590492,-12.19512195,-50.85227273,-81.3459268,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00023643-15,Estrone,170465020,Steroid hormone,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),53-16-7,,33.58747085,0,-4.473822698,-36.07771241,-3,7,,-33.97756789,-30.81463991,0.147171652,0.78461278,,ESR1,Oc3cc4CC[C@@H]1[C@H](CC[C@]2(C)C(=O)CC[C@@H]12)c4cc3,Vitas,STK801833,-13.09309309,-0.78636959,0,-3.08590492,-10.20776874,-5.01893939,-30.81463991,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00181130-02,Eletriptan,170465317,5-hydroxytryptamine receptor 1F Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),143322-58-1,,26.67947643,0,-4.573822698,-28.20954582,-3,7,,-55.92230297,-48.3510341,0.007035651,0.963683148,3355,HTR1F,CN4CCC[C@@H]4Cc2cnc3ccc(CCS(=O)(=O)c1ccccc1)cc23,Sequoia,143322-58-1,-8.47260008,1.19489081,1.60929817,0,0,-7.9,-48.3510341,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00179290-03,Pivampicillin,170466065,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),33817-20-8,,18.88762287,0,-4.723822698,-78.70635309,-2.1,7,,-105.7285634,-98.32308552,0.035113417,0.912059705,,,CC(C)(C)C(=O)OCOC(=O)[C@@H]2N3C(=O)[C@@H](NC(=O)[C@H](N)c1ccccc1)[C@H]3SC2(C)C,Prestwick,Prestw-1009,0,-27.89451998,2.5033527,-5.85585586,2.22760291,-34.4,-98.32308552,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167550-08,Narasin,405558485,Nf-kappa B Signaling Pathway Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),55134-13-9,,21.19226141,0,-4.673822698,-13.43846901,-2.4,7,,-29.94689771,-29.12241476,0.008498535,0.959873869,,,CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)[C@H]5CC[C@](O)(CC)[C@H](C)O5)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@@H]1C)C(O)=O,Enzo,NP198,-4.508356,1.52451586,0,0,2.61501211,-2.9,-29.12241476,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00179501-03,Aurantiamarin (Methyl Hesperidin),225144305,Free Radical Scavenger,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),11013-97-1,; Aurantiamarin; Hesperitin-7-rutinoside;Vitamin P; Hesperetin-7-Rutinoside;Methyl-Hesperidin;Hesperidin; Hesperetin 7 Rutinosid,11.91728437,0,-4.923822698,-17.76362901,-2.4,7,,-22.89770822,-22.41475685,0.002266785,0.979952368,,,COC1=C(O)C=C(C=C1)[C@@H]2CC(=O)C3=C(O2)C=C(O[C@@H]4O[C@H](CO[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)C=C3O,Prestwick,Prestw-400,0,0,0,-2.88288288,0.5811138,-11.9,-22.41475685,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00181325-03,Menaquinone,405558876,bone resorption Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),11032-49-8,,15.00297213,0,-4.823822698,-55.17942801,-2.1,7,,-95.38082728,-87.36724427,0.000189298,0.994330767,,,CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC/1=C(C)/C(=O)C2=C(C=CC=C2)C1=O,Prestwick,Prestw-NAT-0236,0,0,4.33616451,-3.87387387,0,-35.7,-87.36724427,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00162068-06,Opipramol dihydrochloride,170465942,Serotonin 2 (5-HT2) receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),909-39-7,,37.68576212,0,-4.423822698,-28.11009089,-3,7,,-29.62750886,-30.10625738,0.102775969,0.830988395,,,Cl.Cl.OCCN1CCN(CC1)CCCN3c4ccccc4C=Cc2ccccc23,"Prestwick Chemical, Inc.",Prestw-1456,0,-5.50458716,-11.5018315,0,-7.67841012,-0.47348485,-30.10625738,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00094437-05,d-Tryptophan,170465485,Tryptophan metabolism Substrate,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),153-94-6,,21.19226141,0,-4.673822698,-4.956833983,-3,7,,-43.66528926,-40.49586777,0.001000932,0.98680733,,,O=C(O)[C@H](N)Cc2cnc1ccccc12,SIGMA,93660,4.44444444,0,2.78388278,4.58715596,0,0,-40.49586777,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00015818-14,Praziquantel,170464906,antiparasitic agent,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),55268-74-1,"; ; Praziquantel, (R)-Isomer; Praziquantel, (+-)-Isomer;PRAZIQUANTEL;Praziquantel; Praziquantel, (S)-Isomer; Biltricide; Praziquantel",4.228412057,1,-5.373822698,-33.74840091,-1.2,7,,-30.80113636,-24.43919717,0.013951197,0.947544914,,,O=C2CN(CC1c3ccccc3CCN12)C(=O)C4CCCCC4,Vitas,STK030186,0,0,0,0,0,-36.07954545,-24.43919717,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00263874-02,BLEOMYCIN (bleomycin B2 shown),405559102,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),"9041-93-4, 11056-06-7 [bleomycin]",,0.518729931,1,-6.285058692,-83.57583383,-1.2,7,,-37.64673001,-40.4136389,0.000107046,0.995748318,,,CC[C@@H]1OC(OC(C(NC(=O)C2=NC(=NC(=C2C)N)C(CC(N)=O)NCC(N)C(N)=O)C(=O)NC(C)C(O)C(C)C(=O)NC(C(C)O)C(=O)NCCC3=NC(=CS3)C4=NC(=CS4)C(=O)NCCCCNC(N)=N)C5=C[NH]C=N5)[C@@H](O[C@H]6O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]6O)[C@@H](C)[C@@H]1C,Microsource,1503692,-2.40963855,0,-3.88913724,-8.46846847,-32.73607748,-38.1,-40.4136389,,,,,,,,,1.83E-09,9.14E-09,4.57E-08,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,
NCGC00522029-01,Zuclopenthixol Decanoate,405558666,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),64053-00-5,,37.68576212,0,-4.423822698,-31.55278167,-3,7,,-81.54052543,-73.28116266,0.000128108,0.995344379,,,CCCCCCCCCC(=O)OCCN1CCN(CC\C=C/2C3=CC=CC=C3SC4=C2C=C(Cl)C=C4)CC1,Toronto Research,Z701490,-5.20792849,0,-0.75994636,0,0,-0.9,-73.28116266,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00386567-02,FLIBANSERIN,405558804,Serotonin 2a (5-HT2a) receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),167933-07-5,,29.9348649,0,-4.523822698,-2.303022358,-2.4,7,,-34.47121296,-27.89267747,0.006079041,0.966414298,,,FC(F)(F)C1=CC(=CC=C1)N2CCN(CC2)CCN3C(=O)NC4=CC=CC=C34,SIGMA,SML0797,4.508356,0,0,4.77477477,0,0,-27.89267747,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016819-05,Gliquidone,170465581,Cytochrome P450 3A4 Substrate,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),33342-05-1,,18.88762287,0,-4.723822698,-38.7359725,-2.2,7,,-66.01298701,-59.85832349,0.000563541,0.990152394,,,O=C(NC1CCCCC1)NS(=O)(=O)c2ccc(cc2)CCN4C(=O)c3cc(ccc3C(C)(C)C4=O)OC,"Prestwick Chemical, Inc.",Prestw-991,-0.96096096,-0.5242464,-0.51282051,-4.92076731,1.53568202,-19.79166667,-59.85832349,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00021761-05,Flumethasone,170465750,Glucocorticoid receptor Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),2135-17-3,,15.00297213,0,-4.823822698,-15.37761758,-2.4,7,,-29.09386069,-26.32821724,3.87185E-05,0.997452949,,,OCC(=O)[C@@]4(O)[C@H](C)C[C@@H]3[C@]4(C)C[C@H](O)[C@@]2(F)[C@H]3C[C@H](F)C1=CC(=O)C=C[C@@]12C,"Prestwick Chemical, Inc.",Prestw-734,0,0.2621232,0,1.41784821,0,-10.51136364,-26.32821724,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00015856-10,Prochlorperazine dimaleate,170464761,Dopamine D2 Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),1984/2/6,"; ;Prochloperazine dimaleate; Proclorperazina; Prochlorperazine dimaleate; Compazine syrup;Prochlorperazine; Compro; Compazine;Prochlorperazine dimaleate; Maleate, Prochlorperazin",11.91728437,0,-4.923822698,-56.23724227,-2.2,7,,-68.85360095,-61.27508855,0.000844711,0.987898338,1813,DRD2,O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.CN1CCN(CC1)CCCN2c4ccccc4Sc3ccc(Cl)cc23,"Prestwick Chemical, Inc.",Prestw-399,0,-3.53866317,0,0,-14.18247516,-32.10227273,-61.27508855,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00179475-03,Halcinonide,170465389,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),3093-35-4,,4.228412057,1,-5.373822698,-10.28943584,-2.4,7,,-32.15909091,4.84061393,0.001471067,0.994229211,,,ClCC(=O)[C@@]54OC(C)(C)O[C@@H]5C[C@@H]3[C@]4(C)C[C@H](O)[C@@]2(F)[C@H]3CCC1=CC(=O)CC[C@@]12C,"Prestwick Chemical, Inc.",Prestw-655,0,1.83486239,2.27106227,0,-4.4263776,-28.88257576,4.84061393,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00164534-02,4-Phenolsulfonic acid,170465916,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),98-67-9,,8.436791229,1,-5.073822698,-6.889684943,-2.4,7,,-26.20454546,0,0.008426851,0.981166895,,,Oc1ccc(cc1)S(O)(=O)=O,Labotest,LT03353562,0,-1.70380079,1.9047619,0,0,-20.17045455,0,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00162149-07,Demeclocycline hydrochloride,170465205,Bacterial 70S ribosome Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),64-73-3,,9.466235454,1,-5.023822698,-56.32397275,-2.2,7,,-71.34769776,-69.30342385,0.002282967,0.9798391,,,Cl.NC(=O)C=2C(=O)[C@@]3(O)C(O)=C4C(=O)c1c(c(Cl)ccc1O)[C@@H](O)[C@H]4C[C@H]3[C@@H](C=2O)N(C)C,Microsource,1500226,0,3.01441678,4.61538462,-8.25688073,-3.34236676,-41.95075758,-69.30342385,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00274276-01,NCGC00274276-01,225144372,Beta-2 adrenergic receptor Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,18.88762287,0,-4.723822698,-57.4789633,-2.1,7,,-97.37423141,-88.59698155,0.000263802,0.993296051,,,CC(CC1=CC2=C(OCO2)C=C1)NCC(O)C3=CC(=C(O)C=C3)O,GVK,FFS-11-286-NCI-024,0,-4.57354759,1.56459544,-5.31531532,-0.4842615,-29.1,-88.59698155,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00166289-02,Hydroxystilbamidine bis(methanesulfonate),124893257,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,2.99348649,1,-5.523822698,-69.07358155,-1.2,7,,-22.928755,-31.80547792,0.037900981,0.90819677,,,NC(=N)C1=CC=C(C=C1)/C=C/C2=CC=C(C=C2O)C(N)=N,FLUKA,39286,-12.43684415,-13.14379893,-3.53151542,-5.94594595,-13.17191283,-30.9,-31.80547792,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00389390-01,Abiraterone acetate,405558467,Cytochrome P450 17A1 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),154229-18-2,,18.88762287,0,-4.723822698,-4.356747855,-2.4,7,,-32.70290666,-27.66908888,0.000852974,0.987850055,,,CC(=O)OC1CCC\2(C)C3CCC\4(C)C(C\C=C4C5=CN=CC=C5)C3C\C=C2C1,APExBIO,A8202,3.18694131,3.99670375,0,2.34234234,2.71186441,-5.6,-27.66908888,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00181785-03,Aprepitant,,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),170729-80-3,,18.88762287,0,-4.723822698,-38.84964896,-2.2,7,,-64.5941867,-49.69256568,2.45E-07,0.999797914,,,C[C@@H](O[C@H]1OCCN(CC2=NC(=O)NN2)[C@H]1C3=CC=C(F)C=C3)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F,Prestwick,Prestw-1600,0,0.20601566,0,-1.62162162,-5.71428571,-23.6,-49.69256568,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167547-02,Agaric acid,170465652,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),666-99-9,,2.99348649,1,-5.523822698,-95.29711937,-1.2,7,,-84.40078256,-72.83398547,0.001100237,0.986146853,,,O=C(O)C(CCCCCCCCCCCCCCCC)C(O)(CC(=O)O)C(=O)O,SIGMA,A7384,4.66381656,4.07911001,-1.11756817,-14.41441441,-28.18401937,-66.4,-72.83398547,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00092321-03,Tetrabenazine Mesylate,405558756,Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),804-53-5,,2.37781084,1,-5.623822698,-23.7309149,-2.4,7,,-23.4,-9.67020682,0.034336136,0.949514796,,SLC18A2,COC1=C(OC)C=C2[C@@H]3CC(=O)[C@@H](CC(C)C)CN3CCC2=C1,Glixx,GLXC-06104,-5.75204042,-0.86526576,0,0,-13.36561743,-24.5,-9.67020682,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167439-03,Trenbolone (acetate),405558864,Progesterone receptor Binding Agent,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),10161-34-9,,16.8336116,0,-4.773822698,-43.35260222,-2.2,7,,-80.05058692,-72.38680827,3.80284E-05,0.997472391,,,CC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC/4=C/C(=O)CCC4=C3/C=C\[C@]12C,MedChem Express,HY-12360,-1.08822386,0,0,3.24324324,-1.937046,-25.7,-72.38680827,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00024995-43,Paclitaxel,405558867,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),33069-62-4,,26.67947643,0,-4.573822698,-30.16803051,-2.2,7,,-70.52124091,-53.04639463,0.001851685,0.981907778,,TUBB,CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C3=CC=CC=C3)C4[C@@]5(CO[C@@H]5C[C@H](O)[C@@]4(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C6=CC=CC=C6)C7=CC=CC=C7,Aobious,AOB5558,3.10921104,0,0,2.07207207,-7.36077482,-15.4,-53.04639463,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00095082-06,Iopanoic acid,170465056,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),96-83-3,,8.436791229,1,-5.073822698,-26.99193644,-2.2,7,,-46.81936245,-39.31523022,0.000418447,0.991535713,,,Ic1cc(I)c(N)c(I)c1CC(CC)C(=O)O,Microsource,1503923,0,4.19397117,4.61538462,1.1676397,-4.78771454,-24.14772727,-39.31523022,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167564-03,8-Bromotheophylline,170465479,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),10381-75-6,,23.7781084,0,-4.623822698,-11.03587461,-2.4,7,,-30.31050768,-26.09208973,0.003071922,0.976520117,,,O=C2c1nc(Br)nc1N(C)C(=O)N2C,Vitas,STK803299,0,-1.70380079,0,3.41951626,0,-4.45075758,-26.09208973,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00015678-10,Moxisylyte hydrochloride,170465759,Adrenergic receptor alpha-1 Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),964-52-3,,33.58747085,0,-4.473822698,-8.137370578,-2.4,7,,-24.91027154,-23.25855962,5.70E-09,0.999969163,,,Cl.CC(=O)Oc1cc(C(C)C)c(OCCN(C)C)cc1C,"Prestwick Chemical, Inc.",Prestw-42,0,0,0,0,0,0,-23.25855962,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00179596-03,Butoconazole nitrate,170464901,Antifungal Agent,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),64872-77-1, Butoconazol;;Butoconazole nitrate; Femstat,8.436791229,1,-5.073822698,-68.25463378,-2.1,7,,-84.87461629,-83.70720189,8.94044E-05,0.996115356,,,[O-][N+](=O)O.Clc1ccc(cc1)CCC(Sc2c(Cl)cccc2Cl)Cn3ccnc3,"Prestwick Chemical, Inc.",Prestw-408,-1.44144144,0,4.83516484,-1.41784821,-1.17434508,-56.15530303,-83.70720189,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00024246-15,Daunorubicin,170465048,DNA Topoisomerase II Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),20830-81-3," WP900 hydrochloride; Cerubidine;Daunorubicin hydrochloride; ;; Daunoblastine;DAUNORUBICIN; Daunorubicin; Daunomycin HCL; Dauno-Rubidomycine; Daunomycin, hydrochloride; Daunomycin hydrochloride; Daunoblastin; Dauno Rubidomycin;Daunomycin hydrochloride; (-)-Daunorubicin",18.88762287,0,-4.723822698,-39.3226659,-2.2,7,,-72.18181818,-65.2892562,3.30891E-05,0.997643061,,TOP2A,CC(=O)[C@@]4(O)C[C@H](O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1)c5c(O)c3C(=O)c2c(OC)cccc2C(=O)c3c(O)c5C4,Microsource,1500223,0,-1.04849279,0,-2.75229358,0,-19.79166667,-65.2892562,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00164598-03,CEFPODOXIME PROXETIL,405558543,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),87239-81-4,,21.19226141,0,-4.673822698,-31.91102733,-3,7,,-68.31498043,-65.67915036,6.73845E-05,0.996630885,,,COCC/1=C(/N2[C@H](SC1)[C@H](NC(=O)C(=N/OC)/C3=CSC(=N3)N)C2=O)C(=O)OC(C)OC(=O)OC(C)C,Microsource,1505637,0,0,0,-3.78378378,0,-9,-65.67915036,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00346456-05,Macitentan,405558977,Endothelin ETA/ETB Receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),441798-33-0,,23.7781084,0,-4.623822698,-21.17773878,-3,7,,-41.78898826,-39.40749022,0.001229901,0.98534316,,EDNRA,CCCN[S+]([O-])(=O)NC1=NC=NC(=C1C2=CC=C(Br)C=C2)OCCOC3=NC=C(Br)C=N3,Glixx,GLXC-90056,0,0,0,-4.77477477,0,-5.8,-39.40749022,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00161326-08,Calcifediol (monohydrate),405559040,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),63283-36-3,,21.19226141,0,-4.673822698,-46.73708057,-2.2,7,,-70.66349916,-64.89659027,0.004106413,0.972646077,,,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2C(/CCC[C@]12C)=C/C=C3/C[C@@H](O)CCC3=C,MedChem Express,HY-32351A,0.93276331,0,-8.71703174,-7.2972973,0,-19.6,-64.89659027,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00242480-03,Ivacaftor,405559089,CFTR Channel Activator,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),873054-44-5,,10.62129087,0,-4.973822698,-78.70143742,-2.2,7,,-76.05980995,-78.75908329,0.000600458,0.989828089,,CFTR,CC(C)(C)C1=CC(=C(NC(=O)C/2=C/NC3=C(C=CC=C3)C2=O)C=C1O)C(C)(C)C,APExBIO,A5047,-4.97473766,-8.28182942,0,-8.10810811,-5.42372881,-44.9,-78.75908329,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00161419-07,Trimetrexate,404904680,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),[82952-64-5],,26.67947643,0,-4.573822698,-52.20073078,-2.1,7,,-111.7932923,-87.03186138,0.000820993,0.988071107,1719,DHFR,COC1=C(OC)C(=CC(=C1)NCC2=C(C)C3=C(C=C2)N=C(N)N=C3N)OC,NCGCChem,NCGC00161419-05pur,0,0,0,1.8018018,-10.84745763,-22.1,-87.03186138,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00166015-02,C.I. Basic Violet 14,124893209,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,6.701581484,1,-5.173822698,-107.5479551,-2.1,7,,-109.2892118,-98.99385131,5.0281E-06,0.999083265,,,CC1=CC(=CC=C1N)C(C2=CC=C(N)C=C2)=C/3\C=C/C(=N)/C=C3,SigmaAldrich,B0904,-0.54411193,0,0,-7.47747748,-24.69733656,-71.5,-98.99385131,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00090774-05,Nitazoxanide,170465090,antiprotozoal agent,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),55981-09-4,Nitazoxanide; ; Alinia; Nitazoxanida; Nitazoxanide,23.7781084,0,-4.623822698,-41.06425876,-2.2,7,,-75.3961039,-57.49704841,0.017431595,0.940715872,,,O=C(Nc1ncc(s1)[N+]([O-])=O)c2ccccc2OC(C)=O,Vitas,STK395664,0,0,0,4.08673895,-15.80849142,-18.27651515,-57.49704841,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00091695-03,Triethylenetetramine,170465257,Copper Chelating Agent,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),112-24-3,,6.701581484,1,-5.173822698,-53.75385446,-1.2,7,,-62.31523022,-60.80283353,3.30609E-05,0.997643885,,,NCCNCCNCCN,Labotest,LTBB000434,0,0,2.85714286,3.75312761,0,-53.125,-60.80283353,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00164572-02,Rimonabant,170465599,Cannabinoid CB1 Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),168273-06-1, ; Rimonabant;Rimonabant; Rimonabant Base; Rimonabant(Nlt); Rimonabant HCL,23.7781084,0,-4.623822698,-38.1149996,-3,7,,-78.24793388,-75.20661157,0.000833179,0.987981803,56144,CNR1,O=C(NN1CCCCC1)c4nn(c2ccc(Cl)cc2Cl)c(c3ccc(Cl)cc3)c4C,Sequoia,SRP01287r,0,0,-8.27838828,0,0,-8.61742424,-75.20661157,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00420878-02,Dalbavancin,405558602,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),171500-79-1,,4.623185376,1,-5.335058692,-114.1327256,-2.1,7,,-95.85606569,-96.31078815,9.6618E-06,0.998728482,,,CN[C@H]1C(=O)N[C@@H]2CC3=CC=C(OC4=CC5=CC(=C4O[C@@H]6O[C@@H]([C@@H](O)[C@H](O)[C@H]6NC(=O)CCCCCCCCC(C)C)C(O)=O)OC7=CC=C(C=C7Cl)[C@@H](O)[C@@H]8NC(=O)[C@H](NC(=O)[C@@H]5NC(=O)[C@@H](NC2=O)C9=C(Cl)C(=CC(=C9)OC%10=C(O)C=CC1=C%10)O)C%11=CC=C(O)C(=C%11)C%12=C(O[C@H]%13O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]%13O)C=C(O)C=C%12[C@H](NC8=O)C(=O)NCCCN(C)C)C=C3,MedChem Express,HY-17586,-1.63233579,-1.77173465,-5.67724631,-3.06306306,-7.74818402,-61.9,-96.31078815,,,,,,,,,1.83E-09,9.14E-09,4.57E-08,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,
NCGC00390365-01,Delamanid,405558727,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),681492-22-8,,6.701581484,1,-5.173822698,-104.4548104,-2.1,7,,-94.53896031,-85.1313583,0.000329212,0.992501039,,,CC1(COC2=CC=C(C=C2)N3CCC(CC3)OC4=CC=C(OC(F)(F)F)C=C4)C[N]5C=C(N=C5O1)[N+]([O-])=O,Bio Vision,2280,-3.34240187,-5.06798517,1.1622709,-8.73873874,-31.28329298,-58.6,-85.1313583,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00166124-03,Benzyl cinnamate,170465584,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),103-41-3,,26.67947643,0,-4.573822698,-28.56495897,-3,7,,-80.36416992,-72.38680827,0.000618724,0.989672204,,,O=C(OCc1ccccc1)C=Cc2ccccc2,SIGMA,234214,4.66381656,-4.90317264,0,0.27027027,0,-6.1,-72.38680827,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00181788-01,Cefetamet pivoxil HCl,144206472,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),111696-23-2,Cefetamet pivoxil hydrochloride; Ro 15-8075; Ro-15-8075; Cefyl; ,23.7781084,0,-4.623822698,-33.3273003,-3,7,cefetamet pivaloyloxymethyl ester;7-(2 (2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-desacetoxyceph-3-em-4-carboxylic acid pivaloyloxymethyl ester;Cefyl;CIPLUS_685427;CEFETAMET PIVOXIL HYDROCHLORIDE;cefetamet pivoxil;CIPLUS_691806;Cefetamet pivoxil hydrochloride;Cefetamet Pivoxil Hydrochloride;Ro 15-8075;Ro-15-8075;CIPLUS_741318;cefetamet pivoxyl;,-71.3882057,-66.57350475,0.003037875,0.976622905,,,Cl.CC=3CS[C@H]2N(C(=O)[C@H]2NC(=O)C(=N\OC)\c1csc(N)n1)C=3C(=O)OCOC(=O)C(C)(C)C,ACC,CEFETAMET PIVOXIL HCl,-8.23940925,0,0,4.59459459,0,-8.2,-66.57350475,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016362-05,Benzonatate,170465391,Slowly adapting pulmonary stretch receptor Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),104-31-4,,23.7781084,0,-4.623822698,-30.89838998,-2.2,7,,-41.4025974,-37.42621015,0.010394401,0.955280741,,,O=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCOC)c1ccc(NCCCC)cc1,Prestwick,Prestw-12,-4.92492492,-7.33944954,0,0,-0.63233966,-11.07954545,-37.42621015,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00164576-04,Lopinavir,170464773,HIV Protease Inhibitors,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),192725-17-0,;ABT-738; Lopinavir/Ritonavir;Lopinavir;LOPINAVIR; Lopinavir,4.228412057,1,-5.373822698,-47.96473067,-1.2,7,,-44.28977273,-36.71782763,0.006807045,0.964308338,,,CC(C)[C@@H](C(=O)N[C@@H](Cc1ccccc1)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)COc3c(C)cccc3C)N4CCCNC4=O,Bosche,L2844,0,0,0,0,0,-50.28409091,-36.71782763,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00182997-01,Melinamide,144206837,Acyl coenzyme A:cholesterol acyltransferase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),14417-88-0,Melinamide; Artes; Melinamida; ,26.67947643,0,-4.573822698,-14.30898326,-3,7,"MELINAMIDE;LS-173854;N-(2-methylbenzyl)linoleamide;(z,z)-n-(1-phenylethyl)-9,12-octadecadienamide;melinamide;melinamidum;CIPLUS_214142;Artes;Melinamidum;LS-88004;Melinamida;N-(2-methylbenzyl)linoleamide, (S-(Z,Z))-isomer;Melinamide;",-57.08559622,-54.89964581,0.000251007,0.993463871,,,CCCCC\C=C/C\C=C/CCCCCCCC(=O)NC(C)c1ccccc1,Pharmaron,PH-NIH-152054,4.8048048,0,0.73260073,0,0,0,-54.89964581,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00025179-12,Mifepristone,170465151,Progesterone Receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),84371-65-3,RU-486; ;VX-410;RU-38486;VGX-410C;VGX-410;Mifepristone (Mifeprex); Corlux; Mifepristone;C-1073;CI-1073;Mifepristone; Mifeprex,5.972790784,1,-5.223822698,-94.41445015,-1.1,7,,-97.829634,-95.98583235,2.59E-07,0.999792379,5241,PGR,CN(C)c1ccc(cc1)[C@H]5C[C@@]2(C)[C@@H](CC[C@@]2(O)C#CC)[C@@H]4CCC3=CC(=O)CCC3=C45,Prestwick,Prestw-299,0,0,0,-0.25020851,-13.45980126,-73.39015152,-95.98583235,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00095157-05,Oxfendazole,170466223,antiparasitic agent,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),53716-50-0,; OXFENDAZOLE;OXFENDAZOLE;Oxfendazole; ; Synanthic; Oxfendazol,15.00297213,0,-4.823822698,-52.58167894,-2.1,7,,-110.068477,-96.45808737,1.64415E-05,0.998340241,,TUBB,O=C(OC)Nc1nc2cc(ccc2n1)S(=O)c3ccccc3,Vitas,STK378905,4.68468468,0.2621232,2.56410256,3.75312761,0,-39.6780303,-96.45808737,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00024027-09,Methysergide,170464684,Serotonin 7 (5-HT7) receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),361-37-5,,4.74435636,1,-5.323822698,-20.14374833,-1.4,7,,-25.11363636,-21.60566706,0.002289418,0.97982805,,,CC[C@@H](CO)NC(=O)[C@@H]3C=C2c4cccc1c4c(cn1C)C[C@H]2N(C)C3,Enzo,AC577,0,3.80078637,1.46520147,0,1.80668473,-25.09469697,-21.60566706,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00166397-04,Lofepramine hydrochloride,170465926,norepinephrine uptake Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),26786-32-3,,10.62129087,0,-4.973822698,-25.71477489,-2.2,7,,-52.89551357,-43.32939787,0.000154772,0.994880241,,,Cl.Clc1ccc(cc1)C(=O)CN(C)CCCN3c4ccccc4CCc2ccccc23,Sequoia,23047-25-8,3.84384384,2.35910878,4.02930403,3.25271059,-6.77506775,-23.01136364,-43.32939787,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00159481-03,Sofalcone,170466017,Prostaglandin Synthesis and Regulation Modulator,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),64506-49-6,,7.519298098,1,-5.123822698,-78.1204482,-2.1,7,,-94.25926801,-91.9716647,6.2839E-06,0.998974981,,,C/C(C)=C\COc1ccc(cc1)/C=C/C(=O)c2ccc(cc2OCC(=O)O)OC\C=C(/C)C,Bionet,KS-1141,2.88288288,0,0,0,-6.95573622,-62.59469697,-91.9716647,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00179590-04,Syrosingopine,405558663,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),84-36-6,,5.32325539,1,-5.273822698,-133.5824104,-2.1,7,,-106.4422024,-97.98770263,0.000354108,0.992218733,,,CCOC(=O)OC1=C(OC)C=C(C=C1OC)C(=O)O[C@@H]2C[C@@H]3CN4CCC5=C([NH]C6=C5C=CC(=C6)OC)[C@H]4C[C@@H]3[C@@H]([C@H]2OC)C(=O)OC,Glixx,GLXC-06136,-4.11970462,-6.79851669,0,-18.64864865,-36.51331719,-74.8,-97.98770263,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00160454-01,Felbinac ethyl,144205377,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),14062-23-8,ethyl 4-biphenyl acetate; BPAA-Et; ,31.6227766,0,-4.5,-28.56890983,-2.2,7,BPAA-Et;Felbinac Ethyl;FELBINAC ETHYL;ethyl 4-biphenyl acetate;Felbinac ethyl;LS-44075;4-biphenylylacetic acid ethyl ester;CIPLUS_169170;LM-001;ethyl 4-biphenylacetate;felbinac ethyl ester;LM 001;,-46.4234209,-44.10285075,0.004013437,0.972979872,,,O=C(OCC)Cc1ccc(cc1)c2ccccc2,Enamine,T5544767,2.17644773,-6.46889164,0,0,0,-16.2,-44.10285075,,,,,,,,,7.31E-09,3.66E-08,1.83E-07,9.14E-07,0.00000457,2.29E-05,0.000114,,,,,,,,
NCGC00538143-01,NCGC00538143-01,405558668,surfactant homeostasis Activator,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,26.67947643,0,-4.573822698,-24.6817605,-2.2,7,,-60.67579654,-48.2392398,2.13312E-05,0.998109503,,,O[C@H]1CC[C@@H](CC1)NCC2=CC(=CC(=C2O)Br)Br,Pharmaron,PH-NIH-2017-009-L1-3-0,0.77730276,-0.28842192,1.02816272,0,-2.13075061,-10.8,-48.2392398,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00181100-01,Ormeloxifene,144206269,Estrogen receptor Partial Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),31477-60-8,Levormeloxifene; Compound 672; Compound 67-20; Compound 67 2; Centchroman; ,11.91728437,0,-4.923822698,-62.60909433,-2.2,7,"ORMELOXIFENE;levormeloxifenum;Centchroman;(-)-3,4-trans-7-methoxy-2,2-dimethyl-3-phenyl-4-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)chromane;CIPLUS_3865012;LEVORMELOXIFENE;LEVORMELOXIFENE FUMARATE;CIPLUS_676257;CIPLUS_709447;1-(2-(p-(trans-7-methoxy-2,2-dimethyl-3-phenyl-4-chromanyl)phenoxy)ethyl)pyrrolidine;CIPLUS_3853907;ormeloxifenum;Compound 67-20;CIPLUS_3847290;Compound 672;NNC-46-0020 FUMARATE;CIPLUS_177424;CIPLUS_731807;Compound 67 2;Ormeloxifene;LS-137582;Pyrrolidine, 1-(2-(4-(3,4-dihydro-7-methoxy-2,2-dimethyl-3-phenyl-2H-1-benzopyran-4-yl)phenoxy)ethyl)-, trans-;ormeloxifene;levormeloxifene;trans-2,2-Dimethyl-3-phenyl-4-(p-(beta-pyrrolidinoethoxy)phenyl)-7-methoxychroman;LS-137965;Levormeloxifene Fumarate;7-METHOXY-2,2-DIMETHYL-3-PHENYL-4-(4-(2-(PYRROLIDIN-1-YL)ETHOXY)PHENYL)CHROMANE FUMARATE, TRANS-3R,4R, L-;Levormeloxifene;",-90.02068195,-78.0883175,2.22081E-05,0.998070259,,,COc1ccc2c(c1)OC(C)(C)[C@H]([C@@H]2c4ccc(OCCN3CCCC3)cc4)c5ccccc5,NCI,NSC-147956,0,3.79068809,0,-1.53153153,-9.68523002,-43.1,-78.0883175,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00319021-01,NCGC00319021-01,225144375,DNA synthesis involved in DNA replication Activator,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),,,37.68576212,0,-4.423822698,-14.2016574,-3,7,,-43.78731135,-38.84851873,9.23E-07,0.999607845,,,COCC1=C(F)C(=C(COC(=O)C2C(\C=C\C)C2(C)C)C(=C1F)F)F,GVK,FFS-11-286-NCI-255,-0.69957248,0.04120313,0,0,0,0,-38.84851873,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00188863-02,Dronedarone hydrochloride,170465064,"alpha,beta-Adrenoceptor Antagonist",Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),141626-36-0,Dronedarone; Dronedarone,21.19226141,0,-4.673822698,-49.45488018,-2.1,7,,-110.0036333,-81.44214645,1.15438E-05,0.99860995,148,ADRA1A,CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c2c3cc(ccc3oc2CCCC)NS(C)(=O)=O,SIGMA,D9696,4.11970462,1.85414091,1.25167635,0,-6.00484262,-32.5,-81.44214645,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00344524-01,Benzylhexadecyldimethylammonium chloride,170465465,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),122-18-9,,26.67947643,0,-4.573822698,-24.68624248,-3,7,,-97.47009502,-92.509782,4.07654E-05,0.997382389,,,[Cl-].C[N+](C)(Cc1ccccc1)CCCCCCCCCCCCCCCC,SIGMA,13400,1.63233579,-1.03007829,4.73848905,3.69369369,1.4527845,0,-92.509782,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00091250-12,Reserpine,170465405,Alkaloid anitpsychotic,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),50-55-5,,13.37141299,0,-4.873822698,-92.3420952,-2.1,7,,-104.3471074,-95.04132231,0.017682904,0.940233076,,SLC18A2,COc1cc(cc(OC)c1OC)C(=O)O[C@@H]3C[C@@H]4CN5CCc2c6ccc(OC)cc6nc2[C@H]5C[C@@H]4[C@@H]([C@H]3OC)C(=O)OC,Vitas,STK801975,0,1.83486239,0,-24.7706422,-14.00180668,-47.63257576,-95.04132231,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00095099-05,Sildenafil citrate,170465285,Phosphodiesterase V (PDE5) Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),171599-83-0, ; Sildenafil(Viagra); SILDENAFIL;SILDENAFIL; Caverta; Viagra;SILDENAFIL CITRATE,16.8336116,0,-4.773822698,-57.5553832,-2.1,7,,-86.75324675,-80.87367178,0.001431894,0.984144738,8654,PDE5A,CN1CCN(CC1)S(=O)(=O)c4cc(C3=Nc2c(CCC)nn(C)c2C(=O)N3)c(OCC)cc4.O=C(O)C(O)(CC(=O)O)CC(=O)O,Microsource,1504099,0,-1.17955439,0,-9.92493745,0,-30.77651515,-80.87367178,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00023217-08,Meclofenamate sodium,170464886,Cyclooxygenase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),6385-02-0,,8.436791229,1,-5.073822698,-41.74510106,-1.2,7,,-45.35596222,-46.16292798,0.001719077,0.982586996,,,[Na+].O.Clc2ccc(C)c(Cl)c2Nc1ccccc1C([O-])=O,Microsource,1500377,0,-5.76671035,1.97802198,0,1.89701897,-34.75378788,-46.16292798,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00263906-02,Rolitetracycline,170465919,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),751-97-3,,18.88762287,0,-4.723822698,-26.34218055,-2.2,7,,-67.5909091,-55.37190083,0.00017417,0.994565234,,,O=C(NCN1CCCC1)C4=C(O)[C@@H](N(C)C)[C@@H]5CC3C(C(=O)c2c(O)cccc2[C@@]3(C)O)=C(O)[C@]5(O)C4=O,Microsource,1505684,4.32432432,0,3.58974359,0,0,-19.22348485,-55.37190083,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00274060-01,Posaconazole,170464963,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),171228-49-2,,6.701581484,1,-5.173822698,-96.1926177,-2.1,7,,-97.80578512,-93.62455726,0.000377948,0.991957598,,CYP51A1,C[C@H](O)[C@H](CC)N1N=CN(C1=O)c2ccc(cc2)N3CCN(CC3)c4ccc(cc4)OCC6C[C@@](Cn5cncn5)(OC6)c7ccc(F)cc7F,Selleck,S1257,-0.12012012,3.27653997,0,-10.09174312,-16.89250226,-66.95075758,-93.62455726,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00016391-13,Clioquinol,170465019,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),130-26-7,,2.667947643,1,-5.573822698,-116.3341889,-1.1,7,,-97.04663518,-99.52774498,0.000078448,0.996362454,,,Oc1c(I)cc(Cl)c2cccnc12,Microsource,1505114,3.72372372,0.91743119,3.003663,-0.25020851,-34.05600723,-91.19318182,-99.52774498,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00253737-01,Istradefylline,174007485,Adenosine A2A Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),155270-99-8,Istradefylline,21.19226141,0,-4.673822698,-15.18698699,-2.2,7,,-47.28571428,-35.06493506,0.000458485,0.991136473,135,ADORA2A,COc1ccc(cc1OC)/C=C/c3nc2c(C(=O)N(CC)C(=O)N2CC)n3C,GVK,FFS-12-73-NCI-1738,3.003003,3.93184797,0.36630037,0,0,-12.40530303,-35.06493506,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00167525-02,Tazarotene,170464671,,Spike-ACE2 protein-protein interaction (AlphaLISA),Approved Drugs Collection (NPC),118292-40-3, ; Tazarotene;Tazarotene; Zorac; Tazorac;Tazarotene (Avage),26.67947643,0,-4.573822698,-6.796593962,-2.4,7,,-30.14403778,-28.45336482,0.005672797,0.96762021,5915,RARB,O=C(OCC)c1ccc(nc1)C#Cc2ccc3SCCC(C)(C)c3c2,Sequoia,SRP01178t,4.92492492,-1.44167759,0,0,0,-0.47348485,-28.45336482,,,,,,,,,3.66E-09,1.83E-08,9.14E-08,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,
NCGC00371120-06,Dapivirine?TMC-120,363678036,Human immunodeficiency virus type 1 reverse transcriptase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,244767-67-7,,20.08688273,0,-4.697087456,-32.89333223,-2.2,7,,-70.25138122,-52.46316759,0.000719102,0.98885298,,,CC1=CC(=C(NC2=NC(=NC=C2)NC3=CC=C(C=C3)C#N)C(=C1)C)C,Glixx,GLXC-04864,0,2.42666257,3.65186615,-3.1292517,-4.47396963,-19.15281719,-52.46316759,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00241099-04,Saracatinib,384568470,cSRC Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,379231-04-6,,15.9555781,0,-4.797087456,-34.96140847,-2.2,7,,-49.12154696,-45.92541436,0.015544656,0.944344277,,SRC,CN1CCN(CCOC2=CC3=NC=NC(=C3C(=C2)OC4CCOCC4)NC5=C6OCOC6=CC=C5Cl)CC1,Selleck,S1006,4.7871167,-1.76624174,-7.31981982,-6.2244898,-0.98517715,-16.45723551,-45.92541436,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00387263-05,Oltipraz,434147134,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,64224-21-1,,17.90245307,0,-4.747087456,-22.4169314,-3,7,,-66.94475138,-62.45395948,0.000223121,0.993840973,,NRF2,C\C1=C(\SSC1=S)C2=CN=CC=N2,SIGMA,O9389,0,0,3.78056628,0,4.34743312,-8.79610863,-62.45395948,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00345492-06,PCI-34051,384568736,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,950762-95-5,,8.972480931,1,-5.047087456,-76.06195519,-2.1,7,,-102.929558,-88.9732965,0.000113707,0.995615444,,HDAC8,COC1=CC=C(C[N]2C=CC3=C2C=C(C=C3)C(=O)NO)C=C1,Selleck,S2012,2.81638356,0,3.94144144,-5.57823129,-14.8318872,-51.0336441,-88.9732965,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00378916-02,MK-5172,405558457,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1350514-68-9,,12.67396618,0,-4.897087456,-52.4088377,-2.2,7,,-44.66969306,-43.53130755,0.017989261,0.939700105,,,COC1=CC2=C(C=C1)N=C3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N5C[C@@H](C[C@H]5C(=O)N[C@@]6(C[C@H]6C=C)C(=O)N[S+]([O-])(=O)C7CC7)OC3=N2)C(C)(C)C,MedChem Express,HY-15298,-2.58107214,-1.21333129,-12.75740026,-4.01360544,-9.04736081,-22.9023105,-43.53130755,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00016028-08,Tyrphostin AG 555,90341437,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,2.8373476,1,-5.547087456,-114.6594367,-2.2,7,,-90.02071823,-76.77255985,0.007000013,0.963769926,,,OC1=C(O)C=C(C=C1)\C=C(/C#N)C(=O)NCCCC2=CC=CC=C2,SigmaAldrich,Lopac-T-4818,0.02206045,0.0614345,-13.15958816,-27.87414966,-36.21655821,-48.2569923,-76.77255985,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00510505-01,WT-161,384569466,HDAC Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1206731-57-8,,4.496892897,1,-5.347087456,-109.6288706,-1.1,7,,-104.1464088,-96.43186004,0.000312398,0.992697001,,HDAC1,ONC(=O)CCCCCCC(=O)N\N=C\C1=CC=C(C=C1)N(C2=CC=CC=C2)C3=CC=CC=C3,MedChem Express,HY-100871,0,0,3.61969112,-8.28231293,-21.97216197,-81.69841913,-96.43186004,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00390724-02,E-7449,384569209,PARP Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1140964-99-3,,22.53785311,0,-4.647087456,-51.95747369,-2.2,7,,-66.46685083,-61.87845304,0.010315408,0.95543853,,PARP1,O=C1NNC2=C3C(=NC(=N2)CN4CC5=C(C4)C=CC=C5)C=CC=C13,MedChem Express,HY-12418,-4.03706155,-10.82782983,-10.64993565,-5.78231293,0.94902386,-11.97811107,-61.87845304,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00015950-14,SB-415286,434147196,GSK-3 beta Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,264218-23-7,,10.06728919,0,-4.997087456,-65.91677981,-2.1,7,,-97.39654696,-90.76887661,2.75666E-05,0.997849124,,GSK3B,OC1=C(Cl)C=C(N\C2=C(\C(=O)NC2=O)C3=C(C=CC=C3)[N+]([O-])=O)C=C1,MedChem Express,HY-15438,0,0,0,4.20068027,-5.1428055,-47.70976895,-90.76887661,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00017375-03,Berbamine dihydrochloride,406861834,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,6078-17-7,,20.08688273,0,-4.697087456,-28.51799658,-2.2,7,,-73.55248618,-56.10036832,0.000185854,0.994384224,,,COC1=CC2=C3C=C1OC4=C(OC)C(=CC5=C4[C@@H](CC6=CC=C(O)C(=C6)OC7=CC=C(C[C@@H]3N(C)CC2)C=C7)N(C)CC5)OC,Prestwick,Prestw-NAT-0350,0,3.53248349,2.54182754,2.63605442,-3.60629067,-17.69355493,-56.10036832,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00025029-03,U-0126,26752096,Mek 1/2 inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,218601-62-8,U0126;U0126-EtOH;U-0126,11.29568425,0,-4.947087456,-64.13904669,-2.2,7,"1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene;UO126;CIPLUS_753356;U0126 ethanolate;U 0126;UO-126;1,4-Diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)butadiene;U0126;U126 cpd;1,4-Diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)butadiene ethanolate;NCGC00094462-02;NCGC00094462-01;NCGC00016074-01;UO 126;U-0126;NCGC00025029-03;NCGC00025029-02;NCGC00025029-01;U0126 cpd;",-71.97790055,-65.33149171,0.005806898,0.967183905,5604,MAP2K1,NC(/SC1=CC=CC=C1N)=C(C#N)\C(C#N)=C(N)\SC2=CC=CC=C2N,BIOMOL,EI282,0.88977131,1.50514514,-3.82882883,-12.73809524,-11.52386117,-33.40089177,-65.33149171,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00522593-01,RSV604 (R enantiomer),434147176,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,932108-20-8,,12.67396618,0,-4.897087456,-14.37257642,-2.2,7,,-40.62707182,-34.94475138,0.002600447,0.978446293,,,FC1=CC=CC=C1NC(=O)N[C@@H]2\N=C(C3=CC=CC=C3)/C4=CC=CC=C4NC2=O,MedChem Express,HY-12993B,0,0,4.84234234,1.9047619,4.16666667,-13.90352655,-34.94475138,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00482751-01,Casticin,434147155,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,479-91-4,,4.007860013,1,-5.397087456,-74.97825028,-1.2,7,,-42.08694423,-42.33425414,0.011150469,0.953543384,,,COC1=C(O)C=C(C=C1)\C2=C(/OC)C(=O)C3=C(O)C(=C(OC)C=C3O2)OC,DC Chemicals,DCM-037,-4.0958894,-3.57855936,-8.96074646,-14.67687075,-15.3922632,-38.36643697,-42.33425414,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00346655-06,Linagliptin,384568886,DPP-IV Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,668270-12-0,,20.08688273,0,-4.697087456,-42.1102939,-2.2,7,,-74.43370166,-56.7679558,0.000450861,0.991207364,,DPP4,CC#CC[N]1C(=NC2=C1C(=O)N(CC3=NC4=CC=CC=C4C(=N3)C)C(=O)N2C)N5CCC[C@@H](N)C5,MedChem Express,HY-10284,-0.84565042,0.35324835,2.44530245,-2.32993197,-8.57736804,-22.55776246,-56.7679558,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00090782-17,Nelfinavir Mesylate,406861837,HIV Protease Inhibitors,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,159989-65-8,,15.9555781,0,-4.797087456,-42.08270412,-2.2,7,,-87.74033149,-66.09116022,0.001003845,0.986782543,,,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC3=CC=CC=C3)NC(=O)C4=C(C)C(O)=CC=C4)[C@@H](C2)C(=O)NC(C)(C)C,APExBIO,A3653,3.59585264,2.30379358,4.92277992,-5.34013605,-3.26283442,-29.97567896,-66.09116022,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00350413-05,ESI-09,434147260,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,263707-16-0,,7.996732047,1,-5.097087456,-93.58282838,-2.1,7,,-100.461326,-85.40515654,3.79714E-05,0.997474124,,,CC(C)(C)C1=CC(=NO1)C(=O)\C(=N\NC2=CC=CC(=C2)Cl)C#N,MedChem Express,HY-16704,1.80160306,-1.81231762,-4.74581725,-8.58843537,-22.11677513,-55.85731658,-85.40515654,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00346526-03,PHA-680632,384568820,Aurora-A/B/c Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,398493-79-3,,22.53785311,0,-4.647087456,-19.96025007,-3,7,,-53.40055249,-43.96869245,3.15895E-05,0.99769805,,AURKA,CCC1=CC=CC(=C1NC(=O)N2CC3=C(C2)C(=N[NH]3)NC(=O)C4=CC=C(C=C4)N5CCN(C)CC5)CC,Selleck,S1454,0,0,2.01093951,-0.49319728,0,-7.96513985,-43.96869245,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00183808-18,ML324,434147059,JMJ Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,4.496892897,1,-5.347087456,-103.8668593,-1.1,7,,-99.29171271,-98.50368324,1.66335E-05,0.998330504,,JARID2,CN(C)CCCNC(=O)C1=CC=C(C=C1)C2=CC3=CC=CN=C3C(=C2)O,NCGCChem,GRB059-084,1.16920362,0.69113807,2.31660232,-4.03061224,-16.33224873,-83.11714633,-98.50368324,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00017325-10,KOJIC ACID,434146964,Tyrosinase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,501-30-4,,35.48133892,0,-4.45,-3.096174613,-3,7,,-51.4558011,-47.32965009,0.000146449,0.995020761,,,OC\C1=C\C(=O)\C(=C/O1)O,Microsource,1504324,4.24295904,2.07341422,4.63320463,1.2585034,4.83550253,-0.56749088,-47.32965009,,,,,,,,,6.37E-09,3.18E-08,1.59E-07,7.96E-07,0.00000398,0.0000199,9.95E-05,,,,,,,,
NCGC00178090-03,Pristimerin,406861848,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1258-84-0,,4.496892897,1,-5.347087456,-104.8554965,-2.1,7,,-104.25,-94.61325967,5.34351E-05,0.997001105,,,COC(=O)[C@]1(C)CC[C@]2(C)CC[C@]3(C)\C4=C\C=C\5\C(=C(\O)C(=O)\C=C5[C@]4(C)CC[C@@]3(C)[C@@H]2C1)C,SIGMA,P0020,-0.58092507,0,2.83140283,-1.39455782,-26.78054953,-76.36805837,-94.61325967,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00263093-14,Apilimod mesylate,434146923,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,870087-36-8,,7.127094939,1,-5.147087456,-62.23409109,-2.2,7,,-84.46546961,-77.60128913,8.36605E-05,0.996243113,,,CC1=CC=CC(\C=N\NC2=NC(OCCC3=CC=CC=N3)=NC(=C2)N4CCOCC4)=C1,AChemBlock,O33823,0,4.46935955,0.35392535,3.7244898,-10.11388286,-48.43940008,-77.60128913,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00390255-01,Maslinic acid,384569181,Glycogen Phosphorylase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,4373-41-5,,20.08688273,0,-4.697087456,-26.56755946,-3,7,,-70.85911602,-69.61325967,7.00E-10,0.99998916,,PYGL,CC1(C)CC[C@@]2(CC[C@]3(C)\C(=C/C[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O,Adooq,A12089,0,0,0,0,-0.18980477,-2.81718687,-69.61325967,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00015817-17,Promethazine HCl,434146948,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,58-33-3,,25.28788711,0,-4.597087456,-24.98190458,-3,7,,-50.66574586,-45.97145488,7.39894E-05,0.996469796,,,CC(CN1C2=C(SC3=C1C=CC=C3)C=CC=C2)N(C)C,Selleck,S4293,0.09559526,-1.98126248,-1.44787645,-1.2244898,-3.26283442,-4.82367248,-45.97145488,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00018268-05,Itraconazole,434146971,cytochrome inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,84625-61-6,,2.253785311,1,-5.647087456,-92.65778978,-1.2,7,,-62.43443258,-61.74033149,0.000123053,0.995437721,,,CCC(C)N1\N=C/N(C1=O)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(OCC5COC(C[N]6C=NC=N6)(O5)C7=CC=C(Cl)C=C7Cl)C=C4,Prestwick,Prestw-1139,-1.44863593,-2.10413147,-0.16087516,-3.94557823,-26.27440347,-67.24766923,-61.74033149,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00017338-03,Antimycin A,124883057,Antifungal Agent,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1397-94-0,Antimycin A;ANTIMYCIN A1,8.972480931,1,-5.047087456,-65.98278985,-2.1,7,"Antimycin- A from Streptomyces sp.;Antimycin A1;NCGC00016578-01;9   Antimycin A (A3+A4 >90%);ANTIMYCIN A;ANTIMYCIN A (A1 shown);NCGC00142516-03;NCGC_Prestw-222;NCGC00095884-01;ANTIMYCIN A1;Butanoic acid, 2(or 3)-methyl-, 3-((3-(formylamino)-2-hydroxybenzoyl)amino)-8-hexyl-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-7-yl ester;LS-86460;CIPLUS_155874;Antimycin A;NCGC00142516-02;CIPLUS_158270;",-90.16436464,-81.28453039,1.37705E-05,0.998481452,,,CCCCCC[C@@H]1[C@@H](OC(=O)CC(C)C)[C@H](C)OC(=O)[C@@H](NC(=O)C2=C(O)C(=CC=C2)NC=O)[C@@H](C)OC1=O,BIOMOL,NP-009,0,0,2.04311454,1.70068027,-10.58387563,-46.67612485,-81.28453039,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00250401-11,Flavopiridol,384568550,CDK1/2/4/6/7/9 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,146426-40-6,,25.28788711,0,-4.597087456,-2.459447631,-2.4,7,,-34.46961326,-25.39134438,0.003525561,0.974771356,,CDK1,CN1CC[C@H]([C@@H](O)C1)C2=C(O)C=C(O)C3=C2O\C(=C/C3=O)C4=CC=CC=C4Cl,MedChem Express,HY-10005,4.3017869,0.3839656,4.26319176,1.76870748,0,-2.41183624,-25.39134438,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00346504-07,Avagacestat,384568808,g-Secretase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1146699-66-2,,28.373476,0,-4.547087456,-40.17877451,-2.2,7,,-42.09423893,-36.04972376,0.00470581,0.970649337,,NOTCH1,NC(=O)[C@@H](CCC(F)(F)F)N(CC1=C(F)C=C(C=C1)C2=NOC=N2)[S+]([O-])(=O)C3=CC=C(Cl)C=C3,MedChem Express,HY-50845,-2.49283036,-2.88742129,-7.23938224,-6.76870748,-7.78199566,-11.63356303,-36.04972376,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00178332-02,Genkwanin,434147049,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,437-64-9,,11.29568425,0,-4.947087456,-89.49698563,-2.2,7,,-76.97138389,-73.6878453,0.002223657,0.980112523,,,COC1=CC2=C(C(=C1)O)C(=O)\C=C(/O2)C3=CC=C(O)C=C3,DC Chemicals,DCY-091,-4.61063313,-5.91307019,-7.72200772,-9.25170068,-24.14135936,-38.32590191,-73.6878453,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00015829-14,PROMAZINE HYDROCHLORIDE,434146949,Serotonin 2a (5-HT2a) receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,"53-60-1, 58-40-2 [promazine]",,10.06728919,0,-4.997087456,-62.81456261,-2.2,7,,-68.12154696,-61.51012891,0.001456504,0.984007669,,,CN(C)CCCN1C2=C(SC3=C1C=CC=C3)C=CC=C2,Microsource,1500509,0,0,-7.20720721,-4.11564626,-14.6691974,-32.93473855,-61.51012891,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00159554-09,Salubrinal,406861841,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,405060-95-9,,4.007860013,1,-5.397087456,-79.59677809,-2.2,7,,-80.75414364,-69.88950276,0.000167546,0.994669641,,,ClC(Cl)(Cl)C(NC(=O)\C=C\C1=CC=CC=C1)NC(=S)NC2=C3N=CC=CC3=CC=C2,SIGMA,SML0951,1.7868961,4.91475964,-3.02445302,-3.46938776,-25.73210412,-53.58735306,-69.88950276,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00165841-02,NH125,434147032,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,278603-08-0,,11.29568425,0,-4.947087456,-72.0507119,-2.1,7,,-107.5,-98.98710866,8.36611E-05,0.996242913,,,CCCCCCCCCCCCCCCC[N+]1=C(C)[N](CC2=CC=CC=C2)C=C1,Selleck,S7436,-1.87513788,0.33788972,-2.46138996,0,0,-48.88528577,-98.98710866,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00386265-04,TCID,434147128,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,30675-13-9,,7.127094939,1,-5.147087456,-84.34871431,-2.1,7,,-104.0831492,-99.30939227,0.000178923,0.994489509,,,ClC1=C(Cl)C(=C2C(=O)CC(=O)C2=C1Cl)Cl,APExBIO,B1467,2.65460696,4.80724927,1.46396396,-5.98639456,-9.57158351,-64.67369274,-99.30939227,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00319175-08,Rilpivirine,434147081,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,500287-72-9,,8.972480931,1,-5.047087456,-73.92837955,-2.2,7,,-93.6961326,-78.91344383,0.000987754,0.986890271,,,CC1=C(NC2=CC=NC(=N2)NC3=CC=C(C=C3)C#N)C(=CC(=C1)\C=C\C#N)C,MedChem Express,HY-10574,4.9488933,-2.16556597,-4.55276705,1.49659864,-19.15220535,-47.73003648,-78.91344383,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00250390-07,ISOX,434146930,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1045792-66-2,,7.996732047,1,-5.097087456,-74.12165367,-2.1,7,,-96.96546961,-94.08379374,4.1569E-06,0.999166578,,HDAC6,CC(C)(C)OC(=O)NC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NCCCCCCC(=O)NO,Axon Medchem,1645,3.21347158,0,0,0.34013605,-4.38358641,-58.59343332,-94.08379374,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00159462-20,Ritonavir,434147007,HIV Protease Inhibitors,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,155213-67-5,,22.53785311,0,-4.647087456,-12.74229513,-3,7,,-52.24585635,-38.44383057,0.00052486,0.99050552,,,[H][C@](CC1=CC=CC=C1)(C[C@]([H])(O)[C@]([H])(CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)NC(=O)[C@@]([H])(NC(=O)N(C)CC4=CSC(=N4)C(C)C)C(C)C,MedChem Express,HY-90001_cm1,3.448783,1.48978652,0,4.28571429,0,-8.87717876,-38.44383057,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00016246-21,Chlorhexidine HCl,434146896,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,3697-42-5,,8.972480931,1,-5.047087456,-82.5341471,-2.2,7,,-78.76382556,-64.20349908,0.000470583,0.991013572,,,ClC1=CC=C(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC2=CC=C(Cl)C=C2)C=C1,APExBIO,B1695,-2.61048607,-4.16218707,-5.30888031,-6.13945578,-25.46095445,-41.52817187,-64.20349908,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00378990-05,Ledipasvir (D-tartrate),434147111,Nonstructural protein 5A Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1502654-87-6,,5.045596817,1,-5.297087456,-122.3406082,-2.1,7,,-102.125,-97.26058932,0.000216528,0.99393248,,,COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1C3=NC=C([NH]3)C4=CC5=C(C=C4)C6=C(C=C(C=C6)C7=CC=C8N=C([NH]C8=C7)[C@@H]9[C@H]%10CC[C@H](C%10)N9C(=O)[C@@H](NC(=O)OC)C(C)C)C5(F)F,MedChem Express,HY-15602B,-7.61085374,1.21333129,-5.82368082,-6.2755102,-30.34164859,-75.59789218,-97.26058932,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00179135-02,EPICATECHIN MONOGALLATE,,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1257-08-5,,2.008688273,1,-5.697087456,-151.4111618,-1.1,7,,-102.6745301,-97.81307551,0.000003248,0.999263421,,,OC1=CC2=C(C[C@@H](OC(=O)C3=CC(=C(O)C(=C3)O)O)[C@H](O2)C4=CC(=C(O)C=C4)O)C(=C1)O,Microsource,MS-00210238,-0.16913008,-3.25602826,-7.46460746,-18.99659864,-53.335141,-84.15079043,-97.81307551,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00015385-22,Dipyridamole,384567839,Phosphodiesterase PDE3 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,58-32-2,,17.90245307,0,-4.747087456,-50.52290732,-2.2,7,,-103.6519337,-79.28176796,1.46816E-05,0.998431921,,PDE5A,OCCN(CCO)C1=NC(=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO)N4CCCCC4,Prestwick,Prestw-142,0,3.25602826,2.47747748,-0.17006803,-5.99240781,-31.98216457,-79.28176796,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00346487-05,Quisinostat,385842041,HDAC Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,807640-87-5,,25.28788711,0,-4.597087456,-28.85499078,-3,7,,-42.44198896,-34.04696133,0.031056269,0.918125652,,HDAC1,C[N]1C=C(CNCC2CCN(CC2)C3=NC=C(C=N3)C(=O)NO)C4=CC=CC=C14,ActiveBioChem,A-1162,3.38995514,-1.67409,-3.1048906,-6.81972789,-7.34815618,-9.34333198,-34.04696133,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00178714-18,Topiramate,434147050,Na channel blocker,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,97240-79-4,,17.90245307,0,-4.747087456,-13.40893507,-3,7,,-39.79834254,-38.85819521,0.0032302,0.97587616,,,CC1(C)O[C@@H]2CO[C@@]3(CO[S+](N)([O-])=O)OC(C)(C)O[C@H]3[C@@H]2O1,DC Chemicals,DC9074,-0.00735348,-4.17754569,1.25482625,2.22789116,3.04591468,-1.98621808,-38.85819521,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00095095-04,SENNOSIDE A,434147215,Helv Chim Acta 33: 313 (1950),Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,81-27-6,,2.8373476,1,-5.547087456,-124.3789323,-1.1,7,,-101.7950276,-96.54696133,3.66133E-05,0.99751974,,,[H][C@@]1(C2=CC(=CC(O)=C2C(=O)C3=C1C=CC=C3O[C@@H]4OC(CO)C(O)C(O)C4O)C(O)=O)[C@@]5([H])C6=CC(=CC(O)=C6C(=O)C7=C5C=CC=C7O[C@@H]8OC(CO)C(O)C(O)C8O)C(O)=O,Microsource,MS-01504078,3.31642033,0,0,-9.4047619,-37.24692697,-86.76530199,-96.54696133,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00169713-02,Oxyresveratrol,434147255,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,8.972480931,1,-5.047087456,-80.86147937,-2.1,7,,-99.97790055,-82.48158379,3.52581E-05,0.997566437,,,OC1=CC(=C(C=C1)\C=C\C2=CC(=CC(=C2)O)O)O,Analyticon,NP-003143,-0.78682256,0,0.75611326,-3.63945578,-21.24909617,-49.10822862,-82.48158379,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00017251-06,alpha-MANGOSTIN,434146890,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,6147/11/1,,1.790245307,1,-5.747087456,-132.5830188,-1.1,7,,-99.54088398,-96.27071823,2.13583E-05,0.998107494,,,COC1=C(CC=C(C)C)C2=C(OC3=C(C(=C(CC=C(C)C)C(=C3)O)O)C2=O)C=C1O,Microsource,MS-01504015,2.1104493,2.48809707,-0.72393822,-8.70748299,-53.1362979,-83.74543981,-96.27071823,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00013226-25,Trifluoperazine hydrochloride,384567788,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,440-17-5,,17.90245307,0,-4.747087456,-44.16925734,-2.2,7,,-93.7679558,-69.52117864,2.39182E-05,0.9979972,,DRD2,CN1CCN(CCCN2C3=C(SC4=C2C=C(C=C4)C(F)(F)F)C=CC=C3)CC1,MedChem Express,HY-B0532A,0,4.10075257,1.57657658,0.68027211,-5.17895879,-29.40818808,-69.52117864,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00165722-19,Plerixafor hydrochloride,384568275,Chemokine CXCR4 (SDF-1 Receptor) Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,4.007860013,1,-5.397087456,-54.42471762,-1.2,7,,-52.53867404,-48.13535912,0.001114887,0.986055296,7852,CXCR4,C1CNCCNCCCN(CCNC1)CC2=CC=C(CN3CCCNCCNCCCNCC3)C=C2,NCGCChem,AED021-093,2.83109052,3.17923514,-1.36743887,-3.7414966,-10.27657267,-44.89258208,-48.13535912,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00384199-05,4SC-202,384569106,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,910462-43-0,,7.127094939,1,-5.147087456,-63.38972622,-2.2,7,,-77.95856353,-68.71546961,3.30697E-05,0.997643599,,HDAC1,C[N]1C=C(C=N1)C2=CC=C(C=C2)[S+]([O-])(=O)[N]3C=CC(=C3)/C=C/C(=O)NC4=C(N)C=CC=C4,MedChem Express,HY-16012A,0,0,2.54182754,-0.10204082,-14.84996385,-43.71706526,-68.71546961,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00017376-12,Tetrandrine,434146967,Calcium Channel Blocker,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,518-34-3,,11.29568425,0,-4.947087456,-58.4781987,-2.2,7,,-71.37707183,-63.92725599,0.000510288,0.990636257,,,COC1=CC=C2C[C@@H]3N(C)CCC4=C3C(=C(OC)C(=C4)OC)OC5=C(OC)C=C6CCN(C)[C@@H](CC7=CC=C(OC1=C2)C=C7)C6=C5,Prestwick,Prestw-NAT-0181,0,-0.3839656,0.61132561,-6.02040816,-12.84345625,-32.87393595,-63.92725599,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00685392-02,Cenicriviroc Mesylate,,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,497223-28-6,,4.007860013,1,-5.397087456,-95.49548663,-1.1,7,,-93.52348066,-95.18876611,7.36718E-05,0.996475623,,,CCCCOCCOC1=CC=C(C=C1)C2=CC=C3N(CC(C)C)CCCC(=CC3=C2)C(=O)NC4=CC=C(C=C4)[S@@+]([O-])CC5=CN=CN5CCC,MedChem Express,HY-14882A,0,4.02395945,2.23616474,0,-12.08423717,-82.91447102,-95.18876611,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00159337-04,Efavirenz,170464810,Reverse Transcriptase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,154598-52-4," Sustiva;0   Efavirenz;DMP-266;L-743726; ;Stocrin;Sustiva; efavirenz (EFV or EFZ); Efavirenz;Efavirenz; efavirenz, (R)-isomer",22.53785311,0,-4.647087456,-18.62805843,-2.4,7,,-34.46132597,-26.63443831,0.000232282,0.993723779,7015,TERT,FC(F)(F)[C@@]3(C#CC1CC1)OC(=O)Nc2ccc(Cl)cc23,Vitas,STK582240,-0.30149276,-0.21502073,-1.11003861,0,-3.17245119,-8.39075801,-26.63443831,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00161621-13,Cepharanthine,406861842,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,481-49-2,,8.972480931,1,-5.047087456,-64.82139494,-2.2,7,,-81.08287293,-66.73572744,0.000335108,0.992434038,,,[H][C@@]12CC3=CC(OC4=CC=C(C[C@]5([H])N(C)CCC6=C5C(OC7=CC1=C(CCN2C)C=C7OC)=C8OCOC8=C6)C=C4)=C(OC)C=C3,APExBIO,N2771,1.08096184,2.01197973,-0.51480051,-8.19727891,-12.96999277,-40.81880827,-66.73572744,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00024936-06,N-Desmethylclozapine,406861836,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,6104-71-8,,20.08688273,0,-4.697087456,-15.24873648,-2.4,7,,-36.4917127,-26.24309392,0.000232217,0.993723635,,,ClC1=CC2=C(NC3=C(C=CC=C3)C(=N2)N4CCNCC4)C=C1,Adooq,A13762,2.36046768,0,0.67567568,-0.34013605,-1.63593637,-10.1945683,-26.24309392,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00163651-06,DIHYDROTANSHINONE I,434147021,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,10.06728919,0,-4.997087456,-85.6354744,-2.1,7,,-106.3342541,-94.15285451,0.000282563,0.993058853,,,C[C@H]1COC2=C1C(=O)C(=O)C3=C2C=CC4=C3C=CC=C4C,Microsource,1505825,3.68409442,0.61434495,-2.96010296,-8.29931973,-16.69378163,-52.31049858,-94.15285451,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00346692-04,CUDC-907,434146886,PI3K Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1339928-25-4,,5.661252742,1,-5.247087456,-100.2349783,-2.1,7,,-101.3530387,-87.54604052,0.000229575,0.993750611,,PIK3CA,COC1=CC=C(C=N1)C2=NC3=C(SC(=C3)CN(C)C4=NC=C(C=N4)C(=O)NO)C(=N2)N5CCOCC5,Selleck,S2759,3.34583425,1.48978652,-3.89317889,-11.66666667,-24.39443239,-64.97770572,-87.54604052,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00345794-11,MLN-4924,384568745,NEDD8-Activating Enzyme (NAE) Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,905579-51-3,,22.53785311,0,-4.647087456,-29.10634822,-2.2,7,,-76.55524862,-56.86003683,0.001847774,0.981926277,,NAE1,N[S+]([O-])(=O)OC[C@@H]1C[C@H](C[C@@H]1O)[N]2C=CC3=C2N=CN=C3N[C@H]4CCC5=C4C=CC=C5,ChemieTek,CT-M4924,4.05176851,2.82598679,-3.74839125,3.63945578,-4.02205351,-16.68017835,-56.86003683,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00090774-05,Nitazoxanide,170465090,antiprotozoal agent,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,55981-09-4,Nitazoxanide; ; Alinia; Nitazoxanida; Nitazoxanide,14.22042395,0,-4.847087456,-31.89383386,-2.2,7,,-61.99447514,-56.81399632,0.000411168,0.991608778,,,O=C(Nc1ncc(s1)[N+]([O-])=O)c2ccccc2OC(C)=O,Vitas,STK395664,0,-0.69113807,0.86872587,-2.29591837,3.28091106,-18.22051074,-56.81399632,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00165962-02,L-685458,434147034,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,292632-98-5,,20.08688273,0,-4.697087456,-38.47031551,-2.1,7,,-102.6671271,-88.74309392,0.000003758,0.999207655,,,CC(C)C[C@H](NC(=O)[C@@H](C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OC(C)(C)C)CC2=CC=CC=C2)C(=O)N[C@@H](CC3=CC=CC=C3)C(N)=O,Glixx,GLXC-06622,1.2574454,3.20995239,0.38610039,0.42517007,0.73210412,-16.70044589,-88.74309392,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00386289-08,Dynasore,387065823,Dynamin-2 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,[304448-55-3],,8.972480931,1,-5.047087456,-100.6728943,-2.1,7,,-112.0552486,-88.5359116,7.47328E-05,0.996450392,10059,,OC1=C(O)C=C(C=C1)\C=N\NC(=O)C2=C(O)C=C3C=CC=CC3=C2,Tocris,2897,-0.28678579,0.93687606,-5.0997426,-11.29251701,-29.13051338,-54.56019457,-88.5359116,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00263173-05,Rucaparib,384568643,PARP Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,459868-92-9,,20.08688273,0,-4.697087456,-22.99440667,-3,7,,-42.67679558,-31.81399632,0.073958455,0.862904154,,PARP1,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=CC(=CC(=C34)[NH]2)F,Selleck,S1098,3.19876461,-4.19290432,3.97361647,0.51020408,-11.54193782,-9.5460073,-31.81399632,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00346531-06,Oligomycin A,406861853,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,579-13-5,,10.06728919,0,-4.997087456,-60.3491545,-2.2,7,,-82.11878453,-76.0359116,0.000618394,0.989674613,,,[H][C@@]1(C)[C@@H]2CC[C@@H](CC)\C=C/C=C\C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@]([H])(O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)\C=C\C(=O)O[C@H]1[C@H](C)[C@@]3(CC[C@H](C)[C@H](C[C@@H](C)O)O3)O2,APExBIO,A5588,2.08103537,3.71678698,-0.08043758,-6.63265306,-6.69739696,-40.94041346,-76.0359116,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00509859-02,Paritaprevir,434147165,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1216941-48-8,,12.67396618,0,-4.897087456,-40.85774129,-2.2,7,,-61.44475138,-55.63996317,0.00057901,0.990016176,,,CC1=CN=C(C=N1)C(=O)N[C@H]2CCCCC\C=C/[C@@H]3C[C@]3(NC(=O)[C@@H]4C[C@H](CN4C2=O)OC5=NC6=C(C=CC=C6)C7=C5C=CC=C7)C(=O)N[S+]([O-])(=O)C8CC8,MedChem Express,HY-12594,0,3.51712487,-2.63835264,-2.90816327,-2.37707881,-26.0640454,-55.63996317,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00481588-01,ACY-241,384569257,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,22.53785311,0,-4.647087456,-23.40770591,-3,7,,-49.19613259,-37.26979742,0.009393124,0.957645038,,HDAC1,ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C2=CC=CC=C2)C3=C(Cl)C=CC=C3,APExBIO,B5936,0,0,0,2.84013605,-7.65545915,-9.93109039,-37.26979742,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00018130-08,PHENAZOPYRIDINE HYDROCHLORIDE,434147257,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,"136-40-3, 94-78-0 [phenazopyridine]",,10.06728919,0,-4.997087456,-84.97649702,-2.1,7,,-97.29676844,-92.67955801,5.33776E-05,0.997002844,,,NC1=CC=C(\N=N\C2=CC=CC=C2)C(=N1)N,Microsource,MS-01500473,-1.08096184,-1.85839349,-5.51801802,-4.88095238,-12.69884309,-48.68261046,-92.67955801,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00263136-04,Pracinostat,363677222,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,929016-96-6 ,,25.28788711,0,-4.597087456,-35.3018221,-3,7,,-81.82872928,-71.52394107,0.000816461,0.988105664,,HDAC1,CCCCC1=NC2=CC(=CC=C2[N]1CCN(CC)CC)/C=C/C(=O)NO,Arking Pharma,SB-939,0,-2.79526954,1.93050193,0.54421769,-7.00469993,-7.21524118,-71.52394107,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00015693-13,Mitoxantrone,434146945,DNA Topoisomerase II Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,70476-82-3,,0.400786001,1,-6.397087456,-198.1449302,-1.1,7,,-102.2493094,-99.74677716,1.97754E-05,0.998179167,,TOP2A,OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C3=C(C(=CC=C3O)O)C2=O,Selleck,S1889,0,4.79189065,-9.13770914,-46.29251701,-86.14425163,-96.5139846,-99.74677716,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00016000-18,Disulfiram,170464767,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,97-77-8, ;Tetraethylthiuram disulfide; Disulfiram; Tetraethylthiuram disulfide; Disulfiramo; Teturam; Antabuse;Disulfiram;DISULFIRAM,12.67396618,0,-4.897087456,-53.4321764,-3,7,,-40.90062631,-36.00368324,0.236122121,0.693766238,217,ALDH2,CCN(CC)C(=S)SSC(=S)N(CC)CC,Microsource,1500262,-3.448783,-1.91982798,-8.94465894,-15.13605442,-18.32067968,-9.8094852,-36.00368324,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00346833-03,PD-151746,434147096,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,179461-52-0,,10.06728919,0,-4.997087456,-95.11223219,-2.1,7,,-101.1276681,-91.82780847,1.60112E-05,0.99836221,,,OC(=O)/C(S)=C/C1=C[NH]C2=C1C=C(F)C=C2,Glixx,GLXC-06766,-1.71336128,-4.39256643,-4.72972973,-6.47959184,-19.47758496,-52.71584921,-91.82780847,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00389393-01,Lopinavir,434147138,HIV Protease Inhibitors,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,192725-17-0,,17.90245307,0,-4.747087456,-11.65171349,-3,7,,-45.35359116,-39.96316759,0.000754103,0.988582748,,,CC(C)C(N1CCCNC1=O)C(=O)NC(CC(O)C(CC2=CC=CC=C2)NC(=O)COC3=C(C)C=CC=C3C)CC4=CC=CC=C4,APExBIO,A8204,0,3.76286285,1.91441441,0,4.13051338,-6.3842724,-39.96316759,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00381565-04,RG2833,434147119,Histone deacetylase 3 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1215493-56-3,,22.53785311,0,-4.647087456,-14.44056192,-3,7,,-37.91712708,-34.57642726,0.000231732,0.993726418,8841,HDAC3,CC1=CC=C(C=C1)C(=O)NCCCCCC(=O)NC2=CC=CC=C2N,MedChem Express,HY-16425,0,-0.29181385,-1.67310167,1.8537415,0,-3.1617349,-34.57642726,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00016961-11,ATOVAQUONE,434146960,"Synergistic with proguanil, mitochondrial sensitizer (cytochrome bc1 complex)",Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,95233-18-4,,1.267396618,1,-5.897087456,-94.89274708,-2.2,7,,-73.84530387,-63.76611418,0.007367587,0.962772535,,,O\C1=C(/C2CCC(CC2)C3=CC=C(Cl)C=C3)C(=O)C4=C(C=CC=C4)C1=O,Microsource,1504210,2.30163983,0.73721395,-3.36229086,-16.95578231,-43.88105568,-43.02796919,-63.76611418,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00482591-01,Atractylon,,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,6989-21-5,,31.6227766,0,-4.5,-49.23684447,-2.1,7,,-84.71270718,-82.6427256,3.82397E-05,0.997465189,,,CC1=COC2=C1C[C@H]3C(=C)CCC[C@]3(C)C2,DC Chemicals,DCZ-188,1.81631002,4.34649055,0,-0.52721088,0,-36.50182408,-82.6427256,,,,,,,,,9.55E-09,4.78E-08,2.39E-07,1.19E-06,0.00000597,0.0000299,0.000149,,,,,,,,
NCGC00164140-08,DOCUSATE SODIUM,434146916,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,577-11-7,,17.90245307,0,-4.747087456,-15.81947324,-2.4,7,,-33.38674034,-29.48895028,4.52E-07,0.999725906,,,CCCCC(CC)COC(=O)CC(C(=O)OCC(CC)CCCC)[S]([O-])(=O)=O,Microsource,1503881,0,0,0,0,0,-7.80299959,-29.48895028,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00096023-03,"3,4 -DIHYDROXYFLAVONE",434147002,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,14919-49-4,,1.006728919,1,-5.997087456,-100.3921419,-1.2,7,,-61.06906077,-59.32320442,0.000407273,0.991648049,,,OC1=CC=C(C=C1)C/2=C(O)/C(=O)C3=C(O2)C=CC=C3,Microsource,1505138,-3.58114567,3.80893872,0.498713,-15.30612245,-41.36840202,-57.05310093,-59.32320442,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00508898-01,UCPH 101,434147164,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,[1118460-77-7],,10.06728919,0,-4.997087456,-60.84871095,-2.1,7,,-88.63812155,-81.14640884,0.000249224,0.993486006,,,COC1=CC=C(C=C1)C\2C(=C(/N)O\C3=C2C(=O)CC(C3)C4=C5C=CC=CC5=CC=C4)/C#N,Tocris,3490,0,0,3.02445302,4.21768707,-10.80079537,-42.68342116,-81.14640884,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00159456-06,Imatinib,124892208,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,152459-95-5,GGP-57148B; ; Imatinib base; Imatinib base(IMA-3);STI-571; Imatinib;Imatinib;Gleevec; Glivec,15.9555781,0,-4.797087456,-29.61901261,-2.2,7,STI571;Imatinib mesilate;IMATINIB;CIPLUS_700313;Imatinib Mesilate;4-(4-(4-METHYL-1-PIPERAZINYL)METHYL)-N-(4-METHYL-3-((4-(3-PYRIDINYL)-2-PYRIMIDINYL)AMINO)-PHENYL)BENZAMIDE MESYLATE;CIPLUS_670910;Imatinib mesylate;HS_649;imatinib;CPG-57148B;Glivec;Imatinib base;Genpharm brand of imatinib mesylate;IMATINIB MESILATE;Gleevec;CGP-57148;CGP 57148;imatinib mesylate;Imatinib;IMATINIB MESYLATE;CGP57148B;STI 571;imatinibum;Imatinib base(IMA-3);Novartis brand of imatinib mesylate;STI-571;,-57.00552487,-51.51933702,0.000800581,0.988226484,25,ABL1,CN1CCN(CC1)CC2=CC=C(C=C2)C(=O)NC3=CC=C(C)C(=C3)NC4=NC=CC(=N4)C5=CC=CN=C5,Sequoia,IMATINIB,0,2.81062817,-0.997426,-3.1462585,1.87093275,-17.00445886,-51.51933702,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00162068-04,Opipramol dihydrochloride,144206704,Serotonin 2 (5-HT2) receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,909-39-7,"Opipramol dihydrochloride; Insidon; Hydrochloride, Opipramo; ",20.08688273,0,-4.697087456,-8.948634075,-2.4,7,"NCGC00093619-01;opipramol hydrochloride;Opipramol;1-Piperazineethanol, 4-(3-(5H-dibenz(b,f)azepin-5-yl)propyl)-;NCGC00093619-02;CIPLUS_152628;Opipramolum;opipramolum;Opipramol Hydrochloride;OPIPRANMOL DIHYDROCHLORIDE;LS-112246;4-(3-(5H-Dibenz(b,f)azepin-5-yl)propyl)-1-piperazineethanol;LS-112248;OPIPRAMOL;OPIPRAMOL HYDROCHLORIDE;opipramol;Opipramol hydrochloride;Insidon;Hydrochloride, Opipramo;CIPLUS_213844;NCGC00162068-02;Opipramol dihydrochloride;4-[3-(5H-Dibenz[b,f]azepin-5-yl)propyl]-1-piperazineethanol dihydrochloride;NCGC00162068-01;",-31.73480662,-27.27900552,0.00112925,0.98597959,,,Cl.Cl.OCCN1CCN(CC1)CCCN3c4ccccc4C=Cc2ccccc23,Kemprotec,909-39-7,0,0,3.18532819,0,2.10592914,-4.37778679,-27.27900552,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00346565-08,Elvitegravir,434147209,HIV Integrase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,697761-98-1,,6.35203005,1,-5.197087456,-74.01134406,-1.1,7,,-83.42403315,-82.38950276,1.54173E-05,0.998392933,,,COC1=CC2=C(C=C1CC3=C(F)C(=CC=C3)Cl)C(=O)\C(=C/N2[C@H](CO)C(C)C)C(O)=O,APExBIO,A4070,0,0,3.08880309,-1.73469388,-3.02783803,-62.76854479,-82.38950276,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00021305-27,Sirolimus,434146972,mTOR Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,53123-88-9,,8.972480931,1,-5.047087456,-52.71753038,-2.2,7,,-71.77348066,-66.9198895,0.000174822,0.994554325,,MTOR,CO[C@@H]1C[C@@H](CC[C@H]1O)C[C@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C(C)/[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC,Enzo,A275,4.22825208,0,-0.997426,-2.58503401,-4.92588576,-38.40697203,-66.9198895,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00510794-01,KIN1408,406861860,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1903800-11-2,,2.253785311,1,-5.647087456,-114.6159867,-1.1,7,,-87.70911603,-90.19337017,8.5584E-06,0.998803416,,,COC1=CC=C2SC(=NC2=C1)NC(C3=CC=C(OC(F)F)C=C3)C4=CC=C5C=CC=NC5=C4O,SIGMA,SML1866,0,0,-0.9009009,-1.68367347,-28.96782357,-87.04904743,-90.19337017,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00522434-01,DPC-681,434147172,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,284661-68-3,,20.08688273,0,-4.697087456,-32.75349671,-2.2,7,,-60.33425414,-46.08655617,0.000477265,0.990951441,,,CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNCC2=CC=CC(=C2)F)C(C)(C)C)[S+]([O-])(=O)C3=CC(=CC=C3)N,MedChem Express,HY-19400,-0.46326936,2.84134542,-0.61132561,-2.56802721,-5.10665221,-17.67328739,-46.08655617,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00346533-07,Daclatasvir dihydrochloride,434147089,HCV NS5A Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1009119-64-5,,7.996732047,1,-5.097087456,-58.42349502,-2.2,7,,-78.32596686,-74.8388582,6.8732E-06,0.998927985,,,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C2=NC=C([NH]2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C([NH]5)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)C(C)C,MedChem Express,HY-10466,0,2.64168331,0.69176319,0.27210884,-5.1428055,-44.40616133,-74.8388582,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00161626-04,Euphobiasteroid,434147012,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,28649-59-4,,5.045596817,1,-5.297087456,-42.10652276,-1.2,7,,-31.23480663,-31.44567219,0.007647226,0.962056791,,,[H][C@]12CC[C@@]3(CO3)[C@@H](OC(C)=O)[C@@]4([H])[C@@H](OC(=O)CC5=CC=CC=C5)[C@@H](C)C[C@]4(OC(C)=O)C(=O)\C(C)=C\[C@@]1([H])C2(C)C,DC Chemicals,DCQ-059,0.30149276,-5.71340808,-4.63320463,0.20408163,-8.23391179,-26.40859343,-31.44567219,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00018261-09,Perhexiline,384568001,mitochondrial carnitine palmitoyltransferase-1 inhbitior,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,"6724-53-4, 6621-47-2 [perhexiline]",,15.9555781,0,-4.797087456,-30.26993597,-2.2,7,,-31.70994475,-31.00828729,0.043371167,0.900686076,,,C1CCC(CC1)C(CC2CCCCN2)C3CCCCC3,Microsource,1503227,2.36046768,-3.42497312,-5.21235521,-8.62244898,-0.84056399,-12.48479935,-31.00828729,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00163470-28,FK-506,384568242,mTOR Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,104987-11-3,,20.08688273,0,-4.697087456,-22.08394919,-2.2,7,,-48.30386741,-37.73020258,2.83764E-05,0.997819146,,MTOR,CO[C@@H]1C[C@@H](CC[C@H]1O)/C=C(C)/[C@H]2OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@]4(O)O[C@H]([C@H](C[C@@H](C)C\C(=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC)[C@H](C[C@H]4C)OC,Bio Vision,1563,0,0,0,1.54761905,-1.58170644,-12.58613701,-37.73020258,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00388216-01,Corilagin,434146919,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,23094-69-1,,0.126739662,1,-6.897087456,-160.6500534,-1.2,7,,-73.51519337,-70.18876611,0.000216449,0.99393415,,,OC1C2COC(=O)C3=CC(=C(O)C(=C3C4=C(O)C(=C(O)C=C4C(=O)OC1C(O)C(O2)OC(=O)C5=CC(=C(O)C(=C5)O)O)O)O)O,Cayman,11832,2.58107214,-4.13146982,-26.38352638,-46.32653061,-58.23391179,-62.58613701,-70.18876611,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00411883-01,NCGC00411883-01,,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,2.253785311,1,-5.647087456,-78.58635629,-1.2,7,,-65.31491713,-64.18047882,0.000399801,0.991725917,,,COCCNC(=O)NC1=CC2=C(C=C1)N=C(C3=CC=CS3)C(=N2)C4=CC=CS4,NCGCChem,MLS000534714-02pur,0.23531142,0,2.12355212,1.2755102,-30.1428055,-53.68869072,-64.18047882,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00601824-01,UPGL00004,434147181,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1890169-95-5,,20.08688273,0,-4.697087456,-59.59521474,-2.1,7,,-110,-83.33333333,0.000218614,0.993903411,,,O=C(CC1=CC=CC=C1)NC2=NN=C(NC3CCN(CC3)C4=NN=C(NC(=O)CC5=CC=CC=C5)S4)S2,Selleck,S8778,-0.80152952,-1.61265551,2.31660232,0.10204082,-11.19848156,-31.98216457,-83.33333333,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00346694-03,MK-2048,434147095,HIV Integrase Inhibitors,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,869901-69-9,,17.90245307,0,-4.747087456,-59.52863796,-2.1,7,,-100.9809392,-94.24493554,0.004995974,0.96967893,,,CCN1C[C@H](C)[N]2C(=C(O)C3=C2\C(=N/N(CC4=CC=C(F)C(=C4)Cl)C3=O)C(=O)NC)C1=O,APExBIO,A4072,0,4.59222854,-14.81660232,-2.43197279,0,-25.11147142,-94.24493554,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00162073-12,H-89,384568218,AKT Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,130964-39-5,,15.9555781,0,-4.797087456,-28.09634506,-2.2,7,,-54.25414365,-49.05616943,3.2131E-06,0.999267669,,AKT1,[O-][S+](=O)(NCCNC\C=C\C1=CC=C(Br)C=C1)C2=CC=CC3=CN=CC=C23,MedChem Express,HY-15979A,0,0,0,0,0.26211135,-15.78840697,-49.05616943,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00016480-10,Kaempferol,,flavanoid,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,[520-18-3],,2.008688273,1,-5.697087456,-75.65506207,-1.2,7,,-56.98618785,-56.46869245,0.000656325,0.989358188,,,OC1=CC=C(C=C1)\C2=C(O)\C(=O)C3=C(O2)C=C(O)C=C3O,Tocris,3603,0,0,0,-4.9829932,-30.84779465,-44.0008107,-56.46869245,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00390251-01,Isochlorogenic acid A,434147139,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,2450-53-5,,8.972480931,1,-5.047087456,-32.41857624,-2.2,7,,-45.98066299,-39.45672192,0.000437937,0.991338625,,,OC1[C@@H](CC(O)(C[C@H]1OC(=O)\C=C\C2=CC(O)=C(O)C=C2)C(O)=O)OC(=O)\C=C\C3=CC(O)=C(O)C=C3,Adooq,A12072,0,3.63999386,0,-1.98979592,-4.81742589,-23.36846372,-39.45672192,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00510317-02,Elbasvir,405558499,Nonstructural protein 5A Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1370468-36-2,,2.008688273,1,-5.697087456,-132.8220263,-1.1,7,,-100.2116022,-97.9281768,3.7648E-06,0.999206894,,,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C2=NC=C([NH]2)C3=CC=C4C(=C3)O[C@H]([N]5C6=C(C=C(C=C6)C7=CN=C([NH]7)[C@@H]8CCCN8C(=O)[C@@H](NC(=O)OC)C(C)C)C=C45)C9=CC=CC=C9,MedChem Express,HY-15789,1.28685933,0.29181385,1.88223938,-11.2585034,-47.85791757,-85.38710985,-97.9281768,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00094931-06,Lapachol,434146994,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,84-79-7,,39.81071706,0,-4.4,-73.56631435,-2.2,7,,-94.48838769,-75.09208103,0.000361134,0.992141883,,,CC(C)=CCC/1=C(O)/C(=O)C2=C(C=CC=C2)C1=O,Prestwick,Prestw-NAT-0052,-3.81645709,-2.61096606,-3.37837838,-7.89115646,-15.33803326,-32.18483989,-75.09208103,,,,,,,,,6.37E-09,3.18E-08,1.59E-07,7.96E-07,0.00000398,0.0000199,9.95E-05,,,,,,,,
NCGC00686694-01,Remdesivir,406861862,RNA-dependent RNA polymerase inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1809249-37-3,,22.53785311,0,-4.647087456,-24.89774845,-2.2,7,,-51.83425414,-41.9198895,0.001578457,0.983339372,,,CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@](C#N)([C@H](O)[C@@H]1O)C2=CC=C3N2N=CN=C3N)OC4=CC=CC=C4,MedChem Express,HY-104077,-1.46334289,1.16725541,2.49356499,-3.63945578,-2.50361533,-10.27563843,-41.9198895,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00263155-04,Belinostat,384568629,HDAC Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,414864-00-9,,17.90245307,0,-4.747087456,-30.04644607,-2.2,7,,-59.10497238,-49.70073665,1.70E-08,0.999946869,,HDAC1,ONC(=O)/C=C/C1=CC(=CC=C1)[S+]([O-])(=O)NC2=CC=CC=C2,Selleck,S1085,0,0,0,-0.15306122,-1.7263196,-16.11268747,-49.70073665,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00163510-01,Aloe-emodin,26756894,Caspase 3 Activator,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,481-72-1,ALOE-EMODINE;Aloe-emodin,1.006728919,1,-5.997087456,-83.35646867,-1.2,7,"ALOE-EMODINE;Aloe Emodin;aloe-emodin;ALOE-EMODIN;LS-2202;aloe-emodin 1-O-glucopyranoside;Aloeemodin:9,10-Anthracenedione,1,8-dihydroxy-3-(hydroxymethyl)-,;Aloe-emodin;ALOE EMODIN;Anthraquinone, 1,8-dihydroxy-3-hydroxymethyl-;NCGC00163510-02;NCGC00163510-01;aloe-emodin 1-O-Glc;1,8-Dihydroxy-3-(hydroxymethyl)anthraquinone;CIPLUS_153452;",-34.07161573,-38.83517495,0.002591032,0.97848585,836,CASP3,OCC1=CC(O)=C2C(=O)C3=C(C=CC=C3O)C(=O)C2=C1,BIOMOL,BIOMOL_NP-005,-5.62541363,-3.22531101,-11.502574,-12.46598639,-29.38358641,-36.27888123,-38.83517495,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00480778-01,Scutellarin,434147152,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,27740-01-8,,10.06728919,0,-4.997087456,-23.820511,-2.2,7,,-32.62983426,-30.52486188,0.002161804,0.980417579,,,O[C@@H]1[C@@H](O)[C@@H](O[C@@H]([C@H]1O)C(O)=O)OC2=C(O)C(=C3C(=O)/C=C(OC3=C2)/C4=CC=C(O)C=C4)O,Adooq,A12117,0,0,-3.05662806,2.65306122,-1.92516269,-16.39643291,-30.52486188,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00651745-01,ABBV-744,434147256,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,2138861-99-9,,12.67396618,0,-4.897087456,-70.48650401,-2.2,7,,-77.95718232,-71.89226519,0.014546809,0.946308764,,,CCNC(=O)C1=CC2=C(N1)C(=O)N(C)C=C2C3=C(OC4=C(C)C=C(F)C=C4C)C=CC(=C3)C(C)(C)O,Selleck,S8723,1.62511949,1.2901244,-16.44144144,-2.65306122,-13.04229935,-35.81272801,-71.89226519,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00183682-13,VX-765,434147195,Caspase-1 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,273404-37-8,,20.08688273,0,-4.697087456,-9.721774071,-3,7,,-36.70718232,-34.39226519,0.005250882,0.968899114,,CASP1,CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)C3=CC(=C(N)C=C3)Cl)C(C)(C)C,ChemieTek,CT-VX765,0,4.54615266,-2.7992278,3.19727891,0,-1.56059992,-34.39226519,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00016622-11,Hycanthone,434146889,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,3105-97-3,,22.53785311,0,-4.647087456,-45.3141454,-2.2,7,,-80.6160221,-65.23941068,8.76314E-05,0.996154956,,,CCN(CC)CCNC1=C2C(=O)C3=C(SC2=C(CO)C=C1)C=CC=C3,Prestwick,Prestw-355,-1.15449665,0,-3.23359073,-2.46598639,-6.06471439,-18.84880422,-65.23941068,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00390429-01,Isoxanthohumol,434147201,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,70872-29-6,,22.53785311,0,-4.647087456,-23.43959584,-2.2,7,,-64.45027624,-51.15101289,0.000285956,0.993019016,,,COC1=CC(=C(CC=C(C)C)C2=C1C(=O)CC(O2)C3=CC=C(O)C=C3)O,Bio Vision,2529,-1.21332451,0,1.46396396,3.80952381,-0.96710051,-10.64045399,-51.15101289,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00180839-02,Penta-O-galloyl-??-D-glucose hydrate,434147057,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,14937-32-7 (anhydrous),,0.14220424,1,-6.847087456,-236.0569157,-1.1,7,,-100.2707182,-97.83609576,1.19797E-05,0.998583758,,,OC1=C(O)C(=CC(=C1)C(=O)OC[C@H]2O[C@@H](OC(=O)C3=CC(=C(O)C(=C3)O)O)[C@H](OC(=O)C4=CC(=C(O)C(=C4)O)O)[C@@H](OC(=O)C5=CC(=C(O)C(=C5)O)O)[C@@H]2OC(=O)C6=CC(=C(O)C(=C6)O)O)O,SIGMA,G7548,2.41929554,1.48978652,-28.94144144,-76.93877551,-91.24186551,-95.804621,-97.83609576,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00244248-01,NCGC00244248-01,,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,31.83556369,0,-4.497087456,-14.49222473,-3,7,,-40.17541436,-36.11878453,0.007433108,0.962620386,,,CC(C)C[C@H](N[C@@H](CC1=CN=C[N]1CC2=CC(=CC(=C2)Cl)Cl)C(O)=O)C(O)=O,NCGCChem,JKJ16-009,-5.71365542,-0.3839656,2.55791506,0,0.53326103,1.68220511,-36.11878453,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00346534-07,MC-1568,434147252,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,852475-26-4,,5.661252742,1,-5.247087456,-104.9358944,-2.1,7,,-112.378453,-96.82320442,3.43548E-05,0.997597807,,HDAC2,C[N]1C=C(/C=C/C(=O)C2=CC=CC(=C2)F)C=C1\C=C\C(=O)NO,Adooq,A10560,0,0,3.65186615,-7.65306122,-29.85357918,-67.57194974,-96.82320442,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00250412-15,JQ1,434146892,Brd4 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1268524-70-4,,15.9555781,0,-4.797087456,-30.7819699,-2.2,7,,-65.01381216,-57.96500921,0.00055961,0.990187392,,BRD4,CC1=C(C)C2=C(S1)[N]3C(=NN=C3[C@H](CC(=O)OC(C)(C)C)/N=C2/C4=CC=C(Cl)C=C4)C,MedChem Express,HY-13030,4.71358188,0,0,-2.61904762,0.38864787,-18.40291852,-57.96500921,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00091823-01,Chrysophanol,17389107,VEGFR-1/2 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,481-74-3,"CHRYSOPHANOL;Chrysophanic acid (1,8-Dihydroxy-3-methylanthraquinone)",2.8373476,1,-5.547087456,-62.9686803,-2.2,7,"chrysophanic acid, ion (1-);Chrysophanic acid;chrysophanic acid;1,8-Dihydroxy-3-methylanthraquinone;CHRYSOPHANOL;NCGC00160154-01;Chrysophanol:9,10-Anthracenedione,1,8-dihydroxy-3-methyl;CHRYSOPHANIC ACID;Chrysophanic acid (1,8-Dihydroxy-3-methylanthraquinone);AB08582917-01;2-methyl-4,5-dihydroxyanthraquinone;chrysophanol 8-O-(6'-galloyl)glucopyranoside;1,8-Dihydroxy-3-methyl-anthraquinone;chrysophanol;CIPLUS_153453;3-methyl-1,8-dihydroxyanthraquinone;Chrysophanic Acid;NCGC00091823-02;chrysophanol 8-O-GGlc;",-54.97513812,-45.39594843,0.000659191,0.98933686,2321,FLT1,CC1=CC(=C2C(=O)C3=C(O)C=CC=C3C(=O)C2=C1)O,NIEHS,AB08582917,0,2.02733835,-1.96267696,-11.56462585,-23.68944324,-32.0632347,-45.39594843,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00480790-01,Coptisine,,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,3486-66-6,,31.83556369,0,-4.497087456,-16.45986286,-3,7,,-34.14640884,-32.2053407,0.063485469,0.875220205,,,C1OC2=C(O1)C=C3C(=C2)CC[N+]4=C3C=C5C=CC6=C(OCO6)C5=C4,Adooq,A14548,2.84579749,-3.31746276,-8.73552124,-4.06462585,2.86514823,2.43210377,-32.2053407,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00263182-04,Mocetinostat,384568650,HDAC Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,726169-73-9,,20.08688273,0,-4.697087456,-15.4568616,-3,7,,-46.12154697,-44.84346225,3.56803E-05,0.997552862,,HDAC1,NC1=C(NC(=O)C2=CC=C(CNC3=NC(=CC=N3)C4=CC=CN=C4)C=C2)C=CC=C1,Selleck,S1122,0,0,2.17181467,-0.34013605,0,-1.39845967,-44.84346225,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00480772-03,Oroxylin A,376241613,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,480-11-5,,10.06728919,0,-4.997087456,-50.37960709,-2.2,7,,-82.67403314,-75.1611418,3.50065E-05,0.997575231,,,COC1=C(O)C=C2O\C(=C/C(=O)C2=C1O)C3=CC=CC=C3,CANVASS,57a2faeef1704b5b7a46901d,3.2870064,0,2.04311454,2.27891156,-5.59472162,-37.00851236,-75.1611418,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00389721-01,Q-VD-OPh hydrate,363680840,Irreversible pan-Caspase inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1135695-98-5,,25.28788711,0,-4.597087456,-33.91304069,-3,7,,-76.93370166,-70.99447514,3.56329E-05,0.997553684,,CASP3,CC(C)C(NC(=O)C1=NC2=CC=CC=C2C=C1)C(=O)NC(CC(O)=O)C(=O)COC3=C(F)C=CC=C3F,APExBIO,A1901,-1.97808662,-2.28843496,-3.53925354,0.42517007,-0.42480116,-4.5804621,-70.99447514,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00390568-02,Bevirimat,434147142,Gag-Pol polyprotein Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,174022-42-5,,15.9555781,0,-4.797087456,-53.56776327,-2.1,7,,-104.4523481,-88.42081031,9.2129E-06,0.998758472,,,CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O,MedChem Express,HY-N0842,0,3.45569037,0,0,-2.95553145,-32.67126064,-88.42081031,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00385072-01,Schisandrin C,363679517,<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,22.08287043,0,-4.655944476,-23.56537348,-3,7,,-49.91298343,-44.22191529,0.001253734,0.985195235,,,COC1=C2OCOC2=CC3=C1C4=C(CC(C)C(C)C3)C=C5OCOC5=C4OC,Analyticon,NP-015228,-0.12500919,-0.93687606,0.9009009,-3.50340136,0,3.20226996,-44.22191529,,,,,,,,,2.13E-09,1.07E-08,5.33E-08,2.67E-07,0.00000133,0.00000667,3.33E-05,,,,,,,,
NCGC00274060-07,Posaconazole,434147080,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,171228-49-2,,2.008688273,1,-5.697087456,-81.70351992,-1.2,7,,-64.10701256,-54.37384899,0.004494105,0.971319076,,,CC[C@@H]([C@H](C)O)N1\N=C/N(C1=O)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(OC[C@@H]5CO[C@](CN6C=NC=N6)(C5)C7=CC=C(F)C=C7F)C=C4,APExBIO,A1718,2.74284874,2.53417294,4.48841699,-2.26190476,-26.94323933,-70.69314957,-54.37384899,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00094047-16,Ivermectin,434147263,Glutamate-gated Chloride Channel Activator,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,70288-86-7,,6.35203005,1,-5.197087456,-116.0480536,-2.1,7,,-80.75621415,-84.92173112,0.000104806,0.995791953,,,[H][C@@](C)(CC)[C@@]1([H])O[C@]2(CC[C@@H]1C)C[C@@H]3C[C@@]([H])(C\C=C(C)\[C@@H](O[C@@]4([H])C[C@H](OC)[C@@H](O[C@@]5([H])C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)[C@@H](C)\C=C\C=C6/CO[C@]7([H])[C@H](O)C(C)=C[C@@]([H])(C(=O)O3)[C@]67O)O2,MedChem Express,HY-15310_cm1,-6.18427826,-9.55306405,-8.94465894,-14.57482993,-21.48409255,-61.20794487,-84.92173112,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00263192-04,Silmitasertib,384568656,Casein Kinase 2 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1009820-21-6 (parent),,17.90245307,0,-4.747087456,-16.13116376,-3,7,,-35.3839779,-34.06998158,0.044670697,0.898902851,,CSNK2A1,OC(=O)C1=CC2=C(C=C1)C3=CN=CC=C3C(=N2)NC4=CC=CC(=C4)Cl,Axon Medchem,1965,-8.59622031,3.57855936,4.61711712,0,1.41901663,-5.08715039,-34.06998158,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00091208-11,HEXYLRESORCINOL,434146986,Tyrosinase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,136-77-6,,17.90245307,0,-4.747087456,-43.87732703,-2.2,7,,-78.83149172,-61.99355433,8.6107E-06,0.998800007,,,CCCCCCC1=C(O)C=C(O)C=C1,Microsource,1500330,-1.11037576,0,1.23873874,-1.07142857,-5.35972523,-25.05066883,-61.99355433,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00165733-10,Apicidin,434147223,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,183506-66-3,,11.29568425,0,-4.947087456,-20.93182737,-2.2,7,,-51.90607735,-45.00460405,0.000045316,0.997240454,,,CC[C@H](C)[C@@H]1NC(=O)[C@H](CC2=C[N](OC)C3=CC=CC=C23)NC(=O)[C@H](CCCCCC(=O)CC)NC(=O)[C@H]4CCCCN4C1=O,Enzo,GR-340,2.19869108,3.7935801,3.2014157,1.46258503,2.16015907,-20.61207945,-45.00460405,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00249613-08,Carfilzomib,434147069,Proteasome Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,868540-17-4,,31.83556369,0,-4.497087456,-19.72860563,-3,7,,-50.14364641,-46.1786372,0.002570105,0.978571772,,PSMD1,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,Aobious,AOB87759,-0.36032061,0.27645523,-3.33011583,-0.54421769,-4.29320318,3.32387515,-46.1786372,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00249377-04,IU1,363677167,Ubiquitin carboxyl-terminal hydrolase 14 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,314245-33-5,,22.53785311,0,-4.647087456,-34.04748764,-2.2,7,,-87.16574586,-75.13812155,0.000782937,0.988356884,,,CC1=CC(=C(C)[N]1C2=CC=C(F)C=C2)C(=O)CN3CCCC3,Selleck,S7134,3.65468049,1.56657963,2.84749035,-2.82312925,-5.17895879,-11.79570328,-75.13812155,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00163589-02,LUTEOLIN-7-GLUCOSIDE,434147020,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,8.972480931,1,-5.047087456,-81.30357611,-2.2,7,,-80.75414365,-61.55616943,0.00040149,0.991709204,,,OC[C@H]1O[C@@H](OC2=CC(=C3C(=O)\C=C(/OC3=C2)C4=CC=C(O)C(=C4)O)O)[C@H](O)[C@@H](O)[C@@H]1O,Analyticon,NP-001730,1.46334289,-5.29872523,-7.19111969,-10.25510204,-23.16522053,-41.2241589,-61.55616943,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
MLS000543798-03,MLS000543798-03,406861831,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,7.996732047,1,-5.097087456,-126.0763254,-2.1,7,,-103.4495577,-90.76887661,3.0658E-06,0.999284443,,,C1CN(CCO1)C2=NC(NC3=CC=CC=C3)=NC(N\N=C\C4=CNC5=C4C=CC=C5)=N2,Specs,AG-205/33155024,-6.30193397,-6.88066349,-10.15122265,-16.41156463,-30.93817787,-62.6469396,-90.76887661,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00386434-02,GSK744 (S/GSK1265744),363680286,Solute carrier family 22 member 8 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1051375-10-0,,7.996732047,1,-5.097087456,-80.11796342,-2.1,7,,-83.54060773,-84.85267035,0.002990056,0.976811909,,,C[C@H]1CO[C@@H]2CN\3/C=C(/C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)\C(=C3C(=O)N12)O,APExBIO,A8566,-12.43473785,2.84134542,3.31402831,-3.43537415,-4.90780911,-54.60072963,-84.85267035,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00379057-02,TMC353121,434146905,Respiratory syncytial virus Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,857066-90-1,,7.127094939,1,-5.147087456,-78.92012277,-2.1,7,,-96.475,-87.45395948,9.54148E-05,0.995986035,,,CC1=CC=C(CCCO)C(=C1)NCC2=CC=C3N=C(NCCCN4CCOCC4)[N](CC5=NC(=CC=C5O)C)C3=C2,MedChem Express,HY-11097,0,0,0,3.31632653,-16.78416486,-55.45196595,-87.45395948,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00356145-10,CB-839,384569029,Glutaminase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1439399-58-2,,22.53785311,0,-4.647087456,-10.04697035,-3,7,,-36.45856353,-31.21546961,0.003055554,0.97657276,,GLS,FC(F)(F)OC1=CC=CC(=C1)CC(=O)NC2=NN=C(CCCCC3=NN=C(NC(=O)CC4=CC=CC=N4)S3)C=C2,MedChem Express,HY-12248,2.37517465,3.30210413,0,0.66326531,-2.53976862,-2.99959465,-31.21546961,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00016872-19,Ticlopidine hydrochloride,384567964,P2Y12 (P2T) Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,53885-35-1,,20.08688273,0,-4.697087456,-8.603394975,-3,7,,-35.65469614,-34.34622468,0.004112696,0.972641128,,P2RY12,ClC1=C(CN2CCC3=C(C2)C=CS3)C=CC=C1,MedChem Express,HY-B0153A,2.50753732,0.29181385,0,-2.78911565,4.40166305,0,-34.34622468,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00483024-01,BMS-791325 hydrochloride,377020421,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,958002-36-3,,7.996732047,1,-5.097087456,-75.02779243,-2.1,7,,-87.61325967,-80.80110497,0.000654526,0.98937169,,,COC1=CC2=C(C=C1)C3=C(C4CCCCC4)C5=C(C=C(C=C5)C(=O)N[S+]([O-])(=O)N(C)C)[N]3C[C@]6(C[C@@H]26)C(=O)N7[C@H]8CC[C@@H]7CN(C)C8,DC Chemicals,DC9232,-1.81631002,0.30717248,4.44015444,-8.01020408,-11.16232827,-50.06080259,-80.80110497,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00601806-01,TH34,434147179,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,2196203-96-8,,25.28788711,0,-4.597087456,-30.57646826,-3,7,,-36.12707182,-30.93922652,0.023837891,0.929531659,,,CC1=CC=C(C=C1NCC2=CC=CC=C2)C(=O)NO,Selleck,S8773,-5.41951614,2.67240055,-5.38931789,-4.06462585,-5.41395517,-9.38386704,-30.93922652,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00390769-01,HIV-1 integrase inhibitor,434147147,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,544467-07-4,,31.83556369,0,-4.497087456,-39.83645159,-3,7,,-76.88121547,-70.94843462,0.000696135,0.989033957,,,OC(=O)\C(O)=C\C(=O)C1=CC=CC(=C1)CN=[N+]=[N-],MedChem Express,HY-13025,0.58092507,-2.62632468,-8.38159588,-4.50680272,-2.57592191,-3.93190109,-70.94843462,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00168776-10,Delavirdine (mesylate),434147213,Human immunodeficiency virus type 1 reverse transcriptase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,147221-93-0,,22.53785311,0,-4.647087456,-17.2720963,-3,7,,-70.75966851,-61.04972376,0.000197476,0.994209311,,,CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C([NH]3)C=CC(=C4)N[S+](C)([O-])=O,MedChem Express,HY-10571A,3.7723362,0,4.90669241,0.35714286,0.96710051,-4.84394001,-61.04972376,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00018100-16,Fasudil hydrochloride,384567990,ROCK Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,105628-07-7,,31.83556369,0,-4.497087456,-37.23214351,-3,7,,-67.13950276,-64.15745856,0.005883446,0.966956947,,ROCK1,[O-][S+](=O)(N1CCCNCC1)C2=C3C=CN=CC3=CC=C2,MedChem Express,HY-10341,3.94881977,-5.19121487,-9.74903475,-2.95918367,-6.01048445,-1.90514795,-64.15745856,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00378657-01,Simeprevir,405558913,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,923604-59-5,,7.996732047,1,-5.097087456,-74.68011825,-2.1,7,,-96.90856353,-89.80202578,1.08716E-05,0.998651062,,,COC1=C(C)C2=C(C=C1)C(=CC(=N2)C3=NC(=CS3)C(C)C)O[C@@H]4C[C@@H]5C(C4)C(=O)N(C)CCCC\C=C/[C@@H]6C[C@]6(NC5=O)C(=O)N[S+]([O-])(=O)C7CC7,MedChem Express,HY-10241,0,0.87544156,0,2.80612245,-9.68004338,-55.6749088,-89.80202578,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00480888-01,STING agonist G10,434146932,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,702662-50-8,,12.67396618,0,-4.897087456,-37.8086409,-2.2,7,,-65.44475138,-59.80662983,0.000422398,0.991492985,,,FC1=C(CN2C(=O)CSC3=CC=C(C=C23)C(=O)NCC4=CC=CO4)C(=CC=C1)Cl,Glixx,GLXC-07341,0,0,0,-2.56802721,2.6120752,-24.05755979,-59.80662983,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00263103-09,Pelitinib,434147073,EGFR Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,257933-82-7,,11.29568425,0,-4.947087456,-52.18429646,-2.2,7,,-68.41436464,-60.45119705,0.004697916,0.970648176,,EGFR,CCOC1=C(NC(=O)\C=C\CN(C)C)C=C2C(=C1)N=CC(=C2NC3=CC(=C(F)C=C3)Cl)C#N,MedChem Express,HY-32718,0.31619972,1.18261404,3.21750322,-9.76190476,-9.77042661,-29.50952574,-60.45119705,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00017236-16,Baicalein,384567977,Cyp2C9 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,491-67-8,,15.9555781,0,-4.797087456,-38.9580333,-2.2,7,,-89.90331491,-69.24493554,4.48642E-05,0.997253606,,CYP2C9,OC1=CC2=C(C(=O)\C=C(/O2)C3=CC=CC=C3)C(=C1O)O,APExBIO,N1858,4.74299581,0,2.76705277,2.70408163,-3.10014461,-29.06364005,-69.24493554,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00024415-61,Doxorubicin,434146978,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,23214-92-8,,17.90245307,0,-4.747087456,-42.61911859,-2.2,7,,-66.47237569,-50.73664825,3.85101E-05,0.997456983,,TOP2A,COC1=CC=CC2=C1C(=O)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C(=O)CO)C(=C3C2=O)O,Microsource,1505483,-0.68387381,-1.22868991,0.01608752,-1.20748299,-8.46890817,-23.73327929,-50.73664825,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00482878-01,VR23,434147217,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1624602-30-7,,5.661252742,1,-5.247087456,-102.2095848,-2.1,7,,-102.218232,-89.22651934,7.48417E-05,0.99644773,,,[O-][N+](=O)C1=CC=C(C(=C1)[N+]([O-])=O)[S+]([O-])(=O)N2CCN(CC2)C3=CC=NC4=CC(=CC=C34)Cl,DC Chemicals,DC8448,0,2.0580556,-4.85842986,-5.27210884,-30.34164859,-62.93068504,-89.22651934,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00015735-22,Niclosamide,,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,50-65-7,,3.183556369,1,-5.497087456,-57.53582605,-1.2,7,,-52.07734807,-49.60865562,0.000442975,0.991285466,,STAT3,OC1=C(C=C(Cl)C=C1)C(=O)NC2=C(Cl)C=C(C=C2)[N+]([O-])=O,MedChem Express,HY-B0497,3.59585264,-1.65873138,2.25225225,-4.03061224,-15.01265365,-43.2914471,-49.60865562,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00522552-01,PI4KIIIbeta-IN-10,434147175,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1881233-39-1,,11.29568425,0,-4.947087456,-80.88262972,-2.1,7,,-87.87430939,-81.46869245,0.003155839,0.97615324,,,COC1=CC=C(C=C1[S+]([O-])(=O)NC2=CC=C(O)C=C2)C3=C(C)N=C(NC(=O)C(C)(C)C)S3,MedChem Express,HY-100198,2.84579749,-3.85501459,-13.0952381,-4.69387755,-12.8615329,-43.69679773,-81.46869245,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00186460-07,Bardoxolone methyl,,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,218600-53-4,,17.90245307,0,-4.747087456,-37.35538475,-2.2,7,,-90.48342541,-66.27532228,0.000129649,0.995316346,,NFKB1,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]3C(=O)\C=C\4[C@@](C)(CC[C@H]5C(C)(C)C(=O)\C(=C/[C@]45C)C#N)[C@]3(C)CC2,Adooq,A11323,4.90477241,0,4.44015444,0,-3.19052784,-27.34089988,-66.27532228,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00015273-15,Chlorpromazine hydrochloride,124879758,Histamine H1 receptor Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,69-09-0,,20.08688273,0,-4.697087456,-43.80881618,-2.2,7,CHLORPROMAZINE HCl,-83.59392265,-63.32872928,3.50391E-05,0.997574358,,,CN(C)CCCN1C2=C(SC3=C1C=C(Cl)C=C3)C=CC=C2,BIOMOL,AC749,1.68394735,0,-2.05920206,-0.37414966,-5.57664497,-24.86826105,-63.32872928,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00263180-08,Trametinib,384568648,Mek 1/2 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,871700-17-3,,25.28788711,0,-4.597087456,-21.0526649,-3,7,,-56.50276244,-44.84346225,0.003064856,0.976522543,,MAP2K1,CN1C(=O)C(=C/2N(C(=O)N(C3CC3)C(=O)C2=C1/NC4=CC=C(I)C=C4F)C5=CC=CC(=C5)NC(C)=O)\C,APExBIO,A3018,0,0,4.66537967,0,-4.63665944,-7.60032428,-44.84346225,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00510789-01,RSV604,434147167,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,676128-63-5,,17.90245307,0,-4.747087456,-8.04589678,-2.4,7,,-35.91712708,-24.93093923,0.001098045,0.986179922,,,FC1=CC=CC=C1NC(=O)N[C@H]2\N=C(\C3=CC=CC=C3)C4=CC=CC=C4NC2=O,SIGMA,SML1695,2.02220752,3.42497312,4.2953668,0,0,-9.1609242,-24.93093923,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00378881-01,Tegobuvir,363678254,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1000787-75-6,,20.08688273,0,-4.697087456,-20.95082597,-2.4,7,,-39.21823204,-29.76519337,0.001946713,0.981451933,,,FC1=CC=CC=C1C2=NC3=C[N](CC4=NN=C(C=C4)C5=CC=C(C=C5C(F)(F)F)C(F)(F)F)C=CC3=N2,MedChem Express,HY-10544,-2.09574233,2.07341422,1.41570142,-1.49659864,-3.31706435,-11.12687475,-29.76519337,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00095987-05,NCGC00095987-05,434147001,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,14.10776693,0,-4.850541724,-37.39057569,-2.2,7,,-64.90607735,-57.50460405,3.16E-07,0.999770441,,,CC(C)[C@@H]1NC(=O)[C@H](C)OC(=O)[C@H](NC(=O)[C@H](OC(=O)[C@@H](NC(=O)[C@H](C)OC(=O)[C@@H](NC(=O)[C@H](OC(=O)[C@@H](NC(=O)[C@H](C)OC(=O)[C@H](NC(=O)[C@H](OC1=O)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C,Analyticon,NP-007859,0,0,0,0,-0.78633406,-20.02432104,-57.50460405,,,,,,,,,2.87E-09,1.43E-08,7.16E-08,3.58E-07,0.00000179,0.00000896,0.0000448,,,,,,,,
NCGC00386421-08,Verdinexor,434146891,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1392136-43-4,,10.06728919,0,-4.997087456,-67.54107039,-2.2,7,,-76.24033149,-76.61141805,0.000888199,0.987582904,,XPO1,FC(F)(F)C1=CC(=CC(=C1)C(F)(F)F)C2=N[N](\C=C/C(=O)NNC3=CC=CC=N3)C=N2,MedChem Express,HY-15970,0.22795794,-9.41483643,-3.08880309,-0.03401361,-3.87744035,-41.95379003,-76.61141805,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00483210-07,NCGC00483210-07,,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,20.08688273,0,-4.697087456,-45.5209433,-2.2,7,,-82.42541437,-62.82228361,6.61874E-05,0.996661186,,,CC1=NOC(C)=C1C2=CC3=C(N=C(N=C3C=C2)C4=CN(CC(C)(C)O)N=C4)N5CCOC[C@@H]5C6=CC=CC=C6,NCGCChem,YSM025-049,0,-0.92151743,1.36743887,-2.56802721,-6.98662328,-24.42237535,-62.82228361,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00346883-02,6-Bromoindirubin-3'-acetoxime,384568960,GSK-3 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,[667463-85-6],,5.661252742,1,-5.247087456,-126.7808022,-2.1,7,,-127.125,-95.83333333,0.000133012,0.995254885,,GSK3B,CC(=O)O\N=C1\C(NC2=CC=CC=C12)=C3/C(=O)NC4=C3C=CC(=C4)Br,Tocris,3874,0,2.65704193,-3.97361647,-22.02380952,-37.84345625,-71.99027158,-95.83333333,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00180626-04,Cephaeline,434147234,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,483-17-0,,31.83556369,0,-4.497087456,-0.406062943,-2.4,7,,-32.70994476,-26.84162063,0.002967826,0.976929991,,,CC[C@H]1CN2CCC3=C(C=C(OC)C(=C3)OC)[C@@H]2C[C@@H]1C[C@H]4NCCC5=C4C=C(OC)C(=C5)O,Carbosynth,FC19891,4.83123759,0,2.84749035,2.31292517,0,1.86461289,-26.84162063,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00164574-25,Erlotinib,434147028,EGFR Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,183321-74-6,,20.08688273,0,-4.697087456,-21.00654009,-3,7,,-81.22790055,-77.83149171,7.54989E-05,0.996432269,,EGFR,COCCOC1=CC2=NC=NC(=C2C=C1OCCOC)NC3=CC=CC(=C3)C#C,DC Chemicals,DC2101,1.33098022,0,4.64929215,3.96258503,0,-1.15524929,-77.83149171,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00246187-06,Pyronaridine Tetraphosphate,434147065,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,76748-86-2,,8.972480931,1,-5.047087456,-80.87201442,-2.1,7,,-109.5994475,-89.24953959,5.89253E-05,0.996850126,,,COC1=CC=C2NC3=C(C=CC(Cl)=C3)C(N=C4C=C(CN5CCCC5)C(=O)C(CN6CCCC6)=C4)=C2N1,AvaChem,1554_cm1,4.14001029,1.53586239,1.59266409,-7.05782313,-19.65835141,-52.26996352,-89.24953959,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00180911-03,Pyrvinium pamoate,434146893,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,3546-41-6,,1.59555781,1,-5.797087456,-149.7082062,-1.1,7,,-99.98784531,-99.19429098,1.07E-07,0.999866281,,,CN(C)c1ccc2[n+](C)c(\C=C/c3cc(C)n(c3C)-c4ccccc4)ccc2c1.Oc5c(cc6ccccc6c5Cc7c(O)c(cc8ccccc78)C([O-])=O)C([O-])=O,Prestwick,Prestw-1040,0.71328774,0,0,-7.55102041,-60.31272596,-97.28415079,-99.19429098,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00091367-08,DANTHRON,434146873,DNA topoisomerase II alpha Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,117-10-2,,1.422042395,1,-5.847087456,-75.57574029,-1.2,7,,-54.18922652,-50.94383057,0.000407038,0.991651197,,,OC1=CC=CC2=C1C(=O)C3=C(O)C=CC=C3C2=O,Microsource,MS-00211468,0.86035738,0,4.15057915,-10.83333333,-30.45010846,-46.41264694,-50.94383057,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00386235-06,Cobicistat,434146931,Cytochrome P450 3A Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1004316-88-4,,14.22042395,0,-4.847087456,-20.40065485,-2.2,7,,-38.59668508,-34.92173112,0.000395103,0.991781269,,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,Cayman,13433,-0.46326936,-1.15189679,-0.16087516,2.24489796,0.85864064,-12.84961492,-34.92173112,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00090548-05,Deferiprone,434147239,Iron Chelating Agent,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,30652-11-0,,31.83556369,0,-4.497087456,-7.150822743,-3,7,,-45.95303868,-39.87108656,0.000575821,0.990047224,,,CN/1\C=C/C(=O)/C(=C1C)O,APExBIO,B1723,0.08824178,0,1.8018018,0.74829932,4.23897325,2.91852452,-39.87108656,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00378947-03,AMD-070 (hydrochloride),434147108,Human immunodeficiency virus 1 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,880549-30-4,,0.799673205,1,-6.097087456,-92.23494261,-1.2,7,,-54.23264642,-35.54327808,0.049333412,0.892709295,,,NCCCCN(CC1=NC2=CC=CC=C2[NH]1)[C@H]3CCCC4=CC=CN=C34,MedChem Express,HY-50101A,3.7723362,0,-1.09395109,3.57142857,-68.59182936,-52.55370896,-35.54327808,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00095709-02,Tanshinone IIA,50107688,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,568-72-9,TANSHINONE IIA,10.06728919,0,-4.997087456,-70.82821381,-2.1,7,"Tanshinone Iia;tanshinone;Tanshinone IIA;CIPLUS_762550;1,6-dimethylphenanthro(1,2-b)furan-10,11-dione;NCGC00095709-01;Tanshinon I;NCGC00095709-02;tanshinone IIB;tanshinone IIA;LS-175776;TANSHINONE IIA;tanshinone II A;CIPLUS_742126;tanshinone II B;",-102.2375691,-93.73848987,0.000217599,0.993917452,7124,TNF,CC1=COC2=C1C(=O)C(=O)C3=C2C=CC4=C3CCCC4(C)C,"Prestwick Chemical, Inc.",GPN1A_01G09,0,3.45569037,3.07271557,-4.54081633,-9.66196674,-46.5139846,-93.73848987,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00189220-03,UNC-0638,363677129,EHMT2 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1255580-76-7,UNC0638;UNC-0638,14.22042395,0,-4.847087456,-16.01954492,-2.4,7,,-30.03867403,-27.53222836,0.005192618,0.969097675,10919,EHMT2,COC1=C(OCCCN2CCCC2)C=C3N=C(N=C(NC4CCN(CC4)C(C)C)C3=C1)C5CCCCC5,SGC,UNC0638 ,2.88991838,0,0,-3.18027211,1.0032538,-10.41751115,-27.53222836,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00164126-01,Octyl gallate,26757543,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1034-01-1,,17.7827941,0,-4.75,-92.81342994,-2.1,7,"OCTYL-GALLATE;CIPLUS_197519;NCGC00164126-01;3,4,5-trihydroxybenzoic acid octyl ester;octyl gallate dihydrate;Octyl gallate;octyl gallate;",-103.2348066,-92.31123389,0.000482557,0.990896748,,,CCCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1,SigmaAldrich,MFCD00002197,0,2.58024881,-4.82625483,-11.12244898,-16.91070137,-56.34373733,-92.31123389,,,,,,,,,6.37E-09,3.18E-08,1.59E-07,7.96E-07,0.00000398,0.0000199,9.95E-05,,,,,,,,
NCGC00408830-04,BRD73954,434147150,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1440209-96-0,,22.53785311,0,-4.647087456,-5.533272538,-3,7,,-43.90331491,-35.33609576,0.000380782,0.991932903,,,ONC(=O)C1=CC(=CC=C1)C(=O)NCCC2=CC=CC=C2,Tocris,6284,3.97823369,1.68944863,3.15315315,3.40136054,0,-3.24280503,-35.33609576,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00483135-03,CPI-0610,384569263,Bromodomain-containing protein 4 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1380087-89-7,,22.53785311,0,-4.647087456,-11.6020588,-3,7,,-42.01657459,-30.84714549,0.003578418,0.974564434,,,CC1=NOC2=C1C3=CC=CC=C3C(=N[C@H]2CC(N)=O)C4=CC=C(Cl)C=C4,ChemieTek,CT-C0610_cm2,3.43407603,3.77822147,0.27348777,-1.97278912,0.04519161,-7.39764897,-30.84714549,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00486904-01,MRT-68601 hydrochloride,377020217,IKK-epsilon Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,17.90245307,0,-4.747087456,-27.82343612,-2.2,7,,-67.93922651,-49.95395948,0.000592706,0.989897459,,IKBKE,O=C(NCCCNC1=C(C=NC(=N1)NC2=CC=C(C=C2)N3CCOCC3)C4CC4)C5CCC5,Tocris,5067,4.28707993,0,0,4.11564626,-4.04013015,-19.98378597,-49.95395948,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00487399-01,TAK-779,434147161,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,229005-80-5,,4.496892897,1,-5.347087456,-85.8626459,-2.1,7,,-94.42831492,-89.11141805,9.95306E-05,0.995899702,,,CC1=CC=C(C=C1)C2=CC\3=C(CCC\C(=C3)C(=O)NC4=CC=C(C[N+](C)(C)C5CCOCC5)C=C4)C=C2,SIGMA,SML0911,0,0,4.81016731,4.13265306,-18.88105568,-68.07863802,-89.11141805,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00274056-12,Risedronate sodium,434147079,Farnesyl diphosphate synthase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,35.72008996,0,-4.447087456,-9.391505181,-2.4,7,,-30.44198896,-25.36832413,0.045367638,0.898052388,,,OC(CC1=CC=CN=C1)(P(O)(O)=O)P(O)([O-])=O,Selleck,S1428,3.74292227,1.62801413,-5.27670528,-0.51020408,-3.35321764,2.26996352,-25.36832413,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00346475-02,Birinapant,384568790,IAP Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1260251-31-7,,5.5166642,1,-5.258323451,-74.68910943,-2.2,7,,-49.65776022,-45.3038674,0.002229882,0.980092792,,XIAP,CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1CC2=C([NH]C3=C2C=CC(=C3)F)C4=C(C[C@@H]5C[C@H](O)CN5C(=O)[C@H](CC)NC(=O)[C@H](C)NC)C6=C([NH]4)C=C(F)C=C6,Selleck,S7015,-5.91955291,-2.67240055,-4.42406692,-10.6292517,-16.00686913,-26.16538306,-45.3038674,,,,,,,,,1.59E-09,7.96E-09,3.98E-08,1.99E-07,9.95E-07,0.00000498,0.0000249,,,,,,,,
NCGC00263117-14,Panobinostat,,HDAC Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,404950-80-7,,20.08688273,0,-4.697087456,-84.32262567,-2.1,7,,-112.637713,-89.29558011,0.002985365,0.976831445,,HDAC1,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=CC=CC=C3[NH]1,Aobious,AOB87727,-1.80160306,-1.44371064,-10.11904762,-6.75170068,-20.43564714,-34.77908391,-89.29558011,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00024246-18,Daunorubicin,434146881,DNA Topoisomerase II Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,23541-50-6,,11.29568425,0,-4.947087456,-70.56280195,-2.2,7,,-80.66436464,-72.95119705,0.001142211,0.985879964,,TOP2A,COC1=CC=CC2=C1C(=O)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C(C)=O)C(=C3C2=O)O,APExBIO,B2285,1.19861755,-1.3515589,-4.37580438,-6.9047619,-16.74801157,-36.33968383,-72.95119705,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00263625-09,AnacardicAcid,434147227,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,16611-84-0,,5.661252742,1,-5.247087456,-85.72374412,-1.1,7,,-93.11933702,-91.43646409,3.8054E-06,0.999202631,,,CCCCCCCCCCCCCCCC1=C(C(O)=O)C(=CC=C1)O,Bio Vision,1849,2.38988161,0,3.1048906,0.90136054,-2.08785249,-81.47547629,-91.43646409,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00015142-02,Benzamide,124879383,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,25.28788711,0,-4.597087456,-21.16280413,-3,7,Benzamide-15N;Benzamide-13C1 (carbonyl-13C);NCGC00015142-01;Benzoylamide;AB07990186-01;Benzamide;benzamide;NCGC00091355-03;CIPLUS_148736;Benzoic acid amide;Benzamide-alpha-13C;NCGC00091355-02;,-55.64640884,-53.63720074,0.000476258,0.990959788,,,NC(=O)C1=CC=CC=C1,NIEHS,AB07990186,2.58107214,-3.13315927,-2.54182754,0.56122449,0,-1.33765707,-53.63720074,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00378936-01,Letermovir,363678286,Tripartite terminase subunit UL28 homolog Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,917389-32-3,,15.9555781,0,-4.797087456,-24.2753779,-2.2,7,,-59.59668508,-47.42173112,0.000207192,0.994068191,3077457,TRM1,COC1=CC(=CC=C1)N2CCN(CC2)/C3=N/C4=C(F)C=CC=C4[C@H](CC(O)=O)N3C5=CC(=CC=C5OC)C(F)(F)F,MedChem Express,HY-15233,-0.37502758,4.28505606,3.00836551,1.15646259,-0.85864064,-18.01783543,-47.42173112,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00167465-07,Calcipotriol,434147225,Vitamin D receptor Activator,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,112965-21-6,,12.67396618,0,-4.897087456,-68.51987529,-2.2,7,,-67.01381216,-62.29281768,0.00705335,0.9636286,,,C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]2CC[C@H]3\C(CCC[C@]23C)=C\C=C/4C[C@@H](O)C[C@H](O)C4=C,MedChem Express,HY-10001,1.56629164,-7.80218092,-10.97168597,-7.55102041,-10.63810557,-31.63761654,-62.29281768,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00017352-31,Resveratrol,434146966,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,5.661252742,1,-5.247087456,-94.05442306,-2.1,7,,-102.775,-93.25506446,0.000003789,0.999204372,,PTGS2,OC1=CC=C(C=C1)/C=C/C2=CC(=CC(=C2)O)O,Analyticon,NP-012969,2.30163983,0,0,-2.09183673,-23.8340564,-64.53182002,-93.25506446,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00181785-11,Aprepitant,434146917,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,170729-80-3,,20.08688273,0,-4.697087456,-8.007417334,-3,7,,-39.80662984,-33.17219153,0.002386629,0.979386228,,,C[C@@H](O[C@H]1OCCN(CC2=NC(=O)NN2)[C@H]1C3=CC=C(F)C=C3)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F,MedChem Express,HY-10052,3.84587102,3.99324221,0.46653797,-1.41156463,2.08785249,-4.60072963,-33.17219153,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00178913-14,Celastrol,434146903,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,[34157-83-0],,6.35203005,1,-5.197087456,-90.98576738,-2.1,7,,-99.03259668,-98.15837937,2.45572E-05,0.997970272,,,CC1=C(O)C(=O)C=C2C1=CC=C3[C@@]2(C)CC[C@@]4(C)[C@@H]5C[C@@](C)(CC[C@]5(C)CC[C@]34C)C(O)=O,Tocris,3203,1.65453342,-3.57855936,1.14221364,-2.04081633,-9.28235719,-69.05147953,-98.15837937,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00379087-02,Tipranavir,405558770,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,174484-41-4,,12.67396618,0,-4.897087456,-45.21811395,-2.2,7,,-76.95303867,-70.41896869,2.71442E-05,0.997865932,,,CCC[C@@]1(CCC2=CC=CC=C2)CC(=C([C@H](CC)C3=CC=CC(=C3)N[S+]([O-])(=O)C4=CC=C(C=N4)C(F)(F)F)/C(=O)O1)\O,MedChem Express,HY-15148,0,0,2.02702703,-1.10544218,0,-30.19862181,-70.41896869,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00094565-03,Hinokitiol,26753708,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,4.007860013,1,-5.397087456,-92.07256303,-1.1,7,"beta-Thujaplicin;hinokitiol;4-isopropyltropolone;alpha-thujaplicin;NCGC00094565-03;NCGC00094565-01;NCGC00094565-02;4-Isopropyltropolone;2-Hydroxy-4-isopropyl-2,4,6-cycloheptatrien-1-one;CIPLUS_153635;HINOKITIOL;Hinokitiol;beta-thujaplicin;beta-thujaplicin, sodium salt;LS-56183;LS-173664;2-hydroxy-4-isopropyl- 2,4,6-cycloheptatriene-1-one;",-96.84502763,-94.22191529,9.2659E-06,0.998754826,,,CC(C)C\1=C\C=C/C(=O)\C(=C1)O,BIOMOL,FR-110,0,4.28505606,2.83140283,3.06122449,-13.63882863,-80.86745034,-94.22191529,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00183867-02,Aloin,434147060,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1415-73-2,,11.29568425,0,-4.947087456,-47.13835052,-2.2,7,,-68.96823204,-60.05985267,0.002544837,0.978675875,,,[H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@@]2([H])C3=C(C(O)=CC=C3)C(=O)C4=C2C=C(CO)C=C4O,APExBIO,N2491,2.56636517,4.83796652,0,-6.76870748,-9.2462039,-29.18524524,-60.05985267,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00346716-03,Dabrafenib,,Raf kinase B Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1195765-45-7,,15.9555781,0,-4.797087456,-30.10548342,-2.2,7,,-65.63812155,-58.81675875,0.000065792,0.996671309,,BRAF,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(F)C(=CC=C3)N[S+]([O-])(=O)C4=C(F)C=CC=C4F,ChemieTek,CT-DABRF,0,0,3.50707851,-0.0170068,0.75018077,-17.73408999,-58.81675875,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00378589-01,Merimepodib,363678106,Inosine-5'-monophosphate dehydrogenase 2 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,198821-22-6,,22.53785311,0,-4.647087456,-47.36342231,-2.2,7,,-77.95027624,-61.32596685,0.00170235,0.982673078,,,COC1=CC(=CC=C1C2=CN=CO2)NC(=O)NC3=CC(=CC=C3)CNC(=O)O[C@H]4CCOC4,MedChem Express,HY-13986,0,-6.88066349,1.3996139,-5.86734694,-4.32935647,-21.24037292,-61.32596685,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00246387-06,Arbidol,434146926,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,131707-23-8,,11.29568425,0,-4.947087456,-55.69418961,-2.2,7,,-86.0441989,-78.8213628,9.0391E-06,0.998770297,,,CCOC(=O)C1=C(CSC2=CC=CC=C2)[N](C)C3=CC(=C(O)C(=C13)CN(C)C)Br,MedChem Express,HY-14904A,0,0,0,0,-1.85285611,-38.18402919,-78.8213628,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00390283-02,Vesatolimod,434147140,Toll-Like Receptor 7 (TLR7) Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1228585-88-3,,25.28788711,0,-4.597087456,-9.638703758,-3,7,,-44.16712707,-33.86279926,0.006798711,0.964351838,,TLR7,CCCCOC1=NC2=C(NC(=O)CN2CC3=CC(=CC=C3)CN4CCCC4)C(=N1)N,MedChem Express,HY-15601,3.84587102,0,2.57400257,4.13265306,-3.51590745,-4.64126469,-33.86279926,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00263153-10,AR-42(HDAC-42),434147262,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,935881-37-1,,25.28788711,0,-4.597087456,-62.98142636,-2.1,7,,-109.445442,-87.13167587,0.000223965,0.993828505,,,CC(C)[C@H](C(=O)NC1=CC=C(C=C1)C(=O)NO)C2=CC=CC=C2,Bio Vision,2716,0,-5.97450468,-6.86936937,-3.28231293,-7.94468547,-22.21321443,-87.13167587,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00601813-01,Bictegravir,434147180,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1611493-60-7,,17.90245307,0,-4.747087456,-63.93658826,-2.1,7,,-113.5609116,-89.24953959,4.99417E-05,0.997101409,,,OC1=C2N(CC3OC4CCC(C4)N3C2=O)C=C(C(=O)NCC5=C(F)C=C(F)C=C5F)C1=O,Selleck,S5911,1.36039415,1.84303486,-3.57142857,-2.63605442,-6.60701374,-37.27199027,-89.24953959,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00510496-01,VLX-1570,384569458,Ubiquitin C-terminal Hydrolase L5 (UCH-L5) Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1431280-51-1,,5.661252742,1,-5.247087456,-59.30854839,-2.2,7,,-68.65331492,-59.64548803,8.35876E-05,0.99624518,,UCHL5,[O-][N+](=O)C1=CC(=CC=C1F)/C=C/2CCN(CC(=C/C3=CC=C(F)C(=C3)[N+]([O-])=O)\C2=O)C(=O)C=C,MedChem Express,HY-12471,4.06647548,0,0.93307593,-4.48979592,-14.41612437,-41.83218484,-59.64548803,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00018158-11,Doxazosin Mesylate,434146894,alpha1-Adrenoceptor Antagonists,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,77883-43-3,,22.53785311,0,-4.647087456,-32.47511025,-2.2,7,,-84.77071823,-66.11418048,0.000171247,0.994610978,,,COC1=C(OC)C=C2C(=NC(=NC2=C1)N3CCN(CC3)C(=O)C4COC5=C(O4)C=CC=C5)N,Selleck,S1324,0,0,1.94658945,4.09863946,-3.04591468,-16.21402513,-66.11418048,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00015436-09,Fluphenazine hydrochloride,124880096,Nicotinic alpha7 Receptor Ligands,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,146-56-5, Motipress; Liogen;Fluphenazine; Flumezin;; ; Fluphenazine dihydrochloride;Fluphenazine di?HCl; Flufenazine; Prolixin; Lyogen; Motival;Fluphenazine dihydrochloride; Fluphenazine Hcl; prolixin S,11.29568425,0,-4.947087456,-80.89286751,-2.2,7,FLUPHENAZINE 2HCl,-73.89226519,-66.16022099,0.014448458,0.946511384,1813,DRD2,OCCN1CCN(CCCN2C3=C(SC4=C2C=C(C=C4)C(F)(F)F)C=CC=C3)CC1,BIOMOL,AC753,0.9338922,-12.28689909,-12.35521236,-9.06462585,-11.9757773,-37.90028375,-66.16022099,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00347064-06,KUC107871N,440681594,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1346527-98-7,,6.35203005,1,-5.197087456,-78.94431671,-1.1,7,,-86.18383977,-85.01381215,1.25087E-05,0.998552794,,VCP,COC1=C2N=C(N=C(NCC3=CC=CC=C3)C2=CC=C1)[N]4C(=NC5=C4C=CC=C5)N,SIGMA,SML1071,0,0,0,0,3.17245119,-73.34819619,-85.01381215,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00016032-14,THIOCTIC ACID,434146951,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1077-24-7,,15.9555781,0,-4.797087456,-32.86765506,-2.2,7,,-76.25966851,-67.24217311,0.000249208,0.993486781,,,OC(=O)CCCCC1CCSS1,Microsource,1503941,3.13993676,4.16218707,0,-2.15986395,1.31055676,-20.34860154,-67.24217311,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00538156-01,NCGC00538156-01,,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,14.22042395,0,-4.847087456,-34.50129488,-2.2,7,,-69.32044199,-63.12154696,0.00018158,0.99444937,,,CN(C)C1=C2C=CC=C(C2=CC=C1)[S+]([O-])(=O)NC3=CC=C(NC(=O)C(C)(C)CO)C=C3,Pharmaron,PH-NIH-2017-009-L2-56-0,0,0,-0.91698842,4.45578231,0.87671728,-22.03080665,-63.12154696,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00379085-03,Kaempferide,434147113,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,491-54-3,,0.799673205,1,-6.097087456,-112.3936661,-1.2,7,,-57.56282935,-51.51933702,0.004649312,0.970804587,,,COC1=CC=C(C=C1)/C2=C(O)/C(=O)C3=C(O)C=C(O)C=C3O2,MedChem Express,HY-15449,0.62504596,1.27476578,-7.11068211,-11.56462585,-52.48553868,-65.74787191,-51.51933702,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00601698-01,Glecaprevir,,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1365970-03-1,,22.53785311,0,-4.647087456,-51.23416776,-2.2,7,,-58.2627829,-47.32965009,0.027476334,0.923593799,,,[H]\C1=C([H])/C(F)(F)C2=NC3=CC=CC=C3N=C2O[C@@]4([H])CN(C(=O)[C@@]([H])(\N=C(O)\O[C@]5([H])CCC[C@@]5([H])OC1)C(C)(C)C)[C@@]([H])(C4)C(\O)=N\[C@@]6(C[C@@]6([H])C(F)F)C(\O)=N\[S+]([O-])(=O)C7(C)CC7,Bio Vision,B2347,-4.31649386,-0.19966211,-0.17696268,-12.39795918,-12.91576283,-18.54479124,-47.32965009,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00686697-01,4E2RCat,434147184,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,432499-63-3,,4.007860013,1,-5.397087456,-94.08076242,-2.1,7,,-95.75,-85.40515654,2.09266E-05,0.998126846,,,OC(=O)C1=CC(=CC=C1Cl)C2=CC=C(O2)\C=C3/SC(=S)N(CC4=CC=CC=C4)C3=O,MedChem Express,HY-100733,4.44885653,0,2.83140283,-6.39455782,-27.48553868,-66.01134982,-85.40515654,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00091231-18,NCGC00091231-18,434146987,Antimalarial Agents; Cytochrome P450 Cyp2d6 Inhibitors,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,28.373476,0,-4.547087456,-25.21903228,-3,7,,-45.54696133,-43.46224678,0.003795199,0.973759641,,,[H][C@@]1(C[C@@H]2CCN1C[C@@H]2C=C)[C@@H](O)C3=C4C=C(OC)C=CC4=NC=C3,BIOMOL,AC-129,0,-5.71340808,-5.63063063,0,0,-2.87798946,-43.46224678,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00481317-01,CB-5083,363681118,p97 ATPase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1542705-92-9,,20.08688273,0,-4.697087456,-21.3375244,-3,7,,-51.52209944,-46.68508287,0.001032048,0.986597992,,VCP,CC1=CC2=C(C=CC=C2C(N)=O)[N]1C3=NC(=C4COCCC4=N3)NCC5=CC=CC=C5,ActiveBioChem,A-1513,0,0,-3.34620335,3.67346939,0,-7.37738143,-46.68508287,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00386028-03,BAICALIN,434147126,prolyl endopeptidase inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,21967-41-9,,25.28788711,0,-4.597087456,-12.89997273,-2.4,7,,-33.96132597,-26.63443831,0.012607075,0.950400281,,,O[C@@H]1[C@@H](O)[C@@H](O[C@@H]([C@H]1O)C(O)=O)OC2=C(O)C(=C3C(=O)\C=C(/OC3=C2)C4=CC=CC=C4)O,Microsource,1505040,1.11772924,0,0.86872587,2.21088435,-5.10665221,-4.39805432,-26.63443831,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00371045-07,AMD-3465,384569040,Chemokine CXCR4 (SDF-1 Receptor) Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,185991-07-5,,4.496892897,1,-5.347087456,-44.3407632,-1.2,7,,-45.51519337,-45.18876611,0.000385908,0.991874033,,CXCR4,C1CNCCNCCCN(CCNC1)CC2=CC=C(CNCC3=NC=CC=C3)C=C2,MedChem Express,HY-15971,4.59592617,0,-2.05920206,0,0,-44.24402108,-45.18876611,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00384596-01,NCGC00384596-01,434147124,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,4.007860013,1,-5.397087456,-93.65862444,-2.2,7,,-73.14364641,-68.6694291,0.000336102,0.992422587,,,OC(=O)[C@@H](CC1=CC(O)=C(O)C=C1)OC(=O)\C=C\C2=C3[C@@H]([C@H](OC3=C(O)C=C2)C4=CC(O)=C(O)C=C4)C(O)=O,Analyticon,NP-017967,0.65445989,-6.98817386,-3.90926641,-8.86054422,-28.80513377,-51.68220511,-68.6694291,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00346581-06,AZ-960,434147092,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,(905586-69-8),,15.9555781,0,-4.797087456,-48.03825746,-2.2,7,,-73.22928176,-67.21915285,7.87375E-05,0.99635642,,JAK2,C[C@H](NC1=NC(=C(F)C=C1C#N)NC2=N[NH]C(=C2)C)C3=CC=C(F)C=C3,SynKinase,SYN-1015,0,-1.4129934,-4.77799228,-1.2244898,-3.58821403,-23.91568707,-67.21915285,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00241102-05,Midostaurin,434147063,PKC/flt3 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,120685-11-2,,15.9555781,0,-4.797087456,-73.91333671,-2.1,7,,-128.9577348,-97.44475138,4.99373E-05,0.997101458,,PRKCA,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N3C4=CC=CC=C4C5=C6CNC(=O)C6=C7C8=CC=CC=C8N2C7=C35)N(C)C(=O)C9=CC=CC=C9,MedChem Express,HY-10230,3.22817854,2.64168331,-0.77220077,-4.09863946,-13.36767896,-45.07498987,-97.44475138,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00180681-03,Isochlorogenic acid C,434147056,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,32451-88-0,,8.972480931,1,-5.047087456,-38.99862855,-3,7,,-40.68232044,-30.98526703,0.166634474,0.764725196,,,O[C@@H]1C[C@@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@H]1OC(=O)\C=C\c3ccc(O)c(O)c3)C(O)=O,DC Chemicals,DCY-070,0,0,-1.06177606,-14.76190476,-14.41612437,-9.97162546,-30.98526703,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00017115-04,Thiethylperazine Malate,,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,52239-63-1,,5.661252742,1,-5.247087456,-128.2455582,-2.1,7,,-101.2273993,-96.1786372,0.000104594,0.995796041,,,CCSC1=CC2=C(SC3=CC=CC=C3N2CCCN4CCN(C)CC4)C=C1,USP,1657005,-7.27259357,-9.01551221,-2.52574003,-11.92176871,-32.78199566,-69.98378597,-96.1786372,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00164555-10,Entacapone,434147024,NCI-H1299 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,130929-57-6,,15.9555781,0,-4.797087456,-56.65859814,-2.1,7,,-85.70718232,-81.97513812,0.005861102,0.967019209,,,CCN(CC)C(=O)/C(=C/C1=CC(=C(O)C(=C1)[N+]([O-])=O)O)C#N,MedChem Express,HY-14280,4.39002868,-4.25433881,-12.78957529,-4.50680272,1.05748373,-24.68585326,-81.97513812,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00263237-09,JZL-184,384568681,Monoacylglycerol lipase (MAGL) Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,15.9555781,0,-4.797087456,-57.9862363,-2.1,7,,-102.4502762,-82.15930018,2.8601E-06,0.999308897,,MGLL,OC(C1CCN(CC1)C(=O)OC2=CC=C(C=C2)[N+]([O-])=O)(C3=CC4=C(OCO4)C=C3)C5=CC=C6OCOC6=C5,SIGMA,J3455,0,0,0,1.10544218,-7.2758496,-35.46817998,-82.15930018,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00263598-10,Chidamide,434147077,Histone deacetylase 8 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,743420-02-2,,28.373476,0,-4.547087456,-23.16593786,-3,7,,-33.18144584,-31.10036832,0.003193193,0.976036611,,,NC1=C(NC(=O)C2=CC=C(CNC(=O)/C=C/C3=CN=CC=C3)C=C2)C=C(F)C=C1,MedChem Express,HY-13592,-1.11037576,-3.77822147,-0.94916345,-5.76530612,-1.90708604,-3.74949331,-31.10036832,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00346542-10,Hesperadin,434147090,Aurora Kinase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,422513-13-1,,11.29568425,0,-4.947087456,-60.15986016,-2.2,7,,-83.00552487,-73.25046041,0.001012535,0.986723724,,AURKA,CC[S+]([O-])(=O)NC1=CC=C2NC(=O)C(=C(NC3=CC=C(CN4CCCCC4)C=C3)/C5=CC=CC=C5)/C2=C1,Glixx,GLXC-03283,4.36061475,2.11949009,-1.57657658,-6.98979592,-10.78271873,-37.31252533,-73.25046041,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00091023-07,CETYLPYRIDINIUM CHLORIDE,434146985,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,"6004-24-6, 123-03-5 [anhydrous]",,17.90245307,0,-4.747087456,-40.94797997,-2.1,7,,-104.4,-94.75138122,3.96941E-05,0.997417154,,,CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1,Microsource,MS-01500169,2.15457019,4.07003532,0.20913771,-1.07142857,3.00976139,-19.78111066,-94.75138122,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00091469-15,Saquinavir Mesylate,434146988,protease inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,149845-06-7,,7.996732047,1,-5.097087456,-59.39387127,-2.2,7,,-78.54696132,-67.9558011,0.000121708,0.995463039,,,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(N)=O)NC(=O)C4=NC5=C(C=CC=C5)C=C4)[C@@H](C2)C(=O)NC(C)(C)C,Enzo,AC3247,1.77218913,1.72016587,-1.19047619,2.24489796,-14.03651482,-41.69031212,-67.9558011,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00263152-05,Ponatinib,,FGFR Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,943319-70-8,,8.972480931,1,-5.047087456,-73.72637608,-2.1,7,,-109.1562155,-89.38766114,2.67185E-05,0.997882582,,FGFR1,CN1CCN(CC1)CC2=CC=C(NC(=O)C3=CC(=C(C)C=C3)C#CC4=CN=C5C=CC=N[N]45)C=C2C(F)(F)F,Axon Medchem,1857,4.7871167,0,4.40797941,-0.54421769,-16.54916847,-53.66842319,-89.38766114,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00482644-02,Scutellarein,434147154,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,529-53-3,,25.28788711,0,-4.597087456,-21.52869588,-3,7,,-57.18232044,-47.6519337,0.002898448,0.977192271,,,OC1=CC=C(C=C1)C2=CC(=O)C3=C(O)C(O)=C(O)C=C3O2,MedChem Express,HY-N0752,0,2.97957303,2.86357786,-4.52380952,-2.64822849,-5.51276854,-47.6519337,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00247542-02,Amentoflavone,434147240,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1617-53-4,,3.183556369,1,-5.497087456,-135.8481831,-2.1,7,,-105.2601666,-98.15837937,3.76504E-05,0.997484761,,,OC1=CC=C(C=C1)\C2=C\C(=O)C3=C(O2)C(=C(O)C=C3O)C4=C(O)C=CC(=C4)\C5=C\C(=O)C6=C(O5)C=C(O)C=C6O,DC Chemicals,DCS-044,-3.40466211,-1.45906927,-5.03539254,-15.57823129,-44.8571945,-73.89541954,-98.15837937,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00188640-01,NCGC00188640-01,124899261,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,44.66835922,0,-4.35,-52.3306105,-2.2,7,,-78.01657459,-68.34714549,0.00257017,0.978565719,,,C[C@@H](NC(=O)C1=CC(N)=CC=C1C)C2=CC=CC3=CC=CC=C23,Acesys,A9608,-0.12500919,0.49147596,-5.40540541,-6.8537415,-10.31272596,-18.40291852,-68.34714549,,,,,,,,,6.37E-09,3.18E-08,1.59E-07,7.96E-07,0.00000398,0.0000199,9.95E-05,,,,,,,,
NCGC00164615-05,Prulifloxacin,384568265,Antibacterial,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,123447-62-1,,20.08688273,0,-4.697087456,-12.21131583,-3,7,,-52.36740332,-50.32228361,0.000427587,0.991441153,,,CC1SC/2=C(C(O)=O)/C(=O)C3=CC(=C(C=C3N12)N4CCN(CC4)C\C5=C(C)\OC(=O)O5)F,Glixx,GLXC-06577,0,0,4.72972973,0,3.10014461,0,-50.32228361,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00346545-08,Telaprevir (VX-950),384568831,HCV NS3 NS4A Protease Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,402957-28-2,,4.007860013,1,-5.397087456,-120.0742625,-1.1,7,,-106.6546961,-99.21731123,0.000424099,0.99147367,,,CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C3=NC=CN=C3)C4CCCCC4)C(C)(C)C)C(=O)C(=O)NC5CC5,APExBIO,A4031,0,4.03931808,0,-9.67687075,-27.48553868,-88.75152006,-99.21731123,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00378806-01,Nucleozin,363678210,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,341001-38-5,,8.972480931,1,-5.047087456,-52.21307816,-2.2,7,,-69.2058011,-59.82965009,2.10342E-05,0.998122334,,,CC1=C(C(=O)N2CCN(CC2)C3=C(Cl)C=C(C=C3)[N+]([O-])=O)C(=NO1)C4=CC=CC=C4,MedChem Express,HY-50001,0,2.87206266,-0.06435006,-1.93877551,-9.48120029,-35.99513579,-59.82965009,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00378691-05,Asunaprevir (Prop INN; USAN) BMS-650032   Sunvepra  ,434146884,Solute carrier organic anion transporter family member 2B1 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,17.90245307,0,-4.747087456,-20.00132185,-2.2,7,,-64.79281768,-51.35819521,0.000146065,0.995027065,,,COC1=CN=C(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]3(C[C@H]3C=C)C(=O)N[S+]([O-])(=O)C4CC4)C5=CC(Cl)=CC=C15,AK Scientific,Y1367,0,2.90277991,4.77799228,3.18027211,1.18402025,-14.835833,-51.35819521,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00016777-10,Probucol,384567958,Serine Protease Hepsin Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,23288-49-5,,25.28788711,0,-4.597087456,-24.45538993,-2.4,7,,-30.50552486,-28.33793738,0.03899823,0.90669604,,,CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)SC(C)(C)SC2=CC(=C(O)C(=C2)C(C)(C)C)C(C)(C)C,Selleck,S2119,0.80152952,-6.26631854,-7.06241956,-2.72108844,0.62364425,-6.28293474,-28.33793738,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00386310-01,Selinexor,434146875,Exportin-1 Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1393477-72-9,,22.53785311,0,-4.647087456,-12.59254574,-3,7,,-43.13121547,-41.78176796,0.000135734,0.995208774,,XPO1,FC(F)(F)C1=CC(=CC(=C1)C2=N[N](\C=C/C(=O)NNC3=CN=CC=N3)C=N2)C(F)(F)F,Selleck,S7252,0,0,0,3.06122449,0.23499638,-0.30401297,-41.78176796,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00371122-02,Betrixaban,363678038,Coagulation factor X Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,330942-05-7,,22.53785311,0,-4.647087456,-21.68041962,-3,7,,-54.14088398,-45.34990792,0.001926123,0.981539522,,,COC1=CC=C(NC(=O)C2=CC=C(C=C2)C(=N)N(C)C)C(=C1)C(=O)NC3=NC=C(Cl)C=C3,MedChem Express,HY-10268,4.19883815,-2.65704193,0.78828829,-2.46598639,-0.94902386,-8.04620997,-45.34990792,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00386335-01,SC75741,363680219,Nuclear factor NF-kappa-B complex Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,913822-46-5,,7.127094939,1,-5.147087456,-92.61641286,-2.1,7,,-100.0060773,-97.79005525,0.000036666,0.997517991,,,O=C(NC1=NC2=CC=C(C=C2[NH]1)C(=O)C3=CC=CC=C3)C4=CSC(=N4)C5CCN(CC5)C6=C7SC=CC7=NC=N6,Selleck,S7273,1.22803147,-5.09906312,-0.61132561,-1.41156463,-13.27729573,-64.41021484,-97.79005525,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00346532-04,VX-222,434147088,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1026785-59-0,,20.08688273,0,-4.697087456,-56.14174625,-2.2,7,,-65.11140392,-52.37108656,0.002483994,0.978945825,,,C[C@H]1CC[C@@H](CC1)C(=O)N([C@@H]2CC[C@H](O)CC2)C3=C(SC(=C3)C#CC(C)(C)C)C(O)=O,MedChem Express,HY-75800,-5.46363703,-0.01535862,-6.82110682,-8.57142857,-8.3604483,-23.5508715,-52.37108656,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00483052-01,Saikosaponin B2,434147159,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,58316-41-9,,22.53785311,0,-4.647087456,-18.04159171,-2.2,7,,-55.52762431,-40.93001842,0.000580874,0.99000272,,,C[C@H]1O[C@@H](O[C@H]2CC[C@@]3(C)C(CC[C@]4(C)[C@@H]3\C=C/C5=C6\CC(C)(C)CC[C@]6(CO)[C@H](O)C[C@]45C)[C@]2(C)CO)[C@H](O)[C@@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]7O)[C@H]1O,DC Chemicals,DCC-051,0,4.71509753,0,1.8707483,0,-11.81597081,-40.93001842,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00378713-01,Nirogacestat,363678166,g-Secretase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1290543-63-3,,22.53785311,0,-4.647087456,-15.7067463,-3,7,,-66.11878454,-53.01565378,0.000414457,0.99157509,,NOTCH1,CCC[C@H](N[C@H]1CCC2=CC(=CC(=C2C1)F)F)C(=O)NC3=C[N](C=N3)C(C)(C)CNCC(C)(C)C,MedChem Express,HY-15185,0,2.62632468,4.47232947,4.48979592,-0.53326103,-6.87069315,-53.01565378,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00017159-23,Curcumin,384567975,NF-kappaB Activation Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,458-37-7,,1.422042395,1,-5.847087456,-141.2916835,-1.1,7,,-96.19337016,-95.07366482,4.47106E-05,0.99725798,,NFKB1,COC1=CC(=CC=C1O)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(O)C=C2)OC,MedChem Express,HY-N0005,3.13993676,-1.79695899,0.78828829,-15.86734694,-57.78199566,-83.4819619,-95.07366482,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00167972-05,Ciclesonide,,Glucocorticoid receptor Agonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,126544-47-6,,20.08688273,0,-4.697087456,-53.21709317,-2.2,7,,-99.06629834,-76.56537753,9.7506E-06,0.998722755,,,CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]3[C@@H]4CC\C5=C\C(=O)\C=C/[C@]5(C)[C@H]4[C@@H](O)C[C@]23C)C6CCCCC6,MedChem Express,HY-B0625,-0.02206045,0,-0.70785071,-3.21428571,-5.63087491,-28.05026348,-76.56537753,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00247556-02,Fangchinoline,434147067,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,436-77-1,,17.90245307,0,-4.747087456,-57.39502051,-2.2,7,,-91.94751381,-73.06629834,0.000196568,0.994222353,,,COC1=C2OC3=CC=C(C[C@@H]4N(C)CCC5=CC(=C(OC6=C(O)C(=CC7=C6[C@H](CC(=C2)C=C1)N(C)CC7)OC)C=C45)OC)C=C3,DC Chemicals,DCF-007,0,0,0.28957529,-6.36054422,-8.30621837,-30.98905553,-73.06629834,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00183095-07,Tigecycline,384568415,glycylcycline antibiotics,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,220620-09-7,,5.661252742,1,-5.247087456,-83.6687178,-2.1,7,,-90.34419889,-83.65561694,0.000200322,0.994166402,,,CN(C)[C@H]\1[C@@H]2C[C@@H]\3CC4=C(C(=C(NC(=O)CNC(C)(C)C)C=C4N(C)C)O)C(=O)C3=C(O)/[C@@]2(O)C(=O)\C(=C1O)C(N)=O,Enzo,AC3268,2.74284874,2.73383505,-5.26061776,-1.08843537,-18.41106291,-58.93798135,-83.65561694,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00485478-02,Oritavancin (diphosphate),434147160,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,192564-14-0,,1.59555781,1,-5.797087456,-146.5036404,-1.1,7,,-99.01616022,-98.31952118,6.06E-08,0.999899528,,,[H][C@@]1(C[C@](C)(NCC2=CC=C(C=C2)C3=CC=C(Cl)C=C3)[C@@H](O)[C@H](C)O1)O[C@@H]4[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]4OC5=C6OC7=CC=C(C=C7Cl)[C@@H](O)[C@@H](NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@]8([H])C(C=C5OC9=CC=C(C=C9Cl)[C@@H](O[C@@]%10([H])C[C@](C)(N)[C@@H](O)[C@H](C)O%10)[C@]%11([H])NC(=O)[C@]([H])(NC8=O)C%12=CC(=C(O)C=C%12)C%13=C(C=C(O)C=C%13O)[C@]([H])(NC%11=O)C(O)=O)=C6,MedChem Express,HY-B1831A_cm1,0,0,0,-10.86734694,-57.29392625,-91.97405756,-98.31952118,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00344588-04,I-BET151,434147199,Brd4 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,25.28788711,0,-4.597087456,-7.302662633,-2.4,7,,-30.19337017,-20.99447514,0.002493724,0.978942726,,BRD4,COC1=CC2=C(C=C1C3=C(C)ON=C3C)N=CC4=C2N([C@H](C)C5=CC=CC=N5)C(=O)N4,Tocris,4650,0,0,3.57142857,1.29251701,0.18980477,-4.94527767,-20.99447514,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00163572-01,ISORHAMNETINE,26756952,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,3.572008996,1,-5.447087456,-58.39981258,-2.2,7,"ISOHAMNETIN:3'-METHOXY-3,4',5,7-TETRAHYDRO-XY-FLAVONE;3'-Methoxy-3,4',5,7-tetrahydroxyflavone;3-methyl-quercetin;3-methylquercetin;isorhamnetin;CIPLUS_153428;isorhamnetine;NCGC00163572-01;iso-rhamnetin;3'-methoxyquercetin;TAMARIXETINE;NCGC00163572-02;Isorhamnetin;3,4',5,7-tetrahydroxy-3'-methoxyflavone;ISORHAMNETIN;LS-69043;ISORHAMNETINE;CIPLUS_155089;3,4',5,7-tetrahydroxy-3'-methoxy-flavone;",-55.30110497,-49.47053407,0.000168401,0.994657011,,,COC1=CC(=CC=C1O)C2=C(O)C(=O)C3=C(O2)C=C(O)C=C3O,BIOMOL,BIOMOL_NP-148,0.52209721,0,3.00836551,-5.73129252,-19.36912509,-37.21118768,-49.47053407,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00095192-08,Tegaserod maleate,434146928,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,189188-57-6,,15.9555781,0,-4.797087456,-36.05069863,-2.2,7,,-68.20994475,-53.56813996,0.000526612,0.990486202,,HTR4,CCCCCNC(=N)N/N=C/C1=C[NH]C2=C1C=C(OC)C=C2,Cayman,14692,0,0,0,4.59183673,-5.75741142,-23.46980138,-53.56813996,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00346683-02,YM-201636,384568907,PIKfyve Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,371942-69-7,,5.045596817,1,-5.297087456,-106.550249,-2.1,7,,-88.20511278,-82.41252302,5.96762E-05,0.996830097,,PIKFYVE,NC1=CC=C(C=N1)C(=O)NC2=CC=CC(=C2)C3=NC(=C4OC5=NC=CC=C5C4=N3)N6CCOCC6,Selleck,S1219,-0.06618134,-5.80555982,-5.9041184,-8.50340136,-28.78705712,-61.89704094,-82.41252302,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00164319-07,EPIGALLOCATECHIN-3-MONOGALLATE,434147022,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,989-51-5,,0.3572009,1,-6.447087456,-201.5693746,-1.1,7,,-101.5638122,-98.45764273,5.8939E-06,0.999007322,,,OC1=CC(=C2C[C@@H](OC(=O)C3=CC(=C(O)C(=C3)O)O)[C@H](OC2=C1)C4=CC(=C(O)C(=C4)O)O)O,Microsource,MS-00210239,3.19876461,-0.49147596,-11.32561133,-52.73809524,-83.25198843,-94.93311715,-98.45764273,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00384206-05,b-AP15,434147123,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1009817-63-3,,25.28788711,0,-4.597087456,-38.82665591,-2.2,7,,-82.1519337,-66.39042357,0.005973086,0.96669099,,,[O-][N+](=O)C1=CC=C(C=C1)/C=C/2CN(CC(=C/C3=CC=C(C=C3)[N+]([O-])=O)\C2=O)C(=O)C=C,Cayman,11324,0,0,1.97876448,0.90136054,-12.01193059,-13.0320227,-66.39042357,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00510442-01,Abametapir,384569434,MMP-9 (Gelatinase B) Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,15.9555781,0,-4.797087456,-34.22813543,-2.2,7,,-65.44198896,-59.04696133,1.9859E-06,0.999424332,,MMP,CC1=CN=C(C=C1)C2=NC=C(C)C=C2,SIGMA,513040,0,0,0,0,0,-19.27442238,-59.04696133,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00183912-01,FR-180204,174006438,ERK1/2 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,865362-74-9,,20.08688273,0,-4.697087456,-33.04827954,-2.2,7,,-51.81077348,-49.05616943,0.001305946,0.984881612,5598,MAPK7,NC1=N[NH]C2=NN=C(C=C12)C3=C4C=CC=C[N]4N=C3C5=CC=CC=C5,NCGCChem,SP01-087,-3.30171336,0.59898633,-5.96846847,-2.4829932,-0.31634129,-10.41751115,-49.05616943,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00263219-03,Elacridar,384568673,P-Glycoprotein (MDR-1) Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,143664-11-3,,4.007860013,1,-5.397087456,-113.9990635,-1.1,7,,-107.4,-97.97421731,0.00020917,0.99403737,,ABCBA,COC1=C2NC3=C(C=CC=C3C(=O)NC4=CC=C(CCN5CCC6=C(C5)C=C(OC)C(=C6)OC)C=C4)C(=O)C2=CC=C1,Selleck,S7772,3.49290389,0,-0.16087516,-5.5952381,-24.95480839,-87.3530604,-97.97421731,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00347066-11,KUC105555N,384568981,p97 ATPase Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,177355-84-9,,14.22042395,0,-4.847087456,-37.57845866,-2.2,7,,-69.19889503,-63.02946593,1.87818E-05,0.998226014,,VCP,C(NC1=NC2=CC=CC=C2C(=N1)NCC3=CC=CC=C3)C4=CC=CC=C4,MedChem Express,HY-15945,0,0,0,-0.51020408,1.1659436,-22.71990272,-63.02946593,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00093704-43,Cyclosporin A,434147249,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,59865-13-3,,8.743323536,1,-5.058323451,-29.89959875,-3,7,,-36.75414364,-36.1878453,0.027779222,0.923137014,,,CCC1NC(=O)C(C(O)C(C)C\C=C\C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,Selleck,S2286,1.72806824,-8.37045001,2.46138996,-1.2755102,2.91937816,-6.10052696,-36.1878453,,,,,,,,,1.59E-09,7.96E-09,3.98E-08,1.99E-07,9.95E-07,0.00000498,0.0000249,,,,,,,,
NCGC00165993-02,Picolinic acid,170466822,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,98-98-6,,22.53785311,0,-4.647087456,-24.00012378,-3,7,,-82.23618784,-75.20718232,2.58979E-05,0.997915624,,,O=C(O)c1ccccn1,Bosche,P0843,0,0.12286899,2.01093951,3.89455782,1.05748373,-3.60762059,-75.20718232,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00015619-13,Loratadine,170464867,Histamine H1 Receptor Antagonists,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,79794-75-5, Sch2985; ; Claritin; Sch-434;LORATADINE; Wyeth Brand of Loratadine; Clarium; Sch 2985;Loratidine; Alavert; Loratadine Hydrochloride; Sch 434; Loratidine; Loratadine Wyeth Bran; Loratadine W/Pseudo; Loratadine;Loratadine;,20.08688273,0,-4.697087456,-33.23546548,-2.2,7,,-41.54460419,-40.83793738,0.001222443,0.985389335,9704,HRH1,Clc3cc4CCc1cccnc1C(=C2/CCN(CC2)C(=O)OCC)\c4cc3,Vitas,STK574925,-1.69865431,-6.14344955,-1.59266409,-4.71088435,-2.19631236,-10.29590596,-40.83793738,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00274063-04,Pimobendan,434146882,Phosphodiesterase III (PDE3) Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,74150-27-9,,20.08688273,0,-4.697087456,-8.243175425,-2.4,7,,-33.74585636,-29.78821363,0.002091955,0.980748351,,PDE3A,COC1=CC=C(C=C1)C2=NC3=CC(=CC=C3[NH]2)/C4=N/NC(=O)CC4C,Adooq,A10733,0,0,0,4.45578231,1.87093275,-3.14146737,-29.78821363,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00163450-06,"Ilomastat (GM6001, Galardin)",384568240,MMP Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,142880-36-2,,31.83556369,0,-4.497087456,-7.103873357,-2.4,7,,-30.32044199,-26.93370166,0.002987592,0.976853421,,MMP1,CNC(=O)[C@H](CC1=C[NH]C2=C1C=CC=C2)NC(=O)[C@H](CC(C)C)CC(=O)NO,Selleck,S7157,0,0,0.56306306,3.7755102,-1.5274765,0.56749088,-26.93370166,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00165961-04,FTI-277 hydrochloride,434147194,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,7.127094939,1,-5.147087456,-87.47741271,-2.1,7,,-88.34530387,-90.12430939,0.000359132,0.992163117,,,COC(=O)[C@H](CCSC)NC(=O)C1=CC=C(NC[C@@H](N)CS)C=C1C2=CC=CC=C2,Bio Vision,May-74,0,-3.27138688,-8.65508366,1.13945578,-8.64967462,-60.37697608,-90.12430939,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00346946-03,CDK9 Inhibitor,,CDK 9 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1415559-43-1,,15.9555781,0,-4.797087456,-48.86143731,-2.2,7,,-106.160221,-77.39410681,1.56009E-05,0.998383442,,CDK9,CC1=CC=C(NC2=NC=NC(=C2)C3=CC=CC(=C3)N4C(=O)C5=C(C=CC=C5)C4=O)C=C1N[S+](C)([O-])=O,MedChem Express,HY-13231,4.37532171,4.23898019,3.94144144,0.03401361,-9.42697035,-35.10336441,-77.39410681,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00164462-05,NCGC00164462-05,434147251,juvenile hormone metabolic process Modulator,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,19.95262315,0,-4.7,-80.36603578,-2.1,7,,-104,-96.68508287,0.000603526,0.989800896,,,C[C@@H](COc1ccc(Oc2ccccc2)cc1)Oc3ccccn3,EPA,TV000265,-5.31656739,-3.25602826,-2.50965251,2.27891156,0,-54.37778679,-96.68508287,,,,,,,,,6.37E-09,3.18E-08,1.59E-07,7.96E-07,0.00000398,0.0000199,9.95E-05,,,,,,,,
NCGC00385384-01,NCGC00385384-01,434147125,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,14.22042395,0,-4.847087456,-29.84054514,-2.2,7,,-63.2237569,-57.3664825,0.000396305,0.991763829,,,CC(=O)OC(C)(C)CCC(=O)[C@](C)(O)C1[C@H](O)C[C@@]2(C)C3C/C=C/4C(C[C@H](O)[C@@H](O)C4(C)C)[C@]3(C)C(=O)C[C@]12C,Analyticon,NP-015959,0,0,-0.17696268,0,4.47396963,-18.13944062,-57.3664825,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00378604-04,ABT-333,377020340,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1132935-63-7,,10.06728919,0,-4.997087456,-77.80881129,-2.1,7,,-97.04889503,-91.7587477,7.19329E-05,0.99651787,,,COC1=C(C=C(C=C1C2=CC3=CC=C(N[S+](C)([O-])=O)C=C3C=C2)N4\C=C/C(=O)NC4=O)C(C)(C)C,MedChem Express,HY-13998,1.50746378,-0.3225311,-4.55276705,-4.4047619,-8.93890094,-48.78394812,-91.7587477,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00371131-03,NMS-873,434147189,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1418013-75-8,,7.127094939,1,-5.147087456,-37.32222637,-2.2,7,,-45.55248619,-41.71270718,0.004823095,0.970247526,,VCP,CC1=C(C=CC(=C1)OCC2=NN=C(SC3CCCC3)[N]2C4=CN=CC=C4)C5=CC=C(C=C5)[S+](C)([O-])=O,Selleck,S7285,4.4635635,-0.15358624,-5.27670528,1.59863946,-6.84201012,-27.17875963,-41.71270718,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00482994-01,20(S)-Ginsenoside Rh2,434146921,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,67400-17-3,,12.67396618,0,-4.897087456,-41.92649497,-2.2,7,,-73.85082873,-67.31123389,0.00028799,0.992992532,,,CC(C)=CCC[C@](C)(O)[C@H]1CC[C@@]2(C)[C@H]1[C@@H](O)CC3[C@@]4(C)CC[C@@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)(C)C4CC[C@@]23C,DC Chemicals,DCR-036,0,0,-0.64350064,0.13605442,3.46167751,-29.08390758,-67.31123389,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00091914-04,Cichoric Acid,434146991,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,12.67396618,0,-4.897087456,-65.3053977,-2.2,7,,-65.7320442,-51.3121547,0.011476006,0.952808512,,,OC(=O)[C@H](OC(=O)\C=C\C1=CC(=C(O)C=C1)O)[C@@H](OC(=O)\C=C\C2=CC=C(O)C(=C2)O)C(O)=O,Analyticon,NP-015790,-4.28707993,1.32084165,-6.0006435,-9.11564626,-22.33369487,-26.26672071,-51.3121547,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00345539-05,Dacinostat,434147084,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,404951-53-7,,20.08688273,0,-4.697087456,-42.01952159,-2.2,7,,-77.48618785,-58.70165746,0.002109391,0.980648773,,HDAC1,OCCN(CCC1=C[NH]C2=C1C=CC=C2)CC3=CC=C(\C=C\C(=O)NO)C=C3,Selleck,S1095,0,4.13146982,0,-3.23129252,-10.11388286,-21.38224564,-58.70165746,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00346743-03,Givinostat hydrochloride,384568939,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,20.08688273,0,-4.697087456,-43.4484694,-2.2,7,,-53.71546961,-42.58747698,0.042094169,0.90234957,,HDAC1,CCN(CC)CC1=CC2=C(C=C1)C=C(COC(=O)NC3=CC=C(C=C3)C(=O)NO)C=C2,Bio Vision,May-31,-1.36039415,4.3772078,-6.51544402,-9.06462585,-11.84924078,-16.03161735,-42.58747698,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00522503-02,VELPATASVIR,434147174,Nonstructural protein 5A Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,4.496892897,1,-5.347087456,-105.2050002,-2.1,7,,-105.45,-95.25782689,1.25416E-05,0.998550878,,,COC[C@H]1C[C@H](N(C1)C(=O)[C@H](NC(=O)OC)C2=CC=CC=C2)C3=NC=C([NH]3)C4=CC=C5C(=C4)COC6=CC7=C(C=CC8=C7[NH]C(=N8)[C@@H]9CC[C@H](C)N9C(=O)[C@@H](NC(=O)OC)C(C)C)C=C56,Astatech,40127,1.97808662,3.76286285,-0.64350064,-7.00680272,-27.63015184,-73.49006891,-95.25782689,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00356067-12,OTX-015,434147098,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,202590-98-5,,17.90245307,0,-4.747087456,-45.50061585,-2.2,7,,-93.7679558,-69.52117864,0.000208321,0.994050465,,,CC1=NN=C2[C@H](CC(=O)NC3=CC=C(O)C=C3)N=C(C4=C(SC(C)=C4C)N12)C5=CC=C(Cl)C=C5,APExBIO,A3692,0,3.17923514,4.82625483,-1.61564626,-7.58315257,-28.94203486,-69.52117864,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00510316-01,ombitasvir,434147243,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1258226-87-7,,4.496892897,1,-5.347087456,-103.0528067,-1.1,7,,-100.1519337,-97.69797422,1.2562E-06,0.999542137,,,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC2=CC=C(C=C2)[C@@H]3CC[C@H](N3C4=CC=C(C=C4)C(C)(C)C)C5=CC=C(NC(=O)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)C(C)C)C=C5,MedChem Express,HY-13997,0,2.24235908,0,-2.70408163,-22.35177151,-75.47628699,-97.69797422,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00346629-09,GSK1349572,,HIV Integrase Inhibitors,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1051375-16-6,,3.572008996,1,-5.447087456,-77.78303209,-1.1,7,,-83.49290636,-76.74953959,0.000117813,0.995536256,,,C[C@@H]1CCO[C@H]2CN\3/C=C(/C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)\C(=C3C(=O)N12)O,DC Chemicals,DC7273,4.61063313,4.28505606,2.23616474,-0.06802721,-0.89479393,-83.84677746,-76.74953959,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00346519-03,Teicoplanin,,glycopeptide antibiotic,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,20.08688273,0,-4.697087456,-45.64626452,-2.2,7,,-78.27900552,-60.05985267,0.000814604,0.988120646,,,CC(C)CCCCCCCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC2=C3OC4=CC=C(C[C@H]5NC(=O)[C@H](N)C6=CC(=C(O)C=C6)OC7=CC(=CC(=C7)O)[C@H](NC5=O)C(=O)N[C@H]8C(=O)N[C@H]9C(=O)N[C@@H]([C@H](O[C@@H]%10O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%10NC(C)=O)C%11=CC(=C(OC2=CC8=C3)C=C%11)Cl)C(=O)N[C@@H](C(O)=O)C%12=CC(=CC(=C%12C%13=C(O)C=CC9=C%13)O[C@H]%14O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]%14O)O)C=C4Cl,MedChem Express,HY-A0097,2.16927715,0.3225311,-0.94916345,-5.27210884,-8.57736804,-23.26712606,-60.05985267,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00015508-23,Hydrochlorothiazide,384567858,Hypertension treatment,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,58-93-5,,31.83556369,0,-4.497087456,-11.34380859,-3,7,,-38.41712708,-34.57642726,0.002186265,0.980299561,,,N[S+]([O-])(=O)C1=C(Cl)C=C2NCN[S+]([O-])(=O)C2=C1,Enzo,AC3145,0.4044415,2.58024881,2.18790219,-2.67006803,-1.43709328,0,-34.57642726,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00250410-11,GSK-650394,384568558,SGK1 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,890842-28-1,,22.53785311,0,-4.647087456,-23.39208186,-2.2,7,,-83.5,-66.66666667,1.86234E-05,0.998233463,,SGK1,OC(=O)C1=C(C=C(C=C1)C2=C[NH]C3=NC=C(C=C23)C4=CC=CC=C4)C5CCCC5,MedChem Express,HY-15192,1.71336128,3.53248349,3.95752896,2.14285714,0.18980477,-11.85650588,-66.66666667,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00356072-01,N/A,363677795,Lysine-specific histone demethylase 1 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,15.9555781,0,-4.797087456,-13.06617113,-3,7,,-38.85082873,-33.97790055,0.003914542,0.973338415,,,N[C@H]1C[C@H]1C2=CC=C(C=C2)C3=CC=CC(=C3)O,Selleck,S7237,2.30163983,-2.65704193,1.25482625,4.77891156,1.12979031,-8.91771382,-33.97790055,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00163489-05,Shikonin,434147017,Drugs Acting on Chemokine Receptors,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,517-89-5,,1.59555781,1,-5.797087456,-141.600943,-1.1,7,,-104.0883978,-98.5267035,1.7026E-06,0.999466865,,CCR5,CC(C)=CC[C@@H](O)C/1=C/C(=O)C2=C(O)C=CC(=C2C1=O)O,Cayman,14751,3.52231782,3.71678698,0.70785071,-11.41156463,-55.93817787,-94.3858938,-98.5267035,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00015992-01,Tyrphostin A9,11111849,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,1.790245307,1,-5.747087456,-98.3984326,-1.2,7,"NCGC00015992-01;[[3,5-bis(1,1-Dimethylethyl)-4-hydroxyphenyl]methylene]propanedinitrile;SF6847;Malonoben;CIPLUS_168096;[[3,5-bis(1,1-Dimethylethyl)-4-hydroxyphenyl]methylene]-propanedinitrile;NCGC00094494-01;TYRPHOSTIN 9;NCGC00094494-02;NCGC00094494-03;NCGC00094494-04;SF 6847;3,5-di-tert-butyl-4-hydroxybenzylidenemalononitrile;SF-6847;tyrphostin A9;Tyrphostin A9;",-53.16903121,-48.91804788,0.015877122,0.943677351,,,CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)C=C(C#N)C#N,SigmaAldrich,Lopac-T-182,-3.24288551,0.49147596,-5.96846847,-12.43197279,-30.25126537,-64.04539927,-48.91804788,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00016012-08,Triflupromazine hydrochloride,124881619,Muscarinic acetylcholine receptor M2 Antagonist,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,17.90245307,0,-4.747087456,-45.77651726,-2.2,7,"Triflupromazinum;NCGC00094410-03;triflupromazinum;10H-PHENOTHIAZINE-10-PROPANAMINE, N,N-DIMETHYL-2-(TRIFLUOROMETHYL)-;Triflupromazine Hcl;NCGC00094410-02;NCGC00094410-01;CIPLUS_208142;Triflupromazine Hydrochloride;NCGC_Prestw-53;Phenothiazine, 10-(3-(dimethylamino)propyl)-2-(trifluoromethyl)-, monohydrochloride;Trifluopromazine;NCGC00016012-02;NCGC00016012-01;NCGC00024300-04;Triflupromazina;TRIFLUPROMAZINE HYDROCHLORIDE;TRIFLUPROMAZINE;TRIFLUPROMAZINE MALEATE;trifluopromazine;Triflupromazine;LS-105501;Vesprin;Triflupromazine hydrochloride;LS-105500;10-3-(DIMETHYLAMINO)PROPYL-2-(TRIFLUOROMETHYL)PHENOTHIAZINE;triflupromazine;Vesprin hydrochloride;10-(3-(DIMETHYLAMINO)PROPYL)-2-(TRIFLUOROMETHYL)PHENOTHIAZINE MONOHYDROCHLORIDE;10H-PHENOTHIAZINE-10-PROPANAMINE, N,N-DIMETHYL-2-(TRIFLUOROMETHYL)-, MONOHYDROCHLORIDE;CIPLUS_170810;10H-Phenothiazine-10-propanamine, N,N-dimethyl-2-(trifluoromethyl)-;CIPLUS_152129;",-69.37569061,-53.31491713,0.004378558,0.971714792,1129,CHRM2,CN(C)CCCN1C2=C(SC3=C1C=C(C=C3)C(F)(F)F)C=CC=C2,SIGMA,T-2896,4.03706155,1.47442789,-5.72715573,-6.30952381,-7.80007231,-25.23307661,-53.31491713,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00346712-02,Verteporfin,440681570,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,129497-78-5,,1.790245307,1,-5.747087456,-134.6947834,-1.1,7,,-97.81077348,-97.28360958,3.7733E-06,0.999205995,,,COC(=O)CCC1=C(C)C2=CC3=NC(=CC4=C(C)C(=C([NH]4)C=C\5N=C(C=C1[NH]2)\C(=C5C)CCC(O)=O)C=C)\C6=C\C=C(/[C@@H](C(=O)OC)[C@@]36C)C(=O)OC,Selleck,S1786,2.46341643,0.18430349,-0.19305019,-1.29251701,-51.23825018,-94.22375355,-97.28360958,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00379189-01,P005091,434147115,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,[882257-11-6],,2.528788711,1,-5.597087456,-61.95437946,-1.2,7,,-54.43922652,-51.79558011,0.000155453,0.994867718,,,CC(=O)C1=CC(=C(S1)SC2=CC=CC(=C2Cl)Cl)[N+]([O-])=O,Tocris,4733,3.83116406,1.10582092,2.63835264,-2.84013605,-18.03145336,-50.12160519,-51.79558011,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00522453-02,IXAZOMIB CITRATE,434146871,Proteasome subunit beta type-5 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,31.83556369,0,-4.497087456,-11.04560571,-2.4,7,,-33.24861879,-29.37384899,0.024232149,0.92886389,5693,PSMB5,CC(C)C[C@H](NC(=O)CNC(=O)C1=CC(=CC=C1Cl)Cl)B2OC(=O)C(CC(O)=O)(CC(O)=O)O2,MedChem Express,HY-10452,-6.34605486,3.27138688,1.88223938,0,1.54555315,0,-29.37384899,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00247668-03,LDN-57444,384568515,"Reversible, competitive Inhibitor of UCH-L1 deubiquitinase",Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,668467-91-2,,7.996732047,1,-5.097087456,-84.6938025,-2.1,7,,-98.98839779,-92.6335175,7.03367E-05,0.996556904,,,CC(=O)O/N=C/1C(=O)N(CC2=CC(=CC=C2Cl)Cl)C3=CC=C(Cl)C=C13,XcessBio,M60204-2s,0,0,-4.31145431,1.32653061,-14.43420101,-57.15443859,-92.6335175,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00482709-01,Licochalcone A,,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,58749-22-7,,4.007860013,1,-5.397087456,-107.8081511,-2.1,7,,-102.8,-93.27808471,3.60762E-05,0.997538112,,,COC1=CC(=C(C=C1\C=C\C(=O)C2=CC=C(O)C=C2)C(C)(C)C=C)O,DC Chemicals,DCG-033,0,0,0,-2.12585034,-30.84779465,-74.34130523,-93.27808471,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00017388-08,(+)-Usniacin,434147230,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,7562-61-0,,20.08688273,0,-4.697087456,-23.76042578,-2.2,7,,-62.21270718,-45.99447514,0.002884272,0.977249995,,,CC(=O)C1=C(O)C(C)=C(O)C2=C1OC3=CC(=O)C(C(C)=O)=C(O)[C@@]23C,DC Chemicals,DCS-001,3.52231782,4.20826294,-4.11840412,2.60204082,-1.49132321,-16.35589785,-45.99447514,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00402349-02,GN6958,363681035,Sentrin-specific protease 1 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1392278-32-8,,5.045596817,1,-5.297087456,-68.8092209,-2.2,7,,-71.98618784,-67.44935543,7.54E-07,0.999645461,29843,SENP1,CCOC(=O)C1=CC=CC(=C1)CNC2=CC=C(C=C2)N(C)C(=O)NC3=CC=CC=C3,Glixx,GLXC-02687,1.7868961,0.07679312,0.74002574,-1.73469388,-15.24765004,-50.52695582,-67.44935543,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00346498-06,Danoprevir,434147087,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,850876-88-9,,17.90245307,0,-4.747087456,-15.01194058,-2.4,7,,-32.11325967,-28.84438306,2.16E-07,0.99981033,,,CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]3C[C@H](CN3C1=O)OC(=O)N4CC5=C(C4)C(F)=CC=C5)C(=O)N[S+]([O-])(=O)C6CC6,MedChem Express,HY-10238,0,0,0,0,0,-6.97203081,-28.84438306,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00263102-06,Degrasyn,384568591,Jak2 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,856243-80-6,,8.972480931,1,-5.047087456,-45.44863203,-2.2,7,,-57.83563536,-52.04880295,0.000132685,0.995262118,,JAK2,CCC[C@H](NC(=O)\C(=C\C1=NC(=CC=C1)Br)C#N)C2=CC=CC=C2,MedChem Express,HY-13264,0.43385543,1.32084165,0.64350064,-4.03061224,-6.66124367,-30.6445075,-52.04880295,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00370887-06,AC-55541,434146897,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,916170-19-9,,10.06728919,0,-4.997087456,-81.48558313,-2.1,7,,-101.0875691,-96.52394107,2.03691E-05,0.998152036,,,C\C(=N/NC(=O)C(NC(=O)C1=CC=CC=C1)C/2=N/NC(=O)C3=CC=CC=C23)C4=CC=CC(=C4)Br,MedChem Express,HY-14350,0.55151114,-1.84303486,-2.10746461,-5.25510204,-7.85430224,-51.64167004,-96.52394107,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00390587-03,G-007-LK,434147143,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,5.045596817,1,-5.297087456,-35.1744761,-2.2,7,,-41.08563536,-36.04972376,0.000377473,0.991967316,80351,TACR1,C[S+]([O-])(=O)C1=CC=C(N=C1)C2=NN=C(\C=C\C3=NN=C(O3)C4=CC=C(C=C4)C#N)[N]2C5=C(Cl)C=CC=C5,APExBIO,B5830,0,4.14682844,0,-0.11904762,-9.445047,-26.773409,-36.04972376,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00371133-07,Atglistatin,363678049,Patatin-like phospholipase domain-containing protein 2 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1469924-27-3,,12.67396618,0,-4.897087456,-65.85795488,-2.1,7,,-91.625,-86.21086556,0.000412931,0.991588895,57104,PNPLA2,CN(C)C(=O)NC1=CC=CC(=C1)C2=CC=C(C=C2)N(C)C,Glixx,GLXC-04086,1.46334289,-7.44893258,-3.63577864,0.6122449,-4.49204628,-37.6773409,-86.21086556,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00168902-03,Hyperoside,434147043,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,,,8.972480931,1,-5.047087456,-60.20737917,-2.2,7,,-70.82872928,-62.56906077,0.001798407,0.982175575,,,OC[C@H]1O[C@@H](O\C2=C(\OC3=C(C(=CC(=C3)O)O)C2=O)C4=CC(=C(O)C=C4)O)[C@H](O)[C@@H](O)[C@H]1O,Analyticon,NP-001009,-1.12508273,-4.23898019,2.62226512,-0.56122449,-16.62147505,-34.49533847,-62.56906077,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00181129-22,Dasatinib,434146874,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,302962-49-8,,20.08688273,0,-4.697087456,-38.45260534,-2.2,7,,-66.91436464,-51.45027624,0.000177174,0.994518717,,,CC1=NC(=CC(=N1)NC2=NC=C(S2)C(=O)NC3=C(Cl)C=CC=C3C)N4CCN(CCO)CC4,Selleck,S1021_CM1,0,-1.38227615,-2.05920206,1.00340136,-6.390094,-20.30806648,-51.45027624,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00356069-06,GSK1324726A,434146895,Bromodomain-containing protein 4 Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,1300031-52-0,,22.53785311,0,-4.647087456,-29.93672392,-2.2,7,,-62.10497238,-49.70073665,4.3037E-06,0.999152301,23476,BRD4,C[C@H]1C[C@@H](NC2=CC=C(Cl)C=C2)C3=C(C=CC(=C3)C4=CC=C(C=C4)C(O)=O)N1C(C)=O,MedChem Express,HY-13960,0,-1.64337275,-0.61132561,-0.6462585,-1.78054953,-13.15362789,-49.70073665,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00378687-03,Verbascoside,434147241,,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,61276-17-3,,22.53785311,0,-4.647087456,-34.34263697,-2.2,7,,-78.43370166,-60.93462247,8.79177E-05,0.996148726,,,C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](OCCC3=CC(=C(O)C=C3)O)O[C@H](CO)[C@H]2OC(=O)\C=C\C4=CC(=C(O)C=C4)O)[C@H](O)[C@H](O)[C@H]1O,MedChem Express,HY-N0021,2.33105375,0,-2.42921493,-0.18707483,-2.03362256,-16.68017835,-60.93462247,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
NCGC00510921-01,Lucanthone,384569494,DNA Topoisomerase II Inhibitor,Spike-ACE2 protein-protein interaction (AlphaLISA),Anti-infectives,548-57-2,,6.35203005,1,-5.197087456,-97.03570007,-2.1,7,,-102.2925414,-96.24769797,0.000246892,0.993516534,,TOP2A,CCN(CC)CCNC1=C2C(=O)C3=CC=CC=C3SC2=C(C)C=C1,SantaCruz Bio,sc-396381,0,0,3.07271557,-8.82653061,-15.78994939,-68.86907175,-96.24769797,,,,,,,,,3.18E-09,1.59E-08,7.96E-08,3.98E-07,0.00000199,0.00000995,0.0000498,,,,,,,,
